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 Abstract 
Mitochondria are dynamic organelles whose principal role is the generation of cellular 
energy (ATP) through oxidative phosphorylation (OXPHOS). 13 OXPHOS subunits 
are encoded by the mitochondrion’s polyploid circular genome (mtDNA), and the 
nuclear genome (nDNA) encodes the remaining subunits as well as proteins required 
for mtDNA maintenance. In addition to mitochondrial number, mtDNA copy number 
(mtDNA CN) varies between cell and tissue type, depending on metabolic demand 
and baseline mtDNA quality, and ranges from hundreds to thousands of copies per 
cell. mtDNA CN is often linked to mitochondrial dysfunction and the ubiquity of 
mitochondria results in a broad spectrum of dysfunction and clinical phenotypes; 
ranging from primary mitochondrial disorders to complex diseases such as cancer, 
type 2 diabetes, and Parkinson’s disease. 
Given the variability in mtDNA between individuals, it is possible that mtDNA CN is 
influenced by secondary factors. I hypothesise that nDNA diversity is a major 
component of mtDNA variability between individuals and will test this hypothesis by 
conducting a genome wide association study (GWAS) in a large, European, 
asymptomatic cohort (>8000 individuals), comparing nDNA genotype to mtDNA 
copy-number as a QTL. 
Peripheral blood mtDNA CN was correlated to array-based and imputed nDNA 
genotype in a two-stage QTL analysis, utilising three independent replicative cohorts: 
UKBS, Newcastle, and ALPAC. In addition the effect of potential confounding 
biological variables such as age, gender, blood count, and potential methodological 
confounders such as assay variation, technical and biological replicate numbers, and 
differences in genotype platform were all assessed and used to improve the GWAS 
analysis. 
Individual cohort analysis identified nuclear gene UNC13C (Unc-13 Homolog C), two 
intergenic, and one intronic SNP, which is in close proximity to PSMD3 (Proteasome 
26S Subunit, Non-ATPase 3), to be genome wide significant (GWS) (p< 1.00E-07) in 
individual cohort analysis. However these hits could not be replicated in meta-
analysis. mtDNA variant analysis in all three cohorts revealed that mtDNA SNPs 
G5460A and G5046A, which identify as mitochondrial haplogroup W, were 
significantly associated to a significant reduction in mtDNA CN. Furthermore, our 
work identified gender-specific genetic differences, which was supported by a 
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significant decrease in mtDNA CN in males with age, but not females, and significant 
changes in mtDNA CN relative to blood cell type and proportions highlighted the 
importance of regulating for cellular heterogeneity. Additionally, no difference in 
mtDNA CN was observed between pre- and post-menopausal women. 
This work indicates that there are likely genetic variants present at the population 
level modulating mtDNA CN, but that this process is complex and multifaceted. 
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This thesis is dedicated to my family; to those who have passed and to 
those who are present. I hope this makes you proud.  
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1.1 The Mitochondrial Organelle  
Mitochondria are double membrane-bound organelles in eukaryotic cells which are 
fundamental to cellular maintenance. Described as the powerhouse of the cell, 
mitochondria generate over 80% of cellular energy in the form of adenosine 
trisphosphate (ATP). They also regulate calcium signalling, cell growth, and 
differentiation, cell cycle control, and cell death. 
The mitochondrial structure consists of an outer membrane (OMM) and an inner 
membrane (IMM) separated by an intermembrane environment space (Figure 1.1). 
Mitochondria have their own matrix separate to that of the cellular cytoplasm, which 
provides an independent environment for mitochondrial-specific metabolic reactions 
to occur as well as mitochondrial DNA replication. 
The OMM is porous and readily diffuses ions and uncharged molecules into the 
mitochondria through porins, or uses protein translocases to transport larger 
molecules (Weeber et al., 2002). Evidence suggests that porins on the OMM are 
crucial for regulating mitochondrial calcium-induced calcium release, as the porins 
network with the adenine nucleotide transporter in the IMM and cyclophilin D in the 
mitochondrial matrix (Crompton et al., 1998; Vyssokikh et al., 2001). 
The IMM on the other hand is non-porous, and all molecules and ions are 
transported into the mitochondrial matrix by specific membrane transport proteins 
(Kühlbrandt, 2015).  The IMM forms cristae structures which increase surface area 
for aerobic respiration components to anchor (Schenkel and Bakovic, 2014). Both the 
OMM and IMM are made up of basic phospholipids, however phosphatidylglycerol 
and cardiolipin are specific to the mitochondria (Ren et al., 2014). 
The intermembrane space between the IMM and OMM is where the mitochondrial 
membrane potential (ΔΨ) is generated due to the constant flux of ions across the 
IMM. The ΔΨ is usually around 180mV but is vital to mitochondrial maintenance and 
ATP generation (Kühlbrandt, 2015). 
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Figure 1.1: Membrane compartments in the mitochondrion. Image taken from (Kühlbrandt, 2015)  
1.1.1 Mitochondria Evolution 
Eukaryotic cells did not always contain mitochondria. Mitochondria are actually 
endosymbiotic remains and evolved from an invading α-proteobacterium billions of 
years ago (Nass and Nass, 1963a; Nass, 1966; Margulis, 1971; Lang et al., 1997; 
Koonin, 2010), however uncertainty still remains. Despite the evidence of 
phylogenetic alignments suggesting this might be true (Ingman et al., 2000), Gray 
argues the majority of the mitochondrial proteome exists outside of the α-
proteobacteria’s evolutionary origin (Gray, 2012), and recent evidence suggests that 
the original host cell was already genetically chimeric before the mitochondrial 
symbiosis occurred. This suggests that mitochondria evolved later in eukaryotic 
evolution than was initially thought (Pittis and Gabaldón, 2016). 
The smallest genomes recorded are in symbiotic bacteria in the stomachs of cicada 
(McCutcheon et al., 2009), which evolved due to pressures exerted by intracellular 
conditions and competitions with other endosymbionts (Van Leuven et al., 2014). 
Eukaryotic mitochondria also developed a smaller and more compact genome over 
time due to intracellular pressures, but many genes are believed to have translocated 
to the nuclear genome (Brown et al., 1979; Lane and Martin, 2010b). 
Beneficial genes and single-nucleotide polymorphisms (SNPs) have been conserved 
through evolution (Koonin, 2010), providing functional advantages to the cell under 
different pressures. The tricarboxylic-acid (TCA) cycle metabolic network has been 
the most highly conserved across species through evolution, demonstrating that the 
main function of the mitochondria is centred around the TCA cycle and oxidative 
phosphorylation (OXPHOS) activity (Chang et al., 2010). 
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1.2 Metabolism and the Mitochondria 
Mitochondria are present in multiple species, including prokaryotes, and bring a 
number of benefits to the cell. They store calcium, and synthesise haem, 
phospholipids, and cholesterol, and regulate cell apoptosis (Susin et al., 1999; 
Duchen, 2000; Malik and Czajka, 2013). Mitochondria regulate cellular metabolic 
activity, playing a major role in cell homeostasis by generating energy in the form of 
ATP through OXPHOS. In eukaryotes, they are able to produced 36 molecules of 
ATP per glucose molecule metabolised through aerobic respiration, which is more 
beneficial than five ATP molecules generated through anaerobic respiration (Lin et 
al., 2012; Müller et al., 2012). 
Additionally, mitochondria contribute to the anabolic and catabolic metabolism of 
carbohydrates, amino acids, and lipids - as they are home to the TCA, beta-
oxidation, and many amino acid metabolism pathways (Figure 1.2). 
1.2.1 Glycolysis and the TCA Cycle 
Glycolysis is a metabolic pathway which occurs in the cytosol of eukaryotic cells. 
Through a series of enzyme reactions, glucose is broken down into pyruvate which is 
then transported into the mitochondria by the mitochondrial pyruvate carrier 
(Halestrap, 1975), and subsequently metabolised into either acetyl-coA by pyruvate 
dehydrogenase or oxaloacetate by pyruvate carboxylase. Both acetyl-coA and 
oxaloacetate feed in to the TCA cycle and regulate its flux, which is important for 
cellular metabolic equilibrium (Das et al., 2015). During gluconeogenesis, 
lipogenesis, neurotransmitter biosynthesis, and glucose-induced insulin secretion, 
oxaloacetate is an important intermediate to drive TCA cycle (Jitrapakdee et al., 
2008). Acetyl-coA is vital for maintaining cellular respiration from glycolysis and is 
important for acetylating histones which control DNA expression (Wellen et al., 2009; 
Lee et al., 2014a).  
1.2.2 Beta-oxidation 
Pyruvate is a key substance which drives several intersecting pathways within the 
TCA cycle, including beta-oxidation (as reviewed by (Gray et al., 2014)). Both beta-
oxidation and the TCA cycle occur in the mitochondria (Mitchell, 1961), however 
beta-oxidation is the breakdown of  dietary fatty acids (FAs) such as palmitic acid, 
oleic acid, and linoleic acid (Wanders et al., 2010). During beta-oxidation, two-carbon 
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units are removed from the carboxyl end of the FA molecule to produce acetyl-CoA, 
which then feeds in to the TCA cycle, as reviewed by (Bartlett and Eaton, 2004). 
1.2.3 Amino Acid Metabolism 
Metabolism of amino acids is also imperative for metabolic homeostasis, however 
only six amino acids (leucine, isoleucine, valine, asparagine, aspartate, and 
glutamate) can be metabolised by mitochondria (Wagenmakers, 1998; Duan et al., 
2017). Leucine and part of isoleucine support glucose uptake, mitochondrial 
biogenesis, and beta-oxidation, whilst inhibiting protein degradation as they are 
oxidised to acetyl-CoA and utilised in the TCA cycle (Duan et al., 2016). The carbon 
skeletons of the other amino acids are synthesised into glutamine or intermediates 
for the TCA cycle and also help maintain TCA cycle flux. 
NADH and FADH2 are reducing agents generated as bi-products during glycolysis, 
TCA cycle, beta-oxidation, and amino acid metabolism and are important metabolites 
as they power OXPHOS (Figure 1.3). 
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Figure 1.2: The biochemical reactions occurring during glycolysis, the tricarboxylic acid cycle, β oxidation and amino 
acid metabolism. Grey box indicates reactions occurring in mitochondria opposed to those in the cytoplasm. Image 
taken from http://www.indiana.edu/~oso/Fructose/MolBiol.html (Indiana University, 2014). 
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1.2.4 Oxidative Phosphorylation 
On the surface of the mitochondrial IMM sit heteromultimeric structures of proteins 
responsible for OXPHOS. OXPHOS is an aerobic system comprised of five multi-
subunit complexes, known as complexes I, II, III, IV, and V. The network is made up 
of over 70 subunits which are encoded for by the nuclear DNA (nDNA) (Pierron et al., 
2012). Complexes I to IV are responsible for the electron transport chain process, 
where electrons are used from NADH and are transferred across each complex 
through a series of chemical reactions, causing protons to be pumped out of the 
mitochondrial matrix into the intermembrane space, generating a proton motive force 
(PMF). Complex V is an ATP synthase responsible for chemiosmosis, which then 
uses the proton gradient generated to convert ADP in to ATP, which then is released 
into the cell (Figure 1.3).  
 
Figure 1.3: The five electron transport complexes of the oxidative phosphorylation respiratory chain. Blue: complex 
I (NADH/ubiquinone oxidoreductase), pink: complex II (succinate dehydrogenase), orange: complex III 
(cytochrome c reductase), green: complex IV (cytochrome c oxidase) and cream: complex V (ATP synthase). 
Through a series of reactions during oxidative phosphorylation electrons are transported across complexes. 
Complexes I, III and IV pump protons across the inner-mitochondrial membrane, generating a proton gradient which 
drives ATP synthesis. UQ means ubiquinol. Image taken from (Kühlbrandt, 2015). 
1.2.4.1 Oxidative Phosphorylation and Disease 
More than 150 distinct mitochondrial syndromes exist, and are predominantly caused 
by defects in the OXPHOS pathway (reviewed by (Leonard and Schapira, 2000; 
Wallace, 2005a). Changes to diet, and an imbalanced intake of carbohydrate, fat, 
and protein, introduce metabolic pressures which can alter mitochondrial metabolic 
sensitivity and lead to disease (Randle et al., 1963; Sas et al., 2016; Jørgensen et 
al., 2017). However, defects in the human OXPHOS system are the biggest cause of 
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metabolic disorders, with a prevalence between one in 5000 and one in 8000 births 
(Skladal et al., 2003; Thorburn, 2004; Jacobs et al., 2006). 
OXPHOS defects can be multisystemic or tissue-specific and predominantly affect 
high energy demanding tissues like muscle, brain, and the heart. Symptoms can also 
present at childhood or develop later in adulthood. Leigh Syndrome is considered the 
most typical example of an OXPHOS defect disease, where sufferers present with 
optic atrophy, hypotonia, ataxia, and dystonia before the age of two and often die a 
few years later. In addition to this disease, mitochondrial encephalopathy, lactic 
acidosis, and stroke-like episodes (MELAS), and myoclonus epilepsy with ragged red 
fibres (MERRF) are considered ‘classic’ mitochondrial diseases. More detailed 
information about the basis of these, and other, mitochondrial diseases can be found 
here (Smeitink et al., 2001; Thorburn, 2004; Jacobs et al., 2006).  
To diagnose mitochondrial disorders related to OXPHOS defects, skin or muscle 
biopsies are usually taken, and a series of biochemical and enzymology assays are 
performed to identify mitochondrial defects.  
1.2.4.1.1 Biochemical Assays 
Initial, minimally invasive tests can be performed in blood plasma, urine or 
cerebrospinal fluid (CSF) to identify the source of metabolic stress. Elevated lactate 
(cell redox state, normal <20) or pyruvate levels, as well as elevated amino acid 
levels such as alanine or proline, or TCA cycle intermediates, indicate inefficient 
aerobic respiration in mitochondrial disorders (Robinson, 2006; Haas et al., 2008; 
Magner et al., 2011). If initial tests suggest mitochondrial dysfunction, then skin or 
muscle biopsies are usually taken, and biochemical OXPHOS assays are performed. 
These tests assess the function of individual OXPHOS complexes, normally by 
directly measuring metabolite levels such as cytochrome c and coenzyme Q1 
(Thorburn et al., 2004; Haas et al., 2008).  
1.2.4.1.2 Histology/ Histochemical Assays 
Within each dysfunctional tissue, the quality and distribution of mitochondria are 
different. Histological and histochemical analyses of muscle or skin tissues are used 
to identify the severity of OXPHOS defects, and the presence of nuclear or 
mitochondrial-related genetic mutations. The traditional method for diagnosis 
involves using a modified Gomori trichrome stain to identify ragged red fibres (RRF), 
which stains proliferating mitochondria red in the subsarcolemmal space of muscle 
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fibre atrophy (Figure 1.4a). However, other histochemical assays are used to stain for 
NADH dehydrogenase, succinate dehydrogenase (SDH) and cytochrome c oxidase 
(COX) to assess complex I, II and IV activities of OXPHOS respectively (Figure 1.5b 
and c). The COX assay usually stains brown, and produces mosaic patterns for tRNA 
mutations and mitochondrial deletions (Figure 1.4c), whereas the SDH assay stains 
blue, and is useful to identify nDNA mutations, because all SDH subunits are coded 
for by nDNA (Figure 1.4b). The overlay of COX and SDH highlight the RRF staining 
(Bourgeois and Tarnopolsky, 2004; Tanji and Bonilla, 2007). Recently a quadruple 
immunofluorescence technique has been developed to detect complexes I and IV, 
whilst measuring porin to determine mitochondrial mass, as well as staining protein 
laminin to outline muscle cells (Grünewald et al., 2014; Rocha et al., 2015). 
In addition to staining, sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) and blue native polyacrylamide gel electrophoresis (BN-PAGE) are 
used in conjunction with Western Blotting to detect protein levels (Capaldi et al., 
2004; Schagger, 2006; Wittig et al., 2006). Full details of procedures to diagnose 
mitochondrial disorders are detailed here (Jacobs et al., 2006; Haas et al., 2008). 
 
Figure 1.4: [A] Modified Gomori trichrome staining identifies ragged-red fibres – the red deposits around 
subsarcolemmal or intermyofibrillar space (arrow) which depicts abnormal mitochondria in muscle. In the RRF 
(asterisk), histochemical analysis using [B] succinate dehydrogenase and [C] cytochrome c staining identify 
enhanced [B] succinate dehydrogenase/ complex two activity and [C] no cytochrome c/ complex four activity.  Image 
taken from (Smeitink et al., 2001). 
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Computer modelling has been used to predict the effects of enzyme deficiencies or 
defects in OXPHOS components on the TCA cycle and mitochondrial metabolic 
activity (Smith and Robinson, 2011; Zieliński et al., 2016), and it is apparent that 
mitochondria are adaptable; however there is a threshold effect in tissues where 
accumulation of dysfunctional mitochondria result in a range of heterogeneous 
disease (Zeviani and Antozzi, 1997; Breuer et al., 2013; Stewart and Chinnery, 2015)  
OXPHOS defects are not responsible for all metabolic diseases though. 
Mitochondrial quality and biogenesis are also imperative, and both are controlled by 
genetic makeup. 
 
Figure 1.5: An overview of the interconnecting systems which regulate OXPHOS complex formation and function. 
Mitochondrial biogenesis and regulation, membrane dynamics and composition, nucleotide transport and 
mitochondrial DNA maintenance and expression all contribute. Image taken from (Vafai and Mootha, 2012). 
1.3 Mitochondrial Quality Regulation and Biogenesis 
1.3.1 Fusion and Fission in Mitochondria 
Mitochondria are dynamic organelles and resemble their bacterial ancestors as they 
continually migrate bidirectionally around the nucleus using the cytoskeleton’s 
microtubules and actin filament tracks (Hollenbeck and Saxton, 2005). Mitochondria 
continually undergo fusion and fission with one another (Chan, 2012), and interact 
with other cellular components like the endoplasmic reticulum (ER) (Friedman et al., 
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2011; Lewis et al., 2016), undergoing biogenesis and autophagy to regulate 
mitochondrial populations.  
Mitochondrial morphology is dependent on cellular metabolic homeostasis, and 
mitochondrial mass is heterogeneous in each tissue, depending on their 
environmental demands (Rossignol et al., 1999; Mishra et al., 2014). For example, in 
skeletal-muscle mitochondria proficiently oxidise fatty acids, whereas in the brain 
they metabolise ketones, and in adrenal tissue mitochondria actively metabolise 
steroid hormones. Even within individual cells, mitochondria exhibit heterogeneity. In 
skeletal muscle, intermyofibrillar and subsarcolemmal mitochondria have different 
fuel sources and physiological reactions (Cogswell et al., 1993). 
Mitochondrial fusion usually occurs in cells with high metabolic demand, like muscle 
cells. Fusion allows bioenergetically efficient and electrically coupled systems to 
form, and respiratory machinery is shared to protect against high stress-induced 
energy demands or starvation (Figure 1.6) (Skulachev, 2001). Fusion uses GTPase 
machinery embedded in mitochondrial membranes and is controlled by mitofusins 1 
(Mfn1) and 2 (Mfn2), and Opa1. Mfns are located on the OMM and Opa1 is located 
on the IMM. As well as promoting fusion, Opa1 regulates cristae structure which 
contributes to mitochondrial bioenergetic behaviour (Mishra et al., 2014).  
Fission segregates mitochondria during times of low metabolic activity, splitting 
networks to allow smaller mitochondrial units to be transported to other areas of cells 
where metabolic demand is higher (i.e. in neurons) (Westermann, 2010) (Figure 1.6). 
Mitochondrial division sites are marked by ER tubules circling and constricting 
mitochondria. These sites are believed to form as a result of changes in the 
membrane composition or because of calcium-influenced constriction regulation 
(Friedman et al., 2011). Drp1 is an IMM dynamin-related protein which binds to the 
OMM, constricting and fragmenting mitochondria, causing them to undergo fission to 
become highly fragmented organelles (Westermann, 2012; Pyakurel et al., 2014).  
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Figure 1.6: Schematic representation of mitochondrial morphological network changes when cellular metabolic 
demands change. At times where respiratory activity is low, mitochondria are fragmented. As respiratory activity 
increases, mitochondria fuse to form more dynamic and integrative networks. Image reproduced from (Westermann, 
2012). 
As a result of undergoing fission, some mitochondria may lack replication machinery 
or sufficient mitochondrial DNA (mtDNA), which can result in the loss of the 
mitochondrion’s OXPHOS function, and loss of the membrane potential. This loss of 
membrane potential usually identifies damaged or poor quality mitochondria, and 
through the PINK1/Parkin signalling system, a mito-autophagosome forms around 
the mitochondria and they are selectively removed through a process known as 
mitophagy (Narendra et al., 2010; Youle and Narendra, 2011). 
Despite fission systems like PINK1/Parkin being important, especially in Parkinson’s 
disease development (Narendra et al., 2010; Pickrell and Youle, 2015), fusion 
machinery has been reported to be more important in managing mitochondrial 
biogenesis in yeast, C. elegans and differentiated muscle (Chen et al., 2010; Hori et 
al., 2011; Meyer and Bess, 2012). This is because when mitochondria, or 
mitochondrial DNA (mtDNA), are damaged, fusion events functionally compensate by 
sharing mtDNA and replication machinery, thereby maintaining replication and 
mitochondrial homeostasis. This suggests that the number of mtDNA are an 
additional, and important factor to manage mitochondrial biogenesis. 
1.3.2 Mitochondrial Biogenesis 
Mitochondrial maintenance is a fine balance between mitophagy and biogenesis, and 
is dependent on biochemical signalling and genetic response. Maintenance is 
especially important during differentiation (Westermann, 2010; Palikaras et al., 2015) 
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and constant mitochondrial production is imperative because cell division relies on 
mitochondrial concentration (Jajoo et al., 2016).  
As previously described, mitochondria are biochemically adaptive organelles and 
respond to changing cellular energetics. In muscle, increased levels of ATP-citrate 
lyase (ACL) cause increased cardiolipin levels in mitochondria without changing 
cardiolipin synthesis gene expression levels, and improves OXPHOS complex 
formation and mitochondrial respiration (Das et al., 2015). ACL was activated by 
insulin-like growth factor-1 (IGF-1) through the PI3K/AKT pathway, which is known to 
control mitochondrial mass – pathway details are provided here (Egerman and Glass, 
2014). 
Sirtuins (SIRT), a family of nicotinamide adenine dinucleotide (NAD)-dependent 
deacetylase proteins, are also known to control mitochondrial biogenesis. SIRT1 is 
the most well studied sirtuin and is mostly present in the nucleus. SIRT1 has been 
known to deacetylate PGC-1α and regulate gene expression of many metabolic-
related genes (Nemoto et al., 2005; Rodgers and Puigserver, 2007). SIRT5 on the 
other hand is extensively located in the mitochondria, but is also regulated by PGC-
1α (Buler et al., 2014). SIRT5 has recently been found to directly bind cardiolipin and 
regulate OXPHOS activity (Zhang et al., 2017). A more detailed overview of sirtuins’ 
effects on mitochondrial biogenesis is reviewed here (Sack and Finkel, 2012). 
Biochemical stimuli and genetic communication interconnect to oversee 
mitochondrial biogenesis. Mitochondria contain their own genome (mtDNA) which 
replicates in the mitochondrial matrix using about 80 nuclear-encoded replication 
proteins (Kenmochi et al., 2001). Mitochondrial biogenesis however requires the co-
ordinated import and regulation of around 1000-1500 nuclear encoded proteins, each 
being translated on cytoplasmic ribosomes before importation (O'Brien, 2002; Baker 
et al., 2007). Some precursor proteins are synthesised to contain positively charged 
N-terminal presequences which transverse with the IMM and OMM. Sorting and 
assembling machinery (SAM) on the OMM inserts β-barrel proteins to allow 
precursors to translocase through the membrane with the aid of the mitochondrial 
membrane potential and heat-shock protein 70 (Hsp70). Hsp70 is regulated by 
presequence translocase-associated motor (PAM) to send precursors into the matrix. 
Precursor proteins are then cleaved by matrix proteases and folded in the 
mitochondrial matrix. Important translocases of the OMM or IMM (TOM) and (TIM) 
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respectively regulate where each protein is directed and are major components of 
biogenesis (Jornayvaz and Shulman, 2010). 
The IMM is composed of boundary membranes, cristae, and cristae junctions. These 
subregions constantly remodel in response to stress and the cell's metabolic needs. 
Hoppins and colleagues, and von der Malsburg and colleagues, both discovered a 
large mitofilin/ Fcj1 protein complex on the IMM which acts as a scaffold for other 
proteins to assemble, regulating IMM morphology and organization. This complex 
also regulates importation of nuclear-encoded proteins needed to assemble IMS 
proteins, which is crucial for mitochondrial biogenesis (Hoppins et al., 2011; von der 
Malsburg et al., 2011).  
Pickard and colleagues also show specialised inter-membrane junctions interact with 
dense mitochondrial cristae junctions for co-ordinated mitochondrial biogenesis 
(Picard et al., 2015). This also involves a number of complex feedback systems 
between nDNA and mtDNA known as anterograde (nuclear to mitochondrial 
signalling), and retrograde (mitochondrial to nuclear) signalling. 
McDermott-Roe and colleagues functionally demonstrated that endocnuclease G 
(ENDOG) in cardiomyocytes boosts mitochondrial biogenesis as well as stimulating 
mtDNA synthesis and transcription. ENDOG increases biogenesis because it is 
directly controlled by oestrogen-related receptor alpha (ERRα) and peroxisome 
proliferator-activated receptor (PPAR) -γ coactivator-1α (PGC1α) transcription 
factors, which are key components in mitochondrial biogenesis. Expression of 
ENDOG also clusters with other mitochondrial and metabolic genes, and McDermott-
Roe et al. show ENDOG binding directly to mtDNA like mitochondrial transcription 
factor A (TFAM) (McDermott-Roe et al., 2011). ENDOG has also been seen to 
directly cleave nDNA and stimulate apoptosis (Li et al., 2001). 
ERRα is one member of a subfamily of nuclear receptors which are known to control 
expression of metabolic genes involved in glucose and glutamine metabolism, 
mitochondrial activity, lipid handling, and energy sensing. ERRs prefer to bind close 
to promoters of genes and work independently of oestrogen signalling, however are 
still important for biogenesis (reviewed by (Audet-walsh and Giguere, 2015)). In 
comparison, oestrogen receptors (ERs) have more strict binding domains and require 
the presence of oestrogen to regulate biogenesis (Chen et al., 2009). 
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Unlike ERs, ERRs are dependent on the presence of PGC1-α and PGC1-β (Gaillard 
et al., 2006; Gaillard et al., 2007). PGC-1α binds PPARs (which are also known to 
control lipid metabolism and sensing (Berger and Moller, 2002)), and activates a 
number of transcription factors including nuclear-respiratory factors (NRFs) and 
TFAM, which regulate mitochondrial replication and transcription (Virbasius and 
Scarpulla, 1994). PGC-1α was first discovered in adipose tissue determining the 
switch between white or brown adipose tissue through adaptive thermogenesis. This 
process involves increased mitochondrial biogenesis and uncoupling of respiration 
(Puigserver and Spiegelman, 2003). PGC-1α is activated by the catalytic AMP-
activated protein kinase (AMPK) alpha subunit via NRF-1 binding. AMPK is activated 
when intracellular levels of ATP decline and intracellular levels of AMP increase, 
such as during nutrient deprivation or hypoxia (Jornayvaz and Shulman, 2010). 
Mitochondrial biogenesis is not regulated by one sole pathway and Figure 1.7 gives 
an overview of the complex network of signalling molecules working together to 
balance both biogenesis as well as mitochondrial quality (Qi and Ding, 2012). 
 
Figure 1.7: Mitochondrial quality control is a fine balance between biogenesis and mitophagy, where both regulate 
overall mitochondrial numbers in a positive or negative manner respectively. Biogenesis and mitophagy occur to 
meet cellular metabolic demands. Activated AMPK activates mammalian Atg-1 homologues (ULK1) to prevent 
mitophagy and trigger mitochondrial biogenesis via PGC-1α-dependent transcription. When nutrients are available, 
mTOR represses mitochondrial biogenesis and ULK1-dependent mitophagy, thus affecting the net balance of 
defective mitochondria with new functional mitochondria. AMPK: AMP-activated protein kinase; mTOR: mammalian 
target of rapamycin; PGC-1α: PPARgamma coactivator 1-alpha; ULK1: the mammalian Atg1 homologs, 
uncoordinated family member (unc)-51: like kinase 1; ERK2: the extracellular signal-regulated protein kinase 2; 
U0126: ERK inhibitor. Reproduced from (Qi and Ding, 2012). 
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Like ERs and ERRs, mechanistic target of rapamycin (mTOR) also promotes 
mitochondrial function by selectively translating nuclear-encoded mitochondrial 
messenger RNAs (mRNA) by inhibiting the translation of initiation factor 4E (eIF4E)-
binding proteins (Ramanathan and Schreiber, 2009). As a serine/threonine kinase, 
mTOR has been evolutionarily conserved and responds to a number of stimuli, 
reviewed by (Morita et al., 2013), inhibits autophagy, and is important for anabolic 
processes like cellular growth. mTOR is active only when glucose is available (Figure 
1.8) (Chaube and Bhat, 2016). When glucose is limited, AMPK is activated and other 
nutrients like fat and amino acids are metabolised to generate ATP instead. This 
compensatory mechanism is beneficial to maintaining both mitochondrial and cellular 
homeostasis, but it is also detrimental when trying to treat cancer, as it contributes to 
tumorigenesis. This summarises the complex interplay between nutrient and genetic 
regulation of mitochondrial biogenesis pathways. 
 
Figure 1.8: AMPK regulation of mitochondrial biogenesis under different glucose conditions. When glucose is readily 
available, AMPK is inactive and mTOR is activated, causing mitochondrial biogenesis and cell proliferation. In 
glucose deprived conditions, AMPK is activated and mTOR suppressed causing other nutrients like fats and amino 
acids to be oxidatively metabolised to generate ATP. Image taken from (Chaube and Bhat, 2016). 
Radzvilavicius and colleagues used mathematical modelling to argue that the 
complexity behind regulating mitochondrial biogenesis and overall quality is what 
lead to eukaryotes having different gamete producing cells compared to prokaryotes, 
as prokaryotes are less likely to encounter problems and accumulate mutant or 
defective mitochondria (Radzvilavicius et al., 2016).  
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1.4 Mitochondrial DNA 
Reminiscent to their ancestors, mitochondria are unique organelles as they still 
contain their own genome (mtDNA). mtDNA is a double-stranded, circular molecule 
made up of a heavy and a light strand. The heavy strand has a higher molecular 
weight than the light strand due to differences in composition of purines (adenine and 
guanine) and pyrimidines (thymine and cytosine). The heavy strand contains more 
guanine than the light strand (Stewart and Chinnery, 2015).  
mtDNA was first sequenced in 1981 by a group led by Fred Sanger at University of 
Cambridge (Anderson et al., 1981) and was later revised in 1999 by a group at 
Newcastle University (Andrews et al., 1999). The revised Cambridge Reference 
Sequence (rCRS) of human mtDNA is now available online (www.mitomap.org). 
mtDNA consists of 16,569 bp which code for 37 mitochondrial genes, consisting of 
13 OXPHOS subunit-coding polypeptides, translated from 2 dicistronic and 11 
monocistronic mRNAs (Jones et al., 2008). The genome also codes for two 
ribosomal-RNAs (12S and 16S), 22 transfer-RNAs, and a non-coding D loop region 
(Anderson et al., 1981; Taylor and Turnbull, 2005; Malik and Czajka, 2013) (Figure 
1.9).  
 
Figure 1.9: Schematic image of the mitochondrial genome and each respective region of coding or control (D-loop) 
DNA. Image taken from (Chinnery and Hudson, 2013).  
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mtDNA is highly conserved (Brown et al., 1979; Yang et al., 2014) and is inherited 
uniparentally down the maternal line (Hutchison et al., 1974; Giles et al., 1980), as 
paternal mtDNA is engulfed by maternal autophagosomes then degraded by 
lysosomes soon after oocyte fertilisation (Al Rawi et al., 2011; Sato and Sato, 2011). 
During human migration, mtDNA developed stable polymorphisms which now define 
mtDNA as specific haplogroups (van Oven and Kayser, 2009). These haplogroups 
form complex tree-and-branch like structures and are detailed in an online phylotree 
(http://www.phylotree.org/).  
1.4.1 Haplogroups 
Haplogroups are defined as evolutionary inherited mtDNA mutations which have 
created stable population subgroups, but are separated by common sequence 
variation (Chinnery and Hudson, 2013). Haplogroups were thought to have arisen 
over 10,000 years ago from our ancestors who have had to adapt to new diets and 
environments after migrating from our origin in Africa (Mishmar et al., 2003; Cerezo 
et al., 2012; Pierron et al., 2012). In Africa, haplogroup L is most prevalent, whilst in 
Asia haplogroup M is the most common. In European populations, haplogroups H, V, 
J, T, M, I, X, W, U, and K are prevalent for over 95% of individuals (Torroni et al., 
1996). 
Each haplogroup has its own unique set of stable polymorphisms present in the 
coding region of the mitochondrial genome (Torroni et al., 1996), and contribute to 
both assembly of the respiratory chain (Pello et al., 2008), and the bioenergetic 
behaviour of mitochondria (Suissa et al., 2009; Hulgan et al., 2011). For example, 
haplogroup Uk has a strong effect on OXPHOS and changes energy output (Gomez-
Duran et al., 2010). Haplogroup variability and bioefficiency has also been shown to 
effect ageing and regulate mitophagy (Harman, 1956; De Benedictis et al., 2000; 
Gitschlag et al., 2016), and mitochondrial tolerance contributes to cell survival over 
time (Ballard et al., 2007).  
Knowing this, specific haplogroups have been identified to be susceptible to 
developing certain metabolic diseases. Haplogroup J has been seen to modulate the 
penetrance of Leber’s hereditary optic neuropathy (LHON) (Torroni et al., 1997; Rose 
et al., 2001; Hudson et al., 2007b), and haplogroups H and V are more susceptible to 
Parkinson’s disease (PD) (Pyle et al., 2005; Hudson et al., 2013a; Soto-Hermida et 
al., 2014), whereas haplogroup Uk increases Alzheimer’s disease (AD) risk (Lakatos 
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et al., 2010). On the other hand, haplogroups J, T, and K are seen to be protective 
against PD and osteoarthritis (Van Der Walt et al., 2003; Ghezzi et al., 2005; Hudson 
et al., 2013b), and haplogroups U and T protect against AD (Shoffner et al., 1993; 
Chagnon et al., 1999; Van Der Walt et al., 2004). What’s more, haplogroup J 
influences the progression of Aquired Immune Deficiency Syndrome (AIDS) whereas 
haplogroups UK and N* reduce that progression (Hendrickson et al., 2008). Hulgan’s 
team also demonstrated that mitochondrial genomics influence metabolic physiology 
in AIDS patients taking certain medications (Hulgan et al., 2011). 
1.4.2 Mitochondrial DNA Replication 
Like mitochondrial biogenesis, mtDNA replication is tightly regulated through a 
number of pathways to ensure mitochondria can accommodate to the changing 
metabolic demands in individual cells and tissues.  
mtDNA is packaged into spherical shaped nucleoids with a diameter ranging 
between 70 to 100 nm, along with a mixed array of replication proteins - TFAM, 
mitochondrial single-stranded DNA-binding protein (mtSSB), polymerase-gamma 
(POLG), SUV3L, SHMT, and DHX30 (Bogenhagen et al., 2008; Ylikallio et al., 2010). 
TFAM and mtSSB both act as replication and packaging enzymes (Takamatsu et al., 
2002). Nucleoids constantly change shape and distribution when mitochondria 
undergo fusion and fission but they are continually tethered to the IMM where 
replication occurs. 
The D-loop is the only non-coding region within mtDNA and contains the two 
transcription initiator sites PH and PL, as well as the heavy-strand replication origin 
(OH) (Kelly and Scarpulla, 2004). The D-loop forms a triple-stranded structure 
approximately 700 bp from the OH and is thought to regulate replication (Takamatsu 
et al., 2002). Both the heavy and light strand of mtDNA have individual replication 
origin sites (Montoya et al., 1982), however priming of mitochondrial replication 
occurs at the OH promotor on the light chain (Chang and Clayton, 1985), causing the 
heavy chain to be replicated first.  
Replication is believed to be conducted in an asymmetric manner, although a 
simultaneous model has been suggested (Holt et al., 2000). In the asymmetric model 
(Clayton, 1982), transcription is initiated at PL producing mRNA. At the three 
evolutionarily conserved blocks (CSB) I, II, and III, a decision is made to both cleave 
RNA and start DNA replication at OH, or continue with transcription (Clayton, 1987; 
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Kelly and Scarpulla, 2004) (Figure 1.10). TFAM, mtSSB, and POLG bind to mtDNA to 
initiate replication, and TFAM binds four mtDNA sites (two within the promotor origin 
and two downstream) (Suissa et al., 2009) which bends mtDNA into a U shape 
structure to allow the catalytic alpha-subunit of POLG to access the nucleotides and 
replicate them (Ropp and Copeland, 1996; Hallberg and Larsson, 2011). There is 
controversy about how much TFAM there is per mtDNA molecule - some suggest 
TFAM is up to 1700 fold higher than mtDNA (Takamatsu et al., 2002), whereas 
others suggest there is insufficient TFAM per molecule (Bogenhagen et al., 2008). 
Most genes being transcribed have polyadenylated tails added to signal stop codons. 
It is suggested that ribosomes recognise single-stranded start codons or structural 
sequences on the mRNA to translate them (Jones et al., 2008). 
 
Figure 1.10: An overview of the 37 genes and replication sites within mitochondrial DNA. The expanded section 
shows only the non-coding D loop containing the transcription initiation sites PL and PH and the heavy chain 
replication origin OH. Replication machinery polymerase gamma (POLG), transcription factor A (TFAM) and B (TFB) 
bind at PL to start transcription. RNA is synthesised until the machinery passes the evolutionarily conserved blocks 
(CSBs) where a decision is made to either continue transcription or change to DNA synthesis at OH. The blue line 
represents the heavy strand and the red line represents the light strand where replication is asymmetric in a 
bidirectional manner.  Reproduced from (Kelly and Scarpulla, 2004). 
1.4.2.1 Consequences of Errors in Mitochondrial DNA Replication 
mtDNA replication is independent to cell cycle nDNA replication and mtDNA avoids 
recombination (Elson et al., 2001). mtDNA is more susceptible to mutations than 
nDNA because mitochondria lack protective histones, lack DNA repair mechanisms, 
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and compartmentalise DNA in the presence of reactive oxygen species (ROS), 
causing oxidative damage (Wallace et al., 1987).  
ROS are predominantly generated at complexes I and III during OXPHOS and are 
usually neutralised by superoxide dismutase (SOD), catalase, glutathione (GPx), 
thioredoxin and protein thiol systems. However, errors in OXPHOS are known to 
cause an indirect imbalance of nucleotide pools, TCA-cycle flux, one-carbon cycle, 
and ROS signalling, as the PMF is directly altered (Vafai and Mootha, 2012). As a 
result, the downstream effect of affecting nucleotide recycling directly affects 
mitochondrial replication, and errors in nucleotide pooling can lead to the 
development of mitochondrial deletions, or mitochondrial depletion (Nikkanen et al., 
2016). The lack of DNA protection or repair machinery also contributes to mtDNA 
errors. It is predicted that 1 in every 200 women carries a mitochondrial mutation 
(Reddy et al., 2015).  
As a result of exposure to so many possible errors during transcription, defects in the 
mtDNA result in a variety of mitochondrial diseases, with characteristics varying from 
neurological disorders, to muscular weakness, and endocrine dysfunction.  
Mitochondrial diseases arise from large-scale deletions or single point mutations in 
mtDNA. Large-scale deletions are usually sporadic but severe and occur during 
repair or replication of the genome (Krishnan et al., 2008), causing diseases such as 
Pearson’s syndrome or Kearns Sayre Syndrome (Russell and Turnbull, 2014). Single 
point mutations on the other hand generate a greater degree and variety of clinical 
presentations in individuals depending on the mutation and prevalence of it in a given 
tissue. Mitochondrial myopathy and infantile onset spinocerebellar ataxia are 
mitochondrial depletion syndromes which develop as a result of mitochondrial 
deoxyribonucleoside triphosphate (dNTP) pooling defects (El-Hattab and Scaglia, 
2013; Nikkanen et al., 2016).  
Mitochondrial deletions and depletion syndromes are known to develop because of 
defects in nDNA autosomal genes, such as POLG, PEO1, and TFAM, which are 
involved in the maintenance of mtDNA. Thus emphasizing the importance of correct 
mtDNA: nDNA communication (Larsson et al., 1998; He et al., 2002; Nikkanen et al., 
2016).  
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1.5 Nuclear-Mitochondrial Intergenic Communication 
1.5.1 Evolution of Nuclear-Mitochondrial DNA 
During the evolutionary stages of the symbiote with the host cell, the majority of the 
original mtDNA migrated and incorporated into the nDNA in a process known as 
numtogenesis. Numtogenesis is thought to occur when double-stranded breaks 
develop in nDNA, and mitochondria close to the nucleus integrate their mtDNA to 
stabilise nDNA and prevent deletions (Hazkani-Covo and Covo, 2008). As a result, 
numtogenesis has been seen in more than 85 eukaryotic genomes, forming copies of 
the mtDNA in the host nDNA - known as nuclear-mitochondrial DNA segments 
(NUMTs) (Hazkani-Covo et al., 2010). In humans, approximately 64-100% of 
germline NUMTs have mtDNA identities, and have been evolutionarily conserved for 
tens of millions of years (Mourier et al., 2001; Dayama et al., 2014). NUMTs are not 
fully understood in disease, but it has been reported that there are more NUMTs in 
cancer cells than normal cells, and are thought to alter mitochondrial biogenesis 
(Srinivasainagendra et al., 2017). 
Rickettsia prowazekii is an intracellular parasite and is thought to be more closely 
related to mitochondria than any other microbe because both genomes code for TCA 
cycle and OXPHOS components, and report nuclear gene homologues in their nDNA   
(Andersson et al., 1998; Abhishek et al., 2011). Allen suggests that some genes are 
retained in the functional organelles’ DNA, like mitochondria, because they provide a 
reference location for nuclear-encoded genes to integrate to, facilitating rapid and 
direct regulatory coupling (Allen, 2003). 
Stoycheva and colleagues also showed that yeast retrotransposons, such as Ty1, 
integrated from mtDNA into nDNA depending on mitochondrial function. With 
mitochondrial haplogroups developing during human migration, it has been 
suggested that endosymbiotic relationships between nDNA and mtDNA are different, 
and are dependent on an individual’s mitochondrial biogenesis (Stoycheva et al., 
2007; Pierron et al., 2012). 
Using gel retardation, Ozawa’s group also identified that during transcription of 
specific OXPHOS genes, the same nuclear protein factors bound to similar upstream 
sequences in both mtDNA and nDNA, and thus suggested mitochondrial biogenesis 
is finely regulated at a transcriptional level (Suzuki et al., 1991). Taanman’s group 
however argued otherwise, as mtDNA concentration is specific for a given tissue, 
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depending on its metabolic demands and therefore is not comparable (Van den 
Bogert et al., 1993). These studies, combined with genomic studies which identify 
that NUMTs are different in size and continually edited, emphasise the complexity 
and uncertainty in nDNA and mtDNA intergenic communication (Albayrak et al., 
2016; Hazkani-Covo and Martin, 2017). 
1.5.2 The Importance of Nuclear-Mitochondrial DNA Communication for 
Mitochondrial Maintenance 
Mitochondrial maintenance requires finely coordinated communication between 
mtDNA and nDNA and relies on over 70 nuclear-encoded genes. The complex 
intricacies between the two genomes give rise to metabolic variation between 
individuals (Graham, 2012).  
Several key nDNA encoded genes are known to be important for mtDNA regulation. 
TFAM, mitochondrial transcription factors B1 and B2 (TFB1M and TFB2M), POLG, 
mitochondrial helicase (Twinkle or C10orf2), mtSSB, and adenine nucleotide 
translocator 1 (ANT1) are a few well-characterised genes involved in mtDNA 
maintenance (Kaukonen et al., 2000; Spelbrink et al., 2001; Van Goethem et al., 
2001; Kang et al., 2007; Ruhanen et al., 2010; Harvey et al., 2011; Müller-Höcker et 
al., 2011; Ngo et al., 2011; Milenkovic et al., 2013; Rajala et al., 2014). 
1.5.2.1 Mitochondrial Transcription Factors A, B1, and B2 (TFAM, TFB1M, and 
TFB2M) 
TFAM is a mtDNA binding protein that regulates packaging, expression and 
distribution of mtDNA, regulating both mtDNA replication and transcription (Lezza, 
2012). Kaufman’s group show TFAM binds multiple mtDNA as homodimers and 
compacts them in to nucleoids by bending the DNA backbone (Kaufman et al., 2007; 
Ngo et al., 2011). They suggest that TFAM alone is sufficient to organise mtDNA, 
however recent studies oppose this and show TFB2M is vital for initiation of 
transcription as it induces promotor melting, and TFAM alone is insufficient (Posse 
and Gustafsson, 2017; Ramachandran et al., 2017). TFAM is upregulated 
simultaneously with mtDNA amount in COX deficient cells, acting as a compensatory 
mechanism for OXPHOS demands (Konokhova et al., 2016). On the contrary, 
knocking out TFAM in mice causes mitochondria to become stressed and depletes 
mtDNA (Larsson et al., 1998; Ekstrand et al., 2004). 
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1.5.2.2 Polymerase Gamma (POLG) 
POLG is also crucial for mtDNA maintenance. POLG is the enzyme responsible for 
mtDNA replication and is comprised of a catalytic subunit (encoded by POLG), and 
an accessory subunit (encoded by POLG2) (Olson et al., 1995; Ropp and Copeland, 
1996). Increases in the catalytic subunit have not shown to increase mtDNA levels, 
however increasing the accessory subunit does (Lefai et al., 2000; Spelbrink et al., 
2000), suggesting the accessory subunit is more important (Carling et al., 2011). 
Defects in POLG result in a range of mitochondrial diseases (Van Goethem et al., 
2001; Jacobs et al., 2006).  
1.5.2.3 Mitochondrial Helicase (Twinkle) and Single Stranded Binding Protein 
(mtSSB) 
Both Twinkle and mtSSB improve the productivity of POLG (Farr et al., 1999; 
Ruhanen et al., 2010). Twinkle is the hexameric mtDNA helicase coded for by PEO1 
(Spelbrink et al., 2001), and mtSSB is a tetrameric single-stranded binding protein 
coded for by SSBP1. Twinkle binds to nucleoid membranes and recruits mtDNA to 
the IMM where it unwinds it for replication (Milenkovic et al., 2013; Rajala et al., 
2014), whereas mtSSB protects single-stranded DNA and promotes replication 
protein-protein interactions (Ruhanen et al., 2010). Loss of Twinkle in mice, or 
mtSSB in flies and yeast results in mtDNA depletion, as Twinkle is predicted to 
hydrolyse dNTPs which are needed to replenish nucleotide pools (Ruhanen et al., 
2010; Milenkovic et al., 2013; Nikkanen et al., 2016). 
1.5.2.4 Nucleotide Cycling Factors 
To prevent depletion, efficient mtDNA replication also relies on having sufficient pools 
of nucleotides. Two pathways regulate these pools – the cytosolic import pathway, 
which imports nucleotides made by cytosolic ribonucleotide reductase (RNR) into the 
mitochondria, and the mitochondrial salvage pathway, which converts nucleosides 
into nucleotides inside the mitochondria. Mutations in cytosolic import pathway genes 
TYMP (thymidine phosphorylase) and RRMB2B (alternative subunit to RNR), and 
mitochondrial salvage pathway genes TK2 (thymidine kinase 2) and DGUOK 
(deoxyguanosine kinase), all result in mitochondrial depletion syndromes (MDS) with 
varying phenotypes (Smeitink et al., 2001; Limongelli and Tiranti, 2002; Zeviani and 
Di Donato, 2004; Carling et al., 2011). 
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1.5.2.5 Other Genetic Regulators 
NRF1 and NRF2 have also been shown to actively regulate mtDNA, as NRF1 directly 
activates TFAM and binds PGC1 which also controls mtDNA maintenance (Virbasius 
and Scarpulla, 1994; Wu et al., 1999) as it induces approximately 600 genes whose 
products are mitochondrial related (Pagliarini et al., 2008). 
ANT1 codes for the protein which is a core structural element of the mitochondrial 
permeability transition pore and controls nucleotide concentrations in the cytoplasm 
by controlling nucleo-cytoplasmic signalling, which regulates energy consumption to 
OXPHOS. Mendelian mutations in ANT1 cause a rare, autosomal dominant 
mitochondrial-related disorder called progressive external ophthalmoplegia 
(Kaukonen et al., 2000; Limongelli and Tiranti, 2002). 
Changes in mitochondrial morphology also affect cellular homeostasis and a highly 
co-ordinated regulation system is required to maintain mitochondrial number and 
overall mitochondria quality. Suppression of mic60, a morphological mitochondrial 
protein which interacts with mtDNA and regulates D-loop structuring, has been seen 
to reduce mitochondrial transcription and OXPHOS by preventing TFAM and 
mitochondrial RNA polymerase from binding mtDNA (Yang et al., 2015). 
Furthermore, even though TFAM is required for mtDNA segregation (Kasashima et 
al., 2011), the ER has been seen to orchestrate where mtDNA replication occurs and 
how it is distributed to daughter cells (Lewis et al., 2016). 
Additionally, mitochondrial haplogroups have been seen to modulate mitochondrial 
transcription and replication. Haplogroup J for example has increased transcription 
compared to haplogroup H, because haplogroup J variants increase TFAM binding 
(Suissa et al., 2009). 
All these factors emphasise the co-ordinated interactions between mtDNA and nDNA 
to manage mitochondrial maintenance. Genetic variability gives rise to differences in 
mitochondrial quality as well as mtDNA levels. 
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1.6 Mitochondrial DNA Copy Number 
Mitochondrial DNA copy number (mtDNA CN) is central to mitochondrial vitality, 
affecting respiratory chain function (Robin and Wong, 1988; Wallace, 1999; Capps et 
al., 2003; Gu et al., 2013; Fukuoh et al., 2014) and mitochondrial biogenesis (Suzuki 
et al., 1991; Westermann, 2012; St. John, 2016). mtDNA codes for several structural 
OXPHOS subunits, therefore mitochondrial function and survival rely on adequate 
molecules of mtDNA to sustain OXPHOS capacity and maintain cellular homeostasis 
(Shoubridge and Wai, 2007; Van Blerkom, 2011). Changes in mtDNA CN can 
contribute to mitochondrial dysfunction, causing disease (Wallace, 1999; Silva et al., 
2000; Reinecke et al., 2009; Wallace, 2012; El-Hattab and Scaglia, 2013; Giordano 
et al., 2014; Pyle et al., 2015a). 
Each nucleoid contains 1-10 copies of mtDNA (Garrido et al., 2003; Bogenhagen et 
al., 2008) and cells can contain tens to hundreds of nucleoids, resulting in hundreds 
to thousands of copies of mtDNA being present in a single cell. The number of copies 
of mtDNA is known as mtDNA CN. mtDNA CN within each mitochondria is 
dependent on the genomic composition within each nucleoid; where an increased 
proportion of heteroplasmic mtDNA results in an increased number of nucleoids per 
mitochondrion (reviewed by Gilkerson, 2009). 
1.6.1 Mitochondrial DNA Copy Number Regulation 
mtDNA CN is highly balanced between synthesis and degradation for cellular 
maintenance. Despite key regulatory mechanisms not being known, a threshold 
hypothesis (Figure 1.11) has been suggested as a means for mtDNA CN regulation 
(Clay Montier et al., 2009), however mediator mechanisms are still unknown. 
 
General Introduction 
27 
 
 
Figure 1.11: Mitochondrial DNA copy number (mtDNA CN) threshold hypothesis, where mtDNA CN is thought to 
be regulated by thresholds. The lower the threshold of unknown factors triggers up regulation and activation of 
replication machinery mitochondrial single-stranded binding protein (mtSSBP), polymerase-gamma (POLG) and 
replicative helicase (Twinkle). Whilst higher thresholds result in the activation of unknown factors which lead to 
mitochondrial DNA degradation. Reproduced from (Clay Montier et al., 2009). 
Much of the literature has investigated biological factors directly regulating mtDNA 
CN, and amongst the complex signalling networks, protein quality, biochemical 
signalling, nutrient availability, and genetic expression all contribute to overall mtDNA 
CN regulation. However, no study to date has comprehensively investigated genetic 
variants causing mtDNA CN variation. 
1.6.1.1 Protein Quality 
Many of the functioning proteins required to maintain efficient mitochondrial and 
nuclear functions are iron-sulphur containing (Fe-S) clusters. Fe-S clusters 
predominantly form in the mitochondria, and are vital for mitochondrial function by 
regulating iron homeostasis.  Once assembled, Fe-S clusters are then translated into 
Fe-S proteins in the cytoplasm by binding to cysteinyl sulphurs of the associated 
proteins. Enzymes involved in the formation of Fe-S clusters are highly conserved 
across species, from bacteria to humans (Beinert et al., 1997). Fe-S clusters 
contribute to overall genome stability, both in the mitochondria and the nucleus, as 
they make up the majority of the replication, and maintenance proteins like DNA 
polymerases, primases, helicases, and glycosylases (reviewed by (Rouault and 
Tong, 2005; Paul and Lill, 2015)). Knowing this, it poses a confounding factor if 
protein quality might contribute to overall mtDNA CN regulation. 
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1.6.1.2 Biochemical Signalling and Stress Interference 
Calcium is involved in differentiation, especially during development. Variation in 
calcium concentration play a key role in mitochondrial biogenesis changes by 
activating the AMPK pathway through calcium-calmodulin-dependent protein kinase 
kinase 2 (CAMKK2) (Hawley et al., 2005; Woods et al., 2005). AMPK is activated 
when intracellular levels of ATP decline and intracellular levels of AMP increase, 
such as during nutrient deprivation or hypoxia. This is more commonly seen in 
ageing and increased ROS generation, resulting in decreased mtDNA CN levels 
(Gomes et al., 2013). This may be due to a secondary outcome as ROS homeostasis 
relies on the PMF to regenerate mitochondrial NADPH, and PMF drives ATP 
synthesis. PMF also indirectly controls biosynthetic reactions such as Fe-S cluster 
biogenesis and protein import (Vafai and Mootha, 2012). With age, OXPHOS 
efficiency decreases and contributes to more ROS production, therefore acting as a 
vicious cycle to mtDNA CN depletion with age (Fannin et al., 1999; Payne and 
Chinnery, 2015). 
1.6.1.3 Nutrient Availability 
mtDNA CN fluctuates in a number of metabolic diseases such as cancer, type 2 
diabetes mellitus (T2DM), obesity, and neurological disorders like PD. mtDNA CN 
was seen to directly negatively correlate to visceral fat accumulation in young adults 
(Lee et al., 2014b), and improved diet has been able to correct for this (Hernández-
Ríos et al., 2013). Lipid availability has been shown to affect mitochondrial 
biogenesis, clustering, and bioenergetics (Haemmerle et al., 2011; Kim and Park, 
2015), and has been known to affect the quality of mitochondrial membrane 
formation, thus affecting overall quality of mitochondria. This affects their metabolic 
capacity and impacts on signalling, resulting in mtDNA CN changes. 
Pyruvate metabolism has also been shown to contribute to OXPHOS efficiency and 
overall ATP production throughout the cell, and diseases such as cancer, PD, AD, 
and Leigh syndrome are all linked to specific enzyme deficiencies (Gray et al., 2014). 
In PD alone, PGC1-α genes, which are known to regulate pyruvate metabolism are 
under expressed, and overexpression of PGC1-α in mice has been shown to prevent 
dopaminergic neuron loss (Zheng et al., 2010). Furthermore, treatment with pyruvate 
in PD has been shown to alleviate ROS in dopaminergic cells, as pyruvate is a 
scavenger of ROS (Brand, 1997; Varma and Hegde, 2007). In addition to this, amino 
acids also contribute greatly to mitochondrial maintenance, where some of their 
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metabolites support immunological signalling events (reviewed by (Wu, 2009) and 
are known to contribute to disease development. Research is currently turning its 
attention to the human microbiome and its relationship with the nervous system 
(Sampson et al., 2016; Hill-Burns et al., 2017), suggesting nutrition may have an 
important influence on mtDNA CN regulation respectively. 
Furthermore, resveratrol has been shown to increase mitochondrial biogenesis by 
activating SIRT1 (Viscomi et al., 2011), and is suggested to be a good alternative 
therapy to stimulate biogenesis in those with defective mitochondrial function (Poole 
et al., 2015). 
1.6.1.4 Genetics 
Transcription of nuclear-encoded OXPHOS components are mediated by Nrf1 or 
Nrf2 and PGC1-α is the key mediator of mitochondrial biogenesis, increasing 
respiration in muscle cells by interacting with uncoupling protein-2 (UCP2) as well as 
interacting with transcription factors such as PPARs, thyroid hormone, glucocorticoid, 
oestrogen, and oestrogen-related receptors (ERRs) (Jornayvaz and Shulman, 2010; 
Nargund et al., 2015). PPAR pathway has also been involved in T2DM, inflammation, 
demyelination, and cancer (Berger and Moller, 2002). Thyroid hormone receptors 
which are activated by PGC1- α increase the transcription of mitochondrial genes 
(Weitzel et al., 2003). 
As well as PGC-1α, disrupting SIRT-1 expression rescues septic mice from death 
(Liu et al., 2015b). Pyle A. and colleagues showed mtDNA CN decreased in 
neutrophils in blood of septic patients (Pyle et al., 2010), suggesting SIRT-1 may also 
be a critical regulator of mtDNA CN. 
Stem cells especially require fine tuning, as their metabolic demands change during 
development and differentiation, resulting in continual dynamic shifts in mitochondrial 
biogenesis to accommodate to cellular stress (Harvey et al., 2011). Liver kinase B 
(Lkb1) plays an essential role in haematopoietic stem cell maintenance and 
progenitor outcome. Lkb1 regulates haematopoiesis via an mTORC1-independent 
pathway and E2F, Nrf1, and PPAR-γ motifs as the most significantly enriched 
promoter binding elements in the Lkb1 pathway. Lkb1 regulates PGC-1 expression 
and Lkb1 knockout (KO) resulted in decreased PGC-1 expression and decreased 
mitochondrial function. Surprisingly, they also saw an increase in mtDNA CN over 
time, as a compensatory mechanism (Gan et al., 2010). 
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Mitochondrial replication machinery like POLG, mtSSB, and TFAM are well 
characterised intermediates known to regulate mtDNA CN, however this is not the 
complete picture. TFAM overexpression directly increases mtDNA CN, and KO 
causes depletion. Despite these studies, the ratio of TFAM molecules to mtDNA CN 
is variable, ranging from one molecule per 10 to 1000 bp (Ekstrand et al., 2004; 
Carling et al., 2011). TFAM mRNA expression has also been seen to actively 
regulate the expression of sarco/ endoplasmic reticulum calcium ATPase 2 
(SERCA2), which is involved in the uptake of calcium in cardiomyocytes, by binding 
directly to its promoter region on nDNA. mtDNA CN was directly proportional to 
TFAM mRNA levels (Watanabe et al., 2011), however Suarez and colleagues 
showed calcium and TFAM alone are not responsible for mtDNA CN, as increased 
mtDNA CN did not decrease despite diminished SERCA2 expression when cells 
were over exposed to glucose (Suarez et al., 2008). mtSSB has been shown to 
correlate to mtDNA CN (Schultz et al., 1998). 
POLG is located on chromosome 15q24 and codes for a 139.5kDa protein (Ropp 
and Copeland, 1996). Mutations in POLG results in more mtDNA deletions in 
neurons, with increased mtDNA CN, and enhanced OXPHOS. This suggests POLG 
only regulates the quality of the DNA sequence but not overall mtDNA CN (Perier et 
al., 2013b). During differentiation, methylation of POLG at exon 2 decreased mtDNA 
CN expression, introducing epigenetic controls on mtDNA CN (Kelly et al., 2012; Lee 
et al., 2015). Kelly and colleagues support this idea by demonstrating, using different 
mouse tissues, that mtDNA CN could be manipulated by altering DNA methylation of 
POLG-α (Kelly et al., 2012).  
Further to this, mitochondrial-nuclear interactions have been seen to fluctuate during 
the cell cycle in yeast (Grand et al., 2014). Padovan-Merhar and colleagues used 
single-molecule multicolour mRNA fluorescence in situ hybridization to quantify the 
abundance of mRNA to cell volume in single-cell fibroblasts, and demonstrate that 
transcription activity can directly and globally be modulated by cellular volume, 
irrespective of nDNA content (Padovan-Merhar et al., 2014). This suggests mtDNA 
CN regulation may be regulated by physical pressures within the cell that have not 
been well studied. Figure 1.12 gives an overview of the known complex feedback 
systems overseeing mitochondrial maintenance and mtDNA CN changes. 
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Figure 1.12: An overview of the complex systems feeding mitochondrial and nuclear genomic communication 
regulating overall cellular integrity. Byproducts like ATP and NADH from the TCA cycle and OXPHOS contribute to 
epigenetic modifications of nuclear DNA, as well as being involved in gene expression and DNA repair mechanisms 
via the sirtuin, mTOR or AMPK pathways. Oxygen radicals contribute to redox signalling and gene expression 
controlled by p53 and NF-kB pathways. In addition to this, mitochondria synthesise macromolecules and flux 
calcium as well as generating MAVS. Abbreviations: ACL, ATP citrate lyase; AMPK, AMP-activated protein kinase; 
Acetyl CoA - acetyl coenzyme A; ERK - extracellular signal-regulated kinase; HATs - histone acetyltransferases; 
HDACs - histone deacetylases; Hif1-α - hypoxia inducible factor 1 alpha; MAT - methionine adenosyltransferase; 
MAVS - mitochondrial antiviral signalling protein; Met - methionine; mTOR - mechanistic target of rapamycin; NFκB 
- nuclear factor kappa B; PARP - poly(ADP-ribose) polymerase 1; SAM - S-adenosylmethionine; TCA - tricarboxylic 
acid cycle. Reproduced from (Shaughnessy et al., 2014). 
1.6.2 Homoplasmy and Heteroplasmy 
Primary mitochondrial diseases, i.e. those caused by a defect in mtDNA, do not 
follow a Mendelian pattern of inheritance, as they are inherited down the maternal 
line (Giles et al., 1980; Al Rawi et al., 2011). The severity and range of tissues 
affected by mitochondrial disease is very broad and can be individual to each 
sufferer. This is often dependent on the mitochondrial mtDNA heteroplasmy levels in 
each tissue. Tissues can contain cells which are both homoplasmic and 
heteroplasmic. Homoplasmy is when all of the mtDNA within a cell is identical and 
heteroplasmy is when cells contain wildtype and mutant mtDNA (Holt et al., 1990). 
Each tissue has a phenotypic threshold before biochemical manifestations result in 
clinical presentations (Chinnery et al., 1997; Chinnery et al., 2001; Gilkerson, 2009; 
Stewart and Chinnery, 2015). Thresholds are usually reported to be in the range of 
60-95% (Russell and Turnbull, 2014). 
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As mitochondria contribute so significantly to the metabolic requirements within cells, 
highly metabolically demanding cells and tissues are more prone to mitochondrial 
disease and the development of neurological, cardiological, and muscular disorders 
(Taylor and Turnbull, 2005). For example, neurons are more likely to accumulate 
mutations over time because they rarely replicate and have a high metabolic demand 
which leads to higher production of ROS through oxidative stress (Bender et al., 
2006; Kraytsberg et al., 2006; Hegde et al., 2012), whereas post-mitotic tissues are 
also more likely to accumulate rearrangement mutations exponentially with age 
(Coskun et al., 2003). 
Heteroplasmy regulation is still not fully understood, especially during early 
development, or why the presentation of mitochondrial disease symptoms appear in 
individuals at different ages to a varying degree of severity, even within families 
(Crimmins et al., 1993; Chinnery et al., 1997; Nesbitt et al., 2013). For example a 
mother could be mildly affected whereas her daughter/son could be severely affected 
(Ma et al., 2013). One suggestion why heteroplasmy remains during evolution is 
because neither wildtype or mutant mtDNA is capable of fully supporting cell viability 
(Gitschlag et al., 2016). 
Clark and colleagues, and Taylor and colleagues suggest certain mtDNA mutants are 
‘selfish’ and harbour in species, despite being harmful to cells, as they are co-
transmitted with wildtype mtDNA, giving rise to persistent heteroplasmy (Taylor et al., 
2002; Clark et al., 2012). To support this theory, Payne and colleagues use deep-
sequencing to confirm heteroplasmy is transmitted in low levels universally in both 
somatic and germline cells in healthy humans (Payne et al., 2013). Somatic 
mutations accumulate at different rates depending on the tissue type (Wallace, 1999; 
De Benedictis et al., 2000), and clonal expansion of these errors gives rise to varying 
degrees of neurological and age-related diseases. 
1.6.3 Mitochondrial DNA Copy Number between Tissue Types 
Every cell and tissue type has their own metabolic requirements and limitations 
meaning mtDNA levels are not static and can fluctuate, especially during 
development (Michaels et al., 1982). In the early stages of oogenesis, mtDNA levels 
escalate severely before significantly decreasing before implantation and gastrulation 
(Shoubridge and Wai, 2007; Kelly et al., 2012). The decrease in mtDNA enables 
undifferentiated cells to establish their mtDNA CN threshold before differentiating into 
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their respective cells with specific OXPHOS requirements. Lee and colleagues 
suggest this is regulated through methylation profiles and use DNA 
immunoprecipitation techniques to demonstrate that POLG-A (which directly 
modulates mtDNA CN) is highly methylated in pluripotent cells and correlates to low 
mtDNA CN levels, whereas terminally differentiated cells have much higher mtDNA 
CN but lower levels of methylation at POLG-A (Lee et al., 2015). The cell type and 
function normally dictates the mtDNA levels due to metabolic demand and has also 
been suggested to be controlled by mitochondrial-targeted nucleases (Reddy et al., 
2015).  
High energy demanding cells like muscle and neurons usually have high mtDNA CN, 
whereas low energy demanding cells like spleen and endothelial cells contain low 
mtDNA CN (Dickinson et al., 2013; Malik and Czajka, 2013). Mammalian sperm cells 
contain very little mtDNA CN compared to oocytes. Sperm contain about 50-75 
copies per cell versus thousands of copies per cell in oocytes (Michaels et al., 1982; 
Wallace et al., 1999), although these values have been reported to be higher 
depending on cell cycle stage (Harvey et al., 2011). Leucocytes have a high turnover 
rate and a lower metabolic demand than neurons, so they tend to accumulate less 
mtDNA mutations and have consistent mtDNA CN (Pyle et al., 2010). White blood 
cells also contain less mtDNA than skeletal muscle, heart or kidney, and mtDNA CN 
is regulated independently to cytochrome c or citrate synthase activity levels (Van 
den Bogert et al., 1993). Embryonic stem cells are also highly proliferative yet contain 
low mtDNA CN, suggesting mtDNA CN is not solely a product of OXPHOS demand 
(Facucho-Oliveira et al., 2007). 
Varying mtDNA CN between tissue types is believed to be a result of differential 
expression of the three different isoforms of PPARs which are coded by individual 
nuclear genes (Berger and Moller, 2002). Lehman and colleagues also suggest 
PGC1 partners like NRF1 and PPAR control levels of expression of mitochondrial 
maintenance components, and are responsible for mtDNA CN variability between cell 
types (Lehman et al., 2000). 
1.6.4 Importance of Regulating Mitochondrial DNA Copy Number 
In addition to homoplastic and heteroplasmic genetic variability, mtDNA CN has been 
argued to be the most important determinant of cellular homeostasis, especially 
during development (Shoubridge and Wai, 2007; Van Blerkom, 2011). Varied 
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heteroplasmic segregation has been observed through the bottleneck effect 
(Bogenhagen et al., 2008), and nucleoid organisation has been proposed to 
contribute to this, using dynamic fusion and fission to ensure nucleoids have access 
to a larger pool of replication machinery (Bogenhagen et al., 2008). Albeit not fully 
understanding how mitochondria are selected for or assigned to daughter cells 
through the bottleneck effect, Jarou and colleagues demonstrate that mitochondria 
and mtDNA nucleoids in yeast segregate and distribute evenly during mitosis relative 
to the cellular cytoplasm (Jajoo et al., 2016), suggesting mtDNA CN segregation may 
be due to chance. 
Research still has many unanswered questions surrounding the bottleneck effect, 
clonal expansion, and disease development - all of which strongly rely on mtDNA CN 
regulation but are not fully understood. mtDNA CN has been investigated as a 
biomarker of disease in a number of tissues for several years – reviewed by (Malik 
and Czajka, 2013). While mtDNA CN differences are being reported in diseases such 
as cancer, T2DM, and HIV; mtDNA levels are inconsistent between studies, 
suggesting mtDNA CN may be an indicator of disease progression instead of being a 
disease biomarker. 
Intergenic communication has been suggested to be similar to quorum sensing, like 
their bacterial ancestors would do to synchronise gene expression (Ng and Bassler, 
2009). With mtDNA CN being shown to act as both a regulator and a protector of 
disease development and progression, it is important to identify how mtDNA CN is 
regulated intergenomically, especially in relation to disease. 
1.7 Mitochondrial DNA Copy Number in Health and Disease 
Alterations in mitochondrial function contribute to the development of many 
metabolic-related diseases like T2DM (Silva et al., 2000) and cancer (Reznik et al., 
2016), and contribute to the development of complex mitochondrial diseases such as 
Leigh’s syndrome, Leber’s hereditary optic neuropathy (LHON), MERRF, and MELAS 
(Wallace et al., 1988; Santorelli et al., 1993). Additionally, new research is showing 
that mitochondrial defects contribute to autoimmune disorders (Mills et al., 2017; 
Sadatomi et al., 2017). As reviewed by Malik and Czajka, mtDNA CN has been 
measured in numerous metabolic diseases, across multiple tissue types, and mtDNA 
levels are inconsistent across studies (Malik and Czajka, 2013). 
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Mitochondrial biogenesis has been reported to be different between sexes (Khalifa et 
al., 2017; Mauvais-Jarvis et al., 2017) and increasing evidence is emerging to show 
that biogenesis efficiency and response to insult is more important to disease 
progression. Increased levels of mtDNA are being reported to offer a protective effect 
against developing disease. For example, Wang et al. (2012) report that survivors of 
lepromatous leprosy had a significantly higher mtDNA CN than those who did not 
recover (Wang et al., 2012). A similar study on rats also showed neuro-protective 
mechanisms being induced as mtDNA CN increased, despite an increase in mtDNA 
deletions in dopaminergic neurons being present which were similar to levels 
observed in PD patients (Perier et al., 2013a). Cancer patients have been reported to 
have increased mtDNA CN too whereas HIV patients have depleted mtDNA CN (Lan 
et al., 2008). 
1.7.1 Cancer 
Cancer is a term used to describe a disease which involves abnormal and 
uncontrollable cell proliferation in a specific tissue which has the ability to 
metastasise and spread to other parts of the body. Over 200 types of cancer exist but 
breast, lung, prostate, and bowel cancer are the most common (NHS, 2017) and in 
the UK, more than one in three people will develop cancer in their lifetime. 
Cancer cells require functional mitochondria to survive. This has been shown in a 
number of studies using p0 cell lines (reviewed (Wallace, 2012)). The relationship 
mtDNA has with cancer development has also been extensively researched in 
current literature. In NCBI, a search consisting of ‘cancer and mtDNA’ returns 8345 
results, of which 318 results cover ‘mtDNA copy number’.  
Despite the number of studies, the literature continually reports differences in mtDNA 
CN, even in the same type of cancer (Malik and Czajka, 2013; Reznik et al., 2016). 
Xia et al. suggest mtDNA CN changes in females with cancer because of their 
menstruation status, causing changes in expression of oestrogen receptors (Xia et 
al., 2009), although the range in their results is high and there are no controls. Mi J. 
and colleagues meta-analysed literature results from 38 independent study groups 
and  reported mtDNA CN was “consistently overrepresented in cancer cases relative 
to controls in both genders”, but again, their results do not support this as mtDNA CN 
was also reported to be lower in certain cancers compared to their controls, 
supporting that seen in Malik’s review (Mi et al., 2015). This may be because many 
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different types of cancer studies were combined and subjects were very 
heterogeneous, where ethnic origin, sample type, and gender comparisons were not 
consistent. 
In colorectal cancer alone, risk has been associated with mtDNA CN and mortality, 
and affected individuals have amplified aberrant somatic mtDNA mutant variants 
(Polyak et al., 1998; Srinivasainagendra et al., 2017), however most cancers are so 
heterogeneous and physiologically complex these associations are not 
representative across all cancer types. mtDNA CN changes have been suggested to 
be an indication of disease stage, but this is undetermined (Lee et al., 2005). 
1.7.2 Mitochondrial Depletion Syndromes 
Similar to cancer, when mtDNA becomes unstable and depleted, it leads to disease 
(Lee et al., 2005). Profound depletion of mtDNA CN also results in MDS causing 
severe myopathic, encephalomyopathic and hepatocerebral clinical symptoms 
(Alberio et al., 2007), and can often result in organ failure or death (Wallace, 1999). 
MDS signs have also presented in amniotic fluid leading to early-infant death (Blake 
et al., 1999). 
Mitochondrial neurogastrointestinal encephalopathy (MNGIE) disease is a well 
characterised condition that often develops by the age of 20 and affects several parts 
of the body, especially the digestive tract and nervous system (Zeviani and Di 
Donato, 2004). MNGIE develops from a mutation in the TYMP gene which codes 
thymidine phosphorylase, which contributes to reduced dNTP pools, resulting in 
decreased mtDNA CN as mtDNA replication is disrupted (González-Vioque et al., 
2011; Vondráčková et al., 2014). The importance of dNTP pools nucleotide turnover 
and their direct effect on mtDNA CN regulation have been studied in non-diseased 
models elsewhere too (Nikkanen et al., 2016). A group in Barcelona originally 
published that treatment with dNTPs was not a suitable pharmacological approach to 
relieve MDS symptoms, however recently republished results appear to suggest 
otherwise (González-Vioque et al., 2011; Cámara et al., 2014). 
As previously discussed, any Mendelian defects in autosomal nuclear genes 
affecting nuclear-mitochondrial communication affect the stability of mtDNA by 
disrupting mtDNA replication and maintenance, and result in decreased mtDNA CN 
and stressed mitochondria (Limongelli and Tiranti, 2002). 
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1.7.3 Parkinson’s disease 
PD is an age-related neurodegenerative disease which affects around 0.3% of the 
global population, and about 1% of people over 60 years of age (Nussbaum and 
Ellis, 2003; de Lau and Breteler, 2006). PD is the second most common 
neurodegenerative disease after AD and develops as a result of dopamine deficiency 
in the striatum from the loss of dopaminergic neurons in the substantia nigra pars 
compacta (Winklhofer and Haass, 2010). 
mtDNA CN has been reported to be significantly lower in peripheral blood, substantia 
nigra pars compacta, and CSF in individuals with PD (Pyle et al., 2015a; Pyle et al., 
2015b). Increased mtDNA CN on the other hand (and improved OXPHOS) were 
reported to serve neuroprotective effects in substantia nigra pars compacta 
dopaminergic neurons induced with PD-like insults (Perier et al., 2013b), however 
this could be haplogroup specific. Whilst haplogroups have been seen to regulate the 
bioenergetics of mitochondria (Gomez-Duran et al., 2010; Gómez-Durán et al., 2012) 
no large-scale study has investigated the differences in mtDNA CN between 
haplogroups until now. 
Stressed mitochondria are also reported to leak mtDNA into the cellular cytosol and 
stimulate expression of immunological-factors such as interferons and antiviral 
signalling-elements (West et al., 2015). Recent studies have shown circulating, cell-
free mtDNA (ccf-mtDNA) in the CSF of PD patients, and microglia-associated 
inflammation is a pathological marker of PD, and is considered a potential 
therapeutic target (Kannarkat et al., 2013; Su and Federoff, 2014; Wang et al., 2015). 
1.7.4 Type 2 Diabetes Mellitus 
T2DM is a long-term metabolic disorder where insufficient insulin is produced, 
resulting in elevated blood sugar levels (NHS, 2017). T2DM is one of the most 
prevalent, chronic diseases worldwide, estimated to affect 347 million people globally 
in 2011 (Danaei et al., 2011). T2DM is managed with medication and lifestyle 
changes, and has been proven to be reversed when individuals follow a calorie 
restricted diet (Lim et al., 2011). 
Similar to cancer, T2DM is a very complex and heterogeneous disease, and both 
nDNA and mtDNA genes are associated with developing it (Brandon et al., 2005; 
Flannick and Florez, 2016; Fuchsberger et al., 2016). mtDNA CN has also been 
investigated in T2DM, and like cancer, mtDNA CN is both higher and lower in 
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affected individuals than controls (Malik and Czajka, 2013). Low mtDNA CN has 
been considered to contribute to the development of T2DM as it is related to insulin 
resistance, age of onset and complications, and was recently considered a relevant 
predictor of T2DM (Cho et al., 2017), however their diseased group was very small 
(containing 103 individuals). 
What’s more is diabetes is often a symptom of mitochondrial-related diseases such 
as MELAS, and maternally inherited diabetes and deafness (MIDD), and develops as 
a result of accumulated mutant mtDNA with age (Maassen et al., 2004) (Taylor and 
Turnbull, 2005; Jacobs et al., 2006). 
As insulin is known to activate a cascade of metabolic signals within eukaryotes, it is 
difficult to determine whether mtDNA CN is disease-causing or if it is a biomarker of 
disease and physiological stress enforced on cells. 
1.7.5 Leber’s Hereditary Optic Neuropathy 
LHON is the most common mitochondrial disease, affecting 1 in 14000 men 
predominantly harbouring either the 3460G>A mutation in MT-ND1, 11778G>A 
mutation in MT-ND4 or 14484T>C mutation in MT-ND6, all which code for subunits 
forming complex I of the OXPHOS system (Man et al., 2003; Pello et al., 2008).  
LHON is a homoplasmic disease characterised by rapid onset of sudden bilateral 
blindness due to retinal ganglion cell loss, predominantly in the papillomacular bundle 
(Hudson et al., 2007a; Russell and Turnbull, 2014). Visual loss is more likely to occur 
in haplogroup J individuals when harbouring the 11778G>A or 14484T>C mutations, 
or haplogroup type K individuals when harbouring the 3460G>A mutation. 
Contrariwise, haplogroup H has protective effects for those with the 11778G>A 
mutation (Hudson et al., 2007b).  
Only 40% males and 10% females who harbour one of the mutations develop LHON, 
showing incomplete penetrance. Also, approximately 12% of those LHON patients 
are heteroplasmic to both wild-type and mutant DNA, and heteroplasmy has been 
seen to reduce the risk of blindness (Man et al., 2003). Hudson G. et al. showed 
there is no difference in LHON development irrespective of age or X-inactivation, so 
the X chromosome cannot  be the sole cause of incomplete penetrance (Hudson et 
al., 2007a). This in combination with Giordano and colleagues work suggesting there 
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are other contributing factors to disease penetrance, and this may involve 
mitochondrial biogenesis regulation. 
Giordano and colleagues measured mtDNA CN and mass in patients affected by, or 
carriers of, LHON mutants, and reported that carriers had a significantly higher 
mtDNA CN than those of their affected relatives (Giordano et al., 2014). This 
suggests that the excessive mitochondrial biogenesis may have protective effects to 
compensate for the pathogenic mtDNA mutants, and carriers must have cellular 
mechanisms regulating mitochondrial biogenesis more efficiently. This emphasises 
the need to better understand mtDNA CN and nuclear communication in regulating 
mitochondrial biogenesis. 
Genetic regulation of mtDNA CN is not well understood across populations, and most 
genetic studies published are in a small number of individuals or cell lines, which is 
not representative of larger populations. Therefore we designed a study which was 
able to develop on these limitations. 
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1.8 Genome-wide Association Studies 
Although being a significant component of this study, an exhaustive description of 
genome-wide association studies (GWAS) is beyond the scope of this thesis. Rather 
I present a brief description aimed at guiding the reader through some of the key 
points. Interested readers should refer here for further information (Burton et al., 
2007; McCarthy et al., 2008; Wang et al., 2010a; Barsh et al., 2012). 
GWAS are studies where large sets of genetic DNA markers (normally SNPs) are 
genotyped and examined in large populations of unrelated individuals, to identify 
common genetic variants which are associated with a specific phenotype. Published 
GWAS have rapidly increased since genotyping microchips were introduced in the 
early noughties (Figure 1.13A), and from comparing diseased and control cohorts, 
hundreds of thousands of SNPs have been identified to be associated with disease 
across most human genomes (Figure 1.13B) (The Wellcome Trust Case Control 
Consortium, 2007; Hindorff LA. et al., 2017; MacArthur et al., 2017). In combination 
with the international HapMap project, which introduces human chromosome 
variability across different populations, it has made it easier to investigate genomic 
differences by continent too (Belmont et al., 2005). 
GWAS are becoming increasingly popular as the cost of whole-genome sequencing 
has decreased and the availability of genotyping data across large populations has 
increased. As a result, GWAS provide a powerful platform to invest complex traits. 
From the thousands of published GWAS papers, many of which have identified 
genetic variants, both rare and common, causing complex traits and disease (Khor et 
al., 2011; Nalls et al., 2014; Schizophrenia Working Group of the Psychiatric 
Genomics, 2014; Coffee et al., 2015; Farh et al., 2015; Shungin et al., 2015; 
Fuchsberger et al., 2016; Long et al., 2017). 
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Figure 1.13: [A] Number of published genome-wide association studies from 2005 to 2013 and [B] the EMBL GWAS 
catalogue showing all published SNP-trait associations (with p-values ≤5.0 x 10-8) to their respective chromosome 
location. Each linear grey box corresponds to a single chromosome. Coloured spots represent individual SNPs and 
their location. Images from (Hindorff LA. et al., 2017; MacArthur et al., 2017). 
Despite the power and popularity of GWAS, they still contain limitations. To start, 
most GWAS use data generated from DNA extracted from blood. This provides 
limitations when researching diseases which are tissue specific. Additionally, 
common, yet very heterogeneous traits like height, cancer, and T2DM are still not 
fully understood, despite the number of GWAS performed (Aulchenko et al., 2009; 
Marouli et al., 2017). This is believed to be a result of traits not being 100% heritable. 
For example T2DM is only believed to be 10% heritable (Billings and Florez, 2010; 
Marouli et al., 2017). Further to this, GWAS are used to study common genetic 
variants across populations, and are limited to identify rare variants (Figure 1.14), 
and reproducibility of GWAS results are very few compared to the number of studies 
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published. Furthermore they only identify genetic loci which are associated to a 
phenotype, they do not explain the full biological picture as to how the phenotype 
presents. Thus GWAS are only a preliminary indicator of risk loci and suggest where 
to start further biological investigations (McCarthy et al., 2008; Ward and Kellis, 
2012). 
 
Figure 1.14: Image summarising the challenges behind detecting selection bias. Image produced by (McCarthy et 
al., 2008). 
GWAS, like most research methods, have their limitations, however their power to 
identify genetic variability and associations to phenotypes across populations is also 
very advantageous. As literature shows, regulation of mtDNA CN is still not fully 
understood, but is an important system to understand, especially in preventing, 
treating and understanding disease. The literature is flooded with biological evidence 
explaining the complex physiological networks known to cause mtDNA CN changes, 
no definitive study has identified key genes involved in intergenomic communication 
between nDNA and mtDNA in regulating mtDNA CN.  
As mtDNA CN is an easily measured phenotype that has been reported to be 
regulated by common genetic variants, we chose to investigate mtDNA CN by 
performing the largest ever GWAS using actual measures of mtDNA CN as the 
phenotype. Using both mtDNA and nDNA SNP genotyping data in thousands of 
healthy, unrelated, European individuals we have investigated mtDNA CN variability 
across populations and have identified potential nuclear and mitochondrial candidate 
genes involved in mtDNA CN regulation. In addition to this we have investigated the 
accuracy of current methods to measure mtDNA CN and have identified technical 
alterations that need to be considered for future research surrounding mtDNA CN.  
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1.9 Hypothesis 
mtDNA CN is not one trait because mtDNA CN varies between cells, tissues, and 
organs depending on cellular metabolic demand and mitochondrial quality. It is 
therefore rational to hypothesise that mtDNA CN is under significant genetic control 
and is influenced by biological factors. In this study, mtDNA CN will be quantified 
from DNA extracted from white blood cells (WBC) in peripheral blood, and this single 
phenotype will be representative of mtDNA CN regulation in a preliminary study to 
identify genetic and biological factors associated with mtDNA CN changes. By 
performing genetic association tests, using population variants in large well-
characterised cohorts, it will be possible to determine nuclear and mitochondrial DNA 
variants modulating mtDNA CN. Additionally, the effects biological factors such as 
age, gender, blood composition, oestrogen, and mtDNA deletions have on mtDNA 
CN levels will be determined. 
1.10 Aims 
1. Compare and contrast existing mtDNA real-time PCR quantification methods, 
assessing the validity of existing methods in multiple large population cohorts 
2. Use real-time PCR (informed by (1)) to investigate the degree of mtDNA CN 
variation in DNA samples extracted from WBC of unrelated, healthy individuals 
in multiple large, European populations. 
3. Compare mtDNA CN in large populations to demographic data such as age 
and gender, and phenotypic measurements such as blood composition to 
identify significant confounding factors modulating changes. 
4. Conduct a large-scale GWAS analysis of mtDNA CN in multiple large 
population cohorts, comparing nDNA and mtDNA genotypes to mtDNA CN as 
a quantitative trait locus (QTL). 
5. Perform an imputation analysis of (4) to increase our genetic resolution and 
power, and compare established imputation methods. 
6. Perform a replication of (4) in a second large, unrelated cohort - utilising 
existing genotype data available through the Avon Longitudinal Study of 
Parents and Children (ALSPAC) through collaboration with Dr Santiago 
Rodriguez (University of Bristol, UK) and further increase our statistical power. 
7. Identify key genetic loci associated with mtDNA CN changes in WBC to 
investigate in future functional studies to help further understand the biological 
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mechanisms managing mitochondrial maintenance, and contributing to 
disease development. 
Secondary Aims 
8. Explore the degree of protection oestrogen has on mitochondrial biogenesis 
by comparing mtDNA CN in pre- and post-menopausal European women. 
9. Examine the quality of mtDNA in large populations of healthy individuals, and 
investigate the prevalence of mitochondrial deletions and their effect on 
mtDNA CN.
  
 Materials and Methods 
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2.1 Cohorts 
2.1.1 Cohort One - United Kingdom Blood Service Cohort 
In 2005, the Wellcome Trust Case Control Consortium (WTCCC) set up a UK 
national repository in collaboration with the UK Blood Service (hereafter referred to 
as the UKBS cohort) (compromised of NHS Blood Transplant in England, Scottish 
National Blood Transfusion Service in Scotland, and Welsh Blood Service in Wales) 
where 3622 anonymised samples of DNA and mononuclear cells were collected. In 
order to donate blood to these services, a series of strict regulations have to be met; 
where current health and medications being taken, travel outside of the UK, tattoos 
and piercings, and pregnancies are all limitations (NHS Blood and Transplant., 
2017). These strict restrictions ensure that the blood samples provided are ‘normal’, 
and representative of a typical, healthy individual in the population. 
2.1.2 Cohort Two - In house ‘Cohort Two’ 
As part of ongoing work in our laboratory, I had access to 2000 DNA samples from 
1000 mother and child pairs which had been stored at -80ºC from previous work. 
2.1.3 Cohort Three – Avon Longitudinal Study of Parents and Children Cohort 
A collaboration was organised between Dr Santi Rodriguez’s group, in the School of 
Social and Community Medicine at University of Bristol, UK, and Newcastle 
University to use the Avon Longitudinal Study of Parents and Children (hereafter 
referred to as ALSPAC) cohort as a replication cohort for the work in this study. 
ALSPAC is a prospective cohort of mothers and their children, and was established 
to understand how genetics and environment influence health and development in 
parents and children. 5461 ALSPAC mothers were used in this study. 
2.2 DNA Sample Source 
2.2.1 Control Cohort One - UKBS 
Blood was collected from healthy, unrelated donors across 12 Great British health 
regions between September 2005 - February 2006 by UK National Blood Services 
(UKBS). Participant’s ages ranged between 17-69 years, and were recruited based 
on sex and geographical region. Informed consent was obtained from all participants 
in accordance with protocols approved by the Peterborough & Fenland Local 
Research Ethics Committee in September 2005 (approval 05/Q0106/74) (Burton et 
al., 2007). 
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2.2.2 Cohort Two - In house ‘Cohort Two’ 
DNA was sourced from 1000 mother and child pairs living in the former county of 
Avon, UK. Age and gender of samples was not available however mothers could be 
assumed to be female. 
2.2.3 Cohort Three – ALSPAC 
From 1st April 1991 to 31st December 1992, 13,761 women were recruited during 
pregnancy (aged between 16-43 years), who were living in the former county of 
Avon, UK (Boyd et al., 2013; Fraser et al., 2013). For the duration of the study, these 
women had to complete up to 20 detailed questionnaires, and had data extracted 
from their medical records. Full details of all the data available is accessible online: 
http://www.bris.ac.uk/alspac/researchers/data-access/data-dictionary/. Ethical 
approval for the study was obtained from the ALSPAC Ethics and Law Committee 
and the Local Research Ethics Committees. 
2.3 Generation of Blood Count Data 
2.3.1 Cohort One - UKBS 
Full blood count data (FBC) was generated from ethylenediaminetetraacetic acid 
(EDTA) anticoagulated samples of blood drawn from the pouches of the donation 
collections. Samples were transferred at room temperature to a single testing centre 
in Cambridge, and FBC measurements were generated 16-24 hours after 
phlebotomy using a Beckman‐Coulter GenS (Gieger et al., 2011).  
The Beckman‐Coulter GenS uses fluorescence-activated cell sorting technology to 
separate and count each cell type. Individual cells are forced through an aperture 
tube by a vacuum which is suspended in some conductive liquid. As each blood cell 
moves through the aperture tube and liquid, the blood cell insulates the current and 
causes an increase in electrical resistance which generates a pulse. Each pulse 
correlates to one cell, and the size of the resistance recorded is proportional to the 
cell volume (Figure 2.1). Following this, a series of low and high frequency currents 
measure internal and external cell volume respectively, and then light and the 
addition of cell-specific staining dyes identify individual white blood cells (WBC) 
(Beckman Coulter Inc., 2011a). Total WBC count was reported in thousands of cells 
per ml, and sub-type specific cell counts were calculated by multiplying the proportion 
of the WBC count, comprised by each cell type, by the total WBC measure (Nalls et 
al., 2011). Blood data consisted of raw cell counts and whole blood cellular 
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proportions for basophils, eosinophils, lymphocytes, monocytes, and neutrophils, as 
well as platelet (PLT) count, white blood cell (WBC) count, red blood cell (RBC) 
count, haematocrit (HCT), haemoglobin (HB), mean corpuscular volume (MCV), 
mean corpuscular haemoglobin (MCH), and mean corpuscular hemoglobin 
concentration (MCHC) (Table 2.1). 
 
Figure 2.1: Diagram of how the Beckman-Coulter GenS counts and sizes individual blood cells. Image taken from 
(Beckman Coulter Inc., 2011a). 
Through collaboration with Professor Willem H Ouwehand at University of 
Cambridge, FBC data was provided to Newcastle University for 2617 UKBS samples. 
FBC data is numeric; however absolute basophil, and absolute eosinophil counts 
included a verbose output stating “less than 0.01”. These data (n=2337, and n=180 
respectively) had a value of zero assigned because I was unable to determine the 
exact values. Absolute basophil count was then considered a binary trait, because 
values were either zero or 0.1. Details of the FBC abbreviations, and their respective 
units were provided in the Beckman Coulter manual, and are detailed in Table 2.1 
(Beckman Coulter Inc., 2011b). 
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Table 2.1: Details of full blood count measurements generated by a Beckman‐Coulter GenS, and the number of 
UKBS samples with blood count data. Data was provided by Willem Ouwehand at University of Cambridge. 
2.3.2 Cohort Two - In house ‘Cohort Two’ 
Blood count data was not available for cohort two samples. 
2.3.3 Cohort Three – ALSPAC 
The Accessible Resource for Integrated Epigenomics subset (ARIES) is a sub-study 
of ALSPAC including 1018 mother-child pairs. Blood cell proportions were estimated 
from DNA methylation data which was derived from maternal antenatal samples as 
part of the ARIES study (Relton et al., 2015). Samples were assayed on the Illumina 
Infinium HumanMethylation450 BeadChip (450K) array (Illumina, San Diego, 
California, USA), and cell count composition was determined from this estimated data 
using the Houseman method (Houseman et al., 2012). Data was processed using the 
‘estimateCellCounts’ function of the R Bioconductor package ‘minfi’ (Jaffe and 
Irizarry, 2014; Richmond et al., 2015), and 546 ALSPAC mothers had estimated cell 
count data generated. 
2.4 DNA Extraction and Preparation 
2.4.1 Cohort One - UKBS 
Following blood sample collections, DNA extractions were performed by the 
respective collection centre. Blood was separated by density centrifugation, and 
white blood cells were retained to perform phenol DNA extractions. Following 
extraction, samples were provided to the Wellcome Trust Sanger Institute where 
DNA quality was assessed on a 0.75% agarose gel, and was quantified using the 
PicoGreen® method to ensure heavily degraded samples were eliminated. DNA was 
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eluted in 10 mM Tris and 100 μM EDTA and normalised to 200 ng/μl per well. Full 
details are provided here (Burton et al., 2007). 
2.4.2 Cohort Two - In house ‘Cohort Two’ 
1889 DNA samples (89% maternal and 100% child) were extracted from blood, and 
111 (11.1%) maternal samples were extracted from buccal samples. DNA extraction 
and preparation details were not available at the time of writing (Table 2.2). 
2.4.3 Cohort Three – ALSPAC 
DNA was extracted from blood using a phenol-chloroform method (Fraser et al., 
2013). 5461 maternal samples were used in this study, of which 2056 samples 
(37.6%) had been extracted from whole blood and 3405 samples (62.4%) had been 
extracted from white cell pellets (Table 2.2). 
2.5 Nuclear DNA SNP Genotyping 
2.5.1 Cohort One - UKBS 
UKBS DNA samples with a concentration of ≥50 ng/μl-1 which showed limited or no 
degradation were initially genotyped with a MassEXTEND™ and/or iPlex® assay 
which arrays up to 38 SNPs to experimentally confirm the sex of each sample. DNA 
samples that were initially arrayed successfully were sent for whole genome SNP 
genotyping. As part of the WTCCC2, SNP genotyping was performed on the Illumina 
1.2M Duo array (Illumina, San Diego, California, USA), and were aligned to the 
NCBI36-hg18 human genome build (Wellcome Trust Sanger Institute, 2008). 
1,152,686 variants were successfully genotyped for 2735 individuals of European-
ancestry and was then provided to Newcastle University to be analysed. 
2.5.2 Cohort Two - In house ‘Cohort Two’ 
Cohort two samples were not genotyped for nuclear DNA SNPs. 
2.5.3 Cohort Three – ALSPAC 
All ALSPAC maternal DNA samples were genotyped on the Illumina Human660W-
Quad array (Illumina, San Diego, California, USA) at the Centre Nationale du 
Génotypage. Genotypes were called using Illumina GenomeStudio® and were 
aligned to the NCBI36-hg18 human genome build. 526,688 variants were 
successfully genotyped. This data was then analysed at University of Bristol.
  
 
 
 
 
 
 
Table 2.2: Summary of cohorts used in this study and their demographic details including ratio of males to females, age range (years), DNA source, the cell type DNA was extracted 
from, the DNA isolation method used, and the results chapters where each respective cohort was used for data analysis. UKBS: United Kingdom Blood Service Cohort. ALSPAC: Avon 
Longitudinal Study of Parents and Children Cohort. WB: Whole Blood. WBC: White Blood Cells. * indicates samples were extracted from blood samples but blood cell type was unknown 
and buccal samples were excluded for all analysis.  
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2.6 Mitochondrial DNA Genotyping and Sequencing 
2.6.1 Cohort One – UKBS 
UKBS samples were genotyped as part of the WTCCC2 (Wellcome Trust Sanger 
Institute, 2008) using the Illumina 1.2M Duo SNP array (Illumina, San Diego, 
California, USA) which contains 138 mitochondrial SNPs (mtSNPs) (Hudson et al., 
2014). 132 mtSNPs were successfully genotyped (>99.0%) for 2735 individuals. This 
data was then provided to Newcastle University to be analysed. 
2.6.2 Cohort Two - In house ‘Cohort Two’ 
Cohort two samples were not genotyped, and instead were outsourced to Source 
BioScience™ in Nottingham, UK, where mtDNA was sequenced using mitochondrial-
targeted Illumina next generation DNA sequencing. Library preparation was 
performed using PCR amplicon sequencing using a Fluidigm Access Array™ 
(Fluidigm, UK). Unique sequence-specific tags and sample-specific bar codes were 
added to each DNA sample and were pooled together and run on a single 
sequencing experiment. Using Access Array Integrated Fluidic Circuits™ (Fluidigm, 
UK), approximately 100 amplicons were designed (150 to 200 bp) to cover the entire 
mtDNA. 48 PCR reactions were performed on each sample. Following this, PCR 
products were purified and quantified before sequencing by an Agilent 2100 
Bioanalyzer™ (Agilent, UK). PCR products were then pooled in equal volumes to 
create one PCR product library which were then purified by AMPure XP beads 
(Beckman Coulter Life Sciences, Buckinghamshire, UK). PicoGreen fluorimetry was 
used to quantify the PCR product library prior to loading for DNA sequencing. DNA 
sequencing was finally performed on the Illumina HiSeq 2000™ array (Illumina, San 
Diego, California, USA) using 100 bp paired-end reads, generating 150 million 
clusters. 
1627 samples (81.35%) had their mtDNA successfully sequenced. Raw data files 
were then provided to Newcastle University and were subjected to the same 
bioinformatic analysis. Raw FASTQ reads were filtered using FASTQ (version 0.11.2) 
and were aligned to both the rCRS (NM_012920.1) and the human reference 
genome (hg19) using BWA (version 0.7.12). Duplicate reads were then removed 
using Picard (version 1.130). Subsequent variant calling was performed using 
VarScan (version 2.3.7). Coverage of the mtDNA was generated for all samples and 
samples <99% coverage were removed from further analysis. FASTQ files generated 
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using the 180-amplicon enrichment strategy (Source BioScience™ Nottingham, UK) 
were subjected to primer trimming using cutadapt (version 1.14). Exact primer 
sequences were then trimmed from the 5’ end of each FASTQ read and subsequent 
trimmed FASTQ files were subjected to the same bioinformatic pipeline as above. 
This data was then used to assign mitochondrial haplogroups (section 5.3.2.2). 
2.6.3 Cohort Three – ALSPAC 
ALSPAC maternal samples were not genotyped directly for mtSNPs. Instead, 9912 
ALSPAC children (male and female) were genotyped on the Illumina HumanHap550-
Quad array, by 23andme, the Wellcome Trust Sanger Institute (Cambridge, UK), and 
the Laboratory Corporation of America (Burlington, North Carolina, USA), and were 
called for using the Illumina GenomeStudio®. The Illumina HumanHap550-Quad 
genotyping array contained 7554 custom mitochondrial probes, targeting 2824 
unique mtDNA positions. 
Using PLINK (version 1.07) software (Purcell et al., 2007), individuals were excluded 
from further analysis for having incorrect gender assignments, minimal or excessive 
heterozygosity (<0.320 and > 0.345 for the Sanger data and <0.310 and >0.330 for 
the LabCorp data), disproportionate levels of individual missingness (>3%), evidence 
of cryptic relatedness (>10% IBD), and being from non-European ancestry (as 
detected by a multidimensional scaling analysis seeded with HapMap 2 individuals). 
EIGENSTRAT analysis revealed no additional obvious population stratification and 
genome-wide analyses with other phenotypes indicate a low lambda) (Price et al., 
2006). 8365 unrelated individuals passed QC analysis.  
Prior to QC, all heterozygous genotype calls (i.e. heteroplasmy) were set to missing 
using PLINK (Purcell et al., 2007). Genotype calls obtained from each probe were 
compared to the human mitochondrial database of non-pathological mitochondrial 
sequence variants (http://www.hmtdb.uniba.it:8080/hmdb/) to ensure that known 
allelic variants were being called. Probes were excluded in cases where genotype 
calls were not represented in the revised Cambridge Reference Sequence (rCRS) 
reference or one of the known allelic variants. Probes with an overall call rate of 
<95% were excluded prior to analysis. The genotyping concordance of the remaining 
probes was investigated by comparing the genotype calls in 445 replicate samples. 
With the exception of probe failure (i.e. missing data), a 100% genotyping 
concordance rate was obtained for each probe. All probes with a failure rate of >5% 
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in the replicate sample were further excluded. A total of 1062 probes passed QC for 
the batch that was genotyped by Laboratory Corporation of America (n=7590), whilst 
629 probes passed QC for the batch genotyped by the Sanger Institute (n=775). 308 
of these probes overlapped with each other across the two arrays. Where there were 
several probes genotyping the same mtDNA variant, we used a consensus of the 
probes, and removed all duplicates. This resulted in 105 unique variants, all with 
MAF >0.01 (29 with MAF >0.05). mtDNA genotyping QC analysis was conducted by 
Dr Mesut Erzurumluoglu as part of his PhD with Dr Santi Rodriguez in the School of 
Social and Community Medicine at University of Bristol. 
As mtDNA is inherited maternally (Hutchison et al., 1974; Giles et al., 1980), 
ALSPAC children mtSNP genotypes were assigned to their respective ALSPAC 
mothers. 3405 mothers were assigned mtSNP genotyping data. 
2.7 DNA Samples in Newcastle 
2.7.1 Cohort One - UKBS 
3091 genomic DNA samples were provided to Newcastle University, in two panels, 
from the University of Cambridge, and NHS Blood and Transplant UK, as part of the 
WTCCC2 control group (Wellcome Trust Sanger Institute, 2008). Upon arrival, 
samples were diluted to 2 ng/μl in nuclease-free water in 96 PCR well plates 
(translucent shell) (BioRad, Hertfordshire, UK) and were covered with aluminium- foil 
sealing tape (StarLab, Milton Keynes, UK), and then were stored at -20°C until use. 
All patient identities were anonymised. 
2.7.2 Cohort Two - In house ‘Cohort Two’ 
Before analysis, all 2000 samples were defrosted from -80°C and diluted to 5 ng/µl in 
nuclease-free water in 384-well PCR plates (clear shell, white well) (BioRad, 
Hertfordshire, UK) and were covered with aluminium- foil sealing tape (StarLab, 
Milton Keynes, UK), and then were stored at -20°C until use. 
2.7.3 Cohort Three – ALSPAC 
All ALSPAC DNA samples were handled and analysed at University of Bristol. No 
ALSPAC DNA samples were analysed at Newcastle University, except in the 
quantitative real-time PCR (qPCR) assay validation test detailed in section 4.4.3.1. 
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2.8 Measuring Mitochondrial DNA Copy Number using Quantitative PCR 
2.8.1 Cohort One - UKBS 
In order to perform a QTL GWAS, using mtDNA CN as the phenotype, mtDNA CN 
was measured in all UKBS samples using qPCR. Beta-2-microglobulin (B2M) was 
used as the nuclear reference and housekeeping gene to correct for the number of 
cells in each extract, and mitochondrially encoded NADH-ubiquinone oxidoreductase 
core subunits 1 and 4 genes (MT-ND1 and MT-ND4 respectively) and mitochondrially 
encoded 16S ribosomal RNA (MT-RNR2) acted as references for the number of 
mtDNA molecules. MT-ND1 and MT-ND4 were multiplexed with B2M in a triplex 
reaction for all qPCR assays, except where an ‘alternative’ qPCR assay is detailed in 
section 5.3.6 and MT-RNR2, MT-ND4, and B2M were multiplex together (Table 2.8). 
As MT-ND4 is diametrically opposed to MT-ND1 and MT-RNR2 in mtDNA, we could 
calculate mtDNA CN relative to each gene. This acted as a quality control step for 
calculating mtDNA CN and helped monitor the quality of the mtDNA, and the 
efficiency of the run, and enabled the calculation of mitochondrial deletion levels (He 
et al., 2002; Krishnan et al., 2007; Grady et al., 2014a; Rygiel et al., 2015). 
2.8.1.1 Polymerase Chain-Reaction (PCR) and Control Template Preparation 
To generate standard curves, templates of each gene of interest were generated to 
validate amplification specificity and assay efficiency. Primers were designed to B2M 
(Genbank accession ID: NM_004048), MT-ND1, MT-ND4, and MT-RNR2 (Genbank 
accession IDs: MT-ND1, MT-ND4, and MT-RNR2 NC_012920). Templates were 
generated from control DNA which was extracted from whole blood from healthy, 
anonymous donors using the Illustra® DNA extraction kit (GE Healthcare Life 
Sciences, Buckinghamshire, UK). Control DNA was amplified by PCR using gene-
specific primers (Integrated DNA Technologies, Leuven, Belgium) in Table 2.3.
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Table 2.3: A list of forward and reverse primer 5’-3’ sequences used to generate standard template from control 
DNA using PCR.  PCR templates amplified are nuclear gene beta-2-microglobulin (B2M); (Genbank accession ID: 
NM_004048) and mitochondrially encoded NADH-ubiquinone oxidoreductase core subunits 1 and 4 genes (MT-
ND1 and MT-ND4 respectively) and mitochondrially encoded 16S ribosomal RNA (MT-RNR2) (Genbank accession 
IDs: MT-ND1, MT-ND4, and MT-RNR2 NC_012920). All primers were provided by Integrated DNA Technologies in 
Leuven, Belgium. 
Reaction conditions for PCR master mix were: 0.4 µM of each forward and reverse 
primer, 1x MyTaq™ reaction buffer (contains MyTaq™ buffer, dNTPs, MgCl2, 
enhancers and stabilizers), and one unit MyTaq™ DNA polymerase (Bioline, London, 
UK). All reactions used Ambion® nuclease free water (Thermo Fisher Scientific, 
Loughborough, UK) and were set up on ice. Approximately 50 ng/µl DNA was loaded 
into the PCR mastermix, which was then amplified on an Applied Biosystems® Veriti® 
96 well thermal cycler in Applied Biosystems® MicroAmp® optical 96-well PCR plates 
(both Life Technologies, Paisley, UK). The PCR cycling conditions were; initial 
activation at 95°C for one minute, then 30 cycles of denaturation at 95°C for 15 
seconds, annealing at 61°C for 15 seconds, and extension at 72°C for 10 seconds, 
followed by a final extension step at 72°C for 10 minutes. Negative controls were 
used to eliminate any potential contamination. 
2.8.1.2 Agarose Gel Electrophoresis 
Following the amplification of standard DNA templates, agarose gel electrophoresis 
was used to visually inspect and isolate the template PCR products. Multiple PCRs 
(typically n=10) for each template product were pooled and combined with 20% v/v 
orange G loading buffer (Orange G powder, 50% v/v glycerol (both Sigma Aldrich 
Company Ltd, Dorset, UK) and 50% v/v water). A negative PCR reaction was mixed 
50% v/v with orange G loading buffer, as was a 1Kb DNA ladder (Promega, WI, 
USA). Positive template PCR products were loaded into a single large well on a 1% 
agarose gel (1% w/v agarose (Bioline, London, UK) in 1x tris-acetate-EDTA (TAE) 
buffer (5 Prime GmbH, Hilden, Germany), and 0.4 mg/µl UltraPure™ ethidium 
bromide (Invitrogen, Paisley, UK)). Ladder and negative products were loaded in 
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separate wells. Agarose gels were electrophoresed at 65 V for 90 minutes in 1x TAE 
buffer. 
2.8.1.3 Template PCR Purification and Quantification 
Agarose gels were imaged and analysed using the UVP GelDoc-It™ imaging system 
and UVP Launch Vision Works LS software (UVP, Cambridge, UK). The pooled 
template PCR products were first sized against the molecular weight DNA ladder to 
check that the template PCR products were specific, and of the correct size. 
Template PCR products were then isolated from the gel using the UVP Syngene 
Ultraviolet Gel Tray (UVP, Cambridge, UK). The gel extract was purified using 
QIAquick Gel Extraction Kit; micro-centrifugation protocol – according to 
manufacturer’s instructions (QIAGEN, Manchester, UK). Extract concentrations were 
calculated by a Nanodrop 2000 UV-Vis spectrophotometer (Thermo Fisher Scientific, 
Loughborough, UK) using Nanodrop 2000 software, measuring concentration/µl and 
260/280 nm wavelength ratio with a baseline correction of 340 nm. Template PCR 
product purity was assessed using both the 260/280 ratio, where measurements 
between 1.8 and 2.0 were accepted, and the 260/230 ratio, where measurements 
between 2.0 and 2.2 were accepted. The DNA concentration was used to calculate 
DNA copy number of the template with Equation 2.1. Template DNA was stored 
at -20°C until use. 
𝐶𝑜𝑝𝑦 𝑛𝑢𝑚𝑏𝑒𝑟 = [𝐶 ÷ (𝐿 𝑥 2 𝑥 330)] 𝑥 𝐴 
Equation 2.1: Formula used to calculate DNA copy number (copies/μl) once template DNA was extracted and 
concentration was determined by Nanodrop 2000 UV-Vis spectrophotometer (Thermo Fisher Scientific, 
Loughborough, UK) in ng/µl. C is DNA concentration in nanolitres (10-9), L is amplicon length in base pairs and A 
is Avogadro’s constant (6.023 x 10^23). 
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2.8.1.4 Quantitative Real-Time PCR 
To quantify mtDNA CN, qPCR was used. Quantifying MT-ND1, MT-ND4, and B2M in 
a triplex qPCR reaction is an established method to determine mtDNA CN (Pyle et 
al., 2010; Pyle et al., 2015a; Pyle et al., 2015b), therefore B2M, MT-ND1, and MT-
ND4 were measured in every UKBS sample (n=3091). Every qPCR run had a calibre 
control, a known deletion sample and a standard curve on the same plate with UKBS 
samples. Control DNA was the same as for PCR reactions (section 2.8.1.1). Calibre 
deletion DNA was extracted from trans-mitochondrial cybrids (provided by Professor 
CT Moraes, Miller School of Medicine, University of Miami, U.S.A.). The cybrids 
contained a single, large-scale mitochondrial deletion spanning the major arc from 
positions m.7982 to 15504 (Diaz et al., 2002) at a heteroplasmy level of 
approximately 70%. Control and deletion DNA were diluted to 1/100 in water. To 
generate a standard curve, each standard template (B2M, MT-ND1, and MT-ND4) 
was freshly prepared and multiplexed in water to a single dilution of 1.00 x 109 
copies/μl, and then serially diluted from 108 to 102 copies/μl. Standard curves were 
analysed simultaneously with calibre DNA and samples. 
The triplex qPCR mastermix consisted of 0.2 µM of each TaqMan™ probe 
(Integrated DNA Technologies, Leuven, Belgium) (Table 2.4), 1x iTaq™ Universal 
Probes Supermix (BioRad, Hertfordshire, UK), and 0.3 µM of each forward and 
reverse primer (Integrated DNA Technologies, Leuven, Belgium) (Table 2.4). All 
reactions used Ambion® nuclease free water (Thermo Fisher Scientific, 
Loughborough, UK) and were set up on ice. qPCR products generated from the 
primers were B2M, MT-ND1, and MT-ND4 (Table 2.4). 2 ng of DNA was loaded with 
9 µl of mastermix on to each Hard-Shell®, thin wall 384 PCR plate (clear shell, white 
well), and was covered with a Microseal® ‘B’ seal plate seal (both BioRad, 
Hertfordshire, UK). All DNA samples, control and deletion calibres, and standards 
were measured in triplicate (Grady et al., 2014b). 
qPCR reactions were amplified on a CFX384 Touch™ Real-Time PCR Detection 
System (BioRad, Hertfordshire, UK), and the conditions were; initial denaturation 
95°C for three minutes, followed by 40 cycles of denaturation at 95°C for 10 seconds, 
and annealing and extension at 62°C for one minute.
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Table 2.4: A list of forward and reverse primer 5’-3’ sequences and TaqMan™ probe sequences with their respective fluorophores for triplex quantitative PCR reactions. Genes 
amplified in all UKBS and ‘Cohort Two’ samples are nuclear gene beta-2-microglobulin (B2M) and mitochondrially encoded NADH-ubiquinone oxidoreductase core subunits 1 and 4 
genes (MT-ND1 and MT-ND4 respectively). As detailed in section 5.4.6.2, mitochondrially encoded 16S ribosomal RNA (MT-RNR2) was quantified instead of MT-ND1. All primers and 
probes were synthesised by Integrated DNA Technologies in Leuven, Belgium. 
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2.8.1.5 Calculating Relative Mitochondrial DNA Copy number 
After each qPCR run, initial analysis was performed using Bio-Rad CFX Manager 3.0 
software. First, calibre DNA triplicates were checked for each amplicon, and 
replicates greater than 0.5 Ct difference were removed. For the first run, each 
fluorophore baseline threshold was set to an optimum, where standards were running 
parallel (Figure 2.2). Thresholds for MT-ND1-HEX and MT-ND4-Cy5 were set 
accordingly to B2M calibre Ct values. Average Ct values were noted for both control 
and deletion DNA calibre samples for each amplicon, and differences calculated. In 
every experiment following this, the reaction baseline threshold was then set to the 
control calibre DNA for each amplicon, and the difference between the average Ct for 
each amplicon for the control calibre was consistent (Table 2.5). Additionally, 
standard dilution replicate measurements were checked. The strongest and weakest 
standard dilution curves, and replicates greater than 0.5 Ct difference were removed 
to generate the most efficient standard curve for each fluorophore. A minimum of four 
standards dilutions were used for each amplicon, and samples had to sit within the 
selected standard curve range to have mtDNA CN calculated (Figure 2.3). 
Standard curve efficiencies were only accepted above 90% for each fluorophore and 
negative control contamination above 35 Ct values. The Ct value for each standard 
dilution was not allowed to drift over one Ct from run to run as well, as this indicated 
standard templates were degrading (Table 2.5). Samples were analysed once 
thresholds were set and standard curves were running efficiently and parallel to each 
other. Sample replicates for each fluorophore were checked and replicates greater 
than 0.5 Ct difference were removed. Raw data was exported in to Microsoft Excel 
2010, and mtDNA CN was calculated for each sample using Equation 2.2. Overall 
mtDNA CN calculated is an average of each individual replicate delta Ct value (Table 
2.6), and is reported as copies per cell (copies/cell). 
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑀𝑖𝑡𝑜𝑐ℎ𝑜𝑛𝑑𝑟𝑖𝑎𝑙 𝐷𝑁𝐴 𝐶𝑜𝑝𝑦 𝑁𝑢𝑚𝑏𝑒𝑟 =  2(2^-∆Ct) 
Equation 2.2: Calculation used to calculate mitochondrial DNA copy number (mtDNA CN) for each sample 
measured using qPCR. -∆Ct is the Ct difference between the mitochondrial reference gene (either MT-ND1, MT-
ND4 or MT-RNR2) Ct and B2M Ct for each replicate. Overall mtDNA CN is an average of each 2(2^-∆Ct) replicate 
value. Relative mtDNA CN is recorded as copies/cell. 
3028 UKBS samples (97.96%) successfully had relative mtDNA CN measured 
(n=1512 males, n=1516 females).   
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Table 2.5: An overview of how standard optimum efficiencies were assigned and baseline thresholds were set to 
the control calibre DNA across three qPCR runs. The differences between control calibre Cts for each fluorophore 
is consistent between runs and is always set to B2M. This table also helped monitor standard template quality, 
deletion calibre quality and monitor overall run efficiency. RFU means relative fluorescent units. 
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Figure 2.2: Images of amplification curves (top) and standard curves (bottom) for each respective fluorophore during 
quantitative real-time PCR analysis. [A] B2M detection using FAM. [B] MT-ND1 detection using HEX. [C] MT-ND4 
detection using Cy5. [D] All three fluorophores overlaid. A-D show quantification of standard serial dilutions (small 
circles) and highlight where the control (large blue circle) and deletion (large green circle) calibre DNA amplify 
relative to the standard DNA. The large red circle in [C] depicts contamination >35 Cts. Analysis was performed on 
BioRad CFX 3.1 software. 
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Figure 2.3: Images of amplification curves (top) and standard curves (bottom) for each respective fluorophore during 
quantitative real-time PCR analysis. [A] B2M detection using FAM. [B] MT-ND1 detection using HEX. [C] MT-ND4 
detection using Cy5. [D] All three fluorophores overlaid. Images include amplification curves of UKBS samples 
(n=95) relative to the standard curves for each respective fluorophore. Analysis was performed on BioRad CFX 3.1 
software.
  
 
 
 
 
 
 
Table 2.6: An example of the table used to calculate relative mitochondrial DNA copy number for each UKBS sample using 2(2^-∆Ct) (Equation 2.2). Raw data for each sample from 
qPCR analysis was imported in to the table for B2M-FAM and MT-ND1-HEX and delta Ct calculations were applied respectively to each replicate. Relative mitochondrial DNA copy 
number was an average of each replicate’s delta Ct calculation and is represented as copies/cell. Note – deletion calibre sample only has two replicates because one replicate was 
removed during QC. Analysis was performed in Microsoft Excel 2010. 
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2.8.1.6 Z-scoring 
To normalise the distribution of mtDNA CN, and to accurately compare data between 
cohort populations in this study, Z-scoring was applied to each raw mtDNA CN value 
using Equation 2.3. 
𝑍 𝑠𝑐𝑜𝑟𝑒 =
𝑥 −  𝜇
𝜎
 
Equation 2.3: Z-score calculation used to normalise mtDNA CN values. x is the raw mtDNA CN data value, μ is the 
population mean, and σ is the population standard deviation. 
2.8.2 Cohort Two - In house ‘Cohort Two’ 
Cohort two samples had mtDNA CN determined using exactly the same methods 
detailed in section 2.8.1, however ‘Cohort Two’ samples were measured in 
quadruplicate instead of triplicate measurements using qPCR (Table 2.8). Z-scoring 
mtDNA CN was also applied to mother and child cohorts separately.1854 (92.7%) 
samples had mtDNA CN determined. 
2.8.3 Cohort Three – ALSPAC 
5461 maternal ALSPAC samples had mtDNA CN assayed at the same time points 
blood cell proportions were estimated from methylation data (section 2.3.3) (Relton et 
al., 2015). mtDNA CN was determined using an in-house qPCR assay which was 
optimised by Dr Philip A.I. Guthrie (PG) (who was formerly part of Dr Santi 
Rodriguez’s group in the School of Social and Community Medicine at University of 
Bristol, UK). PG developed a singleplex assay which quantified the relative 
proportion of a region (bases 317 to 381) in the mitochondrial D-loop (GenBank: 
NC_012920.1) to nuclear reference gene B2M (chr 15, GenBank: NC_000015.10), 
using the established delta Ct calculation (section 2.8.1.5 - Equation 2.2). 
For each qPCR reaction, a master mix was made using 5 μL of 2x SensiFAST 
SYBR® No-ROX Kit (Bioline, London, UK), 250 nM of each forward and reverse 
primer (Table 2.7), and 0.5 μL water (Malik et al., 2011). 0.25 ng/μL of DNA was 
added to the mastermix to make a final volume of 10μL per well. Each mitochondrial 
and nuclear gene was measured in triplicate. Samples were assayed using a Roche 
LightCycler LC480 and 384-well plates under the following thermocycler conditions: 
one cycle for 5 minutes at 95⁰C, followed by 45 cycles of: 5 seconds at 95⁰C, 15 
seconds at 55⁰C, 15 seconds at 72⁰C, and then 1 second at 78⁰C. Standard curves 
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were generated from pooled results of quadruplicate DNA measurements, and were 
used to calculate reaction efficiencies, which were then used to adjust raw Ct data. 
Three calibrator DNAs were run on every plate, and an average of each calibrator 
was calculated for each plate. This average was compared between plates, and was 
compared to the average of all of the calibrators across all plates, allowing the 
derivation of a per-plate calibration factor, by which each plate value was multiplied. 
This controlled for run-to run variability (Guyatt et al., 2017). ALSPAC raw mtDNA CN 
values were then z-scored using Equation 2.3, and z-scored values were used in all 
further analysis. 5461 samples had mtDNA CN determined. 
 
Table 2.7: Details of forward and reverse quantitative PCR primers used to quantify nuclear gene B2M and 
mitochondrial D-loop region in ALSPAC samples. Assay optimised by Dr Philip A.I. Guthrie (PG) (who was formerly 
part of Dr Santi Rodriguez’s group in the School of Social and Community Medicine at University of Bristol, UK).
  
 
 
 
 
 
 
Table 2.8: Summary of quantitative real-time PCR methods used to quantify mitochondrial DNA copy numbers in samples from each cohort throughout this study, and details of when 
each qPCR assay was used to generate results for each respective results chapter. Cohorts 1 and 2 were measured at Newcastle University, UK. Cohort 3 was measured at University 
of Bristol, UK and data was used in collaboration with Dr Santi Rodriguez.   
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2.9 Investigating Quantitative PCR Reproducibility 
qPCR is a sensitive method, and a number of factors can contribute to variation 
recorded between replicates, including the quality of reagents or DNA, evaporation, 
and pipetting error. This variation contributes to differences in overall final mtDNA CN 
calculations. Therefore, before embarking on measuring relative mtDNA CN in a 
large cohort of samples (n=3091), the number of replicate qPCR measurements was 
assessed and established in a smaller pilot cohort (n=8) to ensure precise mtDNA 
CN values were recorded throughout the project. In addition, mtDNA CN consistency, 
calculated using either MT-ND1 or MT-ND4 was assessed between replicate 
measurements. 
2.9.1 Identifying the Most Suitable Number of qPCR Replicates 
Eight independent samples of control DNA (detailed in section 2.8.1.1) were diluted 
to 1/10 (approximately 70 ng/μl) and were run in replicates of eight against triplicates 
of standard DNA and calibre deletion DNA (detailed in section 2.8.1.4) on a Hard-
Shell®, 96 well PCR plate (white well, green shell) (BioRad, Hertfordshire, UK). The 
entire experiment was repeated twice. Relative mtDNA CN was then calculated for 
each individual replicate for each control sample using Equation 2.2 (Pyle et al., 
2007). mtDNA CN was calculated using either MT-ND1 or MT-ND4 relative to B2M to 
compare mtDNA CN differences dependent on the mitochondrial reference gene. 
To investigate the variability in mtDNA CN when including a different number of 
averaged replicates in the delta Ct calculation, the cumulative average and standard 
deviation for each number of replicates was calculated and compared. For example; 
for three replicates, the average of the first three mtDNA CN measurements was 
recorded and then the standard deviation calculated to identify the amount of 
variation between those three individual mtDNA CN measurements. This was 
repeated where one to eight replicates were compared to calculate mtDNA CN in the 
delta Ct calculations (Figure 2.4). Tables a-d in Figure 2.4 summarise the average 
mtDNA CN and standard deviation across eight control samples calculated using the 
respective number of replicates. 
Figure 2.4 shows a general pattern where standard deviations start to decrease as 
more replicates are included to calculate mtDNA CN, then the standard deviations 
plateau between three to five replicates, and then they start to increase again as 
more replicates are included. 
Materials and Methods 
69 
 
As advised by Robert Kitchen (Kitchen et al., 2010) - no fewer than three technical 
replicates should be used when performing qPCR measurements on biological 
samples. Additionally, he states that increasing the number of replicates only 
improves measurement precision, and you need to increase sample numbers to 
record true biological differences (Kitchen et al., 2010). Following this advice, and in 
conjunction with the results in Figure 2.4, we measured samples in triplicate or 
quadruplicate (Table 2.8).  
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Figure 2.4: Graphs showing mitochondrial DNA copy number (mtDNA CN) changes (copies/cell) (y-axis) depending 
on the number of cumulative averged replicates included in the delta Ct calculation (x-axis), and the consistency 
between two separate qPCR runs. [A] – [D] use MT-ND1: B2M to calculate mtDNA CN. [E] - [H] use MT-ND4: B2M 
to calculate mtDNA CN. Tables a-d summarise means and standard deviations of mtDNA CN calculated for each 
number of replicates across eight control samples measured. 
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2.10 Determining which Mitochondrial Reference Gene to Use to 
Calculate Mitochondrial DNA Copy Number 
To determine which mitochondrial reference gene would be more appropriate to 
calculate relative mtDNA CN, and elaborating on the work in section 2.9, relative 
mtDNA CN was calculated for each number of replicates from the eight controls 
using either MT-ND1 or MT-ND4 in Equation 2.2. After repeating the assay, the 
difference in mtDNA CN using either gene was calculated and compared (Figure 
2.5). 
 
Figure 2.5: Graphs reporting the percentage differences in relative mitochondrial DNA copy number (mtDNA CN) 
(y axis) between two experiments when using the cumulative average of different number of replicates (x axis). [A] 
Uses MT-ND1: B2M to calculate mtDNA CN. [B] Uses MT-ND4: B2M to calculate mtDNA CN. Tables summarise 
the average differences in mtDNA CN (y axis) between runs per number of replicates included across eight control 
samples, and their standard deviations. This was repeated across two separate qPCR runs. 
The average difference between qPCR runs, when using MT-ND1: B2M calculations 
was -5.07% (±35.33 s.d) (Figure 2.5A), whereas the average difference when using 
MT-ND4: B2M calculations was -25.76% (±27.97 s.d) (Figure 2.5B). This suggests 
MT-ND4 is more variable between runs. Although these values are high, similar 
differences between the MT-ND1 and MT-ND4 calculations have been reported in 
another study, although they only reported a 2.5% difference (He et al., 2002). 
MT-ND4 is extensively researched and is known to be susceptible to mutations and 
deletions, therefore I chose to use MT-ND1 to calculate mtDNA CN, to generate 
more consistent results and keep in line with previously optimised qPCR assays (He 
et al., 2002; Payne et al., 2011; Yu-Wai-Man et al., 2011; Phillips et al., 2014; Rygiel 
et al., 2015). 
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2.10.1 Run to Run Variability 
As reported above (section 2.9), run to run variation also affects mtDNA CN 
reproducibility. As shown in Figure 2.4, mtDNA CN values were not replicated, 
irrespective of the number of replicates used. This may be due to technical error 
between runs which causes inconsistent quantification of each gene being 
measured, leading to variation between mtDNA CN values calculated. Figure 2.6 
confirms this and shows the differences in mtDNA CN between runs when comparing 
MT-ND1 and MT-ND4 genes. 
 
Figure 2.6: Graphs reporting the percentage differences in relative mitochondrial DNA copy number (mtDNA CN) 
values when mtDNA CN is calculated using MT-ND1: B2M and MT-ND4: B2M (y axis) calculations. mtDNA CN was 
calculated using a cumulative average of a specific number of replicates (x axis).Tables summarise the average 
differences in mtDNA CN (y axis) per number of replicates included across eight control samples, and their standard 
deviations. This was repeated across two separate qPCR runs. 
The average difference between MT-ND1: B2M calculated or MT-ND4: B2M 
calculated mtDNA CN values, across all replicates; in run 1 was 0.06% (±14.22 s.d). 
However, excluding the outlier sample (Figure 2.6A, blue line), the average 
difference was -4.84% (±3.25 s.d). For run 2 (Figure 2.6B), the average difference 
across all replicates was 23.12% (±5.67 s.d). This demonstrated that run-to-run 
variability could range between 5% and 23% depending on the number of replicates 
measured, and the reference gene being used to calculate mtDNA CN. 
To investigate this further, a random selection of UKBS samples had their mtDNA CN 
measured across several different qPCR runs. To identify the real technical error 
contributing to noise, samples were measured in triplicate and relative mtDNA CN 
was calculated using delta Ct of MT-ND1: B2M because there was less variability in 
mtDNA CN between runs (Figure 2.5A). 
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35 UKBS samples were measured across two separate experiments, and 59 UKBS 
samples were measured across three separate experiments. The mtDNA CN 
generated across the two-run tests varied by an average of 16%, with differences 
ranging from 1-34%. The mtDNA CN generated across the three-run tests varied by 
an average of 18%, with differences ranging from 1-45%. These data, combined with 
that reported above, suggests there is an approximately 20% degree of run-to-run 
variation in mtDNA CN values from accumulated technical error. As a consequence 
of this, any results will need to factor a 20% difference in to be significant; otherwise 
the result may be due to technical variability. 
2.11 Power Calculations 
Statistical power calculations were performed using a G×G or G×E interaction, 
Windows-based software program called QUANTO (Morrison and Gauderman, 
2002). 
Based on previous publications, mean mtDNA CN calculated from genomic DNA 
extracted from blood ranges from 50 to 400 copies/cell, with standard deviations 
ranging from 5 to 37% (Gahan et al., 2001; Xing et al., 2008; Phillips et al., 2014; 
Ding et al., 2015; Pyle et al., 2015a; Guyatt et al., 2017). mtDNA CN heritability is 
estimated at 65% (Xing et al., 2008). Being conservative, power calculations were 
generated on the assumption that mean mtDNA CN would be 200 copies/cell, with a 
standard deviation of 15% (equating to ±30 copies/cell). 
Calculations used a continuous trait study design, based on an additive, gene-only 
effects hypothesis in independent individuals. Allele frequencies between 0.01 and 
0.51, with an effect size (βG) of 0.8 to 6.0 were simulated to a type one error rate of 
5.00E-08 (genome-wide significance) to detect power. Based on the UKBS cohort 
size (n=3091), there is 83.52% power to detect a nuclear variant with a βG of 6.0, with 
a minor allele frequency (MAF) of 21%. As mtDNA CN variability is common, I expect 
to detect a variant with a higher allele frequency. This study has 80.45% power to 
detect a nuclear variant with a βG of 4.8, with a MAF of 51% (Figure 2.7). 
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Figure 2.7: Simulated power calculations to determine a genome-wide significant (p=5.00E-08) nuclear variant 
associated with mitochondrial DNA copy number (µ=200 copies/cell ±30 copies) in UKBS samples (n=3091). 
Individual lines represent variant minor allele frequencies. Red dotted line indicates 80% power threshold. 
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3.1 Introduction 
Mitochondrial DNA (mtDNA) was originally discovered in chick embryos using 
electron cytochemical techniques (Nass and Nass, 1962; Nass and Nass, 1963b), 
where two to six copies of mtDNA were yielded from each mitochondrion (Nass, 
1969). The number of mtDNA in every cell, across a number of tissues and species, 
was originally thought to be the same (Nass et al., 1965; Schneider and Kuff, 1965; 
Parsons and Simpson, 1967), however, in 1990, Karen Veltri and colleagues 
challenged this, reporting distinctly different numbers of mtDNA across a number of 
organs from mice (Veltri et al., 1990). The advance of research since then has 
identified that mitochondria contain tens to thousands of mtDNA molecules per 
mitochondrion (Garrido et al., 2003; Bogenhagen et al., 2008). However, beyond 
energetic demand (Dickinson et al., 2013; Fukuoh et al., 2014), we know little of why 
mtDNA CN varies between individuals at the organism, tissue or cellular level, or 
what other factors modulate mtDNA levels. 
mtDNA is packaged into nucleoids which are approximately 100 nm in size (Ylikallio 
et al., 2010), and can contain between 1-10 copies of mtDNA, but this depends on 
cellular metabolic demand, the stage of cell cycle, and redox state within the cell 
(Garrido et al., 2003; Bogenhagen et al., 2008; Malik et al., 2011; Malik and Czajka, 
2013). For example, high energy-demanding cells such as neurons can contain 
around 2000 mitochondria (Uranova et al., 2001), containing tens of thousands of 
mtDNA molecules (Dickinson et al., 2013). However, different regions of the brain 
contain varying mtDNA CN (Fuke et al., 2011; Rice et al., 2014). Less energy-
demanding cells, such as white blood cells, contain less than one hundred 
mitochondria, which can contain up to approximately 50 mtDNA molecules per cell 
(Selak et al., 2011). mtDNA CN is considered an important indicator of mitochondrial 
activity because mitochondrial gene transcripts are proportional to mtDNA CN 
(Williams, 1986). 
In NCBI PubMed, a search of [mitochondrial copy number] yields >2000 publications. 
Within the literature it is becoming more apparent the importance of understanding 
mitochondrial maintenance and mtDNA CN regulation, especially as mtDNA CN is 
thought to be a biomarker of disease susceptibility (Malik et al., 2011; Giordano et al., 
2014; Lee et al., 2014b; Pyle et al., 2015b; Wei et al., 2017), progression, and 
severity (Malik and Czajka, 2013). In mice, increased mtDNA CN has been seen to 
be detrimental, as it causes increased nucleoid enlargement, leading to defective 
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transcription, and results in the accumulation of mtDNA deletions, and OXPHOS 
defects (Ylikallio et al., 2010). However, this may have been a result of the mouse 
model’s phenotype overexpressing Twinkle or TFAM, continually stressing 
mitochondria to replicate. Needless to say, there has been a growing importance to 
understand the regulation of mtDNA CN; however no study has investigated mtDNA 
CN differences in large populations before. This is the first study to address this. 
3.1.1 Principles of Quantitative-PCR 
Since the introduction of quantitative PCR (qPCR) in 1996 (Heid et al., 1996), qPCR 
has become the established method to determine mtDNA CN (Wai et al., 2008; Malik 
et al., 2011; Grady et al., 2014a; Pyle et al., 2015a; Rygiel et al., 2015; Pyle et al., 
2016). Previous methods used radiolabelled hybridisation to quantify mtDNA (Veltri 
et al., 1990; Tang et al., 2000; Rodriguez-Enriquez et al., 2009), however qPCR is 
quicker, more widely available, and requires less sample, and is therefore generally 
preferred in practice (Malik and Czajka, 2013). 
The principle of qPCR is similar to that of PCR, whereby a sample of DNA acts as a 
template and undergoes a series of cyclic temperature conditions to; denature DNA, 
allow specific primers to bind, amplify the specific region of interest, then dissociate 
and allow DNA to anneal and extend. qPCR is different to PCR because 
quantification of the amplified product being measured is in real-time, and is 
quantified after each cycle across a number of PCR cycles, usually between 25 to 40 
(Rebouças et al., 2013; Ma and Chung, 2014). Relative mtDNA CN is calculated by 
measuring the proportion of a nuclear housekeeping gene (to adjust for cell number) 
to a mitochondrial reference gene, also known as the Mt/N ratio (Malik et al., 2011).  
Across the literature, a number of different nuclear housekeeping genes are used. 
Globulins (especially β-globin), glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH), ubiquitin C (Ubc), β-actin (ACBT), β-tubulin, and 18S ribosomal protein 
(18S) are a select few (Miller et al., 2003; Shen et al., 2010; Albershardt et al., 2012; 
Kelly et al., 2012; Ridge et al., 2014). Selecting a suitable housekeeping gene for 
qPCR normalisation has been highly debated, and is both tissue and species specific 
(Kelly et al., 2012). For example, in one study, Kelly and colleagues reported that β-
actin and GAPDH varied, whilst 18S was consistent across several different mouse 
cell and tissue types (Kelly et al., 2012). However, Albershardt and colleagues 
argued Ubc was the most stable housekeeping gene in mouse lymphocytes 
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(Albershardt et al., 2012). B2M has been identified as the most suitable 
housekeeping gene to determine mtDNA CN in human tissue because it is present in 
a single copy, and has little variability (Malik et al., 2011; Venegas and Halberg, 
2012; Phillips et al., 2014; Rygiel et al., 2015), therefore I used B2M as the 
housekeeping gene in this work. 
MT-ND1 is established as the mtDNA CN reference gene used to measure mtDNA 
CN as it is less prone to mtDNA deletion (Krishnan et al., 2007; Shen et al., 2010; 
Pyle et al., 2015b). However, other studies have measured regions in the 
mitochondrial D-loop (Phillips et al., 2014), cytochrome B (Malik et al., 2009), tRNA-
Leu, and COX-IV (Venegas and Halberg, 2012; Rooney et al., 2015). The 
mitochondrial D-loop is generally avoided because it is a triple stranded region, 
thought to regulate mtDNA replication, and contains hypervariable regions which can 
interrupt PCR amplification machinery (Anderson et al., 1981; Takamatsu et al., 
2002; J Nicholls and Minczuk, 2014; Jemt et al., 2015). Careful consideration needs 
to be made when designing mitochondrial amplicons, as nuclear-mitochondrial DNA 
segments (NUMTs) in nDNA may cause co-amplification of nDNA, which can affect 
the mtDNA CN outcome (Hazkani-Covo et al., 2010; Calabrese et al., 2012). 
The efficiency and consistency of qPCR results are dependent on a number of 
factors, including: reagents, such as primers and probes, DNA quality and source, 
size of the amplicon being amplified, and the number of replicates used. For 
example, single stranded breaks in mtDNA interrupt binding of DNA polymerases 
(Ponti et al., 1991; Gonzalez-Hunt et al., 2016), and freeze-thawing DNA samples 
can reduce the quality of DNA (Ross et al., 1990), emphasising the importance of 
DNA quality for qPCR measurements. Triplicate measurements are also the most 
common number of replicates used in qPCR, and as my work in section 2.9.1 
showed, mtDNA CN differs across varying replicate sizes. However, some studies 
only use duplicate measurements (Shen et al., 2010). Gervais and colleagues also 
showed that qPCR protocol temperature, DNA amplicon size, and amplicon region all 
affect primer efficiencies (Gervais et al., 2010). 
In qPCR, SYBR® green has traditionally been used to measure mtDNA CN because 
it provides a quick and convenient master mix of all the components (except primers) 
needed for qPCR, along with a fluorophore that binds to double-stranded DNA, and 
is easily detectable (Applied Biosystems, 2002; Fuke et al., 2011; Chan et al., 2013; 
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Rooney et al., 2015; Gonzalez-Hunt et al., 2016). However, the introduction of 
specific 5’-3’ exonuclease technology TaqMan™ probes in 1991, meant several 
primer-specific and probe-specific reagents could be multiplexed together to detect 
multiple genes at once. TaqMan™ probes are also more specific than SYBR® green 
as they target a specific area of the amplicon whereas SYBR® green targets any 
sequence of double stranded DNA. As a result, TaqMan™ probes revolutionised 
qPCR because it meant both mtDNA CN and mitochondrial deletions could be 
detected in one measurement, and with a higher degree of accuracy (Holland et al., 
1991; Nicklas et al., 2004; Grady et al., 2014a; Phillips et al., 2014). What’s more is 
recently droplet-digital PCR (ddPCR) is becoming more commonly used, because it 
can detect low levels of mtDNA, which SYBR® green and TaqMan™ cannot (Henrich 
et al., 2012; Taylor et al., 2014; Belmonte et al., 2016; Ye et al., 2017). On the 
contrary, some studies have also used exome or next generation sequencing to 
calculate mtDNA CN, by calculating the ratio of aligned mitochondrial reads to 
aligned nuclear reads. However, this is under the assumption that both nuclear and 
mitochondrial regions of the genome are of equal ploidy, and are sequenced to 
comparable depths, and is not an actual measure of mtDNA CN (Guo et al., 2013; 
D'Erchia et al., 2014; Cai et al., 2015; Ding et al., 2015; Reznik et al., 2016). 
In addition to qPCR technical limitations, the source of genomic DNA also affects 
mtDNA CN outcome. For example, saliva is a readily accessible, and much cheaper, 
source of genomic DNA. However, it is less commonly used in research studies 
because little is known about the source of the DNA (whether it be host, or 
contaminated genomes from food or bacterial sources (Takeshita et al., 2016)), and 
larger volumes of sample are needed to yield sufficient DNA (Ridge et al., 2014). 
74% of DNA in saliva is believed to come from white blood cells, with leukocyte levels 
ranging from 2 to 1.36E+05 cells/ml, and up to 1.10E+06 cells/ml in patients with oral 
cavity inflammation (Thiede et al., 2000). However, white blood cells, extracted from 
whole blood, are still the preferred source of genomic DNA for studies as they are 
known to contain a large amount of DNA. 
3.1.2 Other Confounding Factors Affecting Mitochondrial DNA Copy Number 
3.1.2.1 DNA Quality Effect on Mitochondrial DNA Copy Number 
The median and mean are central tendency statistical values which provide 
information about population data. Statisticians debate whether it is more accurate to 
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use median values instead of the mean, because the median is a resistant measure 
and is less likely to be affected by outliers. However, the median does not give a 
clear indication of the spread of data across the population like the mean does 
(LeBlanc, 2004). The established method for calculating mtDNA CN uses the mean 
of triplicate or quadruplicate values generated from qPCR measurements (Amaral et 
al., 2007; Phillips et al., 2014; Rooney et al., 2015; Pyle et al., 2016), however no 
study has compared median or mean-derived mtDNA CN values before.  
Aim 1: Identify if there are statistical differences between median and mean-derived 
mtDNA CN values using a large, control, European cohort. 
3.1.2.2 Gender Effect on Mitochondrial DNA Copy Number 
The maternal inheritance of mtDNA has biologically burdened the health of males, 
and is considered a sex-specific selective sieve (Camus et al., 2012). This is because 
males inherit mtDNA which may contain deleterious effects that will negatively impact 
male metabolic systems, that female systems can overcome (Camus et al., 2012; 
Frank, 2012). As a result, mitochondrial biogenesis has been reported to be different 
between sexes, including in rodents (Khalifa et al., 2017; Mauvais-Jarvis et al., 
2017).  
Males have more pronounced metabolic phenotypes than females (Mauvais-Jarvis et 
al., 2017) PD, and amyotrophic lateral sclerosis (ALS) are male predominant, as is 
the primary mitochondrial disease LHON (Man et al., 2003; Van Den Eeden et al., 
2003; Kim et al., 2012). Moreover, mtDNA CN has been reported to be significantly 
lower in males with diseases such as PD (Pyle et al., 2015a), yet has been reported 
to be higher in male cancer patients compared to females (Yin et al., 2004; 
Thyagarajan et al., 2012; Shen et al., 2016). Several studies have reported mtDNA 
CN differences between genders, however no study has directly looked at mtDNA 
CN differences between genders in large, healthy, European populations. 
Aim 2: Investigate whether mtDNA CN differs between genders in a large, healthy, 
European population. 
3.1.2.3 Age Effect on Mitochondrial DNA Copy Number 
mtDNA is more likely to accumulate DNA lesions with age because, unlike nDNA, 
mtDNA lacks nucleotide excision repair mechanisms, and is exposed to higher levels 
of ROS (Harman, 1956; Ledoux et al., 1992). Nearly 5% of oxygen consumed is 
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converted into ROS, meaning all tissues are susceptible to age-related damage 
(Malik and Czajka, 2013). The accumulation of mtDNA defects is reported to 
decrease mtDNA replication and transcription, resulting in mtDNA CN changes 
(Niranjan et al., 1982; Trifunovic et al., 2004; Meyer et al., 2013). This has led to age-
related mtDNA CN changes being reported in a number of different tissues across 
species (Tezze et al.; Barrientos et al., 1997; Barazzoni et al., 2000; Miller et al., 
2003; Cree et al., 2008a; Cheng and Ivessa, 2010; Payne et al., 2011; Mengel-From 
et al., 2014; Laubenthal et al., 2016). T2DM, cancer, and PD are all age-related 
diseases, and are tissue specific (Singh, 2004; Bender et al., 2006; Shen et al., 2010; 
Pringsheim et al., 2014), and mtDNA CN changes have also been observed in these 
diseases (Malik et al., 2009; Shen et al., 2010; Pyle et al., 2015a; Pyle et al., 2015b).  
Additionally, a study which introduced deleterious mtDNA in Drosophila 
melanogaster showed accelerated aging in males compared to females (Camus et 
al., 2012), and primary mitochondrial-related diseases such as LHON are more 
prevalent in males, where age of onset is in late teens (Wallace et al., 1988; Man et 
al., 2003; Hudson et al., 2007b). What’s more is Giordano’s team reported that 
individual’s carrying LHON mutations who do not develop the disease, known as 
incomplete penetrance, also have a higher mtDNA CN (Giordano et al., 2014). These 
data suggest that there may be a gender-specific effect causing mtDNA CN to 
change with age, and there may be compensatory mechanisms to protect against 
mitochondrial genetic insults relative to gender. 
Aim 3: Identify the impact ageing has on mtDNA CN changes in a large, healthy, 
European population, and investigate whether ageing effects are gender-specific. 
3.1.2.4 Blood Composition Effect on Mitochondrial DNA Copy Number 
Peripheral blood cell count differs, depending on age, gender, and ethnicity. For 
example, Bellamy and colleagues report significant changes in white blood cells 
(WBC) subcomponent composition in European children between the ages of two to 
13 months of age (Bellamy et al., 2000), and Bain and colleagues also reported 
significantly lower WBC subcomponent cells in peripheral blood of African and 
Afrocarribean people compared to Caucasian people (Bain et al., 1984; Bain, 1996).  
Changes in WBC in peripheral blood are used as a prognosis index to determine 
host immunity, and the ratio of lymphocytes to neutrophils is a common marker 
(Walsh et al., 2005; Gwak et al., 2007). Neutrophils and macrophages are thought to 
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play a pivotal role in cancer tumour progression, whereby elevated neutrophil and 
monocyte counts in patients with metastatic renal cell carcinoma are considered a 
poor survival prognosis factor, as well as elevated LDH levels (Schmidt et al., 2005). 
This may be because activation of monocytes results in excessive production of 
cytokines and other inflammatory mediators as the immune system is primed, which 
can act as a ‘first hit’ in healthy individuals. However, this is disadvantageous as any 
further injury like sepsis results in a hugely amplified inflammatory response, which 
leads to cell lysis, and the production of cytokine poisoning (O'Sullivan and O'Connor, 
1997). 
Sepsis is a rare, but serious condition which can lead to organ failure and death. 
Sepsis is very much dependent on immune cellular response, and mtDNA CN 
changes dependent on blood cell proportions (Pyle et al., 2010). mtDNA is believed 
to be able to influence the immune system through inflammasomes, because NLRP3 
inflammasome activity is regulated by ROS, which damaged mitochondria are known 
to generate (Gurung et al.; Zhou et al., 2011; Cristina Kenney et al., 2014; Yu and 
Lee, 2016; Harrington et al., 2017). As a result, mtDNA CN has been reported to vary 
in cellular components of blood in patients with sepsis (Lorente et al., 2013), and has 
been reported to change in peripheral blood from patients with metabolic diseases 
such as T2DM, cancer, and obesity (Malik and Czajka, 2013; Lee et al., 2014b; 
Reznik et al., 2016; Cho et al., 2017). Additionally, a decrease in mtDNA CN in 
peripheral blood of 1700 control Chinese individuals was also associated with a 50% 
higher cardiovascular risk (Huang et al., 2016). 
As the literature suggests, mtDNA CN in peripheral blood may act as both a 
biomarker of disease susceptibility, as well as disease progression, and may also be 
a contributing factor to cellular composition changes. 
Aim 4: Identify if mtDNA CN changes in individual blood cell subcomponents, and 
investigate how mtDNA CN changes dependent on blood cell composition in a large, 
healthy, European population. 
3.1.2.5 Inheritance of Mitochondrial DNA Copy Number 
mtDNA is strictly inherited down the maternal line in humans (Birky, 1978; Giles et 
al., 1980), because mtDNA in paternal sperm is degraded by the oocytes autophagy 
mechanisms soon after fertilisation (Al Rawi et al., 2011; Sato and Sato, 2011; Politi 
et al., 2014). This results in the oocyte containing thousands (105) of copies of 
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maternal mtDNA (Michaels et al., 1982), of which all copies contain the same 
wildtype genome (homoplasmic), or are a mixture of wildtype and mutated mtDNA 
(heteroplasmy). Tissues are normally able to withstand up to a heteroplasmy 
threshold of 60-80% before phenotypes show, however this is dependent on the 
mtDNA mutation and tissue (Sciacco et al., 1994; Wallace and Chalkia, 2013; 
Stewart and Chinnery, 2015). Women produce oocytes which contain widely different 
levels of heteroplasmy (Wallace and Chalkia, 2013; Hyslop et al., 2016), and new 
therapies, such as pronuclear transfer, have recently been introduced to prevent the 
transmission of severely heteroplasmic pathogenic variants to offspring (Craven et 
al., 2017).  
Natural selection for mtDNA heteroplasmy genotypes is known as the mitochondrial 
bottleneck. The bottleneck mechanism is still undetermined; however several 
theories have been hypothesised. Cao and colleagues believe heteroplasmy is 
transmitted in mtDNA clusters of identical molecules, and non-mutant mtDNA is 
selected for as a result of preferential replication (Cao et al., 2007; Cao et al., 2009). 
Cree and colleagues however suggest genetic segregation is a result of significantly 
decreased mtDNA CN during early germ line development (Cree et al., 2008b). Wai 
and colleagues challenge this theory by reporting continued high mtDNA CN in 
oocytes, and argue that the bottleneck effect is a result of replicating subpopulations 
of mtDNA during postnatal folliculogenesis, and not during embryonic oogenesis 
(Wai et al., 2008).  
Amongst these theories, mtDNA CN has been considered to be a major player in 
heteroplasmy transmission (Jenuth et al., 1996; Cree et al., 2008b), and it is thought 
that at least one in 200 healthy humans harbour one of 10 pathogenic, potentially 
disease inducing mitochondrial variants (Elliott et al., 2008; Chinnery et al., 2012). 
Wallace emphasises the importance of understanding the quantitative mechanisms 
of mtDNA transmission, and segregation across tissue types during development 
(Wallace and Chalkia, 2013). Shoubridge and Wai also asked if mtDNA CN is a 
mechanism that might be able to compensate for these variant’s effects when being 
transmitted (Shoubridge and Wai, 2007). 
No study has investigated the degree of mtDNA CN difference between mother and 
child before, or if mtDNA CN is inherited. Therefore, using a cohort consisting of 
mother-child pairs I was able to address this. 
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Aim 5: Identify if mtDNA CN is inherited between healthy mothers and children. 
Technical and biological factors introduce differences in mtDNA CN values being 
reported across the literature, making it difficult to compare results, as well as identify 
the expected ‘norm’ of mtDNA CN to reference to, and report deviations from that 
norm. No study has ever investigated mtDNA CN variation in a large European 
population before, especially in relation to age, gender, and DNA source. Therefore, 
using the large, European, UKBS cohort data available, I was able to investigate how 
mtDNA CN changed in relation to these demographic factors. In addition, and 
perhaps more importantly, from investigating these effects, I am able to identify any 
covariates that may need to be introduced when studying genome-wide genetic study 
models, to adjust for factors significantly influencing mtDNA CN changes. 
Additionally, this work will highlight any demographic covariates such as gender, age, 
full blood count data, and heritability that need to be adjusted for in future genome-
wide analysis should they be contributing to significant mtDNA CN differences.  
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3.2 Materials and Methods 
3.2.1 Cohort Details and Mitochondrial DNA Copy Number Generation 
3.2.1.1 Cohort One - UKBS 
Relative mtDNA CN was determined in 3028 (97.96%) UKBS samples using qPCR 
methods detailed in section 2.8.1. 1512 were males (49.9%) and 1516 females 
(50.1%). Age was also available for all samples, and full blood count (FBC) data was 
provided for 2617 UKBS samples. Full details about the UKBS cohort and data 
available is detailed in chapter 2. 
3.2.1.2 Cohort Two – In house ‘Cohort Two’ 
Relative mtDNA CN was determined in 1962 (98.10%) cohort two samples using 
qPCR methods detailed in section 2.8.1. Age, gender, and blood count data was not 
available for cohort two samples, however mother-child pairs were known. Full details 
about the in house ‘cohort two’ cohort and data available is detailed in chapter 2. 
3.2.2 Statistical Analysis 
The distribution of raw mtDNA CN in the UKBS and ‘cohort two’ controls were 
negatively skewed (Figure 3.1 and Figure 3.2 i’s); therefore Z-scoring was applied 
(Equation 2.3 – section 2.8.1.6) to normalise the mtDNA CN distribution (Figure 3.1 
and Figure 3.2 ii’s) to perform further parametric statistical tests. All statistical 
analysis was conducted using IBM SPSS Statistics 22 software (IBM, NY, USA). 
Independent t-tests (ITT), linear regressions, and Mann- Whitney U (MWU) tests 
were performed for variable relationships against mtDNA CN. Tested variables 
included age and gender, as well as FBC data, including absolute and proportional 
counts of individual cell component data such as basophils, neutrophils, eosinophils, 
lymphocytes, and monocytes (refer to Table 2.1 for FBC abbreviations). Confidence 
intervals were accepted at 95%. mtDNA CN, age, and blood cell components were 
treated as continuous traits, and gender was binary. 
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3.3 Results 
3.3.1 Mitochondrial DNA Copy Number Distributions 
To make UKBS and cohort two cohorts comparable for analysis, cohort two was 
restricted to only include samples whose mtDNA CN was determined from genomic 
DNA extracted from blood (n=1854, 94.50%) (Table 3.1). 
 
Table 3.1: Breakdown of relative mitochondrial DNA copy number (copies/cell) across UKBS and cohort two 
samples before and after being filtered for mtDNA CN less than or equal to 900 copies/cell. WBC: DNA extracted 
from white blood cells. * indicates unknown what cell type DNA was extracted from – refer to Table 2.2. 
Table 3.1 summarises the differences in mtDNA CN between UKBS and cohort two 
samples before and after a quality control (QC) filter, which only included individuals 
who had a mtDNA CN of less than or equal to 900 copies/cell, was applied. As 
shown, the mean and median values for both male and females in UKBS samples 
are more similar than that of mother, child, or buccal samples in cohort two. mtDNA 
CN in UKBS samples also ranged from 38.96 to 1187.41 copies/cell, whereas they 
ranged from 11.01 to 583,354.66 copies/cell in cohort two samples. 
To visualise the distributions of mtDNA CN in each cohort, histograms were 
generated (Figure 3.1). Both raw, and z-scored mtDNA CN were plotted to 
demonstrate that z-scoring normalised the distributions between cohorts (Figure 3.1-
ii’s), as raw mitochondrial plots were negatively skewed (Figure 3.1-i’s). However, as 
Table 3.1 shows, the range of mtDNA CN in blood samples from cohort two was 
extremely high (583343.65 copies/cell) compared to UKBS samples (1148.45 
copies/cell). Therefore, to make the cohorts comparable, both cohorts were filtered to 
only include samples which had a mtDNA CN of less than or equal to 900 copies/cell. 
Values above 900 copies/cell were considered outliers. This filter removed two 
(0.06%) UKBS and 119 (6.42%) cohort two individuals respectively. Figure 3.2 shows 
the frequency distributions of raw mtDNA CN in both cohorts is more normally 
distributed after being filtered (Figure 3.2-i’s), and is similar to z-scored mitochondrial 
distributions (Figure 3.2-ii’s). As a result, both raw, and z-scored mtDNA CN could be 
used for demographic analyses.   
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Figure 3.1: Frequency distributions of (i) raw and (ii) Z-scored mitochondrial DNA copy number in unfiltered [A] 
UKBS (n=3028) and [B] – [D] cohort two samples. [B] Cohort two mothers samples from blood only (n=862), [C] 
children samples from blood only (n=992), and [D] mothers samples from buccal only (n=108). 
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Figure 3.2: Frequency distributions of (i) raw and (ii) Z-scored mitochondrial DNA copy number (mtDNA CN) which 
have been selected if mtDNA CN is less than or equal to 900 copies/cell. [A] UKBS samples (n=3026) and [B] – [D] 
cohort two samples. [B] Cohort two mothers samples from blood only (n=764), [C] children samples from blood only 
(n=971), and [D] mothers samples from buccal only (n=99). 
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3.3.2 DNA Quality Effect on Mitochondrial DNA Copy Number Determination 
As described in section 3.1.2.1, no study has previously used median Ct values to 
calculate mtDNA CN, because established methods use the mean value of replicates 
after they have been QC. Using mean Ct values may introduce a bias to mtDNA CN 
calculations because the mean is finding an average adjusted central point. The 
impact of this bias across thousands of samples could be detrimental, therefore, 
using the UKBS cohort, I wanted to compare whether using the median or mean Ct 
values was most appropriate to calculate mtDNA CN, and identify if there were any 
significant differences in values across thousands of samples. 
Of the 3091 UKBS samples measured, 3088 samples (99.90%) had triplicate Ct 
measurements generated using qPCR (Figure 3.3). All three replicates were used to 
calculate median values for each measurement of B2M, MT-ND1, and MT-ND4 for 
each sample. Median derived mtDNA CN was then determined using the same delta 
Ct calculation used previously (section 2.8.1.5 - Equation 2.2), measuring the 
proportion of MT-ND1 or MT-ND4 to B2M. 
 
Figure 3.3: Flow diagram summarising the number of UKBS samples with raw Ct data from the qPCR assay, which 
could either be used to generate median Ct values (requiring a minimum of three replicates), or could be used to 
calculate mitochondrial DNA copy number (mtDNA CN) (copies/cell) with a minimum of two replicates. Additional 
arms highlight samples with SNP genotyping and blood count data. 
To compare the differences between mean-derived, and median-derived mtDNA CN, 
linear regression plots were drawn (Figure 3.4A and B), and linear regression 
analysis and independent t-tests were performed because equal variance was 
calculated. As indicated in Figure 3.4, there is no significant difference in mean-
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derived or median-derived mtDNA CN in UKBS samples, irrespective of using MT-
ND1 (r2= 0.974, β= 0.987, p=0.895) (Figure 3.4A) or MT-ND4 (r2= 0.972, β= 0.986, 
p= 1.00) (Figure 3.4B) as the mitochondrial reference gene, but in fact they are 
strongly correlated. 
 
Figure 3.4: Relationship between mitochondrial DNA copy number calculated using the mean of Ct values (n=3028), 
or the median of Ct values (n=3088) in UKBS samples. [A] Mitochondrial DNA copy number calculated using MT-
ND1: B2M. [B] Mitochondrial DNA copy number calculated using MT-ND4: B2M. Table summarises the statistics 
of mitochondrial DNA copy numbers between mean and median options, and the t-tests performed. 
Having established there was no difference between mean or median-derived 
mtDNA CN, I chose to continue using mean-derived mtDNA CN to keep analysis in 
line with the literature. 
Next, I wanted to investigate the quality of the mtDNA by comparing MT-ND1 
derived-values against MT-ND4 derived values. mtDNA is more likely to develop 
mutations or deletions than nDNA because mtDNA lacks protective histones and is 
exposed to harmful ROS products, which damage the DNA (Gemmell et al., 2004; 
Rygiel et al., 2015). Using UKBS and cohort two samples, linear regression plots 
were drawn to show the relationship between MT-ND1 or MT-ND4 calculated mtDNA 
CN measurements respectively (Figure 3.5A and Figure 3.6). Additionally, median 
MT-ND1 and MT-D4 values in UKBS samples were compared to investigate if the 
statistics altered the outcome of the results recorded. 
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Figure 3.5: Linear regression plot of [A] Mitochondrial DNA copy number derived from using mitochondrial gene 
MT-ND1 against mitochondrial DNA copy number derived from using mitochondrial gene MT-ND4 in UKBS samples 
(n=3028), and [B] raw median Ct values generated from triplicate measurements for MT-ND1 plotted against raw 
median MT-ND4 measurements for each UKBS sample (n=3088). Mitochondrial DNA copy number is copies/cell. 
As Figure 3.5A shows, less than 5% of samples sit outside of the prediction interval 
for MT-ND1 versus MT-ND4 calculated mtDNA CN, and were highly correlated (r2= 
0.875, β= 0.935). This was also consistent with the median MT-ND1 versus MT-ND4 
values, where values strongly correlated (r2= 0.859, β= 0.927). This demonstrated 
that MT-ND1 was proportional to MT-ND4 in mtDNA from these samples and 
suggested the mtDNA quality was good. 
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Figure 3.6: Linear scatter plots of MT-ND1 derived mitochondrial DNA copy number (copies/cell) against MT-ND4 
derived mitochondrial DNA copy number (copies/cell) in cohort two mothers and children which have or have not 
been filtered for mitochondrial DNA copy number <=900 copies/cell. Blood extracted DNA samples only. 
To investigate mtDNA quality in cohort two DNA samples extracted from blood, MT-
ND1 derived and MT-ND4 derived mtDNA CN were compared (Figure 3.6). Cohort 
two was stratified by mothers (n=862) and children (n=992), and then linear 
regression plots were generated for each. The results showed a positive correlation 
(unfiltered mothers: r2=0.991, β=0.995, unfiltered child: r2=0.997, β=0.998). Additional 
QC filters were applied, removing individuals with mtDNA CN greater than 900 
copies/cell, and the same linear regression analysis was performed. 98 (11.37%) 
mother samples and 21 (2.12%) children samples were removed during filtering, 
however the strong positive correlation between MT-ND1 and MT-ND4 derived 
mtDNA CN remained (filtered mothers: r2=0.979, β=0.989, filtered children: r2=0.977, 
β=0.989), thus suggesting cohort two mtDNA samples were good quality. 
Following this series of analysis, I had identified that mtDNA quality for cohort two 
and UKBS samples were of good quality to use for further analysis, and I decided 
that UKBS and cohort two samples needed to be filtered to only include those with a 
mtDNA CN of less than or equal to 900 copies/ cell to remove outliers and make 
cohorts comparable. 
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3.3.3 Gender Effect on Mitochondrial DNA Copy Number 
As detailed in section 3.1.2.2, differences in mitochondrial biogenesis have been 
reported between genders, however no study has investigated mtDNA CN 
differences between genders in a large, healthy, European population before. 
Therefore I was able to utilise the UKBS data to address this.  
In line with previous analysis, UKBS samples were filtered to remove outliers, 
removing two male samples. Subsequently, samples with mtDNA CN values less 
than or equal to 900 copies/cell were included (n=3026). 1510 males (49.9%) and 
1516 females (50.1%) passed QC and were used for analysis. Individuals were 
stratified by gender, and had boxplots generated to compare both raw, and z-scored 
mtDNA CN between genders (Figure 3.7). 
 
Figure 3.7: Boxplots of [A] raw and [B] Z-scored mitochondrial DNA copy number differences between males 
(n=1510) and females (n=1516) in the UKBS samples. Red dotted lines indicate population means (raw: μ=178.32) 
±56.46 s.d). 
The average mtDNA CN in the UKBS cohort was 178.32 copies/cell ±56.46 s.d. 
Independent T-tests (ITT) and Mann Whitney-U (MWU) tests performed on both raw, 
and Z-scored mtDNA CN data reported no significant difference in mtDNA CN 
between males (μ= 179.62 copies/cell ±59.43 s.d) and females (μ= 177.04 
copies/cell ±53.33 s.d) (ITT: p= 0.209, MWU: p= 0.550) (Figure 3.7). This suggests 
that gender does not affect mtDNA CN in the general population. 
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3.3.4 Age Effect on Mitochondrial DNA Copy Number 
Across the literature, mtDNA CN has been reported to change with age, but these 
are only in small populations of individuals. No study has investigated the age related 
effects on mtDNA CN changes in large populations of individuals; therefore, using 
the UKBS data, I investigated the extent mtDNA CN changes in relation to age and 
gender. 
To ensure UKBS samples were suitable to perform age-associated analysis, 
frequency distribution plots were generated to summarise the ages of all UKBS 
individuals (Figure 3.9A), and then by females and males only (Figure 3.9B and C). 
Age distributions were normal and were therefore suitable for testing. Details of age 
distributions are in Table 3.2. 
To keep analysis consistent, UKBS samples with mtDNA CN less than or equal to 
900 copies/cell (n=3026) were analysed against each individual’s age, and results 
were then stratified by gender. Linear regression tests were performed, and linear 
plots were drawn to identify the relationship with mtDNA CN and age (Figure 3.8). 
 
Figure 3.8: Linear regression plots of [A] and [C] raw or [B] and [D] Z-scored mitochondrial DNA copy number 
changes with age in UKBS samples. [A] and [B] depict all UKBS samples (n=3026) and [C] and [D] depict males 
(n=1510, blue) and females (n=1516, green).
  
 
 
 
 
 
Figure 3.9: Frequency distribution curves of ages in UKBS samples (n=3026), stratified by gender (n=1510 males, n=1516 females). Black line indicates normal distribution curve.  
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A summary of the results generated from linear regression tests are presented in 
Table 3.2. Across the UKBS cohort, mtDNA CN statistically significantly decreases 
with age (p= 0.007, β= -0.049, r2= 0.002) however, when stratified by gender, there 
was no statistically significant decrease in mtDNA CN with age in females (p= 0.596, 
β= -0.014, r2= 1.85E-04), but there was a statistically significant decrease in mtDNA 
CN with age in males (p= 4.42E-04, β= -0.090, r2= 0.008). Therefore the significant 
decrease reported in the whole population was a result of a gender specific effect. 
These results show that in the general, healthy population, mtDNA CN does 
statistically significantly change with age in males, but not in females, and this may 
give reason to why males are more affected by age-related, and mitochondrial 
diseases than females (Hudson et al., 2007a; Frank, 2012; Hudson et al., 2013a). 
However, these results are likely not biologically significant because for every 10 
years mtDNA CN decreases by 0.11 copies/cell, 0.18 copies/cell, and 0.03 
copies/cell in the entire UKBS cohort, in UKBS males only, and in UKBS females 
only respectively. 
  
  
 
 
 
 
 
Table 3.2: Summary of UKBS cohort ages, mean mitochondrial DNA copy number, and linear relationship statistics of mitochondrial DNA copy number changes with age, and then 
stratified by gender.  
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3.3.5 Blood Composition Effect on Mitochondrial DNA Copy Number 
Mitochondrial biogenesis has been reported to change in blood cells depending on 
individual blood cellular environment, as well as overall blood cellular composition 
(detailed in section 3.1.2.4). Utilising FBC data available for UKBS samples, I was 
able to investigate mtDNA CN differences in blood across a large, healthy, European 
cohort. 
Prior to performing any mtDNA CN analysis, histograms of each individual blood cell 
component were generated, but only for individuals who had a mtDNA CN of less 
than or equal to 900 copies/cell (n= 3026), to keep analysis consistent (Figure 3.10 
and Figure 3.11). As a result, two individuals with blood count data were excluded. 
2560 individuals (82.82%) had blood count and mtDNA CN data, of which 1267 
(49.49%) were males, and 1293 (50.51%) were females. As Figure 3.10 and Figure 
3.11 show, the distributions of all FBC subcomponents were normal for both counts, 
and overall proportions. 
Histogram frequencies of each blood component for UKBS samples were compared 
to the normal ranges expected for full differential blood count information (Vejabhuti 
Curry, 2015; Mayo Clinic Staff, 2016) to ensure samples were representative of 
healthy individuals in populations (Table 3.3). As Table 3.3 shows, all FBC 
subcomponents were in the expected normal ranges, even when stratified by gender. 
Basophil counts and proportions were the only subcomponents that were not in the 
expected ranges, but this may be a result of 2337 samples having their value 
assigned to zero instead of using the verbose text data which was inconclusive to 
analysis (section 2.3 - Table 2.1). Normal FBC data ranges reassured that further 
investigations of mtDNA CN changes in each blood cell type would be representative 
of active mtDNA CN changes in large populations of healthy, European people, and 
would not be an artefact of abnormal whole blood cellular proportions contributing to 
changeable and incomparable mtDNA CN levels.  
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Figure 3.10: Frequency distribution plots of blood cell components in UKBS samples that have mitochondrial DNA 
copy number less than or equal to 900 copies/cell (n=3026). [A] Graphs related to red blood cell counts (n=2560, 
red); (i) Absolute blood cell counts (RBC), (ii) haemoglobin (HB), (iii) mean corpuscular volume (MCV), (iv) 
haemocrit (HCT, (v) mean corpuscular haemoglobin (MCH), and (v) mean corpuscular haemoglobin concentration 
(MCHC). [Avii] Table explaining how HCT, MCH, and MCHC data are determined from RBC count data. [B] Absolute 
count of platelets (n=2546, yellow). Curves outline normal distributions. 
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Figure 3.11: Frequency distribution plots of white blood cell cell components (n=2560) in UKBS samples that have 
mitochondrial DNA copy number less than or equal to 900 copies/cell (n=3026). [i, iii, v, vii, ix] Absolute counts. [ii, 
iv, vi, viii, x] Relative proportions. (ii) Basophil proportions (BP). (iii and iv) Monocytes (MA and MP). (v and vi) 
Eosinophils (EA and EP). (vii and viii) Lymphocytes (LA and LP). (ix and x) Neutrophils (NA and NP). Absolute 
basophil data not shown because data is binary. Curves outline normal distributions.
 
 
 
 
 
 
 
 
 
Table 3.3: Summaries of the means and standard deviations (s.d) of each blood cell component generated from full blood count data in UKBS samples (n=3026), and stratified 
by gender (n=1510 males and n=1516 females). Recorded means are compared to the expected normal blood count ranges (Vejabhuti Curry, 2015; Mayo Clinic Staff, 2016). * 
indicates tests performed between male and female blood component means. ITT: Independent T-test. MWU: Mann-Whitney U test. 
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To identify blood composition differences between genders in these samples (Table 
3.3), UKBS samples were stratified by gender, and then had mean values generated 
for each FBC subcomponent. Boxplots were generated to visualise the difference in 
means for each cellular component between genders (Figure 3.12 and Figure 3.13). 
ITT and MWU tests were then performed on the means of each FBC subcomponent 
between females and males, and p-values were recorded in Table 3.3. As Table 3.3 
shows, there are significant differences in all FBC subcomponents between males 
and females, except in MCV, BA and BP, and NP. Of the nucleated cells, PLT, MP, 
and LA had the strongest significant differences between males and females (ITT: p= 
8.32E-44, p= 3.76E-31, and p= 3.27E-15 respectively). 
UKBS DNA samples were extracted from WBC pellets, as they contain the most 
genomic DNA in blood. Therefore, to investigate mtDNA CN changes in blood 
components in healthy populations, UKBS FBC data was restricted to only include 
WBCs. Scatter plots were generated to visualise the relationship between mtDNA CN 
and each WBC component – basophils, eosinophils, monocytes, lymphocytes, and 
neutrophils, as well as platelet counts (Figure 3.14). Both absolute counts and 
proportions were compared to identify if results were similar, and linear regression 
analysis was conducted to identify any significant relationships (Table 3.4). Linear 
regression was not performed on BA because the variable was binary. RBCs do not 
contain DNA, therefore they were not included in any mtDNA CN analysis, and 
neither were the related HB, HCT, MCH, MCHC, and MCV components.  
As Figure 3.14 and Table 3.4 show, there were changes in mtDNA CN relative to 
each WBC subcomponent absolute amount and WBC proportion, except MA and 
PLT. Overall, WBC had a significant decrease in mtDNA CN as cell count increased 
(p= 7.02E-09), but when stratified by subcomponents, this effect was a result of a 
strong significant decrease in mtDNA CN with cell count in NA and NP (p= 8.84E-22 
and p= 3.59E-27 respectively). Other cellular subcomponents reported a significant 
increase in mtDNA CN as cell count increased. EA, LA, BP, MP, EP, and LP all had p 
values less than 0.05.  
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Figure 3.12: Boxplots demonstrating the difference in blood cell compositions between males (M, n=1267) and 
females (F, n=1293) in 2560 UKBS individuals which had full blood count determined. [A] Boxplots related to red 
blood cell count data; (i) red blood cell counts (RBC), (ii) haemoglobin (HB), (iii) mean corpuscular volume (MCV), 
(iv) haemocrit (HCT), (v) mean corpuscular haemoglobin (MCH), and (v) mean corpuscular haemoglobin 
concentration (MCHC). [B] Absolute count of platelets. Dotted line indicates population mean. Statistics are in Table 
3.3. 
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Figure 3.13: Boxplots demonstrating the difference in white blood cell compositions between males (M, n=1267) 
and females (F, n=1293) in 2560 UKBS individuals which had full blood count determined. [i, iii, v, vii, ix] Absolute 
counts. [ii, iv, vi, viii, x] Relative proportions. (ii) Basophil proportions (BP). (iii and iv) Monocytes (MA and MP). (v 
and vi) Eosinophils (EA and EP). (vii and viii) Lymphocytes (LA and LP). (ix and x) Neutrophils (NA and NP). 
Absolute basophil data not shown because data is binary. Dotted line indicates population mean. Statistics are in 
Table 3.3.  
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Figure 3.14: Scatter plots showing the relationships between z-scored mitochondrial DNA copy number and [A] Full white blood cell components in UKBS samples – stratified by 
[B] basophils, [C] monocytes, [D] eosinophils, [E] lymphocytes and [F] neutrophils, as well as [G] platelet counts. (i) Indicates absolute count data. (ii) Indicates proportion data. 
Table 3.4 summarises the linear regression analysis results for each respective graph.    
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Table 3.4: Summarises of linear regression analysis conducted to identify the relationship between Z-scored 
mitochondrial DNA copy number and absolute cell counts or total cell proportions of individual white blood cell types 
in UKBS samples. Table correlates to graphs in Figure 3.14. 
3.3.6 Inheritance of Mitochondrial DNA Copy Number 
mtDNA is maternally inherited, however the inheritance of mtDNA CN is not fully 
defined. To investigate this, mtDNA CN was measured in cohort two mother-child 
pairs. Of the 2000 cohort two samples, 855 mother-child pairs had mtDNA CN 
calculated from DNA extracted from blood. To keep analysis consistent, both mother 
and child samples were filtered to include mtDNA CN less than or equal to 900 
copies/cell. This removed 112 pairs (13.10%), leaving 743 pairs (86.90%) to analyse. 
Samples were restricted to mother and child samples only from the pairs, and then 
frequency distribution plots of mtDNA CN were generated to compare frequencies 
(Figure 3.16). 
As Figure 3.16 shows, there is a negative skew in raw mtDNA CN in cohort two 
mothers and child pairs. Mothers have a larger range in unfiltered mtDNA CN 
compared to children. Z-scoring both unfiltered, and filtered mtDNA CN normalised 
the distributions and made them comparable. 
Linear regression analysis was performed on both unfiltered and filtered mother-child 
pairs to ensure that the filtering process had not introduced a bias to the results 
observed in the unfiltered pairs. Unfiltered mother-child pairs (n=855 pairs) showed 
there was no significant relationship between mother and child mtDNA CN (r2= 
1.18E-04, β= -0.011, p= 0.751) (Figure 3.15A and B).  A similar result was also 
reported in filtered mother-child pairs (n=743 pairs) (r2= 0.003, β= 0.055, p= 0.134) 
(Figure 3.15C and D). This data is not able to detect heritability, and does not support 
the hypothesis that mtDNA CN is inherited from mother to child, or that mtDNA CN is 
controlled only by genetics.  
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Figure 3.15: Scatter plots of mother versus child [A] and [C] raw mitochondrial DNA copy number or [B] and [D] z-
scored mitochondrial DNA copy number to show if mitochondrial DNA copy number is inherited from mother to child. 
[A] and [B] Unfiltered mitochondrial DNA copy number (n=855 pairs). [C] and [D] Filtered for mitochondrial DNA 
copy number <= 900 copies/cell in mother and child (n=743 pairs). 
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Figure 3.16: Frequency distributions of [A] and [B] raw and [C] and [D] Z-scored mitochondrial DNA copy number 
in cohort two mother-child pairs which have (i’s) or have not (ii’s) been filtered to include only mitochondrial DNA 
copy number less than or equal to 900 copies/cell. 
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3.4 Discussion 
Current literature is limited by power when reporting active mtDNA CN changes in the 
population, especially in relation to disease or across tissue types, because sample 
sizes are usually in the tens or hundreds and is not representative of large 
populations. This has resulted in conflicting results being reported about mtDNA CN 
changes, especially in disease (reviewed by (Malik and Czajka, 2013). My study is 
the first to address this limitation, as my results show the natural variation in mtDNA 
CN in a large, European population relevative to age, gender, and natural blood 
composition. In the results described, I have identified that there is no significant 
difference in relative mtDNA CN calculated using the mean or median of Ct values. I 
also report no significant mtDNA CN difference in males and females, however there 
is a statistically significant decrease in mtDNA CN with age in males only, albeit this 
may not be biologically significant because male’s mtDNA CN decreases by 0.18 
copies/cell every 10 years. Blood cellular composition is seen to affect mtDNA CN 
changes – having a positive effect in monocytes, eosinophils, lymphocytes, and 
basophils, but having a negative effect in neutrophils. What’s more is I did not report 
any correlation between mtDNA CN between mother and child in an independent 
cohort, suggesting mtDNA CN is not inherited. 
Cohort two samples were restricted to blood-extracted DNA only because tissue 
source affects DNA yield and quality, and buccal swabs are known to produce low 
yield and degrade quickly (Livy et al., 2012; Ghatak et al., 2013). Therefore, to make 
UKBS and cohort two samples comparable, DNA needed to be from the same 
source. 
The differences in mtDNA CN ranges, originally reported between cohort two and 
UKBS samples before they were filtered, may have been as a result of a combination 
of DNA quality and qPCR limitations, whereby cohort two appeared to have poorer 
DNA quality than UKBS samples. When I was measuring cohort two samples using 
qPCR, it was more difficult to generate consistent replicates for each sample, and 
B2M Ct values were far more variable than for UKBS samples. Cohort two samples 
were supplied to the lab in a lower volume (10 µl) rather than the 200 µl volume 
received for the UKBS samples, and cohort two samples had been kept at -80°C for 
long-term storage prior to analysis. The lower volume makes the samples more 
susceptible to freeze-thaw damage (Ross et al., 1990), and as a result DNA damage 
could have decreased qPCR amplification efficiency, giving rise to more varied qPCR 
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Ct readings (Ponti et al., 1991; Gonzalez-Hunt et al., 2016). nDNA is also much 
harder to extract from low quality samples than mtDNA, because nDNA is present in 
much lower copies. If cohort two samples were poor quality samples before DNA 
extraction methods were applied, this might explain why the B2M Ct value variation 
reported would have been so inconsistent. This cumulative effect would impact the 
overall mtDNA CN generated for each sample across the cohort, and could have 
contributed to the large mtDNA CN ranges observed. Rohland and colleagues 
suggest that if handling DNA from poor quality samples, using a silica column-based 
method optimises both yield and DNA quality (Rohland et al., 2010), which might 
improve future DNA management.  
Irrespective of the mtDNA CN differences reported, the overall distribution between 
the cohorts was similar. The strong, positive correlation between MT-ND1-derived 
and MT-ND4-derived mtDNA CN suggests good quality mtDNA, however there is a 
shift in mtDNA CN towards MT-ND4 in Figure 3.5A. Although, looking at raw Ct 
values in Figure 3.5B, MT-ND1 and MT-ND4 are more tightly correlated, which 
suggests that the real-time assay is more selective towards MT-ND1: B2M 
conditions, as mtDNA CN is shifting relative to MT-ND4. This suggests these 
samples may contain deletions (He et al., 2002; Krishnan et al., 2007; Grady et al., 
2014a) which will need to be investigated further. An additional factor to consider 
measuring simultaneously when measuring mtDNA CN would be mitochondrial-
related replication protein levels, such as TFAM. More accurate mtDNA CN levels 
could then be determined relative to replication machinery levels. 
My results do not show a gender effect as mtDNA CN changes, which has also been 
reported between genders in mouse models simulating mtDNA CN replication 
(Ylikallio et al., 2010). Although mtDNA CN changes between genders has been 
vastly reported in the literature, continued conflicting reports are being published. 
This may be a result of tissue-specificity. For example, an age-related decline in 
mtDNA CN is reported in pancreatic beta cells between genders (Cree et al., 2008a), 
however blood cells have a much quicker turnover than pancreatic beta cells. The 
high renewal of blood cells may be masking the real gender effects recorded. Lopez 
and colleagues have reported a gender-specific genetic regulation of mtDNA CN 
using a genome wide linkage analysis approach (López et al., 2012), however their 
work does not include any further functional analysis to support the data. 
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Other studies in mice have reported gender specific differences in mitochondrial 
biogenesis, morphology, respiratory function, and ROS homeostasis (Khalifa et al., 
2017). Khalifa and colleagues report that oxidative stress biomarkers are lower in 
healthy young women in age-matched males (Khalifa et al., 2017). This work is 
further supported by Borrás and colleagues work, where they report that female mice 
express higher levels of antioxidant genes than male mice (Borrás et al., 2003). Work 
conducted by Kim and colleagues also show that cyclophilin D is an essential 
component of oestrogen-mediated neuroprotection for ALS sufferers (Kim et al., 
2012), and because ALS is more common in males, this introduces biological 
protective factors which may be protecting mtDNA from long-term damage.  
Malik and colleagues hypothesise that oxidative stress contributes to mtDNA CN 
changes, as well as mitochondrial number (Malik et al., 2011; Malik and Czajka, 
2013). A study in dialysis patients showed a strong correlation between mtDNA CN 
and oxidative stress (Chen et al., 2008), as was a study conducted by Chan and 
colleagues (Chan et al., 2013), and other studies in T2DM have reported the same 
(Beisswenger et al., 2005; Malik et al., 2009), thus suggesting oxidative stress during 
the immune response might be causing changes in mtDNA CN in cell components. 
Liu and colleagues also support this theory, as they reported an increase in mtDNA 
CN in WBC as redox factors such as retinol, non-protein thiols, and ferritin in blood 
plasma increased. They also reported a decrease in mtDNA CN as vitamin E levels 
increased (Liu et al., 2003). All these results may support why we reported a 
statistically significant decrease in mtDNA CN in males with age, but not in females, 
however further research would need to be conducted to investigate the biological 
signficiance of these differences. 
Measuring ROS or lactate levels directly in cells may act as a useful reference 
variable when calculating mtDNA CN in tissue. As in the diagnosis of mitochondrial 
disorders (section 1.2.4.1), where elevated LDH levels in blood serum are an 
indicator of mitochondrial dysfunction (Robinson, 2006; Haas et al., 2008; Magner et 
al., 2011), LDH levels are also the strongest prognosis factor for survival rate for 
patients receiving treatment for metastatic melanoma, and are used in the American 
Joint Committee on Cancer stage five classification (Balch et al., 2001). Furthermore, 
LDH, and inflammation levels have been monitored in sepsis patients by Domingos 
Corrêa and colleagues, whereby they report changes in mitochondrial function which 
enables certain tissues to recover more readily from sepsis than other tissues 
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(Corrêa et al., 2017). These clinical applications may also support how mitochondrial 
stress leads to mtDNA CN differences reported in respective cells, but also should be 
used to determine likely progress during disease.  
Expanding on this, mitochondrial haplogroups have been reported to reduce risk of 
developing PD, and have a higher sepsis survival rate (Pyle et al., 2005; Lorente et 
al., 2013). This suggests that mtDNA variants may have more protective or 
detrimental implications when mtDNA is exposed to biological stresses, and may 
contribute to mtDNA CN regulation (which is investigated in Chapter 1). Therefore it 
is possible to hypothesise that mtDNA variants may alter the ability for replication 
machinery to bind and function under certain conditions more than that of other 
variants. Which in turn could alter the redox state the cell is performing under, 
leading to further downstream signalling cascades to alter mitochondrial biogenesis. 
For example, changes in redox state trigger mitochondrial fusion events, and the 
efficiency at which mitochondria can accommodate would determine the fate of the 
mitochondrion and cell (Meyer and Bess, 2012). Indications of this are already 
reported in neutrophils of people with SLE, whose neutrophils, which are exposed to 
autoantibodies, release mtDNA instead of undergoing mitophagy (Caielli et al., 
2016). This may have long term mtDNA CN regulation defects. 
Previous literature has reported differences in blood composition between males and 
females (Bain et al., 1984; Bain, 1996). UKBS samples have not had blood 
composition differences reported between genders in their original studies (Gieger et 
al., 2011; Nalls et al., 2011; Van Der Harst et al., 2012), however my results support 
the literature, showing significant differences in blood composition between genders 
in a large European cohort (Figure 3.12 and Figure 3.13). What’s more is these 
results show significant mtDNA CN changes in blood subcomponents, which is 
dependent on overall blood cellular composition (Figure 3.14 and Table 3.4). 
One other study in the literature has investigated mtDNA CN in peripheral blood in a 
Flemish population of 689 persons. Knez and colleagues work reports a significant 
age-related decrease in mtDNA CN in their population, and mtDNA CN is significantly 
higher in females when they adjusted for age. What’s more is they report a significant 
decrease in mtDNA CN as WBC count increased, and this is consistent across WBC 
subcomponents including neutrophils, monocytes, and lymphocytes. They did not 
report any significant changes in mtDNA CN in eosinophils or basophils. On the 
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contrary though, they did report a significant increase in mtDNA CN as platelet count 
increased (Knez et al., 2016). Their results support the results recorded in this study, 
because mtDNA CN did significantly decrease with age, but only in males. My results 
also report significant decreases in mtDNA CN as WBC count increased, but this was 
strongly associated to neutrophils. No significant decreases in mtDNA CN were 
associated in monocytes or lymphocytes. In fact, significant increases in mtDNA CN 
are reported as basophil proportion, lymphocytes, eosinophils, and monocytes 
increase in my work, and there was no significant change relative to platelet count 
(Figure 3.14 and Table 3.4). 
Despite contrary belief by Dr Rushton, who believes we are only sampling 
populations of iron deficient women (Rushton et al., 2001), significantly lower 
haemoglobin and RBC reported in women (Figure 3.12Ai and ii) are also reported in 
the literature, and is believed to be a result of the menstrual cycle. Changes in blood 
composition may be an indicator of how well mitochondria are able to adapt under 
times of high redox, or immune stress. As previously mentioned, elevated 
neutrophils, monocytes, and LDH levels in blood are associated with a poor survival 
rate in patients with metastatic renal cell carcinoma (Schmidt et al., 2005). These 
elevated LDH levels may be an indicator of mitochondrial stress, as cells are trying to 
neutralise increased lactate levels as a result of inefficient aerobic respiration or 
mitochondrial trafficking. Increased lactate production is also apparent in blood from 
patients with mitochondrial diseases, which would support this theory (Robinson, 
2006; Haas et al., 2008; Magner et al., 2011). 
Finally, I was not able to detect heritability of mtDNA CN between mother and child. 
This suggests mtDNA CN is not solely genetically controlled and supports the 
literature that mtDNA CN is biologically regulated, and is not a fixed outcome like that 
of inheriting your mtDNA genome. This result also encourages the need for genome-
wide association studies to identify both nuclear and mitochondrial genes associated 
with mtDNA CN differences between generations, and investigate biological 
mediators further. 
In conclusion, the results reported in this chapter demonstrate that demographic 
factors such as age, gender, and blood count composition contribute to different 
mtDNA CN values observed in DNA samples extracted from blood, and therefore are 
important covariates that should be included in future studies.
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4.1 Introduction 
4.1.1 Nuclear - Mitochondrial Intergenomic Communication 
As well as being the source of cellular energy production, mitochondria are critical for 
managing several other functions involved in cellular homeostasis, including the 
synthesis of nucleotides, amino acids, lipids, and haem, and regulating calcium 
signalling to control cellular apoptosis, and other signalling events (Schatz, 1995; 
Duchen, 2000; Wallace, 2005b; Wallace, 2013).  
Mitochondrial biogenesis is managed by highly coordinated communication systems 
between nuclear DNA (nDNA) and mitochondrial DNA (mtDNA) (Figure 4.1), and 
involves a complex array of signalling networks to maintain both cellular and 
organelle homeostasis (reviewed by (Quiros et al., 2016)). 
 
Figure 4.1: An overview of the complex signalling systems between the mitochondria and nucleus. Image replicated 
from (Quiros et al., 2016). 
Mitochondria rely highly on nDNA, as mitochondria require over 1500 nDNA encoded 
proteins for their maintenance (O'Brien, 2002). Studies in mice which have 
undergone pro-nuclear transfer have shown that the more divergent nDNA is from 
the original genetic material, the harder it is for certain tissues to generate sufficient 
ATP through OXPHOS (McKenzie et al., 2004). Additional studies in mice 
demonstrated that by altering nuclear-mitochondrial genetic material affected their 
physical and metabolic performance (Nagao et al., 1998). This is believed to be a 
result of nDNA struggling to recognise different mtDNA (St. John, 2016). 
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Genetic divergence has also resulted in sections of mtDNA translocating to nDNA 
during evolution (Hazkani-Covo et al., 2010; Lang et al., 2012). These sequences are 
known as nuclear mitochondrial DNA sequences (NUMTs). mtDNA is believed to 
have migrated in to the nDNA under high stress conditions (Ju et al., 2015; 
Srinivasainagendra et al., 2017), and to prevent genetics being inherited as a matter 
of chance through genetic drift (reviewed by (Blanchard and Lynch, 2000)). As a 
result 15 out of 296 NUMTs are larger than 5.8 kb in size (Mourier et al., 2001), and 
more than 95% of mtDNA is believed to be duplicated across nDNA (Malik and 
Czajka, 2013) (Figure 4.2).  
 
Figure 4.2: [A] Nuclear encoded mitochondrial pseudogenes aligned to corresponding mitochondrial DNA 
(NC_012920) regions using BLAST. [B] Locations of mitochondrial pseudogenes homology in each nuclear 
chromosome. Image replicated from (Malik et al., 2011). 
Coincidentally, mtDNA CN has also been reported to change when genetic 
translocations have been reported (Reznik et al., 2016; Srinivasainagendra et al., 
2017), however it is unclear whether these changes are a result of disease 
mechanisms, or genetic translocations. 
4.1.2 Nuclear DNA and Mitochondrial DNA Copy Number Regulation 
85 of the OXPHOS structural subunits are coded for by nDNA (Anderson et al., 1981; 
Wallace, 1999; Smeitink et al., 2001), and mammalian tissues have changing 
bioenergy demands, which results in cells containing different numbers of mtDNA 
(Robin and Wong, 1988; Capps et al., 2003). There is extensive evidence 
demonstrating that the relationship between OXPHOS capacity is relative to mtDNA 
CN (reviewed by (Reinecke et al., 2009)), and that disruptions in OXPHOS 
machinery cause mtDNA CN changes (Collombet et al., 1997; Bonod-Bidaud et al., 
1999; Heddi et al., 1999). 
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Mitochondrial DNA (mtDNA) represents less than 1% of total genomic DNA present 
in eukaryotic cells (Clayton, 1982), however mtDNA replication relies entirely on 
nuclear encoded genes to replicate, and is independent to the cell cycle 
(Bogenhagen and Clayton, 1977). Mitochondrial transcription factor A (TFAM), 
mitochondrial polymerase gamma (POLG), and mitochondrial single-stranded 
binding protein (mtSSB) are nDNA encoded, and are a selection of key proteins 
involved in mitochondrial replication and transcription, and their expression is 
regulated by mtDNA CN levels. For example, in mtDNA depleted cells, TFAM levels 
are slower to recover than mtDNA CN, and this is believed to be a result of mtDNA 
CN stimulating transcription of TFAM (Seidel-Rogol and Shadel, 2002), however this 
may be regulated by NRF-1 and NRF-2, which are also involved in mitochondrial 
biogenesis regulation (Virbasius and Scarpulla, 1994). The relationship between 
TFAM and mtDNA has been extensively researched, and it is believed that TFAM is 
a molecular chaperone for mtDNA, protecting it against oxidative damage during 
transcription (Chinnery and Hudson, 2013). 
mtSSB is a nDNA-encoded protein which stabilises single-stranded regions of 
mtDNA at replication forks during mtDNA replication and transcription, and enhances 
POLG activity (Takamatsu et al., 2002). Loss of mtSSB causes decreased mtDNA 
replication, and decreased mtDNA CN (Ruhanen et al., 2010). 
POLG is the only mitochondrial replication polymerase, and is the main cause for 
mitochondrial instability disorders (Chinnery and Hudson, 2013). POLG has been 
identified in families with autosomal dominant, or autosomal recessive PEO1 
(Twinkle gene) defects, which results in high numbers of mtDNA deletions (Horvath 
et al., 2006). Additionally, mutations in POLG cause diseases such as Alpers 
Syndrome, whereby reduced mtDNA CN results in progressive cerebral atrophy 
(Stewart et al., 2011; Copeland, 2012). 
Genetic defects in nDNA-encoded genes involved in nucleotide metabolism also 
cause mitochondrial-related diseases. Mitochondrial depletion syndromes (MDS) are 
a rare cause of mitochondrial disease, and are characterised by a 30% lower mtDNA 
CN than normal cells (Rötig and Poulton, 2009), which results in multi-organ failure 
as tissues rely highly on aerobic respiration (El-Hattab and Scaglia, 2013). MDS are 
often a result of mutations in nDNA genes such as mitochondrial thymidine kinase 2 
(TK2), deoxyguanosine kinase (DGUOK), and Twinkle (C10orf2). Mutations in TK2, 
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and DGUOK disrupt nucleotide pooling, which reduces mtDNA replication efficiency, 
therefore severely depleting mtDNA CN (Copeland, 2012; Chinnery and Hudson, 
2013). Additionally, mutations in adenine nucleotide translocase 1 (ANT1) interrupts 
mitochondrial membrane ADP-ATP exchange which causes further nucleotide 
imbalances, and mtDNA CN depletion (El-Hattab and Scaglia, 2013; Nikkanen et al., 
2016). MDS has been extensively reviewed in the literature (Rötig and Poulton, 2009; 
Copeland, 2012). 
nDNA and mtDNA inter-genomic communication is extremely sensitive, and Dean 
and colleagues even report complete loss of mtDNA in African trypanosome 
Trypanosoma brucei parasites as a result of small amino acid changes in nDNA 
(Dean et al., 2013). Kelly and colleagues also identified the importance of efficient, 
and co-ordinated nDNA-mtDNA communication during differentiation in mouse 
embryonic stem cells, whereby nuclear reprogramming lead to unregulated mtDNA 
CN levels and ATP content, which prevented normal differentiation (Kelly et al., 
2013b). 
Despite extensive literature reporting genes associated to disease, or mechanisms 
by which mtDNA CN changes, no study has attempted to identify genes that regulate 
mtDNA CN in large populations of healthy individuals. Therefore, to address this, I 
performed a genome-wide association study (GWAS) in a large population of 
unrelated, healthy, European individuals to identify nuclear genes which are 
associated with mtDNA CN changes. 
4.1.3 A Brief History of Genome-wide Association Studies 
A GWAS is an approach that involves finding associations between a particular trait 
and (usually millions of) genetic markers across DNA (National Human Genome 
Research Institute, 2003). The large number of genetic markers being tested makes 
GWAS beneficial for finding genetic variations associated to complex diseases such 
as type 2 diabetes (Morris et al., 2012; Replication et al., 2014; Fuchsberger et al., 
2016), obesity (Locke et al., 2015; Shungin et al., 2015), immune disorders 
(Petukhova et al., 2010; Okada et al., 2014; Ahola-Olli et al., 2017), and neurological 
illness (International Multiple Sclerosis Genetics et al., 2011; Lambert et al., 2013; 
Nalls et al., 2014; consortium, 2015), as well as common traits like height (Wood et 
al., 2014; Marouli et al., 2017). GWAS have increasingly become more popular in 
recent years as genetic sequencing has become cheaper, and data are more 
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accessible. As a result, a catalogue of published GWAS is available (Hindorff LA. et 
al., 2017). 
The introduction of the International HapMap Project in 2003 was also a major 
contribution to the increase of GWAS. As an international consortium, the HapMap 
Project was set up to map common genomic patterns of human DNA sequence 
variation between different populations, in the hope that they could be used to 
identify sequence variants associated with complex diseases. Genomic patterns 
were identified by using more than one million sequence variants, their frequencies, 
and degree of association between them, and the data was freely available to the 
public (International HapMap, 2003). Since then, the HapMap project has continued 
to grow, and in 2007 a haplotype reference panel of 420 haplotypes across 3.1 
million SNPs in three continental populations was available, and more recently the 
1000 Genomes Project has been set up to cumulate a reference panel of 5008 
haplotypes over 88 million variants from 26 worldwide populations using datasets 
from low-coverage whole-genome sequencing (WGS) (Genomes Project et al., 
2015). This resulted in projects collating data together to create haplotype reference 
panels (Genome of the Netherlands, 2014; Sidore et al., 2015), which have been a 
vital resource to be able to increase genetic power in GWAS, as genotyping data can 
be imputed using these reference panels (Marchini et al., 2007; Howie et al., 2009; 
Huang et al., 2015).  
GWAS in centenarians across different populations of people have reported 
inconsistencies in results when searching for loci associated to complex traits, 
because both environmental and genetic factors contribute to the trait developing 
(Aulchenko et al., 2009; Garagnani et al., 2014; Wood et al., 2014). For example, the 
mitochondrial proteome shows tissue specific profiles and has different bioenergetic 
behaviours (Malik and Czajka, 2013). Several GWAS have identified nuclear genes, 
involved in mitochondrial biogenesis, to be associated with age-related diseases; 
such as PPAR-γ, PGC-1α, and UCPs (Jia et al., 2010; Manning et al., 2012; Morris et 
al., 2012; Wallace, 2013; Garagnani et al., 2014). Garagnani and colleagues discuss 
how a number of genes involved in the regulation of mitochondrial bioenergetics also 
contribute to longevity, by looking at nDNA, mtDNA and microbiome DNA interactions 
(Garagnani et al., 2014). 
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Several models for testing continuous traits in an association-like study have been 
suggested (Shin and Lee, 2015; Wu and Pankow, 2015), whereby mixed-models try 
to accommodate to environmental and genetic variability. However, larger sample 
sizes are usually needed, which usually require meta-analysis of datasets, but this 
also has limitations and bias which need to be adjusted for (Egger et al., 1997; 
Rucker et al., 2011; Mueller et al., 2013). Genome-wide significant threshold is 
usually set at 5.00E-08 to avoid false positive discoveries due to hundreds of tests 
being performed across millions of SNPs (Visscher et al., 2014). 
4.1.4 Justification for Study 
A PubMed search for [mitochondrial copy number] reports more than 2000 
publications, however there are no publications whereby a GWAS has been 
performed to identify genetic variants contributing to mtDNA CN changes. Curran 
and colleagues used linkage analysis in 42 extended Mexican-American families to 
try and address this, however they only measured 439 highly polymorphic markers 
(Curran et al., 2007). Cai and colleagues also performed a GWAS in over 10,000 
Chinese individuals, and calculated mtDNA CN as a proxy from low coverage 
sequencing data (Cai et al., 2015). Their study identified a variant in TFAM (p= 
8.73E−28), and variant in CDK6 (p= 6.03E-16) to be associated with mtDNA CN 
changes in individuals with major depressive disorder (MDD). However, another 
GWAS conducted in over 5000 Chinese with MDD, could not replicate these results 
(consortium, 2015). Furthermore, Cai and colleagues did not conduct any real-time 
PCR assay measurements to validate the accuracy of proxy measurements to actual 
mtDNA CN measurements, thereby limiting the reliability of the results. 
Based on my results in section 3.3.6, the heritability of mtDNA CN is also very low, 
however other studies have reported heritability to be about 60% (h2=0.60) (Curran et 
al., 2007; Xing et al., 2008), therefore it would be expected that a few nuclear genes 
would be regulating mtDNA CN, and not a single locus as reported by Cai’s group 
(Cai et al., 2015). Therefore to address this, I performed a GWAS in over 8000 
healthy, European individuals, using actual measures of mtDNA CN. 
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4.2 Aim 
To identify nuclear genetic loci associated with mtDNA CN changes by performing a 
GWAS in a large, healthy, unrelated, European population. Then a meta-analysis will 
be performed in an independent, healthy, unrelated, European population to validate, 
and replicate, the loci identified in the discovery study. 
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4.3 Materials and Methods 
4.3.1 Cohorts 
4.3.1.1 Cohort One - UKBS 
Full cohort details and methods are available in Chapter 2. For work in this chapter, 
3091 UKBS DNA samples which had been extracted from white blood cell pellets 
from blood using phenol-chloroform methods were provided to Newcastle University, 
and FBC data was provided for 2617 samples through collaboration with Professor 
Willem H. Ouwehand at University of Cambridge. Relative mtDNA CN was 
determined using an established triplex TaqMan™ qPCR assay, quantifying 
mitochondrial genes MT-ND1 and MT-ND4, to nuclear housekeeping gene B2M 
(Grady et al., 2014a; Pyle et al., 2015b; Rygiel et al., 2015). 2735 samples had 
1,152,686 variants successfully genotyped on the on the Illumina 1.2M Duo array 
(Illumina, San Diego, California, USA), of which 2682 (n=1336 males, n=1346 
females) had both genotyping and mtDNA CN data.  
4.3.1.2 Cohort Three - ALSPAC 
Full cohort details and methods are available in Chapter 2. For work in this chapter, 
5461 ALSPAC mothers were used as a replication cohort to this study. DNA for 
qPCR analysis was either extracted from whole blood (37.6%) or WBC (62.4%) using 
a phenol-chloroform method (Fraser et al., 2013), and estimated blood cell count 
data was generated for 546 samples. Relative mtDNA CN was determined using a 
singleplex SYBR® Green assay which quantified a region of the mitochondrial D-loop 
to nuclear housekeeping gene B2M. All samples were additionally genotyped on the 
Illumina Human660W-Quad array (Illumina, San Diego, California, USA), and all 
samples had both SNP genotyping and mtDNA CN data. All analysis for cohort three 
was conducted at University of Bristol, and summary data was provided to Newcastle 
University to perform respective meta-analysis’. 
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4.3.2 Pre-Imputation 
4.3.2.1 Cohort One - UKBS 
Following advised quality-control check protocols (Anderson et al., 2010), and in line 
with previous GWAS (Burton et al., 2007; Hudson et al., 2013b; Fuchsberger et al., 
2016), genotyping data was cleaned, and quality control checks were performed 
using PLINK v1.90b3p 64-bit (2 Aug 2014) (Purcell et al., 2007). 
4.3.2.1.1 Genotype Filtering 
Before QC, samples had an average missingness rate of 0.0023 (±0.0058 s.d), and 
11 individuals were removed for missingness >5%. 4,249 variants were removed due 
to missing genotype call rates >5%, 12,344 variants were removed due to Hardy-
Weinberg threshold 1.00E-06, and 187,314 variants were removed due to minor 
allele threshold <1% (Burton et al., 2007). 2724 individuals (1358 males, 1366 
females) and 948,779 variants passed QC, with a total genotyping rate of 0.997998, 
and average missingness data rate of 0.0016 (±0.0048 s.d). Outliers for autosomal 
heterozygosity were calculated as 99.60%. No duplicate SNPs were detected as they 
were removed in the original study (Burton et al., 2007). Genotyping data was then 
restricted to autosomes, and pseudo-autosomal regions of X were removed. This 
removed 27,323 variants, with 921,456 variants remaining. 
4.3.2.1.2 Identical-by-Descent Testing 
Clustering analysis was performed and one single cluster was identified. Identical-by-
descent (IBD) analysis was performed across default size, 500kbp regions, at the 
standard threshold 0.85, then 0.2, and then without a threshold. No individuals were 
IBD at any threshold, which is expected as samples were cleaned in the original 
study (Burton et al., 2007). 
4.3.2.1.3 Principal Component Analysis 
Multi-dimensional scaling was originally used to clean UKBS genotyping data in the 
original study (Burton et al., 2007), however further principal component analysis was 
conducted to detect for any individuals with non-European ancestry. PCA analysis 
was performed using the ‘—PCA’ command in PLINK, and the top 20 principal 
components of the variance-standardized relationship matrix were tested, generating 
respective eigenvalues and eigenvectors (Figure 4.3).  
  
 
 
 
Figure 4.3: Multidimensional scaling analysis on UKBS samples (n=2724). Cluster plots of eigenvectors [A] one and two, [B] two and three, [C] three and four, and [D] four and 
five. [E] Scree plot of each eigenvalue for each respective principal component number.
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4.3.2.1.4 Preparing Files to be Imputed 
To increase the genetic power of performing a GWAS on UKBS samples, SNP 
genotyping were imputed. Two imputation servers were available; the Sanger 
Imputation Server (McCarthy et al., 2015), and the Michigan Imputation Server (Das 
et al., 2016). As I had not performed imputation before, and no literature was 
published comparing imputation servers, I decided to impute UKBS genotyping data 
using both servers, and then compare results to identify which would be most 
suitable to perform my GWAS analysis.  
Both servers required genotyping alleles to be on the forward strand, and in the 
GRCh37-hg19 genome build format. UKBS genotyping data was sequenced to the 
NCBI36-hg18 genome build therefore this needed to be updated. Both servers 
advised using Will Rayner’s toolbox (http://www.well.ox.ac.uk/~wrayner/tools/) to 
perform strand alignments, and to ‘LiftOver’ genotyping data to the correct genome 
build before HRC imputation. 
4.3.2.1.4.1 Strand Alignment 
Strand alignments assume that genotyping calling algorithms use the Illumina top 
strand alleles. Despite UKBS samples being sequenced on an Illumina genotyping 
array system, strand alignment was performed to confirm accuracy. 
Recommended strand alignment instructions 
(http://www.well.ox.ac.uk/~wrayner/strand/) were used, and the ‘update_build.sh’ was 
downloaded along with the NCBI36-hg18 reference strand data - 
Human1.2MDuoCustom_v1_A-b36-strand.zip. Reference data was unzipped, and 
the final few rows of the strand file were removed, as they caused complications later 
in the data conversion. The command to action the strand alignment was:  
<update_build.sh> <UKBS_cleaned_genotype_file> <Human1-2M-
DuoCustom_v1_A-b36.strand> <output_file_name>. This generated three new binary 
files which had been updated to the forward strand alignment. 
4.3.2.1.4.2 LiftOver 
Both imputation servers use the more recent GRCh37-hg19 build of the human 
genome. Therefore the strand aligned data files were converted (‘lifted’) from the 
NCBI36-hg18 build to the GRCh37-hg19 build using UCSC’s Lift Genome Annotation 
(LiftOver) online conversion tool (https://genome.ucsc.edu/cgi-bin/hgLiftOver). Bim 
files can be converted using the online platform, or by downloading reference 
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sequences, and then manually update bim files in Unix. Both methods produced the 
same results, however I used the online tool for this study. 
Before performing any conversions, strand aligned, binary bim files were converted 
to an alternative ‘bed’ format that LiftOver could process (Figure 4.4). The new ‘bed’ 
format had to contain: chromosome number (as chrN), start base position and end 
base position of the variant (both written as a single number), and SNP ID. I also 
included major and minor alleles in the new ‘bed’ format. Once genotyping was in the 
‘bed’ format, genotyping lift over was performed. 
 
Figure 4.4: Example of converting a bim file (top) to a ‘bed’ file (bottom) format for LiftOver. 
Using the online platform; human and Mar. 2006 (NCBI36/hg18) was selected as the 
original human genome assembly build, and human and Feb. 2009 (GRCh37/hg19) 
was selected as the new genome assembly build. The minimum ratio of bases that 
must remap was set to the default of 0.95. The new ‘bed’ format genotype file was 
then uploaded to the online platform and submitted. A new genome build file was 
then generated which was downloaded. 897,705 variants (97.42%) were successfully 
updated to the GRCh37-hg19 genome build. 
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Following conversion, the UKBS converted GRCh37-hg19 build genome file had ‘#’ 
notes removed, and was manually converted back in to the correct bim format 
(Figure 4.4). The original bim file was then filtered against the new bim file to 
generate a list of variants which were not converted. This list of non-converted 
variants was then used to filter the original, strand-aligned, binary files in PLINK, 
producing binary files which contained 897,705 variants which had been strand-
aligned, and converted to the GRCh37-hg19 genome build. These variants were then 
sent for imputation. 
4.3.2.2 Cohort Three - ALSPAC 
19,930 individuals (mothers and children) entered the quality control pipeline, 
including 526,688 variants for mothers. Samples were removed with an average 
missingness rate >5%, and if they had indeterminate X chromosome heterozygosity, 
or extreme autosomal heterozygosity. Variants were removed with missing genotype 
call rates >5%, MAF <1%, and a Hardy-Weinberg equilibrium p value <5.00E-07. 
Multidimensional scaling of genome-wide identical by state pairwise distances, using 
the four HapMap populations as a reference, removed samples showing evidence of 
population stratification. Cryptic relatedness was assessed, and 5461 mothers were 
unrelated with an IBD >0.125. 465,740 variants passed QC, however a further 112 
were removed when genotyping was converted to the GRCh37-hg19 build, and 
another 234 variants were removed due to Hardy-Weinberg Equilibrium. 465,394 
variants were finally used for imputation. 
4.3.3 Imputation 
To increase genetic power, both UKBS and ALSPAC cohorts were imputed using the 
Haplotype Reference Consortium (HRC) reference panel. HRC release 1.0 was 
formed in 2015, and consisted of 64,976 haplotypes of predominantly European 
ancestry from 39,235,157 SNPs (McCarthy et al., 2015). Release 1.1 now contains 
64,940 haplotypes, generated from 40,176,563 SNPs and 32,470 samples 
(McCarthy et al., 2016). Imputing European cohorts is genetically advantageous 
because European-ancestry populations have longer haplotype blocks containing 
highly correlated SNPs, therefore fewer genotyped SNPs are needed for genome-
wide coverage (Edwards et al., 2013). 
ALSPAC samples were imputed to the HRC release 1.0 reference panel before our 
collaboration was organised. Therefore, to maintain consistency between analysis, 
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UKBS samples were imputed to the HRC release 1.0 (r1.0), and HRC release 1.1. 
(r.1.1) reference panels. Imputation results could then be compared between HRC 
r1.0 and r1.1 to identify quality differences. 
4.3.3.1 Cohort One - UKBS 
Following QC, liftover, and strand alignment measures, 897,705 genotyped variants 
were sent for imputation. 
4.3.3.1.1 Sanger Imputation Server 
The Sanger Imputation Service is provided by the Wellcome Trust Sanger Institute 
(Hinxton, UK), and was introduced as part of the first release of the HRC (McCarthy 
et al., 2015). UKBS cleaned genotyping binary files were converted in to VCF format 
using PLINK v1.90b3p 64-bit (2 Aug 2014) (Purcell et al., 2007) and submitted to the 
server. Genotyping data was phased using EAGLE2, which estimates haplotypes 
from the reference panel (Browning and Browning, 2011; Durbin, 2014; Loh et al., 
2016), and imputation was conducted against the HRC reference panel using 
Positional Burrows-Wheeler Transform (PBWT) methods 
(https://github.com/VertebrateResequencing/pbwt), which store and compute on 
genome variation data sets. UKBS genotyping data was submitted twice to the 
Sanger Imputation Server to allow genotyping to be imputed to HRC r1.0, and HRC 
r1.1 reference panels. Following imputation, VCF files were downloaded from the 
server using Globus data sharing. 
4.3.3.1.2 Michigan Imputation Server 
Michigan Imputation Server is a remote server which is powered by Cloudgene and 
supported by the U.S. National Institutes of Health and the FWF Austrian Science 
Fund. UKBS cleaned genotyping binary files were separated in to separate 
chromosome files (1-22), and then were individually converted to VCF format using 
PLINK v1.90b3p 64-bit (2 Aug 2014) (Purcell et al., 2007). All VCF files were 
submitted to the imputation server, and genotyping data was phased using EAGLE2 
(Browning and Browning, 2011; Durbin, 2014; Loh et al., 2016). Imputation was 
conducted against the HRC reference panel using Minimac3 methods, which use low 
computational memory to implement imputation algorithms (Das et al., 2016). UKBS 
genotyping data was submitted twice to the Michigan Imputation Server to allow 
genotyping to be imputed to HRC r1.0, and HRC r1.1 reference panels. Following 
imputation, VCF files were downloaded directly from the server. 
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4.3.3.1.3 Sanger versus Michigan Imputation 
Both imputation servers imputed 39,235,157 variants from the HRC r1.0 reference 
panel, and 39,131,578 variants from the HRC r1.1 reference panel. To compare the 
quality of each imputation server method, MAFs and imputation scores were 
compared. 
4.3.3.1.3.1 Minor Allele Frequencies 
MAFs were generated from VCF files containing genotyped and imputed variants 
using PLINK 1.9b3.44. Scatter plots of MAFs for each variant were plotted using R 
studio version 3.0.1 (2013-05-16), whereby MAFs from Sanger-imputed data were 
compared to Michigan-imputed data (Figure 4.5). 
 
Figure 4.5: Scatter plot comparing the minor allele frequencies of variants from imputed UKBS genotyping data 
using the Sanger Imputation Server and Michigan Imputation Server. [A] Imputed data using HRC release 1.0 
reference panel. [B] Imputed data using HRC release 1.1 reference panel. 
As Figure 4.5 shows, MAFs were positively correlated between imputation servers, 
and there was no difference in variant MAFs when using the HRC r1.0 (Figure 4.5A) 
or HRC r1.1 (Figure 4.5B) reference panels, which suggested the variants in the 
reference panels were very similar. 
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4.3.3.1.3.2 Imputation Scores 
Sanger and Michigan Imputation Servers used different methods to impute 
genotyping data. Sanger used PBWT whereas Michigan used Minimac3. To identify 
the quality of imputation between Michigan and Sanger Imputation Servers, 
imputation scores were extracted from imputed VCF files using vcftools version 
0.1.12b, and using chromosomes 21 and 22 as an example, imputation scores were 
compared (Figure 4.6). 
 
Figure 4.6: Scatter plots comparing imputation scores for each respective SNP that was imputed from the HRC 
release 1.0 reference panel using either the Michigan Imputation Server (x-axis) or Sanger Imputation Server (y-
axis). [A] All chromosome 22 UKBS imputed SNPs. [B] First 5000 imputed SNPs for chromosome 22. [C] All 
chromosome 21 (blue) and 22 (red) UKBS imputed SNPs overlaid. 
  
Nuclear Factors Modulating Mitochondrial DNA Copy Number 
132 
 
As Figure 4.6 shows, imputation scores between Sanger and Michigan Imputation 
servers were not correlated, and were very different. The imputation score 
differences seemed to be a result of imputation method differences. This is because 
the same imputation score pattern replicated between chromosomes 22 (Figure 
4.6A), and 21 (Figure 4.6C). All chromosomes are not displayed because images are 
too noisy and unclear to interpret. Figure 4.6B gives a more detailed view of how 
imputation scores were so different, as only variants 1-5000 on chromosome 22 were 
graphed. The same results were reported for HRC r1.1 imputed variants. 
4.3.3.1.3.3 Variants Remaining Using Different Filters 
To investigate the effect different imputation score and MAF filters had on the 
number of imputed variants that passed QC, both Sanger and Michigan imputed 
datasets were filtered under different conditions (Figure 4.7). Imputed data was 
filtered to include variants with a certain imputation score (Figure 4.7A). All imputed 
data was then filtered to remove variants with a MAF <0.01, and then were filtered 
again using different imputation score conditions (Figure 4.7B). 
 
Figure 4.7: Line graphs depicting the number of variants remaining (y-axis) when different imputation quality scores 
(x-axis) were applied as filters to UKBS genotyped data that had been imputed using the Sanger Imputation Server 
or the Michigan Imputation Server, referenced to HRC r1.0 or HRC r1.1 reference panels. [A] No MAF filter included. 
[B] Variants also filtered for MAF< 0.01.  
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As Figure 4.7A shows, Michigan-imputed variants had more variants removed under 
certain imputation score filter conditions compared to Sanger-imputed variants when 
no MAF filter was applied. When a MAF <0.01 filter was applied, Sanger and 
Michigan-imputed variants had similar numbers of variants removed under different 
imputation score filters (Figure 4.7B). These data suggest that the Sanger Imputation 
Server is more effective at imputing rare variants (MAF< 0.01) than the Michigan 
Imputation Server because more variants are included under different imputation 
score filters in Sanger-imputed data when no MAF filter is applied, but this is 
removed when filtering MAF< 0.01 is applied. No differences were reported between 
HRC r1.1 and HRC r1.0 imputed datasets. 
To investigate this in more detail, chromosome 22 was isolated from all imputed 
datasets (because it is the smallest chromosome to analyse), and imputation score 
and MAF filters were applied, and then the number of variants remaining was 
recorded (Table 4.1). 
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Table 4.1: Number of chromosome 22 imputed variants remaining, when different quality control filters are applied. 
Sanger and Michigan imputation server methods are compared when using reference panel HRC release 1.0 or 
HRC release 1.1. INFO= imputation score. MAF= minor allele frequency. 
Table 4.1 replicates the results reported in Figure 4.7, as the number of variants 
remaining when imputation score filters alone were applied was very different 
between imputation servers. However, when MAF filters were applied, the number of 
variants remaining were very similar between servers. The number of variants 
remaining between imputation servers was more similar the more stringent the MAF 
filter applied. Results for HRC r1.0 and HRC r1.1 imputed datasets were similar 
between imputation server methods. 
Subsequent to this analysis, and following previously established methods to perform 
GWAS using imputed genotyping data, UKBS imputed data was filtered to remove 
variants with MAF <0.01 and imputation score <0.80 (Marchini et al., 2007). The ‘—
keep-allele-order’ command was included in all filtering steps to ensure correct 
reference allele assignment was maintained. 7,441,490 variants, and 2724 
individuals (1358 males, 1366 females) passed QC (Table 4.2). 
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4.3.3.2 Cohort Three - ALSPAC 
All genotyping and imputation was performed by Dr Gibran Hemani (University of 
Bristol), Dr George McMahon (University of Bristol), and Professor Jonathan Marchini 
(University of Oxford). Genotyped data was phased using ShapeIT (version 2.r644) 
(Delaneau et al., 2012; Delaneau et al., 2014; O'Connell et al., 2014), and then 
imputed to HRC version 1.0 reference panel (McCarthy et al., 2016) using IMPUTE 
(version 3) (Marchini et al., 2007; Howie et al., 2009). Following imputation, variants 
with MAF <0.01 and imputation score <0.80 were removed. 7,401,334 variants and 
5461 mothers passed QC (Table 4.2). 
  
 
 
 
Table 4.2: Summary of methods used at Newcastle University and University of Bristol to prepare UKBS and ALSPAC genotyping data for meta-analysis. 
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4.3.4 Genome-wide Association Analysis 
To ensure consistency in comparing analysis between UKBS and ALSPAC cohorts, 
genotyping data imputed to HRC r1.0 was used to match ALSPAC data. Data 
imputed using the Sanger Imputation Server was used for all GWAS analysis 
because more variants remained following QC filters. Linear additive models were 
tested using PLINK v1.90b3p 64-bit (2 Aug 2014) (Purcell et al., 2007), using 
expected allelic score dosage data for ALSPAC, and best guess format data for 
UKBS. The threshold for genome-wide significance was set at p= 5.00E-08. 
4.3.4.1 Cohort One - UKBS 
4.3.4.1.1 Pre-imputation 
Initial GWAS analysis was performed on NCBI36-hg18 genome build SNP genotyped 
data which had autosomes removed, and had been cleaned using filters detailed in 
section 4.3.2.1. 921,456 variants and 2724 individuals (1358 males, 1366 females) 
were included in linear association analysis using logged, z-scored mtDNA CN as a 
continuous phenotype. 2671 individuals had phenotype and genotype data. 
4.3.4.1.1.1 Covariates 
Basic analysis included four PCAs and panel as covariates to adjust for population 
heterogeneity, and genotyping batch effects. Gender, age, and blood count 
information including; absolute eosinophil count (EA), absolute monocyte count (MA), 
absolute lymphocyte count (LA), absolute neutrophil count (NA), and platelet counts 
(PLT) were included as extra covariates to investigate their effect on association test 
results. Four PCAs were determined as most appropriate to include in all analysis 
(Figure 4.3). Blood count information was available for 2305 individuals, however 
2292 individuals had additional platelet count data. 
4.3.4.1.2 Post-imputation 
GWAS analysis was conducted on genotyping data which was imputed using the 
Sanger Imputation Server on the GRCh37-hg19 genome build to the HRC version 
1.0 reference panel (McCarthy et al., 2016). Imputed variants with a MAF <0.01 and 
imputation score <0.80 were removed, and then linear additive association tests were 
performed using logged z-scored mtDNA CN as a continuous phenotype. A further 
filter of MAF <0.01 was included in all association testing, and 95% confidence 
intervals were included in output files using the ‘—ci’ command. 7,441,490 variants 
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and 2724 individuals (1358 males, 1366 females) passed QC and were included in 
analysis when analysing all UKBS data. 2671 individuals had phenotype data. As a 
discovery study, genome-wide significant (GWS) threshold was set at p <5.00E-08. 
4.3.4.1.2.1 Stratifying by Gender 
GWAS analysis was also performed on UKBS imputed data stratified by gender 
using the ‘—filter-females’ and ‘—filter-males’ command in PLINK. Additive, linear 
association testing was then performed on female, and male data individually. 
7,369,986 variants and 1358 individuals were included in male only analysis, of 
which 1333 had phenotypic data, and 7,373,492 variants and 1366 individuals were 
included in female only analysis, of which 1338 had phenotypic data. 
4.3.4.1.2.2 Covariates 
All GWAS analysis had a basic adjustment including four PCAs, panel, age, and 
gender as covariates (removing gender in gender-specific analysis). Full GWAS 
analysis also included absolute neutrophil and lymphocyte counts. Absolute 
monocyte and eosinophil counts data was not available for ALSPAC samples; 
therefore to keep analysis consistent between cohorts, MA and EA were not included 
as covariates for UKBS analysis. 
4.3.4.2 Cohort Three - ALSPAC 
4.3.4.2.1 Post-imputation 
GWAS analysis was conducted on genotyping data which was imputed on the 
GRCh37-hg19 genome build to the HRC version 1.0 reference panel (McCarthy et 
al., 2016). Imputed variants with a MAF <0.01 and imputation score <0.80 were 
removed, and then linear additive association tests were performed using logged, z-
scored mtDNA CN as a continuous phenotype. 7,401,334 variants and 5461 mothers 
passed QC (Table 4.2). As a replication study, GWS threshold was set at p <1.00E-
05. 
4.3.4.2.1.1 Stratifying by DNA Source 
Anna Guyatt at University of Bristol reported significant differences in mtDNA CN 
between samples which had been extracted from whole blood, or white blood cell 
pellets, therefore ALSPAC mothers were stratified by DNA source. 2056 ALSPAC 
mothers were included in whole blood analysis, and 3405 mothers were included in 
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white cell analysis. Basic and full adjustment GWAS were performed on all ALSPAC 
mothers, and then mothers stratified by DNA source. 
4.3.4.2.1.2 Covariates 
Basic adjustment included age, DNA concentration (ng/μL), and two PCAs as 
covariates. Source of DNA (white blood cell pellets, or whole blood cells) was also 
included in basic analysis when analysing all mothers (n=5461). Full adjustment 
analysis also included estimated neutrophil and lymphocyte cell counts as covariates.  
4.3.5 Meta-analysis 
PLINK linear association output files do not contain all the information needed to 
perform a meta-analysis, therefore UKBS GWAS summary data was manually 
manipulated in to the correct format before conducting meta-analysis, adding in 
imputation score and reference allele information (Figure 4.8). Variants in PLINK 
formatted, linear association output files were matched to their previously extracted 
imputation scores (details in section 4.3.3.1.3.2) using their chromosome and base 
position (Figure 4.8B). Columns were then reordered into the correct META format 
using ‘awk’ (Figure 4.8C). The final formatted files were then used for meta-analysis. 
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Figure 4.8: Reformatting process of converting PLINK linear association output files [A], in to META software 
formatted files [C], by first matching variants with their imputation score using their chromosome and base position 
[B]. 
To make cohorts comparable respective to DNA extraction source, meta-analysis 
was conducted using GWAS summary data from all UKBS samples (n=2671), and 
ALSPAC samples extracted from white blood cells (n=3405). A further meta-analysis 
was conducted on only UKBS females (n=1338), with ALSPAC white blood cell 
extracted samples to make cohorts comparable on a DNA, and gender basis. Both 
types of analysis were performed using basic adjusted summary data, and then fully 
adjusted summary data (including cell counts). Random-effects meta-analysis was 
performed using META version 1.7 (Marchini et al., 2007; Liu et al., 2010). Variants 
where then removed if their heterogeneity score was -1, and if the variant was only 
present in one cohort. 7,183,687 variants were included in the final meta-analysis of 
all UKBS, and ALSPAC white cell mothers with basic adjustments. 7,068,168 
variants were included in the final meta-analysis of all UKBS, and ALSPAC white cell 
mothers with full adjustments. 7,142,717 variants were included in the final meta-
analysis of UKBS females only, and ALSPAC white cell mothers with basic 
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adjustments, and 7,034,240 variants were included in the final meta-analysis of 
UKBS females only, and ALSPAC white cell mothers with full adjustments. 
4.3.5.1 Locus Zoom 
Variants with p <=1.00E-05 were extracted from meta-analysis summaries, and 
regions with three or more variants associated to one loci were plotted using 
LocusZoom (Pruim et al., 2010). Meta-analysis summaries were restricted to the 
chromosome where the loci of interest was located. Individual files were then 
uploaded to LocusZoom, and the variant with the smallest p value was used as the 
reference variant. SNPs with a flanking size ± 400 Kb were also plotted, using 
genome build hg19/1000 Genomes Nov 2014 EUR as the reference build. 
4.3.6 Software 
4.3.6.1 Cohort One - UKBS 
GWAS analysis was conducted using PLINK v1.90b3p 64-bit (2 Aug 2014) (Purcell et 
al., 2007). Manhattan and quantile-quantile (QQ) plots were generated using R 
Studio version 3.0.1 (2013-05-16). Manhattan plots were generated using an updated 
version of ‘qqman’ R package, revised by Professor Heather Cordell at Newcastle 
University. Ensembl (Aken et al., 2016; Herrero et al., 2016), and GeneCards (Stelzer 
et al., 2002; Weizmann Institute of Science, 2015) were used to annotate variants to 
their respective genes. META version 1.7.0 was used to meta-analyse results 
(Marchini et al., 2007; de Bakker et al., 2008; Liu et al., 2010). 
4.3.6.2 Cohort Three - ALSPAC 
GWAS were conducted using SNPTEST version 2.5.0 (Marchini et al., 2007). 
Manhattan and QQ plots were created using the ‘qqman’ R package in R 3.0.1 
[http://cran.r-project.org/web/packages/qqman/]. ANNOVAR was used to perform 
gene annotations [http://annovar.openbioinformatics.org/en/latest/] (Wang et al., 
2010b), and the ‘clusterBed’ function of ‘bedtools’ v2 
[https://github.com/arq5x/bedtools2] (Quinlan and Hall, 2010) was used to group 
borderline significant loci into clusters, according to whether they were within 1 Mb of 
each other. META version 1.7.065 was used to meta-analyse results (Marchini et al., 
2007; de Bakker et al., 2008; Liu et al., 2010). Regional association plots were 
produced with LocusZoom v1.3 (Pruim et al., 2010), using the 1000G March 2012 
reference (the most recent hg19 source population available). 
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4.3.7 Statistical Power 
Statistical power calculations were performed using a G×G or G×E interaction, 
Windows-based software program called QUANTO (Morrison and Gauderman, 
2002), and were calculated on the assumption that mean mtDNA CN would be 200 
copies/cell, with a standard deviation of 15% (equating to ±30 copies/cell) (further 
details in section 2.11). 
4.3.7.1 Cohort One - UKBS 
Given an estimated sample size of 3500 individuals, and a type one error rate of 
5.00E-08 (expected GWAS significance level) (International HapMap, 2005; Pe'er et 
al., 2008; Barsh et al., 2012), power calculations indicate that we have >80% power 
to detect a significant association assuming a MAF >0.50, and an effect size (βG) 
of >4.5 (Figure 4.9A). The power of the study will decrease as MAF or βG decreases. 
If βG is reduced to 4.0, then the study will only have 60% power for MAF >0.50. 
Similarly, if MAF >0.30, then the study will only have 65% power for a βG of >4.5. 
4.3.7.2 Cohort Three - ALSPAC 
As a replicate cohort, we will attempt to replicate the top 1% variants (approximately 
5000 variants) in the ALSPAC cohort, therefore power calculations were based on a 
type one error of 1.00E-05 instead. Power calculations were simulated on the same 
conditions as UKBS samples, but using 5461 ALSPAC samples available. There is 
87.77% power to replicate nuclear variant with a MAF of 51%, but with a βG of 3.2 
(Figure 4.9B). 
 
Figure 4.9: Simulated power calculations to determine a significant nuclear variant association with mitochondrial 
DNA copy number (µ=200 copies/cell, ±30 copies) in [A] UKBS samples (n=3091), where p=5.00E-08, and [B] 
replicate cohort ALSPAC samples (n=5461), where p=1.00E-05. Individual coloured lines represent variant MAFs 
– indicated under x-axis. Red dotted line indicates 80% power threshold. 
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4.3.7.3 Meta-analysis 
Given a combined sample size of approximately 9000 individuals, and a type one 
error rate of 5.00E-08 (expected GWAS significance level) (International HapMap, 
2005; Pe'er et al., 2008; Barsh et al., 2012), power calculations indicate that we 
have >80% power to detect a significant association assuming a MAF >0.10, and an 
βG of >4.8. If MAF were to increase, we have >80% power to detect MAF >0.40, and 
an βG of >3.0 (Figure 4.10). 
 
Figure 4.10: Simulated power calculation to determine a significant nuclear variant association with mitochondrial 
DNA copy number (µ=200 copies/cell ±30 copies) in a meta-analysis study of 9000 individuals, where p=1.00E-05. 
Individual lines represent variant MAFs. Red dotted line indicates 80% power threshold. 
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4.4 Results 
4.4.1 Mitochondrial DNA Copy Number Distributions in Study Cohorts 
To ensure mtDNA CN phenotypes were comparable between UKBS and ALSPAC 
cohorts, frequency distribution curves were generated for raw mtDNA CN and logged 
z-scored mtDNA CN in both cohorts (Figure 4.11). UKBS was also stratified by 
gender to visualise mtDNA CN distributions individually. As Figure 4.11 [A]-[D] show, 
the distributions of raw mtDNA CN are negatively skewed in both cohorts, however 
logging and z-scoring values normalised the distributions (Figure 4.11 [a]-[d]). 
Frequency distributions between UKBS gender cohorts were also comparable, 
therefore logged z-scored mtDNA CN values were used for all future analysis. 
4.4.2 UKBS as a Discovery Study 
4.4.2.1 GWAS using Non- Imputed Data 
The UKBS cohort acted as a discovery cohort for this study. Additive linear QTL 
association tests were conducted using UKBS genotyping data (on the human 
NCBI36-hg18 build) which had been cleaned and restricted to autosomes. To identify 
covariates to include in association testing models, factors such as age, gender, and 
blood count information were adjusted for in individual analysis and compared. 
Association models selected were:  
 Four PCAs and panel (UKBS samples were collected as two independent 
panels) 
 Four PCAs, panel, and age 
 Four PCAs, panel, and gender 
 Four PCAs, panel, age, and gender 
 Four PCAs, panel, age, gender, EA, MA, LA and NA 
 Four PCAs, panel, age, gender, EA, MA, LA, NA, and PLT. 
Four PCAs and panel were included in all analysis to adjust for population 
heterogeneity, and genotyping batch effects. GWAS results for each analysis are 
recorded in Figure 4.12, with respective QQ plots (Figure 4.13). Variants with a p 
value <=1.00E-06 were then identified and compared between analysis (Table 4.3). 
As Figure 4.12 and Table 4.3 show, there is no difference in the top results when 
age, and gender are included in the GWAS model. This is also demonstrated by no 
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change in the lambda values in Figure 4.13a-d. Variant rs6421779 on chromosome 1 
consistently has a genome-wide significant p value (p <5.00E-08) across all analysis. 
Variants rs1897023, rs2899527, rs12898299, and rs12901124 on chromosome 15 
consistently have p values <=1.00E-06 across all analysis, except when blood count 
information is included as covariates. Variants rs10119358 on chromosome 9, and 
rs733631 on chromosome 16 are only associated (p <=1.00E-06) with mtDNA CN 
when blood count information is included in association models. rs6421779 on 
chromosome 1 is negatively associated with mtDNA CN, and all other variants are 
positively associated with mtDNA CN. 
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Figure 4.11: Frequency distribution plots of [A]-[D] mitochondrial DNA copy number (copies/cell) and [a]-[d] logged 
z-scored mitochondrial DNA copy number in UKBS and ALSPAC cohorts. [A, a] All UKBS samples (n=2682). [B, b] 
UKBS males only (n=1336). [C, c] UKBS females only (N=1346). [D, d] All ALSPAC samples (n=5461) – graphs 
provided by Anna Guyatt, Dr Santi Rodriguez’s group, University of Bristol, UK.  
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Figure 4.12: Manhattan plots of GWAS linear regression analysis of logged z-scored mitochondrial DNA copy 
number against 921,456 non-imputed genotyped nuclear SNPs in UKBS samples (n=2671). Tests adjusted for; [A] 
four PCAs and panel. [B] Four PCAs. panel, and age. [C] Four PCAs. panel, and gender. [D] Four PCAs. panel, 
age, and gender. [E] Four PCAs. panel, age, gender, and absolute eosinophil, lymphocyte, monocyte and neutrophil 
counts. [F] Four PCAs. panel, age, gender, absolute eosinophil, lymphocyte, monocyte and neutrophil counts, and 
platelet counts. Respective QQ plots are in Figure 4.13. Summary of top hits are in Table 4.3. 
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Figure 4.13: QQ plots of GWAS linear regression analysis of logged z-scored mitochondrial DNA copy number 
against 921,456 non-imputed genotyped nuclear SNPs in UKBS samples (n=2671). Tests adjusted for; [a] four 
PCAs and panel. [b] Four PCAs. panel, and age. [c] Four PCAs. panel, and gender. [d] Four PCAs. panel, age, and 
gender. [e] Four PCAs. panel, age, gender, and absolute eosinophil, lymphocyte, monocyte and neutrophil counts. 
[f] Four PCAs. panel, age, gender, absolute eosinophil, lymphocyte, monocyte and neutrophil counts, and platelet 
counts. X-axis: Expected chi-squared. Y-axis: Observed chi-squared. Respective Manhattan plots are in Figure 
4.12. 
 
  
 
 
 
 
 
 
 
 
Table 4.3: Details of top (p<=1.00E-06) non-imputed, genotyped variants which are linearly associated with logged, z-scored mitochondrial DNA copy number in UKBS samples 
(n=2671), when covariates such as PCAs, panel, age, gender and blood cell counts are adjusted for. PCA: Principal Components. EA: Absolute eosinophil counts. LA: Absolute 
lymphocyte counts. MA: Absolute monocyte counts. NA: Absolute neutrophil counts. PLT: Platelet counts. CHR: chromosome. BP: base position. A1: Minor allele. N: number of 
observations. MAF: Minor allele frequency. BETA: Regression coefficient. STAT: T-statistic. P: P-value.  
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4.4.2.2 GWAS using Imputed Data 
UKBS samples were imputed using the Sanger Imputation Server (McCarthy et al., 
2016). Following imputation, linear GWAS tests were performed on all UKBS data 
(n=2671) using basic or full adjustments (Figure 4.14A and B respectively). Despite 
reporting no significant difference in mtDNA CN between genders (section 3.3.3), 
ALSPAC samples were all female, therefore UKBS samples were stratified by gender 
to maintain consistency between analysis, and identify if there were gender specific 
genetic associations with mtDNA CN differences. Basic and full adjustment linear 
GWAS analysis were performed on each UKBS group (Figure 4.14), and variants 
with a p value <=1.00E-06 were recorded (Table 4.4). Respective QQ plots are 
displayed in Figure 4.15. 
As Figure 4.14 shows, GWAS results were different between genders. As Table 4.4 
summarises, 24 variants were reported in all UKBS, basic adjusted analysis. 20 
variants were located in gene UNC13C on chromosome 15, however only one 
variant was GWS (p <5.00E-08). This result was lost when cell count was adjusted 
for, and only three, single variants were reported in a long intergenic non-coding RNA 
(lincRNA), KANK1, and PPL. Variants rs75741190 in KANK1, and rs733631 in PPL 
were GWS. Three variants, which identified to one intergenic region, and MYT1L 
were top results for male only, basic adjusted analysis, however neither were GWS. 
Only rs13070764 in the intergenic region was replicated in full adjusted analysis, 
however one variant (rs77132217) in SLC25A13 was GWS-associated with a 
positive change in mtDNA CN. In female only, basic analysis, only one top variant 
(rs733631) was reported to PPL. This was replicated when cell count was adjusted 
for, and was close to GWS (p =5.78E-08). Three variants in a lincRNA were also 
reported in this analysis, however they were not GWS.  
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Figure 4.14: Manhattan plots of GWAS linear associations of imputed nuclear SNPs and logged z-scored 
mitochondrial DNA copy number in [A, B] all UKBS samples (n=2671), and UKBS samples stratified by [C, D] males 
(n=1333), and [E, F] females (n=1338). [A] Basic adjusted for four PCAs, panel, age and gender. [B] Fully adjusted 
for four PCAs, panel, age, gender, and absolute lymphocyte, and neutrophil counts. [C] and [E] Basic adjusted for 
four PCAs, panel, and age. [D] and [F] Fully adjusted for four PCAs, panel, age, and absolute lymphocyte, and 
neutrophil counts. Respective QQ plots are detailed in Figure 4.15. Arrows indicate variants where p<=1.00E-06 
(summarised in Table 4.4). 
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Figure 4.15: QQ plots of GWAS linear associations of imputed nuclear SNPs and logged z-scored mitochondrial 
DNA copy number in [a, b] all UKBS samples (n=2671), and UKBS samples stratified by [c, d] males (n=1333), and 
[e, f] females (n=1338). [a] Basic adjusted for four PCAs, panel, age and gender. [b] Fully adjusted for four PCAs, 
panel, age, gender, and absolute lymphocyte, and neutrophil counts. [c] and [e] Basic adjusted for four PCAs, panel, 
and age. [d] and [f] Fully adjusted for four PCAs, panel, age, and absolute lymphocyte, and neutrophil counts. X-
axis: Expected chi-squared. Y-axis: Observed chi-squared. Respective Manhattan plots are in Figure 4.14.  
  
 
 
 
 
Table 4.4: Details of top variants (p <=1.00E-06) for linear association analysis of mitochondrial DNA copy number and imputed nuclear SNPs in UKBS samples, stratified by 
gender. Results reported summarise respective figure data in Figure 4.14.  
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4.4.3 ALSPAC as a Replication Study 
4.4.3.1 Mitochondrial DNA Copy Number Assay Validation 
Before performing genotype analysis between UKBS and ALSPAC cohorts, initial 
tests were performed to check that mtDNA CN values were not significantly different 
between UKBS and ALSPAC samples as a result of using different qPCR assays. 
Therefore, 185 randomly-selected, blinded UKBS samples were sent to Dr 
Rodriguez’s group at University of Bristol, and 169 randomly-selected, blinded 
ALSPAC samples were sent to Newcastle University. PG, who originally measured 
mtDNA CN in all of the ALSPAC samples, no longer worked at University of Bristol 
therefore AG performed qPCR tests. Scatter plots were generated following qPCR 
analysis and compared (Figure 4.16). 
 
Figure 4.16: Scatter plots to identify the correlation of UKBS and ALSPAC Z-scored mitochondrial DNA copy 
number values when using different qPCR assays. [A] ALSPAC samples (n=55) measured by AG and PG at 
University of Bristol. [B] ALSPAC samples (n=169) measured by PG at University of Bristol, and RB at Newcastle 
University. [C] UKBS samples measured by RB at Newcastle University and AG at University of Bristol (n=185). 
Graphs generated by AG in Dr Santi Rodriguez’s group at University of Bristol, UK. 
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As Figure 4.16A shows, qPCR measurements conducted on the same 55 ALSPAC 
samples by AG and PG generated mtDNA CN values which correlated with a 
Pearson’s value of 0.71. This reassured that AG was able to produce comparable 
results to PG’s work. ALSPAC samples, which were measured by RB at Newcastle 
University, and PG at University of Bristol, correlated with a Pearson’s correlation of 
0.66 (Figure 4.16B). UKBS samples measured by AG at University of Bristol 
correlated with measurements generated by RB at Newcastle University with a 
Pearson’s value of 0.36 (Figure 4.16C), however this improved to 0.55 when six 
outlier samples were removed (±2 s.d) (Figure 4.16D). These results validated that 
mtDNA CN values between the cohorts were comparable, despite using different 
qPCR assays, however mtDNA CN values were logged and z-scored to normalise 
results to make them comparable between cohorts. 
4.4.3.2 GWAS using Imputed Data 
Linear association tests were performed using logged, z-scored mtDNA CN as a 
continuous trait. Analysis was performed on all ALSPAC mothers (n=5461), and then 
on mothers extracted from different blood sources – whole blood (n=2056), or white 
blood cell pellets (n=3405) (Figure 4.17). Samples were stratified because mtDNA 
CN differences were reported to be different when extracted from whole blood or 
white cell pellets (Hurtado-Roca et al., 2016), and is dependent on blood cell 
composition (Pyle et al., 2010), therefore we needed to adjust for this in our models. 
Basic adjustment and full adjustments (including cell counts) were performed on 
each group, and variants with a p value <=1.00E-06 were recorded (Table 4.5). 
22 variants, with 19 variants identifying to one major loci spanning PSMD3 on 
chromosome 17 in all ALSPAC, basic adjusted analysis. This signal was lost when 
cell counts were included in the analysis, however 63 variants had a p value 
<=1.00E-06, with 42 variants spanning 10 different loci (Table 4.5B). Analysis 
performed on ALSPAC mothers extracted from whole blood samples recorded five 
variants that were genome-significant, and three variants spanned the TBC1D1 loci. 
These results were lost when cell counts were adjusted for in the model. No variants 
were genome-significant in whole blood, fully adjusted analysis (Table 4.5D). 
Analysis performed in ALSPAC mothers extracted from white blood cell pellets 
reported three variants - two variants were located in the GPC6 loci on chromosome 
19, and the other one in BTBD2 on chromosome 13. These results were also not 
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replicated when cell counts were included in the association model. However, white 
blood cell, full adjusted analysis reported 113 variants with a p value <=1.00E-6, of 
which 80 variants associated to 18 loci (Table 4.5F). Between analysis models, only 
variants located in ENPP2, EVL, PEX11G, RUNX1, and downstream of BACE2, but 
upstream of FAM3B were replicated. These replications were only reported in fully 
adjusted analysis in all ALSPAC mothers, and white blood cell extracted mothers. All 
variants associated to loci regions were positively associated with mtDNA CN 
changes, except for associations in MED24, EVL, and BTBD2 which were negatively 
associated. 
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Figure 4.17: Manhattan plots of GWAS linear associations of imputed nuclear SNPs and logged z-scored 
mitochondrial DNA copy number in [A, B] all ALSPAC maternal samples (n=5461), and ALSPAC samples stratified 
by [C, D] samples extracted from whole blood (n= 2056), and [E, F] samples extracted from white blood cell pellets 
(n=3405). [A] Basic adjusted for two PCAs, DNA concentration, age, and DNA source. [B] Fully adjusted for two 
PCAs, DNA concentration, age, DNA source and estimated lymphocyte, and neutrophil counts. [C] and [E] Basic 
adjusted for two PCAs, DNA concentration, and age. [D] and [F] fully adjusted for two PCAs, DNA concentration, 
age, and estimated lymphocyte, and neutrophil counts. Respective QQ plots are detailed in Figure 4.18. Arrows 
indicate variants where p<=1.00E-06, and details are summarised in Table 4.5. 
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Figure 4.18: QQ plots of GWAS linear associations of imputed nuclear SNPs and logged z-scored mitochondrial 
DNA copy number in [A, B] all ALSPAC maternal samples (n=5461), and ALSPAC samples stratified by [C, D] 
samples extracted from whole blood (n= 2056), and [E, F] samples extracted from white blood cell pellets (n=3405). 
[a] Basic adjusted for two PCAs, DNA concentration, age, and DNA source. [b] Fully adjusted for two PCAs, DNA 
concentration, age, DNA source and estimated lymphocyte, and neutrophil counts. [c] and [e] Basic adjusted for 
two PCAs, DNA concentration, and age. [d] and [f] fully adjusted for two PCAs, DNA concentration, age, and 
estimated lymphocyte, and neutrophil counts. X-axis: Expected chi-squared. Y-axis: Observed chi-squared. 
Respective Manhattan plots are in Figure 4.17.
  
 
 
Table 4.5: Details of top loci with variants (p <=1.00E-06) for linear association analysis of mitochondrial DNA copy number and imputed nuclear SNPs in ALSPAC samples, 
stratified by DNA source. Results reported summarise respective figure data in Figure 4.17.   
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4.4.3.2.1 DNA Source between Cohorts 
GWAS analysis conducted in whole blood extracted, and white blood cell extracted 
samples produced different results (Table 4.5). This suggested that DNA source 
affects the genetic associations of nuclear variants to mtDNA CN regulation. To keep 
analysis consistent between cohorts, and more genetically comparable, ALSPAC 
samples which were extracted from white blood cell pellets were used in meta-
analysis against UKBS samples, which had also been extracted from white blood cell 
pellets. 
4.4.3.2.2 Blood Count Data between Cohorts 
mtDNA CN differs depending on blood cell composition (section 3.3.5), and GWAS 
analysis in ALSPAC samples adjusting for lymphocyte and neutrophil cell counts 
produced different results to analysis excluding cell count adjustments (Table 4.5). 
To keep analysis consistent between cohorts, and to adjust for any blood cell 
composition differences, meta-analysis will include cell count adjustments. 
4.4.3.2.3 UKBS Replication 
Variants which were GWS significant in UKBS analysis (p <5.00E-08) were identified 
in their respective white blood cell extracted ALSPAC analysis to investigate if they 
replicated as GWS (p <1.00E-05). The GWS hit in rs8039424 on chromosome 15, 
which identified as UNC13C, was not replicated in ALSPAC analysis (p= 4.58E-01, 
β= 0.020). The remaining 19 variants in UNC13C were also not GWS in ALSPAC 
analysis. The GWS variants rs75741190 and rs733631, on chromosomes 9 and 16 
respectively, in fully adjusted all UKBS analysis were not present in ALSPAC data, 
and were therefore not replicated. In the UKBS male only, basic adjusted analysis, 
no variants were replicated in ALSPAC data. No variants were also replicated in the 
male only, fully adjusted analysis. The GWS rs77132217 variant (p= 1.54E-08), 
located on chromosome 7 to SLC25A13, p value was 9.89E-02 in ALSPAC analysis, 
and reported opposing beta values. The one variant reported in female only, basic 
analysis was not present in ALSPAC data, and was therefore not replicated. Two 
variants (rs7710144 and rs1154639), located on chromosome 5 to the lincRNA, were 
present in ALSPAC data, however they were not GWS, and reported opposing beta 
values. 
Four GWS variants (p <=5.00E-08) were identified across the UKBS discovery 
analysis, with zero replication using the ALSPAC cohort. In addition, the ALSPAC 
Nuclear Factors Modulating Mitochondrial DNA Copy Number 
 
161 
 
cohort identified over 200 GWS variants (p <=1.00E-05) across all analysis that were 
not seen in the UKBS cohort. 
4.4.3.2.4 Nuclear Genotyping Data are Comparable at the SNP Level 
To identify if the lack of replication in GWAS results was a result of differences in 
allele frequencies between the cohorts, MAFs were generated for both imputed and 
genotyped SNPs in both ALSPAC and UKBS cohorts. Variants were filtered to only 
include those that were present in both cohorts, leaving 7,156,393 SNPs which were 
then compared (Figure 4.19). 
 
Figure 4.19: Scatter plots of MAFs of ALSPAC variants against UKBS variants. [A] All common variants between 
ALSPAC and UKBS (n=7,156,393). [B] Variants with a p value< 1.00E-04 in association tests. AGUG: ALSPAC 
genotyped, UKBS genotyped. AGUI: ALSPAC genotyped, UKBS imputed. AIUG: ALSPAC imputed, UKBS 
genotyped. AIUI: ALSPAC imputed, UKBS imputed. Graphs generated and provided by Anna Guyatt from Dr Santi 
Rodriguez’s group at University of Bristol. 
As Figure 4.19A shows, MAFs of variants in both cohorts were positively correlated, 
although there were several outliers. Analysis of variants with a p <1.00E-04 in 
GWAS analysis (Figure 4.19B) reported a stronger correlation with less outliers, 
suggesting MAFs were not affecting the top results reported between cohorts 
analysis.  
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4.4.4 Meta-analysis 
Figure 4.19 demonstrates there was little difference in genotyping between ALSPAC 
and UKBS cohorts. However, Table 4.6 highlights other factors including mtDNA CN 
assay, mtDNA CN means, and blood count data contributing to heterogeneity 
between cohorts. Therefore, random effects meta-analysis was performed to adjust 
for population heterogeneity. 
Bristol reported significant differences in mtDNA CN between samples extracted from 
whole blood cells, and samples extracted from white blood cell pellets (data not 
provided), and Figure 4.17 reports different genetic associations dependent on DNA 
source. Therefore to make meta-analysis as consistent, and comparable as possible, 
meta-analysis was performed only using ALSPAC samples extracted from white 
blood cells (n=3405). 
As indicated by results in Figure 4.14 and Table 4.4, there may be gender-specific 
genetic effects contributing to mtDNA CN changes between males and females. As 
all ALSPAC samples were female, meta-analysis was performed using all UKBS 
samples (males and females) (n=2671), and then UKBS females only (n=1338). 
As reported in section 4.4.3.2.2, blood cell composition also contributed to different 
GWAS associations to mtDNA CN changes. Therefore meta-analysis was conducted 
without cell count adjustments (basic adjustment), and with cell count adjustments 
(full adjustments).  
Meta-analysis performed were: 
 All UKBS and ALSPAC mothers extracted from white blood cells – basic 
adjustment 
 All UKBS and ALSPAC mothers extracted from white blood cells – full 
adjustment 
 UKBS females and ALSPAC mothers extracted from white blood cells – basic 
adjustment 
 UKBS females and ALSPAC mothers extracted from white blood cells – full 
adjustment 
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Manhattan and QQ plots for all results are shown inFigure 4.20. Variants with a p 
value <=1.00E-06 were isolated from each set of results and are reported in Table 
4.7. 
As Table 4.7 shows, there were no GWS (p <5.00E-08) variants for any meta-
analysis tests. Variant rs56325973, located in an intergenic region on chromosome 5, 
was strongly associated (p= 9.11E-07, β= 0.223) in all UKBS, fully adjusted meta-
analysis with ALSPAC data, however it was not GWS, and was not replicated in 
other analysis. Variant rs116998574, located in PLEKHB1 on chromosome 11, was 
also strongly associated (p= 8.83E-07, β= 0.444) in UKBS females, fully adjusted 
meta-analysis with ALSPAC data, however it was also not GWS or replicated across 
analysis. 
  
    
 
 
 
 
Table 4.6: Demographic details of UKBS and ALSPAC cohorts. * indicates calculations based on individual s with genotyping and phenotype data (n=2671).
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Figure 4.20: Manhattan [A]-[D] and QQ plots [a]-[d] showing the association of imputed nuclear variants with 
mitochondrial DNA copy number changes in UKBS and ALSPAC cohorts which had been meta-analysed using 
random effects. All UKBS (n=2671) and white blood cell extracted ALSPAC samples (n=3405) [A, a] not adjusted 
for cell counts, and [B, b] adjusted for cell counts. UKBS females (n=1338), and white blood cell extracted ALSPAC 
samples (n=3405) [C, c] not adjusted for cell counts, and [D, d] adjusted for cell counts. Arrows indicate variants 
with p<=1.00E-06 detailed in Table 4.7.
  
 
 
 
 
 
 
Table 4.7: Details of top variants (p <=1.00E-06) from meta-analysis performed between UKBS and ALSPAC datasets to identify nuclear variants associated with mitochondrial 
DNA copy number changes. Results correspond to their respective Manhattan plot in Figure 4.20.
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4.4.4.1 Investigating Loci using Locus Zoom 
Figure 4.20 showed there were some regions that may be associated with mtDNA 
CN, but are underpowered. Variants with p <1.00E-05 were extracted from each 
meta-analysis summary file, and regions with three or more variants in one loci were 
investigated, and LocusZoom plots were generated (Figure 4.21 and Figure 4.22).  
In all UKBS, and ALSPAC basic adjusted analysis, 28 variants were identified in an 
intergenic region of chromosome 5 (maximum p= 2.82E-06, β=0.240) (Figure 4.21-
1). Five variants were identified in SNTG1 on chromosome 8 (maximum p= 1.00E-06, 
β= 0.091) (Figure 4.21-2), and 47 variants were identified in a loci spanning CSF3, 
MED24, PSMD3, and GSDMA on chromosome 17 (maximum p= 4.95E-06, β= -
0.064) (Figure 4.21-3). These results were not replicated in full adjustment analysis, 
however three variants in another intergenic region on chromosome 5 were identified 
(maximum p= 9.11E-07, β= 0.214) (Figure 4.21-4). Seven variants spanning CLDN23 
on chromosome 8 (maximum p= 3.07E-06, β= -0.158) (Figure 4.21-5), and 13 
variants were identified in PCSK2 on chromosome 20 (maximum p= 7.22E-06, β= 
0.169) (Figure 4.21-6). 
In female only UKBS and ALSPAC analysis, three variants in loci IQGAP2 on 
chromosome 5 were associated with mtDNA CN (maximum p= 8.26E-06, β= 0.037) 
(Figure 4.22-7), and seven variants in a domain spanning NPRL3, POLR3K, 
SNRNP25, RHBDF1, and MPG on chromosome 16 (maximum p= 2.50E-06, β= -
0.140) (Figure 4.22-8). These results were not replicated in full adjustment analysis, 
however 41 variants in PLEKHB1 on chromosome 11 were reported (maximum p= 
8.83E-07, β= 0.360) (Figure 4.22-10), which was indicated as a top meta-analysis 
variant in Table 4.7. Four variants spanning a loci domain with KPNA1, WDR5B, 
PARP9, DTX3L, and FAM162A on chromosome 3 were also reported (maximum p= 
8.50E-06, β= 0.159) (Figure 4.22-9).
  
 
 
 
 
Figure 4.21: Locus Zoom plots for loci regions with three or more variants p<=1.00E-05 from meta-analysis conducted between all UKBS (n=2671) and ALSPAC females extracted from 
white blood cells (n=3405). Plots correspond to respective Manhattan plots in Figure 4.20 [A] and [B]. [1]-[3] Loci in basic adjusted meta-analysis in graph [A]. [4]-[6] Loci in fully adjusted 
meta-analysis in graph [B]. 
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Figure 4.22: Locus Zoom plots for loci regions with three or more variants p<=1.00E-05 from meta-analysis conducted between UKBS females (n=1338) and ALSPAC females extracted 
from white blood cells (n=3405). Plots correspond to respective Manhattan plots in Figure 4.20 [C] and [D]. [7] and [8] loci in basic adjusted meta-analysis in graph [C]. [9] and [10] loci 
in fully adjusted meta-analysis in graph [D]. 
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Table 4.8: Details of top SNPs from meta-analysis in Figure 4.20 which were used to generate Locus Zoom plots in Figure 4.21 and Figure 4.22, and their corresponding loci regions 
where p<=1.00E-05.  
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4.4.5 Mitochondrial Transcription Factor A (TFAM) Candidate Look Up 
A candidate look up was conducted on the TFAM locus, which has been identified to 
be associated with mtDNA CN in one previous linkage study, and one GWAS which 
calculated a proxy mtDNA CN (Curran et al., 2007; Cai et al., 2015). Variants with 
MAF >0.01 and imputation quality >0.80 in and around TFAM (chr10: 60144782 - 
60158981) were extracted, however no variants were significant (Figure 4.23). 
 
Figure 4.23: [A] – [D] Locus Zoom plots across Mitochondrial Transcription Factor A (TFAM) loci from meta-analysis 
conducted between UKBS and ALSPAC cohorts. [E] Table summarising p values across TFAM loci for each 
corresponding meta-analysis. WC: white cell count extracted samples.  
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4.5 Discussion 
This is the largest, and most comprehensive study of nuclear genetic variants 
associated with directly-assayed mtDNA CN changes to date. Despite little genetic 
heterogeneity between UKBS and ALSPAC cohorts (Figure 4.19), our results report 
considerable differences in phenotypes and experimental measurements both 
between, and within both cohorts, and at the level of gender, DNA extraction source, 
and blood cell counts. The level of experimental heterogeneity reported may 
contribute to the lack of replication recorded between cohort analysis, resulting in no 
genetic loci being GWS (p <5.00E-08) after performing a meta-analysis. However, 
this study has identified critical variables that need to be considered, and adjusted for 
in future genetic studies. 
4.5.1 Cohort One - UKBS Discovery 
UKBS samples were a 50% mixture of male and females, and were all extracted from 
white blood cell pellets. Despite reporting no significant differences in mtDNA CN 
between genders, GWAS results suggest that there may be gender-specific genetic 
variables contributing to mtDNA CN regulation (Figure 4.14). 
The discovery study conducted in the UKBS cohort reported four GWS nuclear 
variants associated to mtDNA CN changes across all analysis (Table 4.4 – section 
4.4.2.2).  
In the full study, unadjusted for cell count, 20 variants were located in UNC13C on 
chromosome 15, however only rs8039424 was GWS (p= 4.20E-08, β= 0.1150) 
(Table 4.4: Details of top variants (p <=1.00E-06) for linear association analysis of 
mitochondrial DNA copy number and imputed nuclear SNPs in UKBS samples, 
stratified by gender. Results reported summarise respective figure data in Figure 
4.14.Table 4.4). UNC13C is a protein which is involved in vesicle maturation during 
exocytosis, and is a target of the diacylglycerol second messenger pathway. 
Although this protein has no direct links to mitochondrial biogenesis, the importance 
of efficient vesicle transportation has been identified to be important in mitochondrial 
dynamics, and regulating mitochondrial fusion and fission, as well as maintaining the 
architectural transmission within the mitochondrial inner membrane (Sugiura et al., 
2014). Emerging evidence is highlighting the importance of mitochondrial-derived 
vesicle (MDV) trafficking in immunological, and neurodegenerative diseases.  For 
example, MDVs play a role in Parkinson’s Disease development – reviewed by 
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(Roberts et al., 2016), which has strong mtDNA CN associations (Pyle et al., 2015a; 
Pyle et al., 2015b). 
In the full study, adjusted for cell count, analysis only one variant (rs75741190) in 
KANK1 on chromosome 2 was GWS (p= 5.43E-10, β= 0.4523) (Table 4.4). This was 
also a top result for the full study, unadjusted for cell count analysis, however it was 
not GWS (p= 6.32E-07, β= 0.3227). KANK1, is a member of the Kank family proteins, 
which contain multiple ankyrin repeat domains. KANK1 also has no direct 
associations with mitochondria, however knock out of KANK1 leads to tumour 
development, and upregulation of KANK1 results in increased apoptosis (Guo et al., 
2014). This suggests that KANK1’s role within regulating the cell cycle, may also be 
contributing to mitochondrial replication timings, as mtDNA CN has been reported to 
increase in cancer tumour development (Jiang et al., 2005; Mambo et al., 2005; 
Higuchi, 2007; Malik and Czajka, 2013). KANK1 was replicated in cell count adjusted 
analysis, but only in the full UKBS cohort analysis, which suggested it may be a 
realistic candidate for mtDNA CN regulation. 
In the full study, adjusted for cell count, analysis only one variant (rs733631) in PPL 
on chromosome 16 was GWS (p= 3.86E-08, β= -0.5820) (Table 4.4). This variant 
was replicated as a top result in both female-only analysis, but was not GWS. PPL, is 
a periplakin, which is a component of desmosomes. Desmosomes are intracellular 
junctions which provide adhesion between cells, but do not mediate intercellular or 
intracellular transport, and are known to interact with protein kinase-mediating 
signalling components, AKT1/PKB. Although no evidence suggests PPL has any 
direct effects on mitochondrial biogenesis, desmosomes and mitochondria are 
reported to form complexes under cellular stress, and can activate inflammatory 
responses (Rassat et al., 1981). These events may be controlled by the AKT1/PKB 
pathway, which is reported to mediate signalling events which lead to inflammation or 
mitochondrial biogenesis, through activation of PGC1-α, and NRF-1 and -2 (Cherry 
and Piantadosi, 2015). 
In male-only, cell count adjusted analysis, only one variant (rs77132217) in 
SLC25A13 on chromosome 7 was GWS (p= 1.54E-08, β= 1.1070) (Table 4.4). 
SLC25A13 on the other hand does have direct links to mitochondria, as it is a 
member of the mitochondrial carrier family. When stimulated by calcium, SLC25A13 
catalyses the exchange of aspartate for glutamate and a proton across the inner 
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mitochondrial membrane (Thangaratnarajah et al., 2014). Although no studies have 
investigated the direct effects of mitochondrial carrier proteins on mtDNA CN in 
humans, a study conducted in yeast identified a novel member of the mitochondrial 
carrier family located within a nDNA suppressor region which was vital for mtDNA 
metabolism and proper cell growth, and inactivation of this gene resulted in complete 
loss of mtDNA (Van Dyck et al., 1995). This suggests that this gene may be 
contributing to mtDNA CN regulation, however the fact only one variant was identified 
to this region, and was not replicated in other analysis suggests this may be a false 
positive association. 
No GWS results were reported in female-only analysis, however female-only, cell 
count adjusted analysis reported three variants in a loci of a lincRNA (RP11-133F8.2) 
on chromosome 5 which may be contributing to mtDNA CN regulation (maximum p= 
5.70E-08, average β= -0.4060) (Table 4.4). This lincRNA does not have a known 
functional role. However, lincRNAs have been reported to be generated from mtDNA 
under regulation of nDNA, and they form intermolecular duplexes in cell- and tissue-
specific quantities, which suggests they may have a functional role in the regulation 
of mitochondrial gene expression (Rackham et al., 2011). These variants were not 
replicated in any other analysis, again suggesting they may be false positive results. 
It is unclear why differences in results between males and females were reported in 
UKBS samples, because mtDNA CN was not significantly different between genders 
(p= 0.209 in section 3.3.3), and the MAFs of their variants were linearly correlated 
(Figure 4.24). Lopez and colleagues also reported differences in GWAS results by 
gender, despite no difference in mtDNA CN (López et al., 2012). However, their 
study was performed in hundreds of individuals, which is underpowered for a GWAS. 
Future work would need to perform mtDNA CN studies in much larger cohorts, and 
stratify by gender to identify if genetic differences reported are a limitation of 
statistical power, or indeed are a result of different genetic associations to mtDNA CN 
regulation between genders. 
Additionally, differences in mtDNA CN were reported between blood cell 
components, and blood cell composition was different between genders (section 
3.3.5), which might suggest that blood composition is also contributing to the genetic 
differences reported between gender GWAS results. 
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Figure 4.24: Minor allele frequencies of 921,456 genotyped variants in 1333 UKBS males and 1338 UKBS females. 
4.5.2 Cohort Three - ALSPAC Replication 
ALSPAC samples were only female, but were a combination of samples extracted 
from whole blood cells, and white blood cell pellets. This initially introduced a large 
amount of phenotypic variability to this study, because mtDNA CN measurements 
were significantly different when extracted from whole blood, or white blood cells 
(buffy coat) (Hurtado-Roca et al., 2016). We adjusted for this as much as possible in 
this study, and limited our analysis to only include samples extracted from white 
blood cells, to make DNA source comparable to UKBS samples. 
GWAS on all ALSPAC, and ALSPAC samples stratified by DNA source reported 37 
different loci associated with mtDNA CN (Table 4.5 – section 4.4.3.2). Cell count 
adjusted analysis in all ALSPAC, and white blood cell extracted samples reported 
multiple variants that replicated in loci of ENPP2, EVL, PEX11G, and RUNX1 (Table 
4.5). However, no loci were replicated from UKBS analysis (Table 4.4 – section 
4.4.2.2). 
In the initial analysis, for all ALSPAC samples, with no cell count adjustment, 19 
variants in the PSMD3 loci on chromosome 17 were reported (p= 6.94E-07) (Table 
4.5). PSMD3 is a proteasome 26S subunit, non-ATPase 3 protein, and is associated 
with neutrophil count (Okada et al., 2010). This association was removed when cell 
counts were introduced to the model (Figure 4.17B), which further suggests that 
mtDNA CN regulation is relative to blood cell composition, and may act as a proxy to 
cell count. This effect is also reported in females only, who have higher lymphocyte 
and neutrophil counts compared to males (section 3.3.5 - Table 3.3). 
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ENPP2 is a phosphodiesterase, and a phospholipase, which catalyses production of 
lysophosphatidic acid in extracellular fluids. Phosphodiesterases are reported to be 
important in mediating mitochondrial respiration, as they mediate cAMP signalling 
cascades in to the mitochondria, and promote mtDNA replication by stabilising TFAM 
(Acin-Perez et al., 2011; Zhang et al., 2015). Two variants were reported to be 
associated with ENPP2, with a maximum p= 2.01E-10, and β= 0.9310. 
12 and 10 GWS variants respectively were associated with EVL, with a maximum p= 
2.14E-08, and β= -0.5260 (Table 4.5). EVL is an actin-associated protein involved in 
a range of processes dependent on cytoskeleton remodelling and cell polarity. 
Mitochondria rely on the actin cytoskeleton for mobility, and to maintain their 
morphology through fusion and fission events (Boldogh and Pon, 2006). Fission and 
fusion events are vital for maintaining mitochondrial biogenesis, because they allow 
for mitochondrial replication machinery to be shared to maintain OXPHOS 
homeostasis and mitochondrial membrane potential. 
Two variants were identified in PEX11G, with a maximum p value of 7.00E-09, β= 
0.8820 (Table 4.5). PEX11G is a member of the PEX11 family which regulate the 
number and size of peroxisomes. As previously described (section 4.5.1), vesicle 
transport and peroxisome interactions with mitochondria are important because they 
rely on one another to maintain cellular metabolic homeostasis. Without efficient 
peroxisome-mitochondrial regulation, cells become stressed and can activate 
inflammasomes which can lead to a number of diseases (Demarquoy and Le Borgne, 
2015). 
Furthermore, four variants were reported to a loci of RUNX1 (Table 4.5), a gene 
which is involved in the generation of hematopoietic stem cells. These variants had a 
stronger positive association with mtDNA CN than other variants (β= 1.5200, p= 
5.38E-09), which suggests this loci may be important, especially as it was identified 
after cell count was adjusted for. 
The associations in these genes have no direct effect on mtDNA CN, but similar to 
the associations reported in UKBS associated genes, there may be several genes 
involved in the regulation of mtDNA CN, and may all have differing levels dependent 
on the individual. 
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4.5.3 Meta-analysis 
Meta-analysis between UKBS and ALSPAC cohorts reported two, independent 
variants in cell count adjusted analysis which identified an intergenic region on 
chromosome 5, and PLEKHB1 on chromosome 11 respectively. However, both 
variants were not GWS (Table 4.7 – section 4.4.4).  
PLEKHB1 is a pleckstrin homology domain containing B1 protein, and is associated 
with Wallerian Degeneration, and amyotrophic lateral sclerosis (ALS). Both Wallerian 
Degeneration and ALS are neurodegenerative diseases which develop as a result of 
immunological insults which are triggered from ROS accumulation (Dupuis et al., 
2004; Gaudet et al., 2011). Mitochondrial biogenesis and mtDNA CN changes have 
been reported in several neurological-based diseases (Keeney and Bennett, 2010; 
Giordano et al., 2014; Rice et al., 2014; Pyle et al., 2015a; Wei et al., 2017), which 
may suggest that there are functional roles associated with these genes to overall 
mtDNA CN regulation. 
As no genes were replicated in the meta-analysis, or across individual cohort GWAS, 
a list of possible candidate genes has been complied which were most significant, 
and consistent, between analyses’ which would be beneficial to explore in future 
work (Table 4.9). 
  
  
 
 
 
Table 4.9: Details of gene regions with most consistent, and significant variants associated with mitochondrial DNA copy number across all GWAS analysis. Gene details provided 
by GeneCards (http://www.genecards.org/) (Stelzer et al., 2002; Weizmann Institute of Science, 2015), and MitoCarta scores were generated using MitoCarta2 (Calvo et al., 
2016).  
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4.5.4 Other Plausible Genetic Candidates 
Somatic cells contain the same nDNA code, but different mtDNA CN. Several 
intergenic loci were reported as top variants in analysis in this study, which suggests 
there may be other epigenetic or biochemical factors contributing to differences in 
mtDNA CN.  
nDNA is highly regulated by epigenetic modifications, and although mtDNA is not 
commonly known to be epigenetically modified, original studies of mtDNA do report 
mtDNA to contain between 12 to 36 methylcytosine residues per mtDNA molecule in 
certain animal cell lines, averaging at one 5’-mehtylcytosine per 500 cytosine 
residues in mtDNA compared to one 5’-mehtylcytosine per 36 cytosine residues in 
nDNA (Nass, 1973). 
mtDNA CN levels are reported to be different between cancers (Malik and Czajka, 
2013), and this may be a result of cells being in an undifferentiated or pseudo-
differentiated state (Dickinson et al., 2013), so when cancer cells try to undergo 
differentiation, they are unable to replicate their mtDNA in a regulated manner, which 
leads to inconsistent levels reported depending on the cancer type and stage (St. 
John, 2016). Treating cancer cells with DNA demethylation reagents, such as 5’-
azacytidine or Vitamin C, results in a synchronous increase in mtDNA CN levels, and 
when DNA demethylation reagents are removed, cancer cells return to their ‘pseudo-
differentiated’ state (Ebos et al., 2009; Zuniga et al., 2010), and resume their 
previous levels of mtDNA CN (Lee et al., 2015; St. John, 2016). This suggests 
epigenetic regulation is overseeing mtDNA CN maintenance (Figure 4.25). 
 
Figure 4.25: Mitochondrial DNA copy number changes when reprogramming cancer cells. Image from (St. John, 
2016). 
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Kelly and colleagues also highlight the importance of nuclear-mitochondrial 
interactions in mitochondrial biogenesis regulation, because they report that 
reprogrammed pluripotent somatic cells are unable to control mtDNA CN levels or 
regulate ATP content, and this may be a result of POLGA and PEO1 which were 
expressed at different levels (Kelly et al., 2013b). This suggests mtDNA CN is not 
completely regulated by genetic code, but also epigenetic machinery and cell 
signalling. 
Cell cycle timing is also critical for mitochondrial regulation (Bogenhagen and 
Clayton, 1977), and 80% of mtDNA is associated at polar ends of mitochondria 
during cell cycle (Nass, 1969). For successful pro-nuclear transfer, nuclei need to be 
transferred in early stages of the cell cycle to increase success rates. Hyslop and 
colleagues also showed that as a result of pro-nuclear transfer mitochondrial gene 
expression did not change (Hyslop et al., 2016). Additionally, studies in mice have 
shown that mixing mtDNA and nDNA interactions across generations has no 
negative effect on the phenotype or development of the mouse compared to controls, 
because mixing of the alleles dilutes the potentially harmful nDNA-mtDNA effects 
(Chinnery et al., 2014). These results suggest that the mitochondria alone are able to 
accommodate dramatic nuclear genetic changes, so long as the genetic code is 
available to support their function, and that mtDNA CN regulation may be an internal 
mitochondria and cellular response, rather than nuclear-mitochondrial genetic 
regulation. 
Martin and colleagues used a new technique known as ChromEMT, which identified 
long range interactions between genes in nDNA in complex diseases (Martin et al., 
2015).  The technique combines electron microscopy tomography with a labelling 
method that selectively enhances the contrast of DNA, which showed that nDNA has 
highly disordered nucleosomes which are packaged into 5-24nm diameters, in 
chromatic concentration volumes between 12% to 52% (depending on cell cycle 
stage), and with different structural and particle conformations. During interphase, 
chromatin is more curvilinear but collapses into compact, and interacting, loops in 
mitotic stages (Ou et al., 2017). This provides evidence of the diverse array of 
different combinations of DNA sequence interactions, and how they are uniquely 
dependent on cell cycle phase in each individual. This, combined with chromatin 
concentration volumes, and individual genomic sequences, adds complexity to 
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understanding how nDNA controls cellular activities. It is possible to hypothesise that 
there may be multiple loci interacting during different cell cycle stages which are 
contributing to mitochondrial biogenesis regulation, and are not being identified 
through GWAS. 
Reinecke and colleagues review the number of mitochondrial-related diseases that 
develop as a result of different expression profiles of OXPHOS genes under different 
cellular circumstances, which were dependent on OXPHOS, calcium signalling, and 
ROS (Reinecke et al., 2009). mtDNA CN may be indicative under different cellular 
circumstances, and this may explain why our GWAS results don’t replicate. 
A GWAS of nearly 28,000 lincRNAs in 1829 samples also identified lincRNAs to be 
highly associated with genetic and expression control, as they originate from 
enhancers, and regulate transcription of their associated SNPs (Hon et al., 2017). 
Additionally, approximately 88% of tagged SNPs lie in the intergenic or intronic 
regions and are likely to influence gene regulation (Edwards et al., 2013). SNP 
functional consequences have been reviewed (Cooper and Shendure, 2011). 
mtDNA may be marker of mitochondrial stress (Malik et al., 2016), however it may 
not be vital for cellular function. Dean and colleagues showed that the mitochondria 
in parasites Trypanosoma brucei, which contained mutations in nDNA which code for 
ATP synthase, have the ability to maintain mitochondrial homeostasis and prevent 
cell death by reversing the ATP synthase pump to pump protons into the matrix to 
maintain the mitochondrial membrane potential (Δψm ) (Dean et al., 2013). This 
suggests Δψm is more important for mitochondrial cell survival than mtDNA to code 
for the machinery needed to maintain the Δψm. 
4.5.5 Imputation Servers 
This is the first study to investigate differences in the methodology between 
established imputation servers, and the quality of imputation reported, having 
imputed UKBS genotyping data using both the Sanger and Michigan Imputation 
Servers, and to both the HRC r1.0 and HRC r1.1 reference panels. 
Very little difference was reported in the MAFs, imputation quality, or the number of 
variants which passed QC when comparing reference panel-imputed datasets 
(Figure 4.7 and Table 4.1). This suggests that there is little difference between 
reference panels HRC r1.0 and HRC r1.1. Differences in imputation scores were 
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reported between imputation servers. The Sanger Imputation Server reported a 
minimum imputation score of 0.4 across all variants, unless the MAF <0.01, whereas 
the Michigan Imputation Server reported a minimum imputation score of 0.1 across 
all variants, unless the MAF <0.01. This suggests there are differences in the 
mathematics behind the imputation methods, which would be expected because the 
Sanger Imputation Server uses PBWT methods, and Michigan Imputation Server 
uses Minimac3 methods. Figure 4.6 highlighted the differences in imputation scores 
by variants between the servers, reporting no correlation between their methods. 
However, this may be due to imputation methods imputing rarer variants better than 
the other. As Figure 4.7A shows, the Michigan Imputation Server had more variants 
removed based on imputation score alone, suggesting variants with a lower MAF (but 
not less than 0.01) were imputed better by the Sanger Imputation Server than by the 
Michigan Imputation Server. There is very little difference in the number of variants 
removed between server methods when removing variants under standard GWAS 
QC conditions (MAF <0.01, INFO <0.80) (Figure 4.7B). 
Having analysed data from both imputation servers, manipulating Sanger-imputed 
data was much more user friendly than Michigan-imputed data, however both 
methods still produced the same set of results. 
4.5.6 Study Limitations 
Following the work in this study, many limitations have been identified which have 
contributed to the lack of replication in this work, but has also highlighted factors 
which other researchers should implement to ensure accurate GWAS reporting, 
especially in meta-analysis work. 
4.5.6.1 Power 
Our initial meta-analysis study was powered to find a single locus which controlled 
mtDNA CN with a MAF >0.10 and an effect size (βG) of >4.8, up to a MAF >0.40 with 
a βG of >3.0, assuming population means of 200 copies/cell, (±30 copies s.d). 
However this study, conducted in over 8000 individuals, indicates multiple loci are 
associated with changes, but with no replication. This suggests this study may be 
underpowered. Using the top list of genes identified to be associated with mtDNA CN 
in this study (Table 4.9), new power calculations were conducted using QUANTO to 
identify the real power of this study. Gene only, additive inheritance models in 
independent individuals were calculated. 
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The average beta (effect size or βG) of the 13 genes reported in Table 4.9 is 0.5152 
(maximum 2.316 for rs941898, minimum 0.0850 for rs8066582), and the average 
MAF is 0.1258 (maximum 0.4631 for rs8066582, minimum 0.01211 for 
rs140416442). Actual population mtDNA CN mean was 178 copies/cell (± 58 copies 
s.d). Assuming no change in our recorded population mean and standard deviation, 
in a worst case scenario, whereby βG was 0.085 and MAF 0.012, >1,000,000 
individuals would be needed to detect an effect at 5.00E-08 with 80% power. In a 
best case scenario, whereby the βG was 2.316 and MAF 0.4631, >50,000 individuals 
would be needed to detect an effect at 5.00E-08 with 80% power. Using the current 
average beta and MAF values, this study has no power to detect an effect at 5.00E-
08. 
As these calculation suggest, and assuming there is no change in the population 
mean and standard deviation, to identify real nuclear genetic associations to mtDNA 
CN changes, much larger sample numbers are going to be needed. This is a result of 
the smaller population mean (178 copies/cell compared to the assumed 200 
copies/cell prior to this study – section 2.11), and the large standard deviation 
recorded in mtDNA CN distribution (±58 copies compared to the predicted ±30 copies 
used to calculate power prior to this study – section 2.11). To reduce the deviation 
from the population mean, a single qPCR user would need to generate all mtDNA CN 
values to minimise technical variability. Kitchen and colleagues also show that the 
variance reported in qPCR measurements cannot be improved by using more 
technical replicates, and more biological replicates are needed to reduce the 
variance (Kitchen et al., 2010). This supports my previous work in section 2.9.1, 
which shows the number of replicates used in qPCR does not improve the precision 
of the mtDNA CN measurement. Furthermore, a more accurate and repeatable 
qPCR assay needs to be designed to reduce mtDNA CN variation. 
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4.5.6.2 Technical 
Several technically limiting factors were identified during this study with introduced 
limitations in our work.  
4.5.6.2.1 Quantitative PCR 
The first, and main technical limitation of this study were the different qPCR methods 
used to determine mtDNA CN in each cohort. UKBS samples used specifically 
targeted fluorescent TaqMan™ probes to quantify genes, however ALSPAC samples 
were quantified using SYBR® Green, which is less specific and binds to any double 
stranded DNA (Applied Biosystems, 2002). As Figure 4.16B suggests, Bristol’s qPCR 
reaction may be plateauing out as a result of using up reagents too quickly, which 
may indicate that the qPCR assay needs to be optimised further. Additionally, primer 
designs need to ensure that the last five nucleotides at the 3´ end do not contain 
more than two G and/or C bases (Applied Biosystems, 2002), however the last five 
nucleotides of Bristol’s mitochondrial primers 3’ end contains four G and C bases 
(CCAGC). ALSPAC samples mitochondrial reference gene is also located in the D 
binding domain of mtDNA, which could potentially be affected by quadruplex 
stranding (J Nicholls and Minczuk, 2014). These technical limitations may explain 
why ALSPAC mtDNA CN values were four times lower than UKBS values, and 
although we tried to accommodate as much as possible to these variations, future 
studies need to conduct mtDNA CN measurements using the same qPCR assay for 
consistency (Kitchen et al., 2010).  
4.5.6.2.2 DNA Handling 
It is well established that DNA handling contributes to DNA quality, which in turn 
affects the ability of qPCR to determine mtDNA CN. Freeze-thaw effects on blood 
samples are reported to decrease DNA integrity by 25% prior to DNA extraction 
(Ross et al., 1990). This is because freezing is thought to mechanically break DNA, 
and ions, solutes, and metals present in water can create concentrated 
microenvironments during freezing which create localised pockets of pH changes 
which can also promote oxidation, and encourage DNA degradation. Adding 
cyroprotecting reagents to the DNA (like glycerol) when freezing maintains the DNA 
quality, even when being subjected to up to 16 freeze-thaw cycles (Schaudien et al., 
2007; Röder et al., 2010), and the addition of Tris is thought to prevent pH-related 
damage (Graf et al., 1984; Brunstein J., 2015).  
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DNA larger than 100kb is thought to be most sensitive to the freeze thaw effect 
(Shao et al., 2012; Brunstein J., 2015), which suggests nDNA may be more 
susceptible to damage than mtDNA, and normalising mtDNA reference genes to 
B2M may be additionally compromised. 
It is uncertain how much UKBS, and ALSPAC samples underwent freeze-thaw 
processes. Although we did the best possible to mitigate the effects in this study, a 
third cohort is needed to be measured at Newcastle to perform another GWAS to 
both increase the study power, and also account for the differences reported from 
qPCR assay effects.  
4.5.6.2.3 Blood Count Data Determination 
Some studies do not see a significant change in their mtDNA CN analysis when 
adjusting for blood cell count proportions, however this may be because their blood 
count measurements are estimates (Ameer et al., 2016). Adjusting for cellular blood 
counts was an important factor in the analysis for this study, because mtDNA CN 
differences have been reported to differ by blood cell component both in this study 
(section 3.3.5), and in previous literature (Pyle et al., 2010). Introducing blood count 
adjustments into the ALSPAC analysis introduced a lot of noise to the GWAS results 
(Figure 4.17B and F), however there was less noise in GWAS results using whole 
blood cell extracted samples (Figure 4.17D). Adjusting for cell counts also removed 
the association to the PSMD3 loci on chromosome 17, which is associated with 
neutrophil count, in the all-ALSPAC, basic adjusted analysis. This suggests blood cell 
adjustments may only be necessary when using whole blood cell extracted DNA or 
when investigating mtDNA CN changes in studies. This has also been advised in 
other genetic association studies (Diroma et al., 2014; Jaffe and Irizarry, 2014). 
Through a sex-specific linkage analysis, Lopez and colleagues also demonstrated 
that separate quantitative trait loci are involved in the control of peripheral blood 
mtDNA content in women and men, however this was only in 386 individuals (López 
et al., 2012).  
Furthermore, ALSPAC cell count data was generated using estimated values, and 
was not a direct measure of cell counts, like in UKBS samples. Data were only 
available for neutrophil and lymphocyte counts, and only in a few hundred ALSPAC 
samples (Table 4.6), which was not representative of the entire cohort. GWAS 
analysis was only adjusted to neutrophil and lymphocytes, and excluded eosinophil, 
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monocyte, and basophil counts. I previously reported significant differences in 
mtDNA CN in eosinophils (section 3.3.5 - Figure 3.14 and Table 3.4), which means 
they have not been accounted for in our study. What’s more is regression coefficients 
between ALSPAC and UKBS blood cell components show UKBS blood cell 
proportions are more similar to ALSPAC blood coefficients, thereby rendering the 
fully adjusted analysis because cell proportions were incomparably adjusted (Table 
4.10). 
Future work would need to ensure full blood count data was available for all samples 
to enable correct adjustments. 
 
Table 4.10: Regression coefficients between blood cell components in ALSPAC and UKBS blood count data. LA: 
absolute lymphocyte count. MA: absolute monocyte count. EA: absolute eosinophil count. NA: absolute neutrophil 
count. LP: lymphocyte proportion. MP: monocyte proportion. EP: eosinophil proportion. NP: neutrophil proportion. 
Boxes indicate similar regression coefficients between lymphocytes (blue), and neutrophils (red). 
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4.5.6.3 Genetic 
Genetic limitations may also be present in this study because UKBS and ALSPAC 
samples were genotyped on different Illumina arrays. Efficiencies of Illumina 
genotyping platforms may vary which will give rise to differences in genotyping 
quality, and may mean SNPs were called for differently (Guo et al., 2013). We tried to 
mitigate these errors by imputing genotypes, and  even though this increased genetic 
power, imputation does come with limitations because SNPs are imputed in linkage 
disequilibrium with one another, and may report SNPs which are not directly causal 
(Zheng et al., 2011; Edwards et al., 2013). What’s more is multiple continuous traits 
are being adjusted for in our study, which could be pulling results in contradictory 
directions. It may have been more accurate to perform a dimension reduction style 
GWAS method, whereby multiple continuous traits are linearly combined to generate 
one value, which is then tested against the genotyping data (Wu and Pankow, 2015). 
Furthermore, to account for population heterogeneity, ideally it would have been 
more accurate to use raw genetic data instead of summary data, whereby both 
populations could have undergone multidimensional testing to adjust for any 
population heterogeneity. 
Despite these limitations, we accommodated to technical and genetic limitations as 
much as possible throughout our work. Limiting our datasets to only include samples 
from the same DNA source, and imputed our genetic data to the same reference 
panel, and filtered data to the same control measures. mtDNA CN assay validation 
tests were also performed to validate phenotype similarities, and blood cell 
components analysis enabled us to perform the most comparable GWAS possible 
with the data available. 
In conclusion, this work has identified the complexities behind correctly conducting 
GWAS, and has explored factors which need to be accommodated for when 
performing meta-analysis between datasets from heterogeneous backgrounds. This 
work has also reiterated the complex nature of mtDNA CN regulation, and suggests 
there is no single locus governing its maintenance like Cai and colleagues suggest 
(Cai et al., 2015). More studies are needed to expand on our work, and to increase 
the statistical power behind results reported. Furthermore, functional work would 
need to be conducted in cell lines and animal models to monitor the real effect 
nuclear genes have on mtDNA CN.
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5.1 Introduction 
5.1.1 Mitochondrial DNA and Mitochondrial DNA Copy Number 
The 16.6 kbp circular, double-stranded mitochondrial DNA (mtDNA) molecule 
encodes 13 out of approximately 85 subunits needed for the OXPHOS structural 
system (Anderson et al., 1981; Wallace, 1999; Smeitink et al., 2001). mtDNA was 
originally larger than it is now, and much of the original genome is believed to have 
translocated to the nuclear genome (nDNA) due to intracellular pressures (Brown et 
al., 1979; Lane and Martin, 2010b; Gray, 2012; Johnston and Williams, 2016). 
mtDNA is a polyploidal genome, and is present in multiple copies within cells, 
however this is dependent on mtDNA quality and cellular metabolic demand (Lee and 
Wei, 2000; Liu et al., 2003; Gilkerson, 2009). As a result, mtDNA CN varies 
considerably between cells (Michaels et al., 1982; Robin and Wong, 1988; Kelly et 
al., 2012). 
5.1.2 OXPHOS and Mitochondrial DNA Copy Number 
The OXPHOS system is made up of five complexes, and of the 13 OXPHOS proteins 
still encoded by mtDNA, seven code for complex I subunits, one codes for a subunit 
in complex III, three code for complex IV subunits, and two code for complex V 
subunits (Figure 5.1). The remaining OXPHOS subunits are coded for by nDNA. 
Lane and Martin (2010) believe that mtDNA has evolved to facilitate higher energy 
output for complex and multicellular organisms (Lane and Martin, 2010a), however 
uncertainty remains as to why mtDNA contains the specific genes it does. The “null 
hypothesis” is that gene loss has been uniform and random (Johnston and Williams, 
2016). However, two other theories have been proposed that mtDNA is selected on 
qualitative measures (Daley and Whelan, 2005); whereby one hypothesises highly 
hydrophobic proteins are retained in mtDNA to bypass difficult transport across 
membranes in to the mitochondria, and the other, known as “colocalisation for redox 
regulation”, hypothesises that critical genes which are vital for localised control of 
energetic machinery are retained to avoid affecting other organelles. Further details 
are described here (Johnston and Williams, 2016). 
mtDNA and OXPHOS have a close relationship because the cell’s energy demands 
are reliant on OXPHOS to generate ATP, and OXPHOS requires mtDNA replication 
and transcription to synthesise respective complexes. Dickinson and colleagues 
report a direct correlation between OXPHOS activity and mtDNA CN changes 
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(Dickinson et al., 2013). LHON is a primary mitochondrial disease which usually 
develops as a result of having one of three common point mutations (G3460A, 
G11778A and T14484C) located in MT-ND1, MT-ND4, and MT-ND6 of mtDNA 
respectively (Hudson et al., 2007b). Not all carriers develop LHON, which is known 
as incomplete penetrance (Wallace et al., 1988), and increased mtDNA CN is 
believed to be the protective mechanism (Giordano et al., 2014). This suggests 
OXPHOS activity and mtDNA CN are regulated independently, but mtDNA CN is 
important because it is a mediator to disease development.  
 
Figure 5.1: Illustration of mitochondrial DNA and the gene coding regions corresponding to their respective 
OXPHOS complex. Image taken from (Mishra and Chan, 2014). 
5.1.3 Mitochondrial Haplogroups, Disease and Mitochondrial DNA Copy 
Number 
Homo sapiens originated from Africa about 150,000 to 200,000 years ago (Cann et 
al., 1987; Wallace et al., 1999; Stewart and Chinnery, 2015). As a result of population 
migration, and exposure to environmental and diet changes, mtDNA accumulated 
mutations which are now seen in high frequencies between populations, and are 
polymorphic. These polymorphisms are associated with specific haplogroups, but all 
stem from the same ancestral tree. The most variation is reported in African 
haplogroups (Johnson et al., 1983), however mtDNA sequences between unrelated 
individuals in human populations can differ by about 50 nucleotides overall (Wallace 
et al., 1999).  
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European haplogroups were defined by phylogenetic analysis which revealed 75% 
European haplogroups did not contain the Ddel site at nucleotide position 10394 
(Torroni et al., 1994; Torroni et al., 1996). Haplogroups lacking the DdeI site are 
haplogroups H, T, U, V, W, and X, whereas haplogroups I, J, and K retained the Ddel 
site (Wallace et al., 1999). Haplogroup R is  defined root of European haplogroups, 
however haplogroup H is the most common haplogroup in Europe, and is comprised 
of approximately 90 different sub-haplogroups (Stewart and Chinnery, 2015). 
Studies have reported specific mitochondrial haplogroups to have different OXPHOS 
capacities (Kofler et al., 2009b; Gomez-Duran et al., 2010; Hulgan et al., 2011), 
which can affect muscle biogenesis (Nagao et al., 1998). Additionally, Northern 
European haplogroups are more tolerant to colder climates, with Southern European 
haplogroups appearing more tolerant to hotter climates (Ruiz-Pesini et al., 2004), 
demonstrating the different coupling effects of OXPHOS as a result of mtDNA 
coding. 
Several studies have linked haplogroup to disease susceptibility (Pyle et al., 2005; 
Hudson et al., 2007b; Pello et al., 2008; Kofler et al., 2009a; Chinnery et al., 2010; 
Gómez-Durán et al., 2012; Soto-Hermida et al., 2014), as well as protecting against 
disease (Ghezzi et al., 2005; Hendrickson et al., 2008; Santoro et al., 2010; Shen et 
al., 2011; Liou et al., 2012; Hudson et al., 2013a; Ridge et al., 2014; Tranah et al., 
2014). Despite many metabolic-related diseases also being considered age-related 
diseases, the longevity association reported to mitochondrial haplogroup J (Rose et 
al., 2001; Dato et al., 2004), is not replicated across all populations (Ross et al., 
2001; Niemi et al., 2003). Mueller’s group used HEK cybrids to identify that 
haplogroup H and T had no OXPHOS or TCA enzyme differences, however 
haplogroup T cybrids had a significantly higher mtDNA CN (Mueller et al., 2012). This 
suggests that mtDNA variants may impact mtDNA CN regulation, but not OXPHOS 
efficiency.  
5.1.4 Mitochondrial Haplogroups and Mitochondrial DNA Copy Number 
Of the studies associating mitochondrial haplogroup to disease, some have identified 
relationships between mtDNA CN and disease development (Wang et al., 2012; 
Giordano et al., 2014). However, very few have reported the relationship between 
mtDNA variants and mtDNA CN changes in relation to the disease onset. For 
example, sepsis has been associated with haplogroups JT (Lorente et al., 2013), and 
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mtDNA CN has been reported to be lower in sepsis patients (Pyle et al., 2010). Also, 
reduced Parkinson’s disease (PD) risk is associated with haplogroups UKJT (Pyle et 
al., 2005), and reduced mtDNA CN is a biomarker of PD (Pyle et al., 2015a; Pyle et 
al., 2015b). What’s more, Ridge and colleagues reported haplogroups U5A1 and T2 
to have significantly higher mtDNA CN in an aged cohort (Ridge et al., 2014). 
However, there are no studies to use as a reference which report mitochondrial 
haplogroup association to mtDNA CN changes in large European populations, or in 
healthy populations. To address this, and following on from previous GWAS work on 
nDNA to identify nuclear variants associated with mtDNA CN changes, I performed a 
GWAS using mitochondrial variants to identify mtDNA variants associated with 
mtDNA CN changes in two large, healthy, European cohorts. 
5.2 Aim 
Similar to my previous work (0), and based on previously published studies in 
disease (described above), I propose that inherited mtDNA variation is likely to 
modulate mtDNA CN. 
The aim of this chapter is to perform two GWAS using mitochondrial SNPs (mtSNPs) 
in two independent control cohorts, finally meta-analysing the data in a combined 
analysis. Additionally, a third independent cohort will be used as replication of these 
results, and will also investigate qPCR assay method effects on genomic results.  
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5.3 Materials and Methods 
5.3.1 Cohorts 
5.3.1.1 Cohort One - UKBS 
Full cohort details and methods are available in Chapter 2. For the work in this 
chapter, 3091 UKBS samples (50% male, 50% female) were used as a discovery 
cohort. UKBS DNA samples were extracted from white blood cell pellets using 
phenol-chloroform methods, and FBC data was provided for 2617 samples. Relative 
mtDNA CN was determined using an established triplex TaqMan™ qPCR assay, 
quantifying mitochondrial genes MT-ND1 and MT-ND4, to nuclear housekeeping 
gene B2M (Grady et al., 2014a; Pyle et al., 2015b; Rygiel et al., 2015). 2735 samples 
had 132 mtDNA SNPs (mtSNPs) (>99%) successfully genotyped on the on the 
Illumina 1.2M Duo array (Illumina, San Diego, California, USA), of which 2682 (50% 
males, 50% females) had both genotyping and mtDNA CN data. 
5.3.1.2 Cohort Two – In house ‘Cohort Two’ 
Full cohort details and methods are available in Chapter 2. For the work in this 
chapter, 2000 ‘cohort two’ samples were used as an independent, in house 
replication cohort. DNA samples were extracted from blood (94.45%) and buccal 
(5.55%) samples from 1000 mother-child pairs. FBC data, DNA extraction method, 
age, and gender of samples was not available at the time of analysis. Relative 
mtDNA CN was determined using the same qPCR assay as cohort one. 1627 
samples had their entire mtDNA sequenced by Source BioScience™ in Nottingham, 
UK on the Illumina HiSeq 2000™ array (Illumina, San Diego, California, USA). 1605 
samples (80.25%) had both mtDNA sequencing and mtDNA CN data. 
5.3.1.3 Cohort Three - ALSPAC 
Full cohort details and methods are available in Chapter 2. For the work in this 
chapter, data for 5461 ALSPAC maternal samples (100% female) was available 
through collaboration with Dr Santi Rodriguez’s group at University of Bristol, and 
was used as an independent replication cohort. DNA samples were previously 
extracted from whole blood (37.6%) or WBC (62.4%) using a phenol-chloroform 
method (Fraser et al., 2013), and relative mtDNA CN was determined using a 
singleplex SYBR® Green assay which quantified a region of the mitochondrial D-loop 
to a region of nuclear housekeeping gene B2M. Estimated blood cell count data was 
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also available for 482 samples. mtSNP genotyping data was assigned to mothers 
using their respective child’s data (as mtDNA is inherited maternally (Hutchison et al., 
1974; Giles et al., 1980)) which had been genotyped directly on the Illumina 
HumanHap550-Quad array (Illumina, San Diego, California, USA). 3405 mothers had 
mtSNP genotyping and mtDNA CN data. All analysis for cohort three was conducted 
at University of Bristol, and summary data was provided to Newcastle University to 
perform respective meta-analysis’. 
5.3.2 Mitochondrial Haplogroup Assignment 
5.3.2.1 Cohort One - UKBS 
The hierarchical relationship amongst mtDNA variants is represented at 
www.phylotree.org. A schematic overview of the mitochondrial haplogroup phylotree 
is shown in Figure 5.3. To investigate the effect mitochondrial genetic variants have 
on mtDNA CN differences, UKBS individuals were assigned to their European 
mitochondrial haplogroup according to published criteria (Torroni et al., 1996). The 
mtSNPs present on the Illumina 1.2M array (detailed in section 2.6.1) were first 
converted from Yoruban to rCRS format using MITOMAP 
(https://www.mitomap.org/MITOMAP/YorubanConversion), and then haplogroups 
were assigned using specific genotyped variants (Figure 5.2). For example 
haplogroup J is defined by variants C295T and T489C. If it was not possible to call a 
major-haplogroup defining SNP then clade specific sub-type variants were used to 
identify mtDNA haplogroups. All samples were assigned a haplogroup. To investigate 
mtDNA CN differences between major European haplogroups, non- European 
haplogroups (non-RHVJTUKWXI haplogroups) were removed (n=45) as a final QC 
metric to avoid the effects of phylogenetic heterogeneity. 
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Figure 5.2: Non-rCRS SNPs on the Illumina 1.2M Dual genotype array used to call for specific mitochondrial 
haplogroups in UKBS samples. For example, haplogroup J genotyping would ideally need to call for C9540T, 
T12705C, A11251G and T489C. Illumina SNPs have been converted from Yoruba to rCRS positions using 
https://www.snpedia.com/index.php/MtDNA_Position_Conversions.   
  
 
 
Figure 5.3: Schematic representation of the human mtDNA phylogenetic tree. Each branch details the evolution of mtDNA which stemmed from mitochondrial eve (mt-MRCA). 
Stable nucleotide polymorphisms in mtDNA give rise to specific mitochondrial haplogroups. The European haplogroup clade is detailed below. Haplogroups highlighted in 
orange are common European haplogroups. Canonical genomic variants below each branch usually define the haplogroup (Torroni et al., 1996). Variants in blue sit in the 
control region of mtDNA. Image is adapted from the revised Cambridge Reference Sequence  (rCRS) (Build 17 (18 Feb 2016)) - http://www.phylotree.org/index.htm (van Oven 
and Kayser, 2009). 
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5.3.2.2 Cohort Two – In house ‘Cohort Two’ 
Cohort two samples were effectively sequenced for mtDNA variation by Source 
BioScience (Nottingham, UK) (detailed in section 2.6.2). Mitochondrial haplogroups 
were also identified using HaploGrep2 (http://haplogrep.uibk.ac.at/) (van Oven and 
Kayser, 2009; Kloss-Brandstätter et al., 2011; van Oven, 2015; Weissensteiner et al., 
2016), and were confirmed using MitoMaster 
(https://www.mitomap.org/foswiki/bin/view/MITOMASTER/WebHome). 1627 samples 
(81.35%) had their mtDNA successfully sequenced and haplogroup defined. As part 
of a further QC step, mitochondrial haplogroups were manually assigned to identify 
the accuracy of HaploGrep2 and MitoMaster. 45 individuals were assigned the 
incorrect haplogroup, suggesting the software is approximately 98% accurate. 
5.3.2.3 Cohort Three - ALSPAC 
ALSPAC samples were genotyped on the Illumina HumanHap550 quad genotyping 
array by 23andMe (detailed in section 2.6.3), and mitochondrial haplogroups were 
assigned using HaploGrep2 (http://haplogrep.uibk.ac.at/) which automatically 
determines mitochondrial haplogroups using Phylotree (van Oven and Kayser, 2009; 
Kloss-Brandstätter et al., 2011; van Oven, 2015; Weissensteiner et al., 2016). 
Samples with a quality score >90% were used for analysis. All mtDNA analysis and 
haplogroup assignment was conducted by Dr Mesut Erzurumluoglu during his PhD 
with Dr Santi Rodriguez at University of Bristol. 
5.3.3 GWAS Analysis 
5.3.3.1 Cohort One - UKBS 
As previously described in section 4.3.2.1, cryptic relatedness tests (IBD score >0), 
and multidimensional scaling analysis confirmed individuals were unrelated, and 
were from European descent (Burton et al., 2007). Further filtering of mtDNA 
genotyped data removed individuals with missingness >3%, and variants with 
missing call rates >5%, and MAF <1%. UKBS were then stratified by gender, and QC 
filters applied to each group. 2520 people (1256 female, 1264 male) and 67 mtSNPs 
passed QC, with a genotyping rate 0.994170. Binary files were then filtered to 
remove non-European haplogroup (M, L, and non-N) individuals (n=45).  2469 
individuals (1228 females, and 1241 males) had mtSNP genotyping and mtDNA CN 
data. 2145 (1073 females, and 1072 males) had additional blood count data.  
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Linear regression association tests were then performed, using logged, z-scored 
mtDNA CN as a continuous, quantitative phenotype. No additional filters were 
included in these tests. Absolute neutrophil and lymphocyte counts were included as 
covariates for cell-count adjusted analysis (Table 5.1). All analysis and filtering was 
performed using PLINK v1.90b3.44 64-bit (17 Nov 2016) (Purcell S et al., 2007). 
5.3.3.2 Cohort Two – In house ‘Cohort Two’ 
Due to time constraints of the project, cohort two was not used to perform a GWAS, 
but was used to replicate a haplogroup effect instead of a genotype effect. 
5.3.3.3 Cohort Three - ALSPAC 
3405 mothers and 105 mitochondrial SNPs, with a MAF >0.01, passed QC checks 
detailed in section 2.6.3. Linear regression association tests were performed, using 
logged, z-scored mtDNA CN as a continuous, quantitative phenotype. No additional 
filters were included in these tests. Absolute neutrophil and lymphocyte counts were 
included as covariates for cell-count adjusted analysis. 
5.3.4 Meta-GWAS Analysis 
UKBS and ALSPAC GWAS summary data was used to perform a meta-analysis, 
however summary files were manually edited prior to analysis. To make analysis 
consistent between cohorts, each original mtSNP had a new ID assigned to it. New 
mtSNP IDs were “chromosome_alleleA_baseposition_alleleB”, whereby allele A was 
A2, and allele B was A1 in UKBS PLINK output files. ALSPAC summary file alleles 
were the wrong way around and were therefore reordered to match UKBS alleles. 
Summary files were then filtered to only include mtSNPs that were present in both 
cohorts (Table 5.1). As variants were not imputed, an imputation score of one was 
assigned to each variant. 
 
Table 5.1: Number of individuals and mitochondrial SNPs used in meta-analysis between UKBS and ALSPAC 
cohorts. WC: white blood cell extracted samples only. 
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All UKBS samples (n=2469) were meta-analysed with white blood cell extracted 
ALSPAC (n=2117) samples, and UKBS females (n=1228) were meta-analysed with 
white blood cell extracted ALSPAC (n=2117) samples. Both meta-analysis was 
performed twice, with and without cell count adjusted summary data (Table 5.1). 
Meta-analysis was performed using META version 1.7 software (Marchini et al., 
2007; de Bakker et al., 2008; Liu et al., 2010) using the inverse-variance method 
based on a fixed-effects model. 
5.3.5 Statistical Analysis 
Linear regression GWAS tests were performed using PLINK v1.90b3.44 64-bit (17 
Nov 2016) (Purcell S et al., 2007). Independent T-tests (ITT) and Mann- Whitney U 
(MWU) tests were conducted using IBM SPSS Statistics v.22 (IBM Corporation, 
2013), and Windows Excel 2013. 
5.3.6 Quantifying Mitochondrial DNA Copy Number using an ‘Alternative’ 
Quantitative PCR Methodology 
As discussed in section 5.4.6, an alternative qPCR assay was designed and an 
alternative region of mtDNA (MT-RNR2) was measured to quantify mtDNA CN. This 
assay was designed to validate the accuracy of the previously established MT-ND1, 
MT-ND4, and B2M assay detailed in section 2.8.1. Further justification for using this 
‘alternative’ qPCR assay is detailed in section 5.4.6. 
5.3.6.1 Cohort One - UKBS 
Full methodology details are in section 2.8.1. All PCR and qPCR methods were 
exactly the same, however MT-RNR2 was measured instead of MT-ND1. MT-RNR2 
DNA standard templates were generated and extracted as detailed in section 2.8.1.1, 
and MT-RNR2 was quantified relative to nuclear housekeeping gene B2M and MT-
ND4 in a selection (n=108) of previously diluted UKBS samples (section 2.7.1) using 
the previously detailed triplex TaqMan™ qPCR assay (section 2.8.1.5) methods. The 
MT-RNR2-HEX fluorophore probe was designed to bind at bases 2980 to 3005. PCR 
and qPCR primer details are in Table 2.3 and Table 2.4 respectively. Each UKBS 
sample was measured in quadruplicate with a standard curve, control, and deletion 
calibre DNA. UKBS samples were measured across three separate qPCR runs 
across two, consecutive days. mtDNA CN was calculated for each sample by 
determining the relative proportion of MT-RNR2 to B2M using Equation 2.2 in section 
2.8.1.5. 105 samples (97.22%) had mtDNA CN values calculated. 
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5.3.6.2 Cohort Two – In house ‘Cohort Two’ 
Full methodology details are in section 2.8.1. A selection (n=40; n=10 mothers and 
n=30 children) of cohort two samples had their mtDNA CN redetermined using the 
‘alternative’ qPCR – detailed in section 5.3.6.1. Cohort two samples were also 
measured in quadruplicate, and samples were measured on one qPCR run on the 
same day they were plated out (i.e. they were not frozen). 
5.3.6.3 Cohort Three – ALSPAC 
ALSPAC samples were not available at Newcastle University and therefore were not 
measured using the alternative qPCR method. 
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5.4 Results 
5.4.1 Mitochondrial DNA Copy Number Distributions in Study Cohorts 
mtSNP genotyping data was available for UKBS and ALSPAC cohorts (as detailed in 
section 2.6), and mitochondrial haplogroups were assigned to samples in all cohorts 
(UKBS, ALSPAC, and ‘Cohort Two’). Before analysis was conducted, frequency 
distributions of mtDNA CN were generated for all cohorts to investigate phenotypic 
differences (Figure 5.4). 
As Figure 5.4 [A] – [G] show, mtDNA CN distributions were negatively skewed in all 
cohorts, however logging and z-scoring values removed this, resulting in normal 
distribution curves which were relative between cohorts (Figure 5.4 [a] – [g]). 
Therefore it was agreed that logged, z-scored mtDNA CN would be used for future 
analysis. 
5.4.2 Cohort One - UKBS as a Discovery Study 
5.4.2.1 Mitochondrial SNP Variants Associated with Mitochondrial DNA Copy 
Number 
Acting as a discovery study, UKBS samples mitochondrial SNP genotyping data was 
cleaned, and linear association tests were performed on all UKBS samples (n=2520), 
UKBS females only (n=1256), and UKBS males only (n=1264). Analysis was 
performed with or without adjusting for blood cell counts. As Table 5.2 shows, two 
mtSNPs – G5046A and G5460A (both call for haplogroup W), were significantly 
associated with mtDNA CN changes across all analysis. mtSNP T12705C (which 
calls for haplogroup R) was significant in UKBS females but not males, and mtSNPs 
G1719A (which calls for haplogroup N1), G12372A (which calls for haplogroup U), 
T6221C (which calls for haplogroup X), and G15043A (which calls for haplogroup I), 
were significant in UKBS males but not females. G1719A and G15043A were not 
significant in males when cell count was adjusted for. 
mtSNPs G5046A and G5460A were both used to call for mitochondrial haplogroup W 
in UKBS samples, and as Table 5.2 shows, they both have a negative effect on 
mtDNA CN. This supports previous results reported in Figure 5.5. 
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5.4.2.2 Mitochondrial DNA Copy Number Differences between Mitochondrial 
Haplogroups 
UKBS samples had their mitochondrial haplogroup assigned using mtSNP data 
(detailed in section 5.3.2). To investigate whether mtDNA CN was different between 
mitochondrial haplogroups, UKBS samples (n=2520) were stratified by mitochondrial 
haplogroups, and bar graphs were generated showing mean mtDNA CN per 
haplogroup (Figure 5.5A). UKBS samples were then stratified by gender to identify if 
mtDNA CN differences by mitochondrial haplogroup were gender specific (Figure 5.5 
B and C). As Figure 5.5 indicates, mitochondrial haplogroup W is significantly lower 
than other European mitochondrial haplogroups, and is not gender specific.
  
 
 
Figure 5.4: Frequency distribution plots of [A-G] mitochondrial DNA copy number (copies/cell) and [a-g] logged z-scored mitochondrial DNA copy number in UKBS, cohort two, 
and ALSPAC cohorts. [A, a] All UKBS (n=2520). [B, b] UKBS males only (n=1264). [C, c] UKBS females only (n=1256). [D, d] All cohort two (n=1735). [E, e] Cohort two mothers 
only (n=764). [F, f] Cohort two children only (n=971). [G, g] ALSPAC mothers (n=3405) – graphs provided by Anna Guyatt, Dr Santi Rodriguez’s group, University of Bristol, UK.  
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Table 5.2: Summary of top mitochondrial SNP hits (p< 0.05) for linear GWAS tests performed on UKBS samples for the association of mitochondrial variants effect on mitochondrial 
DNA copy number variability. Data was stratified by gender then tests were performed with or without cell count (absolute lymphocyte count and absolute neutrophil count) 
adjustments. rCRS BP= revised Cambridge Reference Sequence base position, SE= standard error, MAF= minor allele frequency. 1Associated with 41 clades. 2 Associated with 
33 clades. 
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Figure 5.5: Bar graphs showing the mean mitochondrial DNA copy number for each European mitochondrial haplogroup in UKBS samples. [A] All UKBS (n=2520). [B] UKBS 
males only (n=1264). [C] UKBS females only (n=1256). [D] Table summarising mitochondrial DNA copy number statistics for each respective mitochondrial haplogroup in each 
stratified UKBS group. CN: mitochondrial DNA copy number. SE: standard error. U95: upper 95% confidence interval. L95: lower 95% confidence interval. Red dotted lines 
indicate population means.
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5.4.3 Cohort Three - ALSPAC as a Replication Study 
5.4.3.1 Ensuring Mitochondrial Genotyping Data is Comparable at the SNP 
level 
In collaboration with Dr Santi Rodriguez’s group at University of Bristol, ALSPAC was 
used as a replication cohort. MAFs were generated for ALSPAC and UKBS datasets, 
using PLINK, to investigate population heterogeneity. mtSNP base positions were 
converted from Yoruban to rCRS format using MITOMAP 
(https://www.mitomap.org/MITOMAP/YorubanConversion), then mutual cohort 
mtSNPs MAF were compared using linear regression analysis (Figure 5.6). 
 
Figure 5.6: Scatter plots of the minor allele frequencies (MAF) of mitochondrial SNPs (mtSNPs) in ALSPAC (n=3405) 
and UKBS (n=2520) cohorts. [A] All UKBS versus all ALSPAC mtSNPs (n=67). [B] UKBS females versus UKBS 
males mtSNPs (n=62). [C] All UKBS versus white blood cell (WC) extracted ALSPAC samples mtSNPs (n=53). [D] 
UKBS females versus WC extracted ALSPAC samples mtSNPs (n=51). Lines indicate linear regression relationship. 
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As reported in Figure 5.6A, mtSNP MAFs between all ALSPAC (n=3405) and UKBS 
(n=2520) samples do not correlate (r2= 0.002, β= -0.05), however mtSNPs in UKBS 
females (n=1256) and males (n=1264) positively correlate (r2= 0.994, β= 0.997) 
(Figure 5.6B). ALSPAC samples were restricted to samples extracted from WBC only 
(n=2117), and mtSNP MAFs were compared to all UKBS samples (n=2520) (Figure 
5.6C), or UKBS females (n=1256) only (Figure 5.6D). A positive correlation was 
reported between both analysis (r2= 0.995, β= 0.997) and (r2= 0.995, β= 0.998) 
respectively. This indicated that all UKBS samples, and UKBS females were suitable 
to meta-analyse with ALSPAC mothers extracted from WBC to identify mtSNPs 
associated with mtDNA CN. 
5.4.3.2 Mitochondrial SNP Variants Associated with Mitochondrial DNA Copy 
Number 
ALSPAC samples from University of Bristol were used as a replication study. 
Mitochondrial SNP genotyping data was cleaned, and linear association tests were 
performed on all ALSPAC maternal samples (n=3405), and then maternal samples 
extracted from whole blood (n=1284), and maternal samples extracted from white 
blood cell pellets (n=2117). Analysis was performed with or without adjusting for 
blood cell counts.  
As Table 5.3 shows, 26 mtSNPs were significantly associated with mtDNA CN 
changes across different analysis. No mtSNP was consistent across all analysis, 
however mtSNPs T489C and C16069T (which both call for haplogroup J), and 
T5999C and A6047G (which both call for haplogroup U4), were consistently 
significant for analysis on whole blood cell extracted samples, without cell count 
adjustment. A15218G and A13617G (which both call for haplogroup U5) were 
consistently significant for analysis on whole blood cell extracted samples, with cell 
count adjustment. On the contrary, mtSNPs G8269A and C242T (which both call for 
haplogroup J1b) were consistently significant for analysis on white blood cell 
extracted samples, without cell count adjustment, whereas G5046A and A11947G 
(which both call for haplogroup W) were consistently significant for analysis on white 
blood cell extracted samples, with cell count adjustment.  
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5.4.3.3 Mitochondrial DNA Copy Number between Mitochondrial Haplogroups 
GWAS analysis performed on ALSPAC samples produced results that were 
inconsistent overall (Table 5.3). However, results from white blood cell extracted 
samples were compared to UKBS samples, which were also extracted from white 
blood cells, making the cohorts comparable. Non-cell count adjusted analysis in 
ALSPAC samples had two significant results for mtSNPs G8269A and C242T (which 
both call for haplogroup J1b), which were negatively associated with mtDNA CN. This 
did not replicate UKBS results (Figure 5.5). However, cell count adjusted analysis in 
ALSPAC samples had significant results for mtSNPs G5046A and A11947G (which 
both call for haplogroup W), which were negatively associated with mtDNA CN. This 
replicated the results reported in UKBS samples (Figure 5.5).
  
 
 
 
 
Table 5.3: Summary of top mitochondrial SNP hits (p< 0.05) for linear GWAS tests performed on ALSPAC samples for the association of mitochondrial variants effect on 
mitochondrial DNA copy number variability. Data was stratified by samples extracted from whole blood or white blood cell pellets then tests were performed with or without cell 
count (absolute lymphocyte count and absolute neutrophil count) adjustments. rCRS BP= revised Cambridge Reference Sequence base position, SE= standard error, MAF= 
minor allele frequency. 1Associated with 41 clades. 2Associated with 24 clades. 3Associated with 53 clades.
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5.4.4 Meta-analysis 
To make UKBS and ALSPAC cohorts consistent and comparable, meta-analysis was 
performed on white blood cell extracted samples only. To investigate the effects of 
cell count adjustment on meta-analysed results, meta-analysis was performed using 
the following combinations: 
 ALSPAC mothers extracted from WBC and all UKBS – not cell count adjusted 
 ALSPAC mothers extracted from WBC and all UKBS – cell count adjusted 
 ALSPAC mothers extracted from WBC and UKBS females – not cell count 
adjusted 
 ALSPAC mothers extracted from WBC and UKBS females – cell count 
adjusted 
Meta-analysis results are summarised in Table 5.4. 
As Table 5.4  shows, mtSNP G5046A and G5460A (which both call for haplogroup 
W) are consistently significantly associated with mtDNA CN changes across meta-
analysis, except in female only meta-analysis without cell count adjustment, whereby 
G8269A (which calls for haplogroup J1b) is the only significant mtSNP.  A3720G 
(which calls for haplogroup U2) is significant in all UKBS and ALSPAC mother 
analysis without cell count adjustment. 
Despite their significance, no meta-analysed top mtSNP results have stronger p 
values when combining p value power between cohorts, except G5460A in female 
only, cell count adjusted analysis. This may be due to differences in beta values 
between cohorts. 
Irrespective, both G5046A and G5460A are consistently significant before and after 
meta-analysis, and have negative beta values associated with mtDNA CN. These 
results support the initial results reported in Figure 5.5, and show that haplogroup W 
individuals have a significantly lower mtDNA CN than other European mitochondrial 
haplogroups.
  
 
 
 
 
 
 
Table 5.4: Top mitochondrial SNP hits (p<0.05) from meta-analysis performed between UKBS and ALSPAC cohorts, with and without cell count adjustments. CHR: chromosome. 
RSID: mitochondrial SNP ID.  rCRS pos: revised Cambridge Reference Sequence position. Allele A: major allele. Allele B: minor allele.  P_value: combined P value. SE: combined 
standard error. Q: Cochran's Q statistics. P_heterogeneity: p-value for heterogeneity.  I2: percentage of total variation across studies that is due to heterogeneity. 
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5.4.5 Identifying Mitochondrial DNA Copy Number Differences between 
Mitochondrial Haplogroups 
mtSNP genotyping GWAS analysis identified the importance of controlling for DNA 
source, and adjusting for cell count composition in genomic analysis to ensure 
consistency between cohorts. Comparison of the qPCR measurements between 
UKBS and ALSPAC showed minor differences in actual mtDNA CN values (section 
4.4.3.1 - Figure 4.16). Therefore, to ensure the significant associations to G5046A 
and G5460A (defining haplogroup W) in the meta-analysis results were not an 
artefact of qPCR assay differences between UKBS and ALSPAC cohorts, mtDNA CN 
was measured in an independent, in-house control cohort (‘cohort two’) at Newcastle 
University, critically using the same qPCR method that was used to determine 
mtDNA CN in UKBS samples. Cohort two would act as a third replication cohort. 
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5.4.5.1 Quality Control Measures to Compare UKBS and Cohort Two Cohorts 
mtDNA CN measurements were conducted, and genotyping performed on cohort two 
samples. Of the 1627 cohort two samples that had mitochondrial genotyping data, 
1605 samples (98.64%) also had mtDNA CN determined (Figure 5.7). 
 
Figure 5.7: Flow diagram summarising the number of individuals in the UKBS and cohort two cohorts at each 
respective QC step. 
Cohort two DNA was provided from blood samples and buccal samples. Therefore, to 
fairly compare cohorts, cohort two was filtered to contain mtDNA CN data generated 
from blood-extracted DNA only (n=1503). To keep my current analysis consistent 
with my previous analysis, only European haplogroup samples were selected 
(RIXWJTHVUK), removing a further 10 samples (0.67%). Of the 1493 samples 
remaining, samples with a mtDNA CN value greater than 900 copies/ cell were then 
removed (n=86, 5.76%) because they were considered outliers. This left 1407 
individuals for analysis. Figure 5.7 summarises the QC steps, which were also 
applied to the UKBS cohort. 
As UKBS DNA samples were all extracted from white blood cell pellets, DNA source 
did not need to be accounted for. To make data between UKBS and cohort two 
comparable, UKBS samples with mtDNA CN data less than or equal to 900 copies/ 
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cell, and a common European haplogroup (RIXWJTHVUK) were selected (n=2637, 
85.31%). Table 5.5 summarises the frequencies of each European haplogroup in the 
UKBS and cohort two samples, following QC steps three (Table 5.5A), and six (Table 
5.5B) in Figure 5.7. 
 
Table 5.5: Mitochondrial haplogroup frequencies in UKBS and cohort two samples. [A] Data only includes 
individuals who have mitochondrial DNA copy number and haplogroup data. [B] Data restricted to individuals whose 
DNA is from blood, is a European haplogroup and their mitochondrial DNA copy number is less than or equal to 
900 copies/cell. Chi-squared tests were performed with Yates’ correction. 
The haplogroup frequencies observed in Table 5.5 are similar to haplogroup 
frequencies reported in the literature (Torroni et al., 1998; Hay, 2004; Saxena et al., 
2006). This confirmed that the UKBS and cohort two were both representative of 
European populations. 
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5.4.5.2 Statistical Analysis of Mitochondrial Haplogroup Effect on 
Mitochondrial DNA Copy Number 
Using IBM SPSS Statistics version 22 (IBM Corporation, 2013), haplogroups were 
grouped in to haplogroup versus non-haplogroup, and mtDNA CN differences 
between both groups were compared using ITT, and MWU tests (Figure 5.8 and 
Figure 5.9). 
As Figure 5.8 shows, mtDNA CN is significantly lower in mitochondrial haplogroup W 
for both UKBS (ITT: p= 1.19E-12, MWU: p < 1.00E-04), and cohort two cohorts (ITT: 
p= 0.059, MWU: p= 0.008). No other mitochondrial haplogroup has significant 
differences in mtDNA CN compared to their respective non-haplogroups (Figure 5.9).
  
 
  
 
Figure 5.8: Mitochondrial DNA copy number (copies/cell) (y-axis) differences between UKBS and cohort two (x-axis), stratified by European mitochondrial haplogroups R, I, X, and W. 
Black boxes: Haplogroup. Grey boxes: Non-haplogroup. Error lines indicate standard errors. T= independent T-test. MW= Mann-Whitney U test.
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Figure 5.9: Mitochondrial DNA copy number (copies/cell) (y-axis) differences between UKBS and cohort two (x-
axis), stratified by European mitochondrial haplogroups J, T, H, V, U, and K. Black boxes: Haplogroup. Grey boxes: 
Non-haplogroup. Error lines indicate standard errors. T= independent T-test. MW= Mann-Whitney U test. 
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5.4.6 Validating the Haplogroup W Effect Using an Alternative qPCR Method 
In addition to biological factors contributing to mtDNA CN variability, technical errors 
affect mtDNA CN values (reviewed in section 3.1.2). To investigate whether the 
haplogroup W effect reported was due to technical limitations, I determined if any 
haplogroup-defining variants were located in any of the qPCR primer or probe 
spanning regions, as these variants may decrease their binding specificity and 
reduce PCR amplification or fluorescence (Gervais et al., 2010). 
In the UKBS cohort, genotyping variant A3481G at position 3480, which defines the 
European mitochondrial haplogroup U8b’c, was located at the final base position of 
the forward MT-ND1 primer. In cohort two, one haplogroup-defining variant at 
position 3505 in the mtDNA was located in the MT-ND1 qPCR amplicon region 
(bases 3458 to 3568), and was positioned in the centre of where the HEX probe 
bound (bases 3492 to 3516). This A3505G variant defined individuals as haplogroup 
W, suggesting our haplogroup W results reported may be a result of a technical 
artefact (Figure 5.10).  
 
 
Figure 5.10: A schematic diagram summarising that qPCR DNA primers and probes potentially span across mtDNA 
regions which code for mitochondrial haplogroup variants. This example shows mitochondrial variant A3505G, 
which calls for haplogroup W, is present in the binding region for the MT-ND1-HEX qPCR probe. 
Additionally, no haplogroup defining mtSNPs were located in the MT-ND4 amplicon 
region in UKBS samples, and only one variant at position 11204 was located in the 
MT-ND4 amplicon region (bases 11144 to 11250) in cohort two, and this was used to 
define individuals as mitochondrial haplogroup H. The variant was not located in the 
Cy5 probe region, and no mtDNA CN differences were reported in haplogroup H 
individuals, therefore I did not pursue altering the MT-ND4 primers and probes. 
To address the potentially technical limiting issue of the haplogroup W-defining 
variant being located in the centre of the MT-ND1 fluorophore domain (Figure 5.10), 
an alternative mtDNA amplicon location was researched and designed (method 
details are in section 5.3.6).  
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5.4.6.1 Minor Allele Frequency of Variants around the Mitochondrial Genome 
Polymorphic variants are located across the entire mtDNA molecule (Figure 5.11A), 
however the frequency of these variants varies between populations. To investigate 
regions of mtDNA which contained high frequency variants in European populations, 
I used a dataset where Hudson G. and colleagues downloaded 18,114 human 
mitochondrial genome sequences from the National Centre for Biotechnology 
Information (NCBI) Nucleotide database, and cleaned the data to only contain 
human, non-pathogenic, European and non-truncated sequences. The 9935 
sequences remaining were then aligned to MUSCLE and had their mitochondrial 
haplogroups assigned using Haplogrep (Kloss-Brandstätter et al., 2011; 
Weissensteiner et al., 2016), leaving 2873 variants. These variants were then 
merged with a case-control population of 7729 individuals to perform imputation 
association tests (Hudson et al., 2014).  
Using this dataset, I looked at the MAF of each mitochondrial variant at each base 
position across mtDNA in a large population of people, and if any high frequency 
mtDNA variants (MAF >0.01) were located in any of my PCR and qPCR amplicon 
regions, or primer and probe-binding sites. The MAFs were then plotted and 
compared to see where regions of mtDNA were susceptible to variation in European 
populations (Figure 5.11A). Figure 5.11B summarises the frequency of MAF variation 
across mtDNA, where the majority of mtDNA variants have a MAF of about 0.001. 
As Figure 5.11C and Table 5.6 show, two highly frequent (MAF >0.01) variants are 
located in both the primer and probe binding regions of MT-ND1, but no highly 
frequent variants are located in the MT-ND4 amplicon. 
An amplicon region spanning from bases 2911 to 3036, in MT-RNR2, which codes 
for the mitochondrial 16S ribosomal subunit, was identified as a suitable region to 
quantify instead of MT-ND1. MT-RNR2 neighboured MT-ND1, and was therefore 
adjacent to MT-ND4 if any mtDNA deletions needed to be determined, but also this 
region contained no high frequency variants that spanned primer or probe binding 
sites. Additionally, no haplogroup-defining variants were located in this MT-RNR2 
amplicon region for cohort two, and only G3012A at mtDNA position 3010 was 
present in UKBS genotyping. G3012A called for haplogroups H, J and U, which were 
all reported to have no mtDNA CN changes. Therefore I chose to use this as an 
alternative qPCR site to MT-ND1 to re-quantify mtDNA CN. 
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Figure 5.11: Graphs summarising the MAF of mitochondrial variants across [A] the mitochondrial genome, [C] MT-
ND1, [D] MT-ND4 and [E] MT-RNR2 (16S). In [C] – [E] the black lines represent standard template DNA amplicon 
regions, grey lines indicate qPCR amplicon regions and red lines indicate probe binding regions. Orange boxes 
indicate primer binding sites. [B] Frequency distribution summarising the number of variants with a specific MAF 
across the whole mitochondrial genome in 7729 CEU people (adapted from (Hudson et al., 2014). 
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Table 5.6: Breakdown of the MAF of mitochondrial variants located across qPCR amplicon sites in mtDNA (MT-
ND1, MT-ND4, MT-RNR2 and D-loop). Orange indicates primer binding regions. Pink indicates probe binding 
regions. Blue indicates variants with MAF>0.00 and red indicates variants with MAF>0.01. 
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5.4.6.2 Replicating the Mitochondrial Haplogroup W Effect using an Alternative 
qPCR Method 
5.4.6.2.1 Cohort One - UKBS 
To validate if the significantly lower mtDNA CN reported in haplogroup W individuals 
was real, and not due to technical artefacts, 108 UKBS samples (n=53 haplogroup W 
and n=55 non-haplogroup W) were re-measured using the alternative qPCR method 
which quantified MT-RNR2 instead of MT-ND1 (details in section 5.3.6.1). 105 
samples (97.22%) had mtDNA CN values calculated. These samples were then 
matched with their previous mtDNA CN values, which were calculated using the 
relative proportion of MT-ND1 to B2M, and were grouped in to haplogroup W versus 
non-haplogroup W groups. ITT and MWU tests were performed on each group to 
compare mtDNA CN differences between haplogroups, and the potential effect of the 
qPCR method applied on mtDNA CN values (Figure 5.12). 
Using the original qPCR assay measuring B2M, MT-ND1, and MT-ND4, initial results 
reported mtDNA CN to be significantly lower (p= 9.64E-10) in haplogroup W 
individuals (μ= 130.72 copies/cell, ±37.15 s.d) than in non-haplogroup W individuals 
(μ= 192.56 copies/cell, ±53.09 s.d) (Figure 5.12A). These results were replicated 
when using the alternative qPCR method, measuring B2M, MT-RNR2, and MT-ND4 
because mtDNA CN was still significantly lower (p= 0.026) in haplogroup W 
individuals (μ= 200.31 copies/cell, ±67.77 s.d) than in non-haplogroup W individuals 
(μ= 241.77 copies/cell, ±113.88 s.d) (Figure 5.12B). 
  
 
 
 
 
 
Figure 5.12: Graphs demonstrating the difference in mitochondrial DNA copy number between haplogroup W and non-haplogroup W individuals in UKBS samples. [A] Uses data from 
the original B2M, MT-ND1, and MT-ND4 qPCR assay (n=52 haplogroup W, n=51 non-haplogroup W). [B] Uses data from the alternative B2M, MT-RNR2, MT-ND4 qPCR assay (n=53 
haplogroup W and n=52 non-haplogroup W). [C] Compares data from both qPCR assays. Red dotted line indicates population mean. 
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5.4.6.2.2 Cohort Two – In house ‘Cohort Two’ 
Acting as an independent, replicate study, 40 samples (n=18 haplogroup W and 
n=22 non-haplogroup W) from cohort two also had their mtDNA CN measured again 
using the alternative qPCR method (methods are detailed in section 5.3.6.1). 10 of 
these samples were from mothers and 30 were from children. 
Following analysis, and mtDNA CN generation, each sample was grouped by 
haplogroup, and ITT and MWU tests were performed (Figure 5.13). 
Initial ITT and MWU tests performed between haplogroup W and non-haplogroup W 
individuals for the alternative qPCR assay (using MT-RNR2: B2M) (Figure 5.13B) 
suggested there was no significant difference in mtDNA CN between groups (ITT: p= 
0.925, MWU: p= 0.403). However, when groups were stratified by mothers and 
children, mtDNA CN was significantly lower in haplogroup W children (μ= 163.28 
copies/cell, ±25.57 s.d versus μ= 210.51 copies/cell, ±51.38 s.d) (ITT: p= 0.034, 
MWU: p= 0.032), but not in mothers (μ= 290.23 copies/cell, ±119.99 s.d versus μ= 
216.91 copies/cell, ±94.73 s.d) (ITT: p= 0.308, MWU: p= 0.413). 
Linear regression analysis also reported that there was a positive correlation 
between mtDNA CN values generated using the original versus the alternative qPCR 
method in both UKBS analysis (β= 0.35, r2= 0.114) (Figure 5.12C), and cohort two 
analysis (β= 0.705, r2= 0.497) (Figure 5.13C). 
Overall, these tests confirm that mtDNA CN is significantly lower in mitochondrial 
haplogroup W individuals, and it is not due to qPCR technical artefacts. 
  
  
 
 
Figure 5.13: Graphs demonstrating the difference in mitochondrial DNA copy number between haplogroup W and non-haplogroup W individuals in cohort two samples then stratified by 
children and mothers. [A] Uses data from the original B2M, MT-ND1, and MT-ND4 qPCR assay. [B] Uses data from the alternative B2M, MT-RNR2, and MT-ND4 qPCR assay. [C] 
Compares data from both qPCR assays. Red dotted line indicates population mean. Error bars indicate +/- 2 standard deviations. [D] Summarises the number of mothers and children 
in each mitochondrial haplogroup category.  
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5.5 Discussion 
This is the first, and largest, study to investigate the effect of mitochondrial variants 
on mtDNA CN changes in healthy European cohorts. Using three, independent 
cohorts, I have performed two mtDNA GWAS using mtDNA CN as a continuous 
phenotype, identifying mtDNA variants associated with mtDNA CN changes. Meta-
analysis has strengthened the power of this study by identifying associations in up to 
5921 unrelated, European individuals. An in-house control cohort has further 
supported the results from my meta-analysis, by confirming that mtDNA CN is 
significantly lower in mitochondrial haplogroup W individuals, compared to any other 
European haplogroup. Using an alternative mtDNA reference site to calculate mtDNA 
CN also validated that results reported are not due to technical artefacts. 
5.5.1 Haplogroup W Effect 
Mitochondrial variants G5460A and G5046A, which were used to define haplogroup 
W, were consistently top GWAS hits in both UKBS and ALSPAC cohorts GWAS 
analysis, with or without blood count adjustments. Both variants were negatively 
correlated to mtDNA CN, as initially indicated in Figure 5.5. The individual GWAS for 
ALSPAC samples (Table 5.3) reported many more overall top hits than UKBS GWAS 
(Table 5.2); however meta-analysis showed consistent hits in both variants as power 
increased. The differences reported in ALSPAC samples may have been a result of 
population heterogeneity, as indicated by the significant values in the 
P_heterogeneity column in Table 5.4. However, these results are not reliable 
because mtSNP MAFs strongly correlated between ALSPAC and UKBS before 
analysis (Figure 5.6) to ensure there was no population heterogeneity. Additionally, 
P_heterogeneity is calculated using Cochran's Q test (Q) (StatsDirect Ltd, 2013), and 
Hoaglin argues that many meta-analyses report Cochran's Q test to assess 
heterogeneity, and these authors cite work by W. G. Cochran, without realizing that 
Cochran deliberately did not use Q itself to test for heterogeneity (Hoaglin, 2016). 
This suggests that P_heterogeneity scores may not be a viable indicator of 
differences between cohorts, and ALSPAC and UKBS cohorts were not heterogenic, 
and were comparable. Furthermore, as Table 5.5 shows, the frequency of 
haplogroup W in both UKBS and cohort two cohorts was similar, and agreed with the 
literature (Saxena et al., 2006). This shows that the consistently significantly lower 
mtDNA CN reported in haplogroup W in these cohorts is not a result of differences in 
haplogroup frequencies between the cohorts. 
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Additionally, overall haplogroup frequencies between the UKBS and cohort two 
cohorts were similar, despite significant differences being reported in haplogroups R, 
H, V, and M between cohorts (p <0.05) when chi-squared tests with Yates’ correction 
(designed to improve the chi-square approximation) were performed (Table 5.5A). 
These significant differences were likely due to UKBS samples being assigned to 
their mitochondrial haplogroup using 138 SNPs from SNP genotyping data, whereas 
cohort two used sequencing data which had more variants to define haplogroups 
more accurately. The overall haplogroup frequencies between cohorts were in line 
with the literature though (Torroni et al., 1996; Torroni et al., 2000), and therefore 
UKBS and cohort two were representative of European populations.  
In Europe, mitochondrial haplogroup W is most prevalent in North-eastern countries 
such as Finland (9.5%), Hungary (5%), Latvia (4%), Macedonia (4%), and Belarus 
(3.5%) (Hay, 2004). Haplogroup WIX individuals were more common than 
haplogroup J in an aged Finnish population (Niemi et al., 2003), discrediting the 
original reports suggesting haplogroup J is associated with longevity (Rose et al., 
2001; Dato et al., 2004). However Niemi’s study may be a reflection of the more 
prevalent haplogroup W in the Finnish population than the rest of Europe (Hay, 
2004). 
Furthermore, a study conducted across 1000 LHON-affected families in Finland 
reported that the frequency of LHON associated mtDNA mutations (G3460A, 
G11778A, and T14484C) was much lower in their population than other Northern 
European, UK, and Australian families, and that affected females had a higher 
incidence of affected offspring compared to unaffected females (Puomila et al., 
2007). Mitochondrial haplogroups were not reported in this study, but the higher 
prevalence of haplogroup W in the Finnish population could be contributing to the 
higher incidence of LHON being transmitted to affected mother’s offspring if their 
mtDNA CN was significantly lower as a result of their mitochondrial haplogroup. This 
theory would support Giordano’s study where they reported higher mtDNA CN 
protect against LHON penetrance (Giordano et al., 2014). 
Both the G5046A and G5460A mtSNPs are non-synonymous, and result in amino 
acid changes from a valine to isoleucine (codon 193), and from an alanine to a 
threonine (codon 331) respectively in MT-ND2 (Brandon et al., 2005; Lott et al., 
2013). Gomez-Duran and colleagues reported differences in OXPHOS capacities 
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between haplogroups (Gomez-Duran et al., 2010), and Ruiz-Pesini and colleagues 
reported differences in OXPHOS capacities dependent on reaction coupling 
efficiencies to generate ATP (Ruiz-Pesini et al., 2004). If changes of amino acid are 
introduced to the MT-ND2 subunit during translation in haplogroup W individuals, this 
could be affecting the OXPHOS coupling strength, and potentially changing the 
overall OXPHOS capacity of haplogroup W mitochondria. A pharmaceutical study in 
HIV patients support this theory, as haplogroup W individuals reported to have the 
greatest increase in extremity fat when being treated with antiretroviral treatments 
(Hulgan et al., 2011), and antiviral therapies are reported to affect mtDNA CN (Payne 
et al., 2011), which could introduce a ‘double-hit’ insult to metabolic efficiency of 
haplogroup W individuals to cause fat accumulation. 
Unlike nDNA, mtDNA is predominantly unmethylated (Groot and Kroon, 1979), and 
the inability to establish a mtDNA CN set point in cells can be lethal, especially during 
development (Dickinson et al., 2013; Kelly et al., 2013b). Embryonic stem cell models 
with the same nDNA background, but different mtDNA backgrounds have slightly 
different differential gene expression patterns (Kelly et al., 2013a), as well as 
expression levels of mtDNA replication gene POLG-A (Kelly et al., 2012). This 
suggests that mitochondrial haplogroups might alter the methylation profiles on 
nDNA, which has downstream effects on mitochondrial replication and translation 
rates (St. John, 2016). 
In vertebrates, CpG sites are normally associated with gene promotor regions, and 
genes that are often expressed in tissues contain many CpG sites, normally forming 
CpG islands (Saxonov et al., 2006). This is because CpGs are methylation sites, and 
the binding of methyl groups to cytosine nucleotides causes displacement of 
transcription factors, and attracts gene silencing and chromatin compacting proteins 
(Jaenisch and Bird; Kim et al., 2003; Fazzari and Greally, 2004). Despite the 
importance of CpG sites in development (Singal and Ginder, 1999), nDNA contains 
lower CpG levels than expected; with total nDNA containing 25% CpG sites, 45% 
located in exons and 72% located to promotor regions (Saxonov et al., 2006; 
Chinnery et al., 2012). What’s more is mtDNA contains lower levels of CpG sites than 
expected, which is believed to be a result of natural selection. However, there are a 
high frequency of CpG sites in the OL site, and in between the haplogroup W defining 
SNPs G5460A and G5046A in MT-ND2, of which significantly lower mtDNA CN were 
associated. It is possible to hypothesise that these sites might both be affecting 
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mtDNA replication (Figure 5.14) (Chinnery et al., 2012). Similar to the D-loop region, 
where triple-stranded structures form and interrupt the binding of mtSSB and TFAM 
(Takamatsu et al., 2002); the formation of these methylation sites near the OL may be 
interrupting mtDNA replication. Additionally, Samuels and colleagues use NGS data 
to report recurrent, tissue specific mtDNA mutations across several unrelated 
individuals. These mutations are close to replication sites of mtDNA, but not in the 
coding regions, and further suggest they may be affecting mtDNA replication 
(Samuels et al., 2013). 
 
Figure 5.14: Schematic representation of mtDNA and the distribution of CpG sites relative to mitochondrial 
haplogroup defining polymorphisms. Haplogroup W defining variants G5460A and G5046A are labelled in MT-ND2 
region. Image adapted from (Chinnery et al., 2012). 
Further functional studies would need to be performed in haplogroup W mitochondria 
to investigate the molecular mechanisms regulating mtDNA replication, as well as 
understand the OXPHOS capacities for these mitochondria to operate with 
significantly lower mtDNA CN levels. Population studies may be difficult in 
haplogroup W individuals because they are a rare European haplogroup, however 
use of transfected cybrid cell lines with haplogroup variants, or mutants in MT-ND2 
may be useful to understand biogenesis differences (Pye et al., 2006). 
  
Mitochondrial Genetic Factors Modulating Mitochondrial DNA Copy Number 
231 
 
5.5.2 Blood Composition Differences between Haplogroups 
mtDNA CN was previously reported to significantly change relative to blood 
composition cell counts (section 3.3.5 - Figure 3.14 and Table 3.4). To ensure the 
mitochondrial haplogroup W effect was not a result of differences in blood cell 
composition in UKBS and ALSPAC samples, I investigated whether there were any 
differences in blood cell composition relative to mitochondrial haplogroup using 
UKBS samples. 
As described in section 2.3, UKBS DNA samples were extracted from blood 
donations. Full blood count (FBC) data was also generated using a Beckman‐Coulter 
GenS (Gieger et al., 2011), and both cell counts and proportions were measured 
accordingly. FBC data was available for 2184 non-haplogroup W and 46 haplogroup 
W individuals, and platelet count data was available for 2172 non-haplogroup W and 
45 haplogroup W individuals. Using IBM SPSS Statistics version 22 (IBM 
Corporation, 2013), ITT and MWU tests were conducted (Figure 5.15). 
As Figure 5.15 shows, there is no significant difference in any blood cell composition 
in haplogroup W versus non-W haplogroup individuals. This further supports that 
mtDNA CN is significantly lower in haplogroup W individuals due to genetic 
differences, and not blood composition. 
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Figure 5.15: Differences in [A] eosinophil count, [B] lymphocyte count, [C] monocyte count, [D] neutrophil count, [E] 
platelet count and [F] haemoglobin between haplogroup W (n=52) and non-haplogroup W individuals (n=2585) in 
UKBS cohort.. Error bars indicate +/- 2 standard errors. ITT= independent T-test. MWU= Mann- Whitney U test. 
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5.5.3 Study Limitations 
5.5.3.1 Replicating the Haplogroup W Effect 
The significantly lower mtDNA CN reported in haplogroup W individuals compared to 
non-haplogroup W individuals may not replicate in cohort two mothers using the 
alternative qPCR method because the sample size in cohort two is very small 
(haplogroup W: n=4, non-haplogroup W: n=6) (Figure 5.13D), reporting larger 
deviations between results. Larger sample sizes reduce s.d values, making 
differences more obvious, as indicated in UKBS haplogroup analysis (Figure 5.8). To 
identify if the haplogroup W effect is real in mothers and children in cohort two 
analysis, as originally reported in Figure 5.8, more samples need to be measured to 
minimise the deviation in results reported using the alternative qPCR method. 
To support this logic, mtDNA CN values measured using the original qPCR method 
reported a significantly lower mtDNA CN in haplogroup W individuals than non-W 
individuals, however this effect was lost when comparing the same, but very few 
samples in Figure 5.13A.  Using the original qPCR method, haplogroup W was 
significantly lower in cohort two samples, irrespective of whether the samples were 
from mothers or children (Figure 5.8).  
Additionally, cohort two DNA quality may be poor because very little sample was 
available to perform qPCR on (approximately 8 µl), and smaller DNA volumes are 
more sensitive to the freeze-thaw process (Krajden et al., 1999). This is could explain 
the large s.d values generated for mothers in both Figure 5.13A and B. 
Furthermore, details about the source of cohort two DNA was not available. As 
indicated in the ALSPAC analysis, factors such as DNA source and tissue type need 
to be the same to make data comparable. If cohort two mothers were extracted from 
blood, and cohort two children from white cell pellets, this may explain the 
inconsistent mtDNA CN results reported when using the alternative qPCR method. 
However, the poor DNA quality, and fewer samples is more likely the cause of 
differences. 
5.5.3.2 qPCR Methods 
In addition to potential genetic differences, ALSPAC GWAS results may not have 
replicated exactly to UKBS because of phenotype differences. Bristol used SYBR® 
green to measure mtDNA CN in their samples, and SYBR® green is unspecific as it 
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binds to any double stranded DNA. Additionally, the size of the mtDNA reference 
amplicon region in Bristol’s qPCR method was very small (65 bp) compared to our 
qPCR method (Table 5.6). Amplifying smaller regions of mtDNA, using a less specific 
qPCR probe which could introduce inaccurate mtDNA quantification, which would 
result in mtDNA CN differences between our cohorts. Future work would need to 
ensure that similar qPCR methods were used to calculate mtDNA CN, or respective 
phenotypes, to make meta-analysis more accurate.  
This study has identified the importance of good qPCR design to calculate mtDNA 
CN. Similar to Lemmon and colleagues work, where they reported false positive 
TaqMan™ probe and primer binding sites across 112 bacterial and viral genome 
signatures as a result of poor probe and primer designs (Lemmon and Gardner, 
2008). I have explored the limitations of reference mtDNA regions in qPCR, and have 
identified that both probe and primer sites should be designed away from highly 
polymorphic regions, and ideally away from haplogroup defining variants when 
conducting mitochondrial haplogroup analysis. Measuring several mtDNA regions 
may also be beneficial to normalise to each other before calculating mtDNA relative 
to nDNA. This would ensure full, circular mtDNA was being quantified, and not linear 
molecules. Miller and colleagues used a plasmid in their qPCR analysis to accurately 
quantify mtDNA CN in their samples, which may also offer consistency between 
assay repeats and sample repeats (Miller et al., 2003). Several studies have also 
suggested droplet-digital PCR (ddPCR) is more accurate for mtDNA CN 
determination. This is because DNA in ddPCR is diluted so that, prior to amplification, 
each compartment (or droplet) contains a single piece of DNA. ddPCR uses 
thousands to millions of reaction compartments per assay, and also uses florescence 
probes for detection, which enhances sensitivity and increases precision (Henrich et 
al., 2012; Belmonte et al., 2016; Ye et al., 2017). 
Finally, heteroplasmy is known to effect mtDNA genotype segregation, especially 
during the mitochondrial bottleneck during embryogenesis and development (Cree et 
al., 2008b). This suggests it would be beneficial to determine heteroplasmy levels in 
samples as well as mtDNA CN, to investigate whether mtDNA CN changes are a 
result of heteroplasmy compensation. 
This study is the first study to investigate mtDNA CN changes across three large, 
unrelated, healthy, European cohorts. Despite the thousands of publications 
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reporting mtDNA CN changes or mitochondrial haplogroup associations to disease 
susceptibility, progression, and severity, no study has identified ‘normal’ mtDNA CN 
levels in European populations between mitochondrial haplogroups. Therefore, this 
study acts both as a unique discovery as well as a reference for future work.  For the 
first time, I have identified that mtDNA CN changes are specific to a rare, European 
haplogroup, and that these differences are not a result of technical or biological 
limitations. Furthermore I have identified the importance of good qPCR design, and 
ongoing work needs to further understand the biological mechanisms contributing to 
the results reported in this work.
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6.1 Introduction 
6.1.1 Menopause 
Menopause is when women stop menstruating, and is a natural part of ageing. In the 
UK, 1% of women experience menopause before 40 years old (Coulam et al., 1986; 
NHS, 2017), however the average age of onset is typically between 45 and 55 years 
(Cramer et al., 1995; Torgerson et al., 1997), with over 75% of women undergoing 
menopause before the age of 50 (Broekmans et al., 2004) (Figure 6.1). Onset of 
menopause is multifactorial, and genetic factors have been suggested to play a 
major role, compared to environmental factors (Cramer et al., 1995; van Noord et al., 
1997). Family history is considered a good predictor of menopausal onset (Cramer et 
al., 1995; Torgerson et al., 1997; van Asselt et al., 2004). 
 
Figure 6.1: Observed frequency distribution of ages of women undergoing menopause (n=3483). Image reproduced 
from (Broekmans et al., 2004). 
6.1.2 Oestrogen 
Natural producing oestrogen, known as 17β estradiol, is a multi-disciplinary sex 
hormone which has several biological functions involved in endocrine and 
reproductive functions. In developed countries, women have longer life expectancies 
than men, which is believed to be a result of oestrogen (Viña et al., 2005). 
In the classical model of oestrogen activity, oestrogen binds to the oestrogen 
receptors (ERs) (typically ERα and ERβ1-6) in the cytoplasm, and then translocates 
to the nucleus whereby it interacts with oestrogen response elements (ERE) in 
specific gene DNA sequences which contain two inverted repeats. The ER complex 
binds AP1 enhancer elements, composed of an AP1 ligand and transcription factors, 
which in turn mediates gene transcription (Jensen and DeSombre, 1973; Paech et 
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al., 1997; Arnal et al., 2017). Oestrogen-related receptor alpha (ERRα) is a well-
characterised receptor, which leads to a series of complex downstream signalling 
cascades. More detail can be reviewed here (Arnal et al., 2017). 
6.1.3 Oestrogen and Mitochondria 
Oestrogen has an important relationship with mitochondria. Mitochondria synthesise 
the hormone’s precursor pregnenolone from cholesterol, and mitochondrial function 
and biogenesis is regulated by oestrogen (reviewed by (Velarde, 2014)). 
Many of the mitochondrial biogenesis-regulating genes coded for by nDNA are 
regulated by oestrogen (Chen et al., 2009). For example, oestrogen can directly 
upregulate transcription of nuclear-respiratory factor 1 (NRF-1) (Mattingly et al., 
2008), which is known to regulate mitochondrial biogenesis, as it mediates 
transcription of OXPHOS components (Jornayvaz and Shulman, 2010). NRF-1 also 
increases mtDNA synthesis by directly activating TFAM (Virbasius and Scarpulla, 
1994; Scarpulla, 2006; Mattingly et al., 2008). ERα also interacts with peroxisome 
proliferator-activated receptor gamma coactivator 1 (PGC-1), modulating expression 
of several of its isoforms, which is highly important in mitochondrial biogenesis 
regulation (Scarpulla, 2011; Kemper et al., 2014). Additionally, endonuclease G 
(ENDOG) is directly controlled by ERRα, and has also been reported to increase 
mitochondrial biogenesis in cardiomyocytes, as it clusters with mitochondrial genes 
as well as binding mtDNA directly (McDermott-Roe et al., 2011). Furthermore, 
oestrogen regulates mitochondrial calcium activity, which is important for 
mitochondrial signalling and control of cellular apoptosis through mitogen-activated 
protein kinase pathways (Improta-Brears et al., 1999; Lobatón et al., 2005). 
Oestrogen has been extensively studied and has presented several therapeutic 
effects for protecting mitochondria. As well as upregulating the expression of 
antioxidant genes directly (Borrás et al., 2006; Borrás et al., 2010), oestrogen has 
demonstrated neuroprotective properties, alleviating diseases such as Alzheimer’s 
(Nilsen et al., 2006), and amyotrophic lateral sclerosis (ALS) (Choi et al., 2008; Kim 
et al., 2012), as well as cerebral vascular defects (Stirone et al., 2005; Kemper et al., 
2014), and schizophrenia (Fink et al., 1996; Kulkarni et al., 2012). Targeting ER-β 
has also recently been presented as a therapeutic treatment to prevent mitochondrial 
disease LHON (Pisano et al., 2015). 
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6.1.4 Oestrogen and Menopause 
Oestrogen is predominantly synthesised by granulosa and theca cells of the ovarian 
follicles in women (Young and McNeilly, 2010), whereby the pregnenolone diffuses 
from granulosa cells in to theca cells where it is converted to androstenedione, which 
then diffuses back to the granulosa cells to be converted to oestrogen (Velarde, 
2014).  
Natural reproductive aging results in a gradual decrease in the production of oocytes 
from ovaries, and when follicle levels drop below approximately 1000 follicles, the 
menstrual cycle ceases, and women enter menopause (Velarde, 2014). Several 
endocrinological changes occur in the lead up to menopause, normally presenting at 
the age of 40 by a marked increase of follicle-stimulating hormone, which eventually 
results in a decrease in the sex hormones oestrogen, progesterone, and testosterone 
(Sherman et al., 1976; Burger, 1996; Ferrini and Barrett-Connor, 1998; Stolk et al., 
2012). 
An increased number of damaged mitochondria are reported in ovarian follicles of 
aged women, of which granulosa cells contain high numbers of mitochondria with 
ruptured membranes (Seifer et al., 2002; de Bruin et al., 2004). Increased 
mitochondrial ROS levels in mice also result in infertility, and defective 
folliculogenesis (Lu et al., 2008). This suggests age-related decline in mitochondrial 
function may accelerate the decline in ovarian follicles, and contribute to reproductive 
ageing (Velarde, 2014). 
The onset of menopause results in several age-related conditions such as bone loss 
(leading to osteoporosis), weight gain, hot flushes, disturbed sleep, and skin atrophy. 
Hormone replacement therapies (HRT) have been seen to alleviate these conditions 
(Velarde, 2014), however they are associated with an increased risk of developing 
cancer (Toniolo et al., 1995; Rossouw et al., 2002; Santen et al., 2010). 
Stolk and colleagues performed a meta-analysis of 22 genome-wide association 
studies to identify genes associated with menopause (Stolk et al., 2012). They 
reported 13 novel loci, including genes responsible for DNA repair, such as 
mitochondrial DNA polymerase gamma (POLG), as well as genes involved in 
immune function. Additionally, they reported biological processes linked to 
mitochondrial dysfunction to be related to the timing of menopause. As mtDNA CN 
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changes are highly dependent on POLG activity (Müller-Höcker et al., 2011; Lee et 
al., 2015), and have been reported to change with age (Cree et al., 2008a; Mengel-
From et al., 2014), I set out to investigate changes in mtDNA CN in pre- and post-
menopausal women, because this has not been studied before.  
6.2 Aim 
Explore the biological protective qualities of oestrogen on mitochondrial maintenance 
with age in UKBS females, and investigate the extent oestrogen affects mtDNA CN 
changes in pre- and post-menopausal women. As menopause occurs by 50 years 
old (te Velde et al., 1998; Wallace and Kelsey, 2010), UKBS females can be stratified 
as pre- or post-menopausal by age, and nuclear genetic loci can be investigated to 
be associated with mtDNA CN changes in those groups.  
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6.3 Material and Methods 
6.3.1 Cohort 
This study only used control cohort one – UKBS data. Details of the cohort and 
quantification of mtDNA CN are detailed in sections 2.1 and 2.8. Average age of 
UKBS females was 42 years, ranging from 17 to 69 years (Figure 6.2). The average 
age of menopause is around 50 years old (te Velde et al., 1998; Wallace and Kelsey, 
2010) (Figure 6.1), therefore UKBS females were stratified into two groups - pre-
menopausal if they were younger than 50 years, and post-menopausal if they were 
50 years and older. Demographic analysis was conducted using IBM SPSS Statistics 
version 22 (IBM Corporation, 2013). 
 
Figure 6.2: Frequency distribution of ages of UKBS females (n=1374). 
6.3.2 Genotyping Preparation for Analysis 
UKBS SNP genotyping data was filtered and then imputed using the Sanger 
Imputation Server (detailed in section 4.3.3.1.1). 2724 people (n=1358 males, 
n=1366 females) passed previous QC procedures, of which 2671 had logged, z-
scored mtDNA CN values that were used as the phenotype. 
Individual imputed chromosome VCF files returned from the Sanger Imputation 
Server were initially filtered to only include variants with an imputation score >=0.8 
using bcftools command in SAMtools version 1.3 software (Li et al., 2009). This 
removed 49.40% variants (Table 6.2). VCF files were then converted in to binary files 
using PLINK v1.90b3.44 64-bit (17 Nov 2016) (Purcell S et al., 2007). Due to 
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formatting issues, subsequent fam files were manually updated to contain the correct 
family ID, sample ID, paternal ID, maternal ID, gender and phenotype (which was the 
logged, Z-scored mtDNA CN value) (Table 6.1). 
 
Table 6.1: Example of binary fam files (excluding the headers); [top] incorrectly formatted, [bottom] correctly 
formatted. File contains family and sample IDs that were provided with UKBS samples. UKBS samples were 
unrelated therefore have values of zero in paternal and maternal IDs. Gender: 1 is male and 2 is female. Phenotype 
is logged z-scored mitochondrial DNA copy number values. 
Following this, binary files were filtered for MAF <0.01, removing a further 62.55% of 
variants (Table 6.2). Binary files were restricted to contain only females (n=1366), 
removing 1358 males (49.85%). Details of the number of variants removed at each 
QC stage are detailed in Table 6.2.  
6.3.3 Genome-wide Association Analysis 
Binary files were further stratified to contain pre- (<50 years old, n=921) or post-
menopausal UKBS women (>=50 years old, n=445), of which 903 and 435 had 
phenotype values respectively. Individual linear association tests were performed on 
each group using PLINK v1.90b3.44 64-bit (17 Nov 2016) (Purcell S et al., 2007), 
where an additional filter of MAF < 0.01 was applied. In pre-menopausal women, this 
removed a further 0.77% of variants, whereas in post-menopausal women, this 
removed a further 1.43% of variants (Table 6.2). 7,373,827 variants and 7,324,188 
variants passed QC in pre- and post-menopausal women respectively. Basic analysis 
included four principal components (PCAs), age, and panel as covariates. Full 
analysis included four PCAs, age, panel, absolute neutrophil, and lymphocyte counts. 
Output files were analysed, and Manhattan and QQ plots were generated using R 
version 3.1.3. 
  
 
 
 
 
Table 6.2: Details of the number of imputed variants removed at each stage of filtering in preparation to perform genome-wide association studies on pre- and post-menopausal 
women using UKBS data.  
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6.4 Results 
6.4.1 Demographic Details of Pre- and Post-Menopausal Women 
1346 women (86.84%) from UKBS cohort had both SNP genotyping and mtDNA CN 
data (n=435 women aged 50 or older, n=911 women aged less than 50 years old). 
mtDNA CN distribution between both pre- and post-menopausal women was initially 
assessed before starting analysis, to check for normal distribution. As Figure 6.3 
shows, both raw mtDNA CN, and logged, z-scored mtDNA CN were normally 
distributed. To keep analysis consistent with previous work, logged, z-scored mtDNA 
CN was used in further analysis. 
 
Figure 6.3: Frequency plots of [A] raw and [B] logged and Z-scored mitochondrial DNA copy number (copies/cell) 
distributions between pre- (age<50, n=911) and post-menopausal (age>=50, n=435) women in UKBS samples. 
Curves indicate normal distributions. Mitochondrial DNA copy number was calculated using the delta Ct MT-ND1: 
B2M calculation. 
Age and mtDNA CN information in pre- and post-menopausal women is summarised 
in Table 6.3. 
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Table 6.3: Overview of ages and the distribution of raw mitochondrial DNA copy number in UKBS females with 
genotyping and mitochondrial DNA copy number data, stratified by pre- and post-menopause. 
 
6.4.2 Mitochondrial DNA Copy Number Differences between Pre- and Post-
Menopausal Women 
To investigate any changes in mtDNA CN due to menopause, boxplots were 
generated to compare mtDNA CN between pre- and post-menopausal women 
(Figure 6.4). 
 
Figure 6.4: Boxplot of [A] raw and [B] logged Z-scored mitochondrial DNA copy number between pre- (age<50, 
n=911) and post-menopausal (age>=50, n=435) women in UKBS samples. Red dotted lines indicate mitochondrial 
DNA copy number population mean (μ=176.60 copies/cell). 
As Figure 6.4 shows, there is no significant difference in raw mtDNA CN between 
pre- and post-menopausal women (independent T-test (ITT): p= 0.719, Mann-
Whitney-U (MWU) test: p= 0.950). 
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6.4.3 Ageing Effect on Mitochondrial DNA Copy Number in Pre- and Post-
Menopausal Women 
To identify if there are any age-related changes in mtDNA CN between pre- and 
post-menopausal women, scatter plots were generated and linear regression tests 
were performed (Figure 6.5). As summarised by the table in Figure 6.5, there is no 
significant change in mtDNA CN in pre-menopausal women (r2= 0.001, β= -0.145, p= 
0.436), or post-menopausal women (r2= 0.006, β= -0.962, p= 0.114). This replicates 
the results reported earlier in section 3.1.2.2.
  
 
 
 
 
Figure 6.5: Scatter plots indicating the linear relationship of logged Z-scored mitochondrial DNA copy number changes (y-axis) with age (x-axis) in UKBS females. [A] All females 
(n=1346). [B] Pre-menopause females (ages<50 years, n=911), and [C] post-menopause (ages<=50 years, n=435). Table below indicates respective r2, beta and p values for 
each linear relationship. 
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6.4.4 Mitochondrial Haplogroup W in Pre- and Post-Menopausal Women 
In section 5.4.4, mitochondrial haplogroup W individuals had a significantly lower 
mtDNA CN compared to any other European mitochondrial haplogroup. To 
investigate whether menopause had any further impact on mtDNA CN regulation on 
those individuals who were mitochondrial haplogroup W, pre- and post-menopausal 
women were restricted to only contain haplogroup W individuals (n=13 and n=14 
respectively). Boxplots were then generated to compare logged, z-scored mtDNA CN 
between those individuals from each group (Figure 6.6). 
 
Figure 6.6: Logged Z-scored mitochondrial DNA copy number differences in mitochondrial haplogroup W pre- (n=13, 
μ=-1.04 ±0.97 s.d) and post-menopausal women (n=14, μ=-0.91 ±0.70 s.d). Red dotted line indicates population 
mean (μ=-0.97). 
As Figure 6.6 shows, there is no difference in logged z-scored mtDNA CN between 
pre- (n=13, μ= -1.04, ±0.97 s.d) and post-menopausal (n=14, μ= -0.91, ±0.70 s.d). 
ITT and MWU tests also both reported that mtDNA CN was not significantly different 
(ITT: p= 0.699, MWU: p= 0.616). 
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6.4.5 Nuclear Genetic Variants Affecting Menopausal Changes 
To assess nuclear genetic variants associated with mtDNA CN changes in pre- and 
post-menopausal women, imputed UKBS genotyping data was cleaned to only 
contain variants with an imputation score >=0.8, and MAF >1%. UKBS samples were 
stratified by pre- and post-menopausal women, and linear association analysis was 
performed on each group in PLINK, treating logged, z-scored mtDNA CN as a 
continuous phenotypic trait. 
Basic analysis included four PCAs, age, and panel as covariates, whereas full 
analysis also included absolute neutrophil and lymphocyte counts. Manhattan and 
QQ plots were generated in R 3.1.3 (Figure 6.7 and Figure 6.8). Summaries of 
GWAS hits which had a p value of less than or equal to 1.00E-06 are detailed in 
Table 6.4 to Table 6.6. Genes were annotated to the human GRCh37-hg19 build 
using Ensembl (Aken et al., 2016; Herrero et al., 2016; Yates et al., 2016).  
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Figure 6.7: Manhattan plots of linear genome-wide association tests performed on UKBS pre- (n=903) and post-
menopausal (n=435) women. [A], [C] and [E] Manhattan plots for pre-menopausal women (<50 years old). [B], [D] 
and [F] Manhattan plots for post-menopausal women (>= 50 years old). [A] and [B] No covariates applied. [C] and 
[D] Basic covariates applied including four PCAs, age and panel. [E] and [F] Full covariates applied including four 
PCAs, age, panel, absolute neutrophil count and absolute lymphocyte count. Respective QQ plots are in Figure 6.8. 
Details of top variants are in Table 6.4 and Table 6.5. 
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Figure 6.8: QQ plots of linear genome-wide association tests performed on UKBS pre- (n=903) and post-
menopausal (n=435) women. [a], [c] and [e] QQ plots for pre-menopausal women (<50 years old). [b], [d] and [f] 
QQ plots for post-menopausal women (>= 50 years old). [a] and [b] No covariates applied. [c] and [d] Basic 
covariates applied including four PCAs, age and panel. [e] and [f] Full covariates applied including four PCAs, age, 
panel, absolute neutrophil count and absolute lymphocyte count. Respective Manhattan plots are in Figure 6.7. 
Details of top variants are in Table 6.4 and Table 6.5.
  
 
 
 
Table 6.4: Summary of top hits (p<= 1.00E-06) for genome-wide association study performed on UKBS pre- (n=903) and post-menopausal (n=435) women, where no covariates 
were included in the linear association model. Abbreviations - CHR: chromosome, SNP: SNP ID, BP: base position, A1: minor allele, BETA: beta value, SE: standard error, L95: 
lower bound of 95% confidence interval, U95: upper bound of 95% confidence interval, STAT: T-statistic and P: p-value. 
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Table 6.5: Summary of top hits (p<= 1.00E-06) for genome-wide association study performed on UKBS pre- (n=903) and post-menopausal (n=435) women, where basic covariates 
age, panel and four PCAs were included in the linear association model. Abbreviations - CHR: chromosome, SNP: SNP ID, BP: base position, A1: minor allele, BETA: beta value, 
SE: standard error, L95: lower bound of 95% confidence interval, U95: upper bound of 95% confidence interval, STAT: T-statistic and P: p-value. 
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Table 6.6: Summary of top hits (p<= 1.00E-06) for genome-wide association study performed on UKBS pre- (n=903) and post-menopausal (n=435) women, where full covariates 
age, panel, four PCAs and absolute neutrophil and lymphocyte counts were included in the linear association model. Abbreviations - CHR: chromosome, SNP: SNP ID, BP: base 
position, A1: minor allele, BETA: beta value, SE: standard error, L95: lower bound of 95% confidence interval, U95: upper bound of 95% confidence interval, STAT: T-statistic 
and P: p-value.
M
ito
c
h
o
n
d
ria
l D
N
A
 C
o
p
y
 N
u
m
b
e
r in
 P
re
- a
n
d
 P
o
s
t- M
e
n
o
p
a
u
s
a
l W
o
m
e
n
 
2
5
5
 
Mitochondrial DNA Copy Number in Pre- and Post- Menopausal Women 
 
256 
 
As Table 6.5 shows, in pre-menopausal women, an upstream gene variant on 
chromosome 13 which neighbours UBL3 and LINC00544 is a consistent top hit 
(p<1.00E-06) when adjusted for PCAs, age, and panel. This hit is lost when absolute 
neutrophil and lymphocyte counts are included as covariates (Table 6.6). Table 6.5 
and Table 6.6 consistently report top hits (p <=1.00E-06) in post-menopausal women 
in ABCG1 and RAB27B, with the addition of STARD6 in neutrophil and lymphocyte 
adjusted analysis (Table 6.6). 
6.5 Discussion 
This is the first study which has investigated mtDNA CN changes in healthy women 
who are either pre- or post-menopause. Despite the role of oestrogen in 
mitochondrial biogenesis regulation (section 6.1.3), my results highlight that there is 
no significant difference between mtDNA CN in pre- or post-menopausal women. 
There is also no significant change in mtDNA CN with age in pre- and post-
menopausal women, and supports my previous findings in section 3.3.4, which report 
no mtDNA CN changes with age in females, but a statistically significant, albeit likely 
not biologically significant, decrease in males with age. Women who were defined as 
mitochondrial haplogroup W, and were previously reported to have a significantly 
lower mtDNA CN (section 5.4.4), are shown here to have a similar mtDNA CN in both 
pre- and post-menopausal women. This suggests that mtDNA variants are not 
contributing to menopausal changes. A potential explanation for this may be due to 
medications which may or may not have been provided to individuals during 
menopause. Unfortunately these details were not available to us. 
Despite using a large well-defined female cohort, there are several limitations which 
may explain a negative result. Although we stratified our samples by the average age 
of menopause (te Velde et al., 1998; Wallace and Kelsey, 2010), menopause is 
actually stratified into three stages – pre-, peri- and post-menopause, and it is 
dependent on menstrual bleeding patterns and hormone levels. Oestrogen levels are 
variable between women as they are in the peri-menopausal stage. This introduces 
another category that should have been stratified by in this study to identify more 
accurate differences in mtDNA CN changes, rather than just using age as a factor to 
categorise individuals (Sherman et al., 1976). Stage and age of onset of menopause 
would need to be provided to make this study more precise. 
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HRTs and contraceptives have also been reported to alter oestrogen levels, and 
affect mtDNA CN changes in women. Knez and colleagues reported a significantly 
higher mtDNA CN in females than males, but reported a significantly lower mtDNA 
CN in women taking systemic hormone therapies, including contraceptives, and post-
menopausal therapies (Knez et al., 2016). Therapeutics may explain why I record no 
difference in mtDNA CN, because if both groups have females taking hormonal 
medication, the average mtDNA CN will be lowered to a central mean, showing no 
differences. Medication details would need to be provided to enable analysis to be 
correctly stratified, presuming the medication effected mtDNA CN changes. 
The effect of ageing on mtDNA CN has been well documented, and changes are 
believed to be a result of prolonged ROS exposure causing genomic insults (Cree et 
al., 2008a; Hegde et al., 2012; Mengel-From et al., 2014). Oestrogen binds to ERs on 
the surface of cells, which activates MAP kinases, which activate nuclear factor 
kappa B (NF-κB), which in turn binds to the promotors of superoxide dismutase 
(SOD) and glutathione peroxidase (GPx), and upregulates their levels. SOD and GPx 
neutralise damaging hydrogen peroxide (H2O2) compounds, and significantly higher 
levels of SOD and GPx are recorded in female rats (Viña et al., 2005). Viña and 
colleagues also reported significantly lower levels of mtDNA damage in female Wistar 
rats compared to males, and the increased SOD and GPx levels, stimulated by 
oestrogen production, may be a contributing factor for decreased mtDNA damage 
over time. This may explain why no change in mtDNA CN is reported in UKBS 
females, because if less mtDNA damage has accumulated in females over time 
whilst oestrogen was being produced, and SOD and GPx were being generated as a 
result, insufficient time between pre- and post-menopause had passed to allow the 
effects of ROS to impact mtDNA CN changes. Further work would need to be 
pursued to investigate this further. 
It would have been informative to analyse mtDNA CN in blood cell components 
between pre- and post-menopausal women. Bain and colleagues report higher WBC 
in African women who take oral contraceptives compared to those not taking oral 
contraceptives (Bain et al., 1984). Osteoporosis is a common problem in post-
menopausal women, who are not taking HRT, however oestrogen therapies alleviate 
this (Burger, 1996; Ebeling et al., 1996). Miyazaki argue that mtDNA CN is important 
for maintaining overall bone health, as it oversees osteoclast survival (Miyazaki et al., 
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2012). This suggests a close relationship between oestrogen, blood cell components, 
and mtDNA CN. 
In the GWAS analysis conducted between pre- and post-menopausal women, only 
post-menopausal women had results that were consistent across full and basic 
analysis. In basic adjusted analysis, a strong hit (p <=1.00E-06) in ABCG1 was 
reported, with positive beta values, suggesting a positive control on mtDNA CN 
(Table 6.5). ABCG1 is a member of the ATP binding cassette family, which are a 
group of proteins responsible for transporting various molecules across intra and 
extra-membranes. ABCG1 is a member of the white subfamily, which is involved in 
macrophage cholesterol and phospholipid trafficking (NCBI Gene ID: 9619 details). 
When absolute neutrophil and lymphocyte counts were included as covariates in the 
GWAS model, adjusting for cell count, RAB27B and STARD6 were also included as 
loci associated with mtDNA CN changes in post-menopausal women (Table 6.6), 
however they both had a negative correlation with mtDNA CN. Rab proteins regulate 
vesicular transport steps between membrane-bounded organelles, and are thought to 
be important in targeting, docking, and/or fusion of vesicular carriers with their 
specific acceptor compartments (Simons and Zerial, 1993; Pfeffer, 2001). Rab 
proteins are cell specific, and can act as systemic clocks, regulating exchange of 
molecules like nucleotides between compartments (Zerial and McBride, 2001). 
Certain Rabs have been identified to control mitochondrial relocation by lysosomal 
trafficking (Jin and Mills, 2014), and loss of RAB27B results in damaged mitochondria 
(Chiang et al., 2011).  
STARD6 is domain 6 of the STeroidogenic Acute Regulatory- (StAR) related lipid 
transfer family. This family are highly conserved between plants and animals, and are 
involved in regulating non-vesicular trafficking of lipids and sterols (Létourneau et al., 
2016). STARD6 specifically binds testosterone, and mutations in StARs results in 
absent steroidogenesis, which causes several physiological defects including XY sex 
reversal and enlarged adrenals (Miller, 2010). 
Although the literature reports no direct links between these genes and mitochondrial 
biogenesis affecting mtDNA CN, several functional pathways could have downstream 
effects. As previously described, oestrogen and sex hormones are synthesised by 
cholesterol and heavily rely on mitochondria to synthesise their precursors (Velarde, 
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2014). Enhanced mitochondrial respiration was reported in rats in oestrous stage 
compared to ovex rats (Gigli and Bussmann, 2001), and brain tissue from oestrogen-
treated ovex rats also showed increased mitochondrial respiration (Nilsen et al., 
2006). This suggests that oestrogen increases mitochondrial respiration, and may 
contribute to the steady mtDNA CN previously reported. 
During the initial synthesis of sex hormones, importing cholesterol from the OMM to 
the IMM in mitochondria is a rate-limiting step (Miller, 2013; Velarde, 2014). Acute 
regulation of steroidogenesis is managed by StARs, whereas chronic regulation is 
managed by cytochrome P450 enzymes present on both the mitochondria and ER. 
Supporting this, the conversion of cholesterol to pregnenolone is catalysed by 
cytochrome P450, and involves the oxidation of NADPH (Miller and Auchus, 2011). 
Lewis and colleagues previously reported that interactions between the ER and 
mitochondria were thought to be regulating mtDNA synthesis (Lewis et al., 2016), 
however this might be an observation of oestrogen metabolism effects on the 
mitochondria. 
Overexpression of StARs decreases intracellular lipids and lowers inflammatory 
factors (Ning et al., 2009). During menopause, oestrogen levels decrease, which 
could lead to accumulation of cholesterol and other lipids in mitochondria. This could 
result in increased mitochondrial stress and ROS production, which could contribute 
to defective vesicle trafficking, and could stimulate immune responses. This might 
explain the negative beta association values of post-menopausal mitochondrial 
biogenesis with vesicle trafficking proteins STARD6 and RAB27B. 
Sex hormones stimulate the hypothalamic-pituitary-adrenal gland (HPA), modulating 
stress responses through corticosteroid release (Wilder, 1995; Whitacre, 2001). This 
would imply that in post-menopausal women mitochondrial respiration would be 
decreased, which could further lead to the accumulation of ROS. Malik and 
colleagues propose that mtDNA CN is regulated by ROS levels in mitochondria 
(Malik and Czajka, 2013), which may suggest why post-menopausal mitochondrial 
biogenesis is associated with these genes. 
Furthermore, Graham suggests that changes in expression of mitochondrial fusion 
proteins are the limiting factors to cholesterol efflux efficiency, whereby defects in 
fusion machinery results in inflammation and neurological disorders (Graham, 2015). 
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The decrease of oestrogen production may subject the mitochondria to further 
physiological stresses, and the inability of mitochondria to adapt, and fuse together 
may contribute to the overall stress signals generated by the cell. 
Hormone receptors are on the surface of immune cells (Da Silva, 1995), but cytokine 
receptors IL-1R and IL-18R are also on the surface of hormone-producing tissue, 
which suggests there is a feedback system between the two (Fairweather and Rose, 
2004). We report a lower mtDNA CN as WBC count increases, which is supported by 
other studies (Knez et al., 2016). I previously reported differences in mtDNA CN 
relative to the composition of WBCs in blood (section 3.3.5 - Figure 3.14 and Table 
3.4), which play a role in immune responses. Following the study published by Stolk 
and colleagues, who reported immune genes to be involved in menopause onset, 
further work should investigate the relationship between mtDNA CN changes and 
oestrogen levels, and immune markers to see if there is any correlation (Stolk et al., 
2012). 
Despite the plausible biological explanation of RAB27B, ABCG1, and STARD6 being 
associated with post-menopausal women in this study, Stolk and colleagues do not 
report any of these genes in their meta-analysis study of menopause across 22 
GWAS (Stolk et al., 2012). This study only uses hundreds of individuals to perform 
GWAS analysis, which is statistically underpowered to identify genes regulating a 
complex trait like mtDNA CN. Larger sample sizes would be needed for future work. 
Additionally, a cohort with more elderly women (> 69 years) would need to be used to 
identify real age and oestrogen-related effects on mtDNA CN after menopause. This 
study identified women as pre- or post-menopausal using age as a predictor, 
however this means this study is only 75% accurate because 75% of women 
undergo menopause before 50 years (Broekmans et al., 2004). Ideally I could have 
stratified the cohort as women under 60 years old to be considered pre-menopausal, 
however stratifying at higher ages would have significantly reduced the number of 
samples for comparison, as UKBS females have a 17-69 years age range (Figure 
6.2), therefore this was not possible. 
This study would also need to be replicated in an independent, control cohort. Ideally 
I would have used the ALSPAC cohort as a replicate cohort, however all of the 
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females in this cohort are of child bearing age (16-43 years old), and had not 
undergone menopause yet, and was therefore incomparable. 
Furthermore, mtDNA CN is reported to significantly decrease in females with age in 
the literature (Lee et al., 2010; Mengel-From et al., 2014; Knez et al., 2016). This 
study opposes these results though, as I report no significant change in mtDNA CN 
in women with age. This poses the question – are the results reported a real 
indication of oestrogen or age effects? 
In conclusion, this is the first study to investigate mtDNA CN changes between pre- 
and post-menopausal women. From this work, I have identified limitations that future 
studies need to consider, whilst potentially identifying viable genes that could be 
contributing to menopausal changes in women in relation to mitochondrial biogenesis 
regulation.
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7.1 Introduction 
The mutation rate in mtDNA is 10-20 times higher than that in nDNA, which causes 
point mutations and large-scale deletions to sporadically develop (Richter et al., 
1988; Lynch et al., 2006). 13-30% of all cases of mitochondrial disease, result from 
mtDNA deletions (Krishnan et al., 2007; Grady et al., 2014a), however heteroplasmy 
levels are a contributing factor (Chinnery and Hudson, 2013). Mitochondrial deletion-
related diseases manifest from lower heteroplasmic thresholds (approximately 50–
60%) than other mitochondrial diseases (Rossignol et al., 2003).  
Mitochondrial deletions present as single deletions or as multiple deletions (Krishnan 
et al., 2008), and deletion breakpoints have been mapped (Damas et al., 2014). 
Single deletions are rare, and present in 1-20 people out of every 100,000 in the 
general public (Chen et al., 1995), and give rise to sporadic mitochondrial disease 
such as progressive external opthalmoplegia, Kearns Sayre syndrome, and 
Pearson’s syndrome (Chinnery et al., 2004). Large-scale deletions are more common 
in mtDNA than small-scale deletions because it is believed that smaller mtDNA 
molecules can replicate, and accumulate, faster (Diaz et al., 2002). 
It has been reported that almost half of human oocytes contain 5-10 deleted 
molecules per 100,000 molecules of mtDNA, but only one in 8,000 individuals end up 
harbouring pathogenic deletions during development because of the mtDNA CN 
bottleneck effect (Chinnery et al., 2004). Generally, multiple point mutation 
mitochondrial deletions accumulate in post-mitotic tissues, and high energy 
demanding tissues such as muscle, with age because mtDNA are exposed to genetic 
insults from factors like ROS (Sciacco et al., 1994; Bender et al., 2006; Kraytsberg et 
al., 2006). This, combined with the lack of recombination in mtDNA, also poses a 
disadvantage as mitochondrial deletions accumulate deleterious mutations in a 
‘Muller’s Ratchet’, whereby germline selection is the only method to counteract their 
accumulation (Muller, 1964; Aanen et al., 2014). This is assessed by cell fitness, and 
the ratio of wild-type to mutant mtDNA determines the overall biochemical defects 
(Stewart and Chinnery, 2015). 
The mechanisms by which mitochondrial deletions develop is still unclear, however 
interruptions in mtDNA replication machinery contribute to mitochondrial deletion 
development. For example, decreases in nucleotide pooling, and defects in 
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replication machinery like polymerase-gamma (POLG) result in mtDNA deletion 
(Saada, 2004; Pitceathly et al., 2012; Nikkanen et al., 2016). 
Mitochondrial deletions vary between tissue type (Fischel-Ghodsian et al., 1992), and 
contribute to heteroplasmy levels, although they do not always result in disease 
(Chinnery et al., 2004). This is believed to be a result of clonal expansion regulation, 
where accumulation of mutant mtDNA results in defective OXPHOS. In post-mitotic 
cells such as neurons, the combined accumulation of mtDNA mutations and loss of 
cells from ageing results in neurodegenerative diseases, such as Alzheimer’s 
disease and Parkinson’s disease (Bender et al., 2006). mtDNA deletions have also 
been seen to repopulate quicker in post-mitotic cells because as metabolic activity 
decreases from loss of wildtype mtDNA, causing increased replication of mutant 
mtDNA and slower replication of wildtype mtDNA, resulting in an accumulation of 
mutant DNA, increased ROS, and ageing (Diaz et al., 2002). As a result, overall 
mtDNA CN increases (Chen et al., 2011).  
mtDNA CN, but not mtDNA point mutations, have been argued to be responsible for 
neurodegenerative disease development (Keeney and Bennett, 2010; Giordano et 
al., 2014; Rice et al., 2014; Pyle et al., 2015a; Wei et al., 2017), and a recent study 
also reported specific mutant mtDNA (harbouring a 3.1kb deletion) in C. elegans 
(known as uaDf5) replicated itself by exploiting wildtype mtDNA machinery, despite 
uaDf5 being destructive to the cell. They report the mitochondrial unfolded protein 
response is responsible for uaDf5  levels, as well as mtDNA CN control (Gitschlag et 
al., 2016). Overall providing evidence that mtDNA deletions, and mtDNA CN, have a 
mutual relationship. 
In addition to studying mtDNA CN, I took the opportunity to assess the levels of 
mitochondrial deletions in a large population sample, and to investigate mtDNA 
deletions in relation to mtDNA CN changes, using DNA extracted from white blood 
cells. Despite a study reporting that peripheral blood contains approximately 75% 
abnormal mtDNA molecules (Fischel-Ghodsian et al., 1992), most studies have 
reported blood from healthy individuals to contain no, or few, mitochondrial deletions 
(Maagaard et al., 2006; Van Haute et al., 2013). This is likely to be because of the 
short lifespan of white blood cells, as they are renewed every 1-5 days (Flindt, 2006), 
allowing little time for mitochondrial deletions to accumulate. To date, no study has 
investigated baseline mitochondrial deletion levels in a large population control 
Validating Mitochondrial DNA Deletions 
 
266 
 
cohort. As my DNA samples were all extracted from white blood cell pellets from 
healthy donors, and based on the published literature, it would be unexpected to 
detect any mitochondrial deletions in these samples. Therefore I decided to explore 
this. 
The qPCR method used to quantify mtDNA CN (section 2.8.1.4), was originally 
designed to additionally measure mtDNA deletions by measuring the proportion of 
MT-ND1 in the minor arc to MT-ND4 in the major arc (He et al., 2002; Krishnan et al., 
2007; Grady et al., 2014a; Rygiel et al., 2015). Approximately 85% of mitochondrial 
deletions sit within the major arc region of mtDNA, located between the origin of light 
strand (OL) and heavy strand (OH) replication (Shoffner et al., 1989; Payne et al., 
2011; Phillips et al., 2014; Rygiel et al., 2015). Moreover, approximately 96% of all 
deletions found in patients with COX deficiency were located in the MT-ND4 region 
(He et al., 2002). Therefore, by utilizing this method, calculating mitochondrial 
deletion in each sample, I could also validate the reliability of the qPCR assay whilst 
investigating the prevalence of mitochondrial deletions in European blood samples. 
7.2 Aim 
Identify if mtDNA extracted from white blood cell pellets from the blood of healthy 
individuals in a large, European cohort contain mitochondrial deletions. Long-range 
PCR (LR-PCR) will be used to visualise mtDNA deletion abundance, and validate the 
accuracy of established qPCR methods to calculate mitochondrial deletion levels.  
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7.3 Materials and Methods 
This study was conducted using cohort one - UKBS (n=3091). Full details of the 
cohort and mtDNA CN calculations are in Chapter 2. There was insufficient DNA 
available to analyse cohort two, and the qPCR technique used to determine mtDNA 
CN in the cohort three - ALSPAC cohort used a single mtDNA probe and was 
therefore unable to detect mitochondrial deletions (section 2.8.3). 
7.3.1 Identifying UKBS Samples that Potentially Contain Mitochondrial 
Deletions 
mtDNA CN values were calculated using either MT-ND1 or MT-ND4 as the 
mitochondrial reference gene. As detailed in section 3.3.2 - Figure 3.5, UKBS 
samples had their mtDNA CN determined by the delta Ct calculation using either; the 
mean mitochondrial reference gene Ct values adjusted to the mean housekeeping 
gene (B2M) Ct value, or using the raw median Ct of the mitochondrial reference gene 
adjusted to the raw median Ct of the housekeeping gene (B2M). 
As indicated in section 3.3.2, MT-ND1 derived values were plotted against respective 
MT-ND4 values to both validate the qPCR assay, and identify if any samples 
contained mitochondrial deletions (Figure 7.1). Linear regression lines were plotted to 
identify correlation, along with 95% confidence, and prediction intervals. Samples 
that sat outside of the prediction intervals indicated they contained a deletion (~20%). 
Samples which sat to the left of the lines (n=185) indicated a deletion in MT-ND1, 
and those to the right (n=61) indicated a deletion in MT-ND4 (Figure 7.1A). However 
this was not replicated when looking at the raw median Ct data of these samples 
(Figure 7.1B), suggesting that an artificial deletion effect may have been introduced 
as a result of the qPCR QC steps, and adjustment to B2M. To validate these 
‘deletions’, further tests needed to be performed. As most mitochondrial deletions sit 
within the MT-ND4 region, I decided to validate the samples that sat to the right of 
the line (n=61). 
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Figure 7.1: Linear regression plot of [A] Mitochondrial DNA copy number derived from using mitochondrial gene 
MT-ND1 against mitochondrial DNA copy number derived from using mitochondrial gene MT-ND4 in UKBS samples 
(n=3028), and [B] raw median Ct values generated from triplicate measurements for MT-ND1 plotted against raw 
median MT-ND4 measurements for each UKBS sample (n=3088). 
7.3.2 Detecting Mitochondrial Deletions using Quantitative-PCR 
Standard protocols quantify mitochondrial deletions by measuring the proportion of 
MT-ND4 to MT-ND1 in a multiplex qPCR reaction (He et al., 2002; Krishnan et al., 
2007; Phillips et al., 2014; Rygiel et al., 2015). As detailed in the section 2.8.1.4, 
B2M, MT-ND1, and MT-ND4 were measured in a multiplex qPCR reaction in all 
UKBS samples. Following QC procedures, where thresholds and standards were set 
and replicates greater than 0.5 Ct removed; mitochondrial deletions were quantified 
for each sample using Equation 7.1. Table 7.1 gives an example of the analysis 
performed on each sample across each qPCR run to calculate each sample’s 
mitochondrial deletion percentage (deln (ddCt)). If the ratio of MT-ND4 to MT-ND1 is 
0.9 (90%), this signifies that 10% of mtDNA molecules measured may contain a 
mitochondrial deletion in MT-ND4 (Rygiel et al., 2015). 
ddCt = MT‐ND4 Ct Mean [(Control)  - (Sample)] - MT‐ND1 Ct Mean [(Control) - (Sample)] 
deln = 1 – (2 ddCt) 
Equation 7.1: Equation used to calculate mitochondrial deletions. ddCt is the difference between the MT-ND4 mean 
Ct between the control and the sample and the MT-ND1 mean Ct between the control and the sample. Overall 
deletion is one minus two to the power of ddCt.  
  
 
 
 
 
 
 
 
Table 7.1: An example of the table used to calculate mitochondrial deletion percentages for each UKBS sample. Raw data for each sample from qPCR analysis was imported in 
to the table for MT-ND1-HEX and MT-ND4-Cy5 and calculations were applied respectively (Equation 7.1). ddCt is the difference between the MT-ND4 mean Ct between the 
control and the sample and the MT-ND1 mean Ct between the control and the sample. Overall deletion is one minus two to the power of ddCt and is a decimal percentage. Note 
– the deletion sample only has two replicates because one replicate was removed during QC. Analysis was performed in Microsoft Excel 2010. 
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7.3.3 Visualising and Verifying Mitochondrial Deletions 
LR-PCR was performed on UKBS samples which had a mitochondrial deletion 
percentage >20%, because these samples were outside the mtDNA CN population 
confidence intervals, suggesting they contained mitochondrial deletions (He et al., 
2002) (Figure 7.1). LR-PCR was performed across two different mitochondrial 
regions spanning the major arc - mitochondrial deletion amplicon one (ref: 10R/10F) 
of 9931 bp (Figure 7.2 blue line), and amplicon two (ref: 2F/D1R) of 15432 bp (Figure 
7.2 orange line) using primers detailed in Figure 7.2 table. 
 
 
Figure 7.2: Top: A schematic representation of three different sized long-range PCR amplicon regions in the 
mitochondrial DNA used to detect any mitochondrial deletions. The table details 5’-3’ forward and reverse primer 
sequences used to amplify both the 10F/10R and 2F/D1R regions within mitochondrial DNA. 
7.3.3.1 Optimising LR-PCR assay to DNA extracted from blood 
Similar LR-PCR methods have been described previously (Payne et al., 2011), 
however initial assay optimisation was needed. Therefore a selection of control and 
deletion DNA extracted from different tissues (see Figure 7.3) were used to identify 
optimal conditions to perform LR-PCR across different tissues, especially blood.  
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7.3.3.1.1 Sample Sources 
As deletion assay controls, seven samples were used representing confirmed non-
deleted and deleted samples. d5d25, d5AM017.7, motor neuron, and cerebellum 
samples were kindly donated by Dr Marzena Kurzawa-Akanbi from Newcastle 
University, UK in collaboration with Dr George Tofaris from University of Oxford, UK. 
d5d25 and d5AM017.7 DNA samples were extracted  from differentiated 
dopaminergic neuronal cell lines which had been programmed in to induced 
pluripotent stem cells (iPSCs) from donor control fibroblasts using specialised iPSC 
technology (developed by Dr George Tofaris at University of Oxford). DNA was 
extracted from cell lines 25 days after differentiation from iPSCs (in vitro). Motor 
neuron DNA was extracted from motor cortex tissue from a donor who had 
Alzheimer’s disease and was known to have a mitochondrial deletion. Cerebellum 
DNA was extracted from cerebellum tissue from a healthy donor and did not have 
any mitochondrial deletions detected. WT_546081 was a UKBS sample, and control 
calibre and deletion calibre were DNA as previously detailed in section 2.8.1.4. 
WT_546081 was used to determine optimum assay conditions for all future tests and 
calibre DNA was used to assess specificity (see Figure 7.3). 
 
Figure 7.3: A table summarising the source of and the type (control or deletion) of mtDNA used to optimise the LR-
PCR assay. iPSC cell line, motor neurons and cerebellum tissue extracted DNA were kindly provided by Dr Marzena 
Kurzawa-Akanbi (Newcastle University, UK) and Dr George Tofaris (University of Oxford, UK). 
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7.3.3.1.2 Long Range PCR Reactions 
Each DNA sample was diluted to 40 ng/μl in nuclease free water (Thermo Fisher 
Scientific, MA, USA) and kept at -20°C until use. Fresh mastermix was made for 
each reaction batch, and 10F/10R and D1R/2F reactions were always run 
simultaneously for each sample. All reactions were set up on ice. Mastermix 
consisted of 1x PS PrimeSTAR GXL buffer (contains 1x Mg2+), 0.625 units 
PrimeSTAR GXL DNA polymerase, 0.2 μM of dNTP mix (all Takara Clontech, USA), 
and 0.2 μM of each forward and reverse primer (Integrated DNA Technologies in 
Leuven, Belgium). Mastermix was aliquoted into plastic strip tubes (Starlab, Milton 
Keynes, UK) and approximately 2 ng of each respective DNA sample was added to 
each tube, and sealed securely. Samples were spun down before being loaded into 
an Applied Biosystems® Veriti® 96 well thermal cycler (Life Technologies, Paisley, 
UK). LR-PCR cycling conditions are detailed in Figure 7.4. 
7.3.3.1.3 Long Range PCR Agarose Gel Electrophoresis 
Following amplification of samples, 12 µl of each LR-PCR product was combined 
with 6 μl orange G loading buffer (Orange G powder, 50% v/v glycerol (both Sigma 
Aldrich Company Ltd, Dorset, UK) and 50% v/v water). A DNA negative LR-PCR 
reaction was also mixed with orange G loading buffer, as was a 1 Kb Plus DNA 
ladder (Promega, Southampton, UK). Each UKBS sample LR-PCR product was 
loaded in to individual wells on a 16 well comb on a large, 0.7% agarose gel (0.7% 
w/v agarose (Bioline, London, UK) in 1x tris-acetate-EDTA (TAE) buffer (5 Prime 
GmbH, Hilden, Germany) and 0.4 mg/µl UltraPure™ ethidium bromide (Invitrogen, 
Paisley, UK)). 1 kb Plus DNA ladder (Promega, Southampton, UK) and negative 
products were loaded separately. Agarose gels were initially electrophoresed at 50 V 
for 15 minutes and then at 40 V for three hours in 1x TAE buffer. Agarose gels were 
imaged and analysed using the UVP GelDoc-It™ imaging system and UVP Launch 
Vision Works LS software (UVP, Cambridge, UK). 
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Figure 7.4: LR-PCR PCR reaction conditions for each specified amplicon. * indicates change from 13 minutes to 10 
minutes (Figure 7.5A and B). 
As Figure 7.5 shows, preliminary tests were performed on different tissue samples 
(as detailed in Figure 7.3) to identify optimal LR-PCR conditions. Figure 7.5A 
displays an unknown band of approximately 2000 bp present in all samples which 
have been amplified using D1R/2F primers, and an unknown band of approximately 
2500 bp is present in all samples amplified using 10F/10R primers. These bands 
were thought to be generated from the annealing time being too long, therefore LR-
PCR was repeated on the same tissues but the annealing temperature was reduced 
from 13 minutes to 10 minutes for D1R/2F reactions (Figure 7.5B). As a result, the 
original unspecific bands did diminish slightly, however this might be hard to interpret 
from Figure 7.5B as the image is overexposed. 
As Figure 7.5B shows, there were still some remnants of unspecific bands in all 
tissues LR-PCR products, therefore a final repeat was performed on the same 
tissues, but each primer concentration was decreased to 0.12 μM for all reactions, 
instead of 0.20 μM. The annealing temperature remained at 10 minutes for D1R/2F. 
As Figure 7.5C shows, there were no more unspecific bands in all the LR-PCR 
products. 
Following discussion about these results, it was decided that further LR-PCR would 
use PCR conditions described in Figure 7.4, and primer concentrations of 0.20 μM 
because DNA from blood samples amplified well under those conditions. 
  
 
 
Figure 7.5: Images of LR-PCR products during optimisation steps when performed on a selection of samples. Top images show products using D1R/2F primers. Bottom images 
show products using 10F/10R primers. [A] images LR-PCR products when D1R/2F had an annealing time of 13 minutes at 68°C. [B] and [C] images LR-PCR products when 
D1R/2F had an annealing time of 10 minutes at 68°C. All primer concentrations in [A] and [B] were 0.2μM whereas all primer concentrations in [C] were 0.12 μM. WT= wildtype. 
DEL= deletion. Red arrow indicates an unspecific band (approximately 3500 bp) during optimisation steps. WT_546081 is a UKBS sample from blood. d5d25 and d5AM017.7 
are dopaminergic neuron cell lines differentiated from iPSCs. Motor and cerebellum samples were extracted from human brain tissue. Control DNA is from healthy blood and 
deletion calibre is from cybrid cell lines (section 2.8.1.4). Images were generated on a UVP GelDoc-It™ imaging system and UVP Launch Vision Works LS software (UVP, 
Cambridge, UK). 
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7.4 Results 
Following protocol optimisation, LR-PCR was performed on 61 UKBS samples (n=39 
males and n=22 females) (approximately 2% of all samples), which had a 
mitochondrial deletion percentage of greater than 20%, which was calculated from 
qPCR tests (Table 7.2). Samples with these results were suspected to contain a 
mtDNA deletion in the MT-ND4 gene located in the major arc region. 
7.4.1 Detecting Mitochondrial Deletions in UKBS samples 
Each UKBS sample was defrosted from -20°C, vortex and spun down and then 
freshly diluted to 40 ng/μl in nuclease free water before undergoing LR-PCR. As 
described previously, all reactions were set up fresh, on ice, and both D1R/2F and 
10F/10R reactions were prepared and run at the same time on each respective 
sample to prevent delay leading to sample degradation. LR-PCR reactions were run 
overnight and kept at 4°C until the morning where they were then vortexed and spun 
down before being prepared for gel electrophoresis (as detailed above). D1R/2F 
products were run from the top of each gel, and 10F/10R products were run from the 
centre of each gel. 
Table 7.2 lists all the UKBS samples which underwent LR-PCR. Average age in 
these samples was 40 (range from 15-65 years). The largest deletion reported using 
qPCR analysis was 52.65%. 
Figure 7.6 shows UV images of the DNA fragments generated when performing LR-
PCR on each UKBS sample. No results reported any deletions in any of the samples, 
in either of the amplicon regions. The unspecific band appeared again in two LR-
PCR runs for D1R/2F (Figure 7.6A and D), however they were not indications of 
mtDNA deletions because the control calibre also contained the band.   
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Table 7.2: A list of all UKBS samples (n=61) which had a mitochondrial deletion percentage calculated to be greater 
than 20% using qPCR (Equation 7.1). The table lists the UKBS sample Wellcome Trust Case Control Consortium 
identifier (WTCCC_ID), their gender (M=male, F= female), age and mitochondrial deletion size. 
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Figure 7.6: Images of UKBS samples (n=61) where long-range PCR has been used to identify deletions within the mitochondrial DNA. The top half of each image are products 
which have been amplified using D1R/2F primers (15432 bp region) and the bottom half of each image are products which have been amplified by 10F/10R primers (9931 bp 
region). Arrows indicate the wildtype (WT) and deletion (DEL) fragments. [B]-[E] are separate gel images but all were performed under the same conditions. Only [A] was 
performed with a longer annealing time of 13 minutes instead of 10 minutes for D1R/2F.
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7.5 Discussion 
This is the first study to investigate the abundance of mtDNA deletions in healthy 
individuals from a large, European population. My results show that DNA extracted 
from white blood cell pellets from healthy individuals contain no mitochondrial 
deletions, which opposes the deletion levels determined using established qPCR 
calculations. 
Previous studies have reported DNA samples extracted from peripheral blood to 
contain no mitochondrial deletions (Van Haute et al., 2013), which suggests that the 
results reported in the LR-PCR analysis are accurate, because no deletion fragments 
are recorded. However, this introduces limitations about using qPCR to detect 
mitochondrial deletions because I report deletion values up to 52.65% using qPCR, 
which could not be detected using LR-PCR. 
qPCR is a very sensitive method, and a number of factors can affect the accuracy 
and reproducibility of its results (reviewed in section 4.5.6.2.1). In theory, MT-ND1 
should be proportional to MT-ND4 in complete, circular mtDNA, therefore a decrease 
in MT-ND1 would result in a decrease of MT-ND4 relatively. To calculate deletions in 
MT-ND4 in healthy individuals using qPCR, which do not have any mitochondrial 
deletions, would suggest there was either a higher proportion of MT-ND1 in the cells 
than MT-ND4, or there were errors with MT-ND4 amplification properties. If the 
former was true, then it may suggest there are linear molecules of mtDNA present in 
DNA samples, which are offsetting the proportions between MT-ND1 to MT-ND4 
ratios. Linear molecules of mtDNA could easily be generated from DNA handling 
processes, and freeze-thaw damage (reviewed in section 4.5.6.2.2). 
Previous work conducted in section 5.4.6 identified the importance of correct qPCR 
primer, and probe design for optimal, and reproducible mtDNA analysis. Expanding 
on this work, I wanted to investigate how the detection of mitochondrial deletions 
changed when using different mtDNA reference genes. I used the ‘alternative’ qPCR 
method (detailed in section 5.3.6.1) to quantify mitochondrial deletions in the same 
108 UKBS samples (n=53 haplogroup W and n=55 non-haplogroup W) used for 
original analysis. Mitochondrial deletions were quantified by calculating the proportion 
of MT-RNR2 to MT-ND4, and samples were stratified by haplogroup W to ensure 
mitochondrial reference genes were not having an effect on deletion levels (as 
mtDNA CN was previously reported to be significantly lower in haplogroup W 
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individuals – section 5.4.4). Mitochondrial deletion values were calculated using both 
qPCR methods, and then compared (Figure 7.7). 
As Figure 7.7A shows, mitochondrial deletion values are supposedly significantly 
high (p= 2.026E-12) in haplogroup W individuals using the MT-ND1: MT-ND4 
calculation, however the significant difference is not reported (p= 0.457) when using 
the MT-RNR2: MT-ND4 calculation (Figure 7.7B). These results would support the 
work reported using LR-PCR (Figure 7.6). Figure 7.7C also shows there is a much 
larger spread of deletions using the MT-ND1: MT-ND4 calculations compared to the 
MT-RNR2: MT-ND4 calculations. 
These data demonstrate that incorrect mitochondrial deletion values can be reported 
as a result of technical limitations, and emphasises the importance of optimising 
qPCR assays before attempting to validate mtDNA characteristics. Furthermore, 
polymorphisms are reported across several MT-ND genes (Mitchell et al., 2006), and 
this could potentially lead to inefficient quantification of amplicon regions in qPCR 
which could result in false-positive deletion results. The evidence shown in this study 
suggests the established mitochondrial deletion assay needs to be revised, and 
alternative mtDNA reference gene regions need to be identified before quantifying 
exact mitochondrial deletion levels. 
Alternative methods being used to validate mitochondrial deletion levels include 
Sanger sequencing, deep sequencing, and digital-droplet PCR (ddPCR) (Ameur et 
al., 2011; Van Haute et al., 2013; Belmonte et al., 2016; Rygiel et al., 2016). These 
techniques are considered to be more accurate than qPCR because both Sanger 
sequencing and deep sequencing specifically sequence the mtDNA to identify 
genetic breakpoints and rearrangement regions. ddPCR also uses fluorescent 
probes and droplet technology to quantify individual mtDNA molecules to accurately 
determine deletions. Furthermore, Taylor and colleagues developed a method which 
quantified mitochondrial deletions by sequencing mtDNA in single-cells. They used 
28 pairs of primers to generate overlapping fragment reads which spanned the entire 
mtDNA. From this, they were able to map exact mitochondrial deletion breakpoints, 
and regions of rearrangements (Taylor et al., 2001). 
 
  
  
 
 
 
 
Figure 7.7: Mitochondrial deletion percentage calculated using qPCR methods which either quantified [A] MT-ND1: MT-ND4 or [B] MT-RNR2: MT-ND4 in UKBS samples (n=108). [C] 
Correlation between mitochondrial deletion levels using different qPCR methods.
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Moreover, multiple mitochondrial regions should be used to validate mitochondrial 
deletion levels. Rygiel and colleagues developed a qPCR assay in 2015 which 
measures three mtDNA regions to validate mitochondrial deletions across a number 
of different tissue types (Rygiel et al., 2015), however they use the D-loop as a 
reference region which may cause some inconsistencies because of its associations 
to quadruplex mtDNA stranding issues (Takamatsu et al., 2002). Ideally a qPCR 
assay needs to be designed which quantifies more than three mtDNA reference 
regions that are not located in any highly genetic or structurally polymorphic regions. 
Despite using Takara PrimeSTAR GXL reagents to perform LR-PCR on DNA 
samples, which is considered to be the best polymerase for long-range amplification 
(Jia et al., 2014), an unspecific 4 kbp band was consistently reported in Figure 7.5, 
and in Figure 7.6A and D. It would be interesting to expand on these results, and 
investigate mitochondrial deletions in those UKBS samples with extra LR-PCR 
bands, but by using more accurate techniques like deep sequencing or ddPCR to be 
more comprehensive. 
In summary, this study has identified that there are no mitochondrial deletions in DNA 
of white blood cells in general, healthy, European populations. As a result of this 
work, I have identified the limitations of current methods used to determine 
mitochondrial deletions, and propose that developments are needed to further 
improve the accuracy of mitochondrial deletion detection using qPCR. 
  
  
 General Discussion 
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mtDNA CN is central to both cellular and mitochondrial homeostasis, as mtDNA 
composition dictates OXPHOS efficiency, and is vital for cellular bioenergetics. 
mtDNA CN varies between cell and tissue type (Michaels et al., 1982; Robin and 
Wong, 1988; Kelly et al., 2012), and its regulation has been the focus of much 
research, as it is used as an indicator of disease susceptibility, progression, and 
outcome (Cree et al., 2008a; Pyle et al., 2010; Malik et al., 2011; Giordano et al., 
2014; Reznik et al., 2016). Additionally, circulating, cell-free (ccf)-mtDNA has more 
recently received increased attention as a biomarker for disease (Yu, 2012; Liu et al., 
2015a; Pyle et al., 2015a; Pyle et al., 2015b; Li et al., 2016), thus emphasising the 
importance of understanding mtDNA CN regulation. 
The maintenance of mitochondria, including mtDNA replication and translation, is 
managed by a complex communication system between mtDNA and nDNA, which 
involves more than 1500 nDNA-encoded proteins (O'Brien, 2002). The system is still 
not fully understood, however several studies have identified important mtDNA 
replication machinery components such as POLG, TFAM, and mtSSB to be important 
for mtDNA CN regulation (Takamatsu et al., 2002; Ruhanen et al., 2010; Stewart et 
al., 2011; Chinnery and Hudson, 2013). With so much still unknown about mtDNA 
CN regulation, I aimed to identify whether genetic factors modulate mtDNA CN 
changes in DNA sourced from white blood cell pellets in two large, healthy, and 
unrelated UK cohorts. In the process I have performed the largest, and most 
comprehensive, study of genetic, biological, and technical factors modulating mtDNA 
CN to date. 
8.1 Genetic Factors Modulating Mitochondrial DNA Copy Number 
8.1.1 Nuclear DNA and Epigenetic Factors 
Two previous studies have attempted to identify genetic regulators of mtDNA CN, 
one performing linkage-analysis in Mexican-American families (Curran et al., 2007), 
and a second using low coverage sequencing data to estimate mtDNA CN in a 
cohort of over 10,000 Chinese individuals (Cai et al., 2015). Both studies used 
GWAS to identify loci associated with mtDNA CN changes. The linkage-analysis 
study identified several loci to be significantly associated with mtDNA CN regulation. 
These loci were involved in cellular trafficking, signalling, and metabolic events 
(Curran et al., 2007). The GWAS in Chinese individuals did not replicate these 
results, and reported mitochondrial transcription factor A (TFAM), and cyclin-
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dependent kinase 6 (CDK6) to be significantly associated with mtDNA CN changes 
(p= 8.73E-28, and p= 6.03E-16 respectively), suggesting mtDNA CN may be 
modulated by different loci. Furthermore, both studies had limitations; either using a 
limited number of polymorphic markers to map the genome, or relying on indirect 
measurements of mtDNA CN. 
In an attempt to mitigate these limitations, but still identify genetic factors modulating 
mtDNA CN, I have performed a GWAS in over 8,000 people from two, independent, 
unrelated, healthy UK cohorts, using nearly 7.5 million imputed nuclear genetic 
markers to map loci associated to actual measures of mtDNA CN (0).  
My data indicates that there are likely to be several loci regulating mtDNA CN. 
Analysis in each cohort revealed genome-wide significant (GWS) variants that were 
located in several different loci. Between cohort analyses, no variants or loci were 
replicated, and following meta-analysis of both cohorts, no variants were GWS.  
We identified no GWS results (p <5.00E-08) as a consequence of considerable 
differences in phenotypic and experimental measurements between, and within 
UKBS and ALSPAC cohorts (Table 4.6 – section 4.4.4). Detailed analysis reported 
mtDNA CN proportions to change relative to DNA source (whole blood or white blood 
cell extracted), qPCR assay method, and blood cell component proportions. 
Restricting individuals, and adjusting for these factors in GWAS analysis weakened 
our study power, and as the data suggest, nDNA control of mtDNA CN is also likely 
to be complex. Our original study was powered to detect a low number of high effect 
alleles, however post-hoc power calculations, now based on actual data, determine 
that tens to hundreds of thousands of individuals will be needed to detect GWS loci 
associated with mtDNA CN changes with sufficient power, whilst accommodating to 
study heterogeneity. 
Future work will need to ensure larger sample sizes are used, which have been 
extracted from the same DNA source, and have had their mtDNA CN quantified 
using the same qPCR assay, which is conducted by a single user. By applying these 
measures, relative mtDNA CN deviations will be minimised and will improve overall 
study power. Furthermore, a much more accurate and reproducible qPCR assay 
needs to be designed and optimised to minimise mtDNA CN variability between 
experimental runs, and across the general literature (explored in section 2.9). 
Additionally, if the DNA source is from blood, full blood count information will need to 
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be included and adjusted for in analysis to correct for cellular proportions. Following 
these procedures will minimise heterogeneity between cohorts, which we identified to 
affect GWAS results (Chapter 4). 
Despite no results being definitive from this work, this is the most comprehensive 
study to investigate the effects cellular heterogeneity have on mtDNA CN, and 
GWAS results, and in relation to mtDNA CN regulation. We report gender-specific 
genetic effects on mtDNA CN regulation despite recording no significant difference in 
mtDNA CN between genders. This may be a result of the male nDNA, and likely the 
non-recombining Y chromosome, having to accommodate to newly inherited, also 
non-recombining, mtDNA following fertilisation (Al Rawi et al., 2011; Sato and Sato, 
2011; Politi et al., 2014).  
As previously discussed in section 4.1.1, the intergenic communication between 
nDNA and mtDNA is highly sensitive, and diversions from original nDNA-mtDNA 
communication makes it harder for tissues to generate sufficient ATP through 
OXPHOS (McKenzie et al., 2004), which can alter tissue physical and metabolic 
performance because nDNA cannot recognise the inherited mtDNA (Nagao et al., 
1998; St. John, 2016). This may explain why mitochondrial biogenesis differences 
have been identified between genders in humans and rodents (Khalifa et al., 2017; 
Mauvais-Jarvis et al., 2017). 
The lack of mtDNA CN difference reported between genders in this study is 
contradictory to the literature, because, although not investigated in this study, 
methylation of nDNA genes such as POLGA is likely to modulate mtDNA CN (Amaral 
et al., 2007; Chinnery and Hudson, 2013; Lee et al., 2015). However, Lopez and 
colleagues also reported different GWAS results between genders despite recording 
no significant differences in mtDNA CN, thus supporting our results. Suggesting sex-
specific effects may be possible. 
Elaborating further, mtDNA CN is directly controlled by methylation profiles of nDNA 
genes such as POLGA (Kelly et al., 2012; Lee et al., 2015), and methylation profiles 
are reported to change in blood leukocytes of obese individuals who are 
metabolically stressed (Wang et al., 2010c). Furthermore, despite having low 
participant numbers in their study, Lynch and colleagues reported significantly lower 
natural killer cells, and cytotoxic T lymphocytes in obese individuals compared to 
lean individuals, however metabolically unhealthy obese individuals had significantly 
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lower natural killer cells than metabolically healthy obese individuals (Lynch et al., 
2009). Ineffective mitochondria can also directly contribute to blood composition 
changes (Pyle et al., 2007; Pyle et al., 2010; Jaffe and Irizarry, 2014), and cause 
anaemias because they prevent efficient erthyrocyte synthesis by interrupting iron 
metabolism, which depletes bone marrow stores and increases oxidative damage 
through the Fenton reaction (Ahlqvist et al., 2015). This shows that blood cell 
composition changes dependent on mitochondrial metabolic stress, which could be 
managed by epigenetic programming. 
Additionally, our GWAS performed on the healthy, female-only ALSPAC cohort 
reported multiple variants spanning PSMD3 loci on chromosome 17 when not 
adjusting for blood cell composition. PSMD3 is a gene which codes for a protein that 
is associated with neutrophil count. When blood cell composition was adjusted for, 
this locus association was removed, thus suggesting that mtDNA CN is relative to 
blood cell proportions. Similar findings have been reported in other studies (Pyle et 
al., 2007; Pyle et al., 2010; López et al., 2012), which suggests that mtDNA CN may 
be a proxy to blood cell count, and that mtDNA CN may be regulated through 
complex feedback systems between metabolic stress signalling, which may trigger 
immune system intermediates, by acting through blood cell intermediates. This may 
explain why there were different genetic association results reported between 
gender-specific GWAS analysis. Epigenetic regulation may be contributing to 
differences reported between genders, because males are more susceptible to 
disease such as Parkinson ’s disease (PD) and amyotrophic lateral sclerosis (ALS) 
than females (Van Den Eeden et al., 2003; Kim et al., 2012), and females are more 
susceptible to autoimmune diseases than males (Whitacre, 2001; Fairweather and 
Rose, 2004), and these diseases are strongly determined by mitochondrial 
bioenergetics (Dupuis et al., 2004; Pyle et al., 2015a; Coxhead et al., 2016). 
Genetic and epigenetic factors have also been involved in autoimmune diseases 
(Farh et al., 2015), and long-range interactions have been recorded between nDNA 
genes in autoimmune risk studies (Martin et al., 2015). If there are complex systems 
interplaying between mitochondrial regulation, and immune intermediates which are 
being regulated by blood cell composition, then this may explain why several loci 
were reported in our nDNA GWAS, and it would be interesting to investigate whether 
they interacted on a chromosomal level, or through functional analysis in further 
studies. 
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It is important to consider whether mtDNA CN in blood is just an indicator of 
physiological cell stress, or is in fact just a mediator in triggering an immune 
response, or accommodating to the physiological change. For example, Kilbaugh and 
colleagues demonstrated that mtDNA CN significantly increased in peripheral blood 
from pigs when they had induced traumatic brain injury (Kilbaugh et al., 2015). Also, 
when cells are stressed, cytokines are excreted, and mitochondria migrate between 
stressed cells to rescue aerobic respiration (Wang and Gerdes, 2015). Furthermore 
recent literature demonstrated that mitochondrial and ER interactions directly 
mediate the innate immune responses (Misawa et al., 2017), and mitochondrial-ER 
interactions also directly mediate mtDNA CN (Friedman et al., 2011; Lewis et al., 
2016).  
Expanding on this further, we reported vesicle and peroxisome-related genes as top 
loci regions in our GWAS analysis to be associated with mtDNA CN, and 
peroxisomes, vesicle trafficking and ER maintenance are a tight-net signalling 
network for efficient lipid metabolism and cellular apoptosis regulation, which the 
mitochondria also oversee (Dimitrov et al., 2013) (section 4.4.2). This suggests there 
may be an indirect association of functional genes contributing to mtDNA CN. 
Furthermore, NUMTs have developed through evolution as a result of cellular stress, 
including ROS, which ensures mtDNA codes are selected for rather than relying on 
genetic drift (Ju et al., 2015; Srinivasainagendra et al., 2017). Literature is currently 
realising the extent the immune system cross talks between mtDNA and nDNA, and 
other GWAS have identified genes like interleukin-6 (IL-6), IL-10, superoxide 
dismutase-2 (SOD2), and insulin-like growth factor-1 (IGF1) to be associated with 
longevity (Garagnani et al., 2014). mtDNA CN, and blood cell composition are 
reported to change with age (Niranjan et al., 1982; Trifunovic et al., 2004; Jaffe and 
Irizarry, 2014), which also suggests additional factors contributing to the complex 
interplay between mtDNA CN maintenance. This raises the possibility that immune 
factors could be contributing to mitochondrial stress over time, and the changes 
reported could be a result of natural ageing effects from ROS whereby ROS could be 
interrupting signalling events, to reduce the quality of mitochondria which would 
prevent them from functioning properly. Also, it is possible that ROS may be 
regulating cellular epigenetics which could result in increased immune stimulation, or 
increased autophagy.  With ccf-mtDNA being increasingly recognised as a biomarker 
for disease, it raises the hypothesis that ccf-mtDNA could be an indicator of cell or 
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tissue stress with age which has led to disease, because ccf-mtDNA is generated 
from apoptotic, but not necrotic cells (Suzuki et al., 2008). 
Further work needs to be conducted on individual blood cell components to 
understand their genetic regulation with respect to mtDNA CN, because our work, 
and previous literature, reports that cells operate independently, and mtDNA CN is 
relative to their proportions or activity. We have identified the impact heterogeneity 
has on genetic association studies therefore, if work is going to be conducted in DNA 
from full blood, or white blood cell pellets, then full blood counts needs to be 
accommodated for to adjust for the cellular heterogeneity. As my work shows, not 
adjusting for cellular heterogeneity introduces results bias to more frequent cellular 
populations. 
8.1.2 Mitochondrial DNA 
Studies have reported differences in mitochondrial biogenesis and OXPHOS 
capacities between European mitochondrial haplogroups (Gomez-Duran et al., 2010; 
Gómez-Durán et al., 2012), and mtDNA CN is directly correlated to mitochondrial 
OXPHOS capacity (Dickinson et al., 2013). Yet, this is the first, and largest, study to 
investigate whether mitochondrial DNA variants contribute to changes in mtDNA CN 
(Chapter 1). I performed GWAS across three, independent, unrelated cohorts using 
mitochondrial variants as a continuous quantitative trait. My data indicate that 
significantly lower mtDNA CN is present in individuals who have a mitochondrial 
haplogroup W background, when compared to the other European haplogroups. This 
result replicated in all three cohorts. 
Haplogroup W is a relatively rare European haplogroup (around 3% prevalence). It is 
most prevalent in North-eastern countries such as Finland and Hungary, constituting 
9.5% and 5% of their populations respectively. Due to its rarity, haplogroup W is 
often excluded as a group in studies making it difficult to compare to previous 
studies.  
The two variants used to identify haplogroup W individuals in this study were G5460A 
and G5046A, which are located in the MT-ND2 region either side of the OL strand, 
and cause non-synonymous amino acid changes. Haplogroup WIX appears to be 
more common than haplogroup J in an aged Finnish population (Niemi et al., 2003), 
which either suggests haplogroup W predisposes individuals to age better than other 
haplogroups, or the study is biased because of population stratification numbers. 
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It could be possible that the non-synonymous amino acid changes in haplogroup W 
mtDNA may be altering the OXPHOS capacity of haplogroup W individuals. 
OXPHOS gene expression is known to change dependent on metabolic stress 
conditions from metabolites such as ROS (Morel and Barouki, 1999). With lower 
mtDNA CN, it is also possible to hypothesise that the mitochondria may generate 
less ROS if they are operating at a lower OXPHOS baseline threshold with fewer 
mtDNA molecules. If less ROS is being generated, or accumulated, from reduced 
OXPHOS then this may be preventing ageing events, which is resulting in higher 
numbers of individuals with haplogroup W mitochondria in the Finnish aged 
population. 
Also, cytokine expression is dependent on mtDNA haplogroup variants (Bellizzi et al., 
2006), which suggests that immune response mediators are different between 
mitochondrial haplogroups. In this study, no significant difference in blood 
composition was reported between individuals who were haplogroup W or non-
haplogroup W, which implies that the lower mtDNA CN reported are not an artefact of 
cellular proportions, or immune mediators. However, blood composition is reported to 
change depending on age and methylation profile (Houseman et al., 2012), and CpG 
sites regulate methylation and cell composition. In mtDNA, CpG sites are located 
near OL site, which is where the haplogroup W-defining variants are located. This 
evidence proposes that epigenetic mediators are controlling mtDNA CN relative to 
mitochondrial haplogroup variants. 
Although not studied in this project, it is possible that epigenetics may be contributing 
to mtDNA CN regulation further. CpG islands are recognised to regulate the 
methylation patterns, which are critical for human induced pluripotent stem cells, and 
embryonic stem cells during differentiation. Cancers also have CpG distinguished 
shores (Doi et al., 2009), and mtDNA CN changes are reported in cancers (Jiang et 
al., 2006; Higuchi, 2007; Fan et al., 2008; Malik and Czajka, 2013; Lee et al., 2015). 
Mitochondrial haplogroups in embryonic stem cell models with the same nDNA 
background also have slightly different differential gene expression patterns, 
including POLGA (Kelly et al., 2012; Kelly et al., 2013a). This suggests mitochondrial 
haplogroups are affecting nDNA methylation profiles which may be managing 
mitochondrial replication and translation rates (St. John, 2016).  
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As the haplogroup W–defining variants in this study are located either side of the OL 
site, it may be possible that epigenetic control over these variants may be interfering 
with the binding of replication machinery to the lagging strand, or are causing 
displacement of machinery in that region, which is contributing to decreased mtDNA 
synthesis (details in section 5.5.1). 
Further work needs to be conducted to understand haplogroup W mitochondrial 
maintenance, because evidence indicates their physiology may explain a lot about 
overall mtDNA CN maintenance, and mitochondrial biogenesis. It would be beneficial 
to investigate the mechanisms by which these mitochondria function with lower 
mtDNA CN, as well as explore their tolerance to cellular stress, to further understand 
disease development in relation to mtDNA CN changes. 
8.2 Biological Factors Modulating Mitochondrial DNA Copy Number 
8.2.1 Age and Gender 
Previous research suggests that ROS and oxidants significantly contribute to human 
ageing (Finkel and Holbrook, 2000; Liochev, 2013; Davalli et al., 2016), and it is 
generally agreed that mtDNA CN decreases with age across a number of tissues as 
a result of ROS-induced damage (Tezze et al.; Barrientos et al., 1997; Barazzoni et 
al., 2000; Miller et al., 2003; Cree et al., 2008a; Cheng and Ivessa, 2010; Payne et 
al., 2011; Mengel-From et al., 2014; Laubenthal et al., 2016; Zole et al., 2017), 
however there is no conclusive evidence of any gender effects. This study reports 
statistically significant decreases in mtDNA CN with age, but only in males (section 
3.3.4). Other studies have reported similar findings (Curran et al., 2007), however 
these results may not be biologically signficiant because mtDNA CN decreases by 
0.18 copies/cell every 10 years. Further work is needed to investigate the biological 
impact of this decrease in males with age. 
Despite the potential lack of biological significance, these findings are important 
because they suggest that female mtDNA are less susceptible to oxidative damage 
than male mtDNA with age. Studies in mice have reported differences in 
mitochondrial biogenesis, respiration rate, ROS homeostasis, and morphology 
between males and females, and oxidative stress biomarkers are lower in females 
compared to age-matched males (Khalifa et al., 2017). Additionally, females express 
higher levels of antioxidant genes than males (Borrás et al., 2003). The results in this 
study agree with evidence in the literature, and also agree with Malik and colleagues 
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who hypothesised that mtDNA CN may change in response to oxidative stress (Malik 
et al., 2011; Malik and Czajka, 2013). 
Furthermore, mitochondrial-related diseases such as PD, ALS, and Leber’s 
Hereditary Optic Neuropathy (LHON), which have reports of mtDNA CN changes 
(Wiedemann et al., 2002; Giordano et al., 2014; Pyle et al., 2015a), are more 
predominant in males (Man et al., 2003; Van Den Eeden et al., 2003; Kim et al., 
2012). The penetrance of LHON has also been reduced as a outcome of increased 
mtDNA CN (Giordano et al., 2014), thereby suggesting there may be age-related 
gender-specific mechanisms impacting mtDNA CN levels. These compensatory 
mechanisms are important to understand because they may protect against 
mitochondrial genetic insults, and potentially provide a therapeutic target to prevent 
gender-specific metabolic age-related diseases. 
In addition to this, a study demonstrated that oestrogen was an essential 
neuroprotective factor for age-related diseases such as ALS and LHON (Choi et al., 
2008; Kim et al., 2012; Pisano et al., 2015). This suggested that hormones may be 
protecting mtDNA from long-term oxidative damage.  
8.2.2 Oestrogen-Independent Mitochondrial DNA Copy Number Regulation 
Previous studies recognise oestrogen to have protective mechanisms on 
mitochondrial biogenesis through peroxisome proliferator-activated receptor (PPAR) 
pathways (Scarpulla, 2011; Kemper et al., 2014), and is thought to contribute to the 
longer life expectancy observed in females (Viña et al., 2005). 
To expand on the age, and gender, specific mtDNA CN changes reported in section 
3.3.4, and to investigate whether the changes were a result of oestrogen, I performed 
a study to investigate the differences in mtDNA CN between pre- and post-
menopausal women (Chapter 6). The literature indicates that pre- and post-
menopause can be accurately segregated using age (te Velde et al., 1998; Wallace 
and Kelsey, 2010). However, stratification into pre- and post-menopausal women in 
this study (Chapter 6) identified no significant difference in mtDNA CN between 
groups, as well as no significant nDNA associations. 
So how do we rationalise our lack of association? Pre- and post- menopausal women 
in this study were stratified by age, however stage and onset of menopause, as well 
as medications individuals were administering were not known. This restricted the 
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reliability of our results because population stratification was not accurate, and 
hormone therapies are reported to directly increase mtDNA CN (Knez et al., 2016), 
which would have skewed our results further. 
Needless to say, age is considered a good indicator of menopause, as the average 
female undergoes menopause by 50 years of age (te Velde et al., 1998; Wallace and 
Kelsey, 2010). GWAS analysis in post-menopausal women reported several, 
consistent associations to variants which were located in ABCG1, RAB27B and 
STARD6, which are genes involved in phospholipid transport through vesicle-
mediated pathways.  
Overexpression of StARs is reported to decrease intracellular lipids, and lower 
inflammatory intermediates (Ning et al., 2009). These results further highlight and 
support the results reported in the earlier nDNA meta-analysis work, whereby vesicle 
and lipid-related signalling events were associated with mtDNA CN changes through 
ER maintenance (Dimitrov et al., 2013). If oestrogen levels decrease during 
menopause, it could be possible that the accumulation of lipids and sterols activate 
immune signalling pathways from increased mitochondrial stress, and ROS 
production. This increased physiological stress may be contributing to the 
development of menopause-related conditions such as osteoporosis, weight gain, hot 
flushes, disturbed sleep and skin atrophy. 
The presence of oestrogen also increases mitochondrial respiration (Gigli and 
Bussmann, 2001; Nilsen et al., 2006) which may suggest that oestrogen mediated 
pathways are contributing to downstream beta-oxidation, and lipid signalling and 
trafficking events, which are causing an increase in mitochondrial respiration. Further 
to the points highlighted previously, this proposes the hypothesis that mtDNA CN is 
just an indicator of respiration state, and the genetic maintenance of mtDNA CN is 
what dictates the capacity of mitochondria to accommodate to signalling pressures. 
The ability for mitochondria to accommodate to signalling pressures will then 
contribute to cellular stress signalling outcomes, which may activate the immune 
system. This may then explain why women are more likely to develop autoimmune 
diseases - as an indirect impact of oestrogen signalling overloading mitochondria, 
causing self-autophagy (Fairweather and Rose, 2004).  
Further studies are needed to investigate oestrogen signalling and mtDNA CN 
regulation in more detail. However, exact stage of menopause, and medications 
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would need to be accounted for to ensure more precise analysis of mtDNA CN 
changes in pre- and post-menopausal women. 
8.2.3 The Hereditability of Mitochondrial DNA Copy Number 
Mitochondrial DNA is maternally inherited (Birky, 1978; Giles et al., 1980), because 
paternal mtDNA is degraded soon after fertilisation (Al Rawi et al., 2011; Sato and 
Sato, 2011; Politi et al., 2014). Female oocytes contain both wildtype and mutated 
mtDNA (heteroplasmy) (Wallace and Chalkia, 2013; Hyslop et al., 2016), which can 
be transmitted to the offspring. Heteroplasmy levels inherited dictate phenotype 
presentation, however this is dependent on tissue type and mtDNA mutation load 
(Sciacco et al., 1994; Wallace and Chalkia, 2013; Stewart and Chinnery, 2015). 
mtDNA CN is thought to regulate heteroplasmy transmission (Jenuth et al., 1996; 
Cree et al., 2008b), and mtDNA CN is reported to be between 33-65% inheritable in 
two independent studies in Mexican American families (Curran et al., 2007), and 
monozygotic, dizygotic and sibling pairs (Xing et al., 2008). 
To further validate the heritability of mtDNA CN, I investigated mtDNA CN 
relationships in over 800 mother-child pairs (section 3.3.6). The data recorded 
contradict previous studies, because no correlation in mtDNA CN was recorded. 
However, I did not use any genetic data to perform linkage analysis between pairs, 
therefore limiting my results to not identify the exact heritability of mtDNA CN. 
It would be beneficial to expand on my work in European populations, and identify 
the exact heritability of mtDNA CN in populations, and then compare this to mtDNA 
CN inheritance in other studies to identify if any genetic factors were responsible for 
any inheritance deviations. 
8.3 Technical Factors Modulating Mitochondrial DNA Copy Number 
Previous work conducted by Malik and colleagues demonstrated that it was important 
to design experiments correctly to determine mtDNA CN, to avoid bias or 
amplification of pseudoregions. Their work also identified that it was important to 
amplify non-variable mtDNA regions which are not present in nDNA pseudogenes, 
and highlighted the importance of correct DNA dilution series to ensure accurate 
Mt/N calculations (Malik et al., 2011). 
The work conducted in this study has expanded on Malik’s work, and has 
investigated technical limitations of measuring mtDNA CN, and the effect this has on 
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large, population-based studies. From optimising an established qPCR method 
(Grady et al., 2014a; Pyle et al., 2015b; Rygiel et al., 2015) in advance to conducting 
this study, I identified that triplicate and quadruplicate qPCR measurements were the 
most appropriate number of replicates to use, because more or less replicates 
resulted in increased standard deviations, which decrease genetic power in GWAS. 
Furthermore, I have recorded that there is no difference in mtDNA CN calculated 
using the average of triplicate Mt/N measurements, or using the median. 
Furthermore, I have demonstrated why there are inconsistencies in mtDNA CN 
values reported across the literature. qPCR assay design, DNA handling procedures, 
and assay user all contribute to mtDNA CN variation within control samples (Chapter 
4). Through collaboration with University of Bristol, whereby each cohort used a 
different qPCR assay to determine mtDNA CN, we identified a maximum Pearson’s 
correlation value of 0.66 in mtDNA CN values generated from two different, 
established qPCR assays – one using TaqMan™ probes, and the other using SYBR® 
Green. Both methods use different technologies to determine mtDNA CN, and both 
produce different mtDNA CN results. These differences could be dependent on a 
number of things including DNA quality, DNA volume, and DNA concentration, but 
also the person processing the samples. However, these findings further support the 
need for an accurate and reproducible qPCR assay to be optimised to quantify 
mtDNA CN. 
Additionally, by examining variants MAFs across mtDNA, I was able to identify 
polymorphic variants that may be interrupting established qPCR primer and probe 
binding domains (Chapter 1). By redesigning this assay, and using an alternative 
qPCR assay which quantified a less polymorphic region in MT-RNR2 instead of MT-
ND1, I was able to demonstrate that mtDNA CN values were much more consistent, 
and the ratio to MT-ND4 was much more precise. This further identified the 
importance of needing to re-design established qPCR assays to detect both mtDNA 
CN, and mitochondrial deletions, because the current method of measuring the 
proportions of MT-ND1 to MT-ND4 results in false detections of mitochondrial 
deletions (Chapter 1).  
I used LR-PCR methods to confirm that control samples which were originally 
identified to contain high levels of deletions (>20%) from qPCR analysis, actually 
contained no deletions (Chapter 1). Then, by comparing MT-ND1 analysis with MT-
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RNR2 analysis, indicated this may have been a result of variable MT-ND1 values 
relative to MT-ND4, which could have been caused by a highly polymorphic variant 
being present beneath MT-ND1 qPCR primer and probe binding domains. There are 
inconsistencies across the literature as to which reference genes should be used to 
quantify mtDNA CN, however the work here highlights the importance that qPCR 
design can contribute to inconsistent, and false positive results. 
To compare mtDNA CN between studies, especially in genetic studies, mtDNA CN 
must be measured using the same qPCR assay, and ideally by the same user to 
minimise assay variability. Power calculations, where mtDNA CN standard deviations 
are high, decrease statistical power to identify genetic variants modulating mtDNA 
CN change (discussed in section 4.5.6.1). Therefore it is essential that qPCR assays 
are improved to minimise variation, and to improve precision of results reported 
across the literature. 
Other methods of determining mtDNA CN are now starting to surface to minimise 
technical variations. Droplet-digital PCR (ddPCR) is more frequently being used 
because it is more accurate method to determine mtDNA CN as it amplifies single 
pieces of DNA using fluorescent probes to improve sensitivity and precision (Henrich 
et al., 2012; Belmonte et al., 2016; Ye et al., 2017). Other studies are turning to 
genetic sequencing data to calculate mtDNA CN by calculating the ratio of aligned 
mitochondrial reads to aligned nuclear reads. These methods assume equal ploidy of 
both nuclear and mitochondrial regions of the genome but are becoming more 
popular as they minimise mtDNA CN technical variation between studies (Guo et al., 
2013; D'Erchia et al., 2014; Cai et al., 2015; Ding et al., 2015; Reznik et al., 2016). 
The main limitation to using genomic data to calculate mtDNA CN though is that it is 
not a direct measure of mtDNA CN in cells. For example, Cai and colleagues use 
proxy measurements of mtDNA CN to argue that mtDNA CN is a factor for major 
depressive disorder (MDD) (Cai et al., 2015), however Tang and colleagues report 
mtDNA CN is not associated with MDD after using actual measures of mtDNA CN 
(He et al., 2014). 
Future work needs to investigate how genetic-calculated mtDNA CN values compare 
to actual measures of mtDNA CN before it can be assumed that methods are 
equivalent. However, a reliable, and concise qPCR first needs to be determined to 
compare to.  
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8.4 Conclusions 
This study is the largest study to investigate genetic, biological, and technical factors 
modulating mtDNA CN across healthy, unrelated, European populations.  
In conclusion, I report that: 
8.4.1 Biological Conclusions 
 There is no difference in mtDNA CN between males and females. 
 mtDNA CN decreases with age, however this is significant in males, and not 
females. 
 mtDNA CN changes in individual blood cell components, and this is 
dependent on peripheral blood cell proportions. 
 Blood cell components are significantly different between males and females. 
 mtDNA CN is not inherited maternally. 
 No single nuclear-locus is regulating mtDNA CN, and there are indications 
that several loci are gender-specific. 
 GWAS results are affected by phenotypic and experimental differences 
between cohorts; including DNA source, DNA extraction method, phenotype 
quantification methods, and blood cell proportions (when DNA is sourced from 
blood). All variables need to be adjusted for or minimised between cohorts. 
 Epigenetic factors are likely to be contributing to mtDNA CN changes, and 
these may be influenced by mitochondrial-regulated metabolic activity, which 
is determined by mtDNA CN turnover.  
 Our GWAS results indicate several genes that code for proteins involved in 
lipid signalling and vesicle-trafficking are associated to mtDNA CN regulation. 
 mtDNA CN may change relative to blood cell proportions in response to 
cellular stress feedback mechanisms during immune response events. 
 Mitochondrial variants effect mtDNA CN changes, and mitochondrial 
haplogroup W has significantly lower mtDNA CN compared to other European 
mitochondrial haplogroups. 
 There is no significant difference in mtDNA CN between pre- and post-
menopausal women, which suggests oestrogen is not mediating mtDNA 
numbers. 
 Mitochondrial deletions are not present in healthy individual’s blood. 
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8.4.2 Technical Conclusions 
 There is no difference in mtDNA CN calculated using mean or median values 
from replicates. 
 Triplicate or quadruplicate replicates are the optimum number to use in qPCR 
assays. 
 qPCR conducted by different users, or different qPCR assays (TaqMan™ vs 
SYBR® Green) produce inconsistent mtDNA CN values. 
 mtDNA polymorphisms are altering the efficiency of qPCR primers and 
probes, resulting in inaccurate reporting of mtDNA CN values. 
 MT-RNR2 appears to be a more accurate mitochondrial region to quantify 
instead of MT-ND1. 
 mtDNA CN is significantly different when DNA is extracted from whole blood, 
or white blood cell pellets, and analysis is not comparable between each DNA 
source. 
 mtDNA CN methods need to be improved to find approaches that are 
comparable across the literature, but also representative of real biological 
measures of mtDNA CN in populations. 
 There is very little difference in data imputed by the Sanger or Michigan 
Imputation Servers, and both datasets produce the same GWAS results. 
8.5 Future Study Recommendations  
As a result of this work, it is clear that much larger sample sizes are needed to 
investigate nuclear genetic factors modulating mtDNA CN in European populations. 
To minimise standard deviations, and prevent reduced statistical power, mtDNA CN 
must be extracted, stored, handled, and determined using the same procedures and 
quantitative assays. 
In advance of further large mtDNA CN studies being conducted, it is imperative that 
established qPCR methods are revised, and optimised to measure mtDNA regions 
with few polymorphisms, which will cause technical inconsistencies. Additionally, 
several mtDNA regions need to be quantified in future qPCR assays to identify 
mtDNA quality, and to normalise regions relative to one another to ensure full, 
circular mtDNA is being quantified. 
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Furthermore, qPCR technologies report different mtDNA CN. To make data 
comparable across the literature, standardised methods need to be established and 
used. 
mtDNA CN is different in individual blood cell components, which is dependent on 
overall cellular proportions. When investigating mtDNA CN in DNA extracted from 
blood samples, full blood count must be adjusted for. It would be interesting to 
separate blood cell components using fluorescence activated cell sorting 
technologies, and then perform GWAS in each cell component to identify genetic 
variants associated to mtDNA CN variation. 
Also, performing RNA-sequencing in each blood cell component would be beneficial 
to identify genetic factors modulating the significantly lower mtDNA CN reported in 
mitochondria with haplogroup W mtDNA. Future work should investigate the 
physiological differences in haplogroup W mitochondria compared to other European 
haplogroups, and explore their OXPHOS capacity relative to their metabolic 
demands. 
Further studies should be conducted to identify the inheritance of mtDNA CN in 
European populations, because current available literature is limited, and it would be 
beneficial to understand how mtDNA CN is inherited to predict disease susceptibility. 
Finally, it would be interesting to further investigate the role oestrogen has on mtDNA 
CN regulation, especially following menopause. Another study would need to 
measure mtDNA CN in a larger cohort of females whose menopause stage is exactly 
determined, and can be stratified by any hormone-replacement therapies. 
I propose that the quality of individual mitochondria, combined with epigenetic 
regulation of nDNA contribute to the mitochondria’s ability to manage cellular insult or 
stress. This in turn may contribute to metabolic differences, which then define mtDNA 
CN turnover through the mediation of mtDNA replication efficiency, which is affected 
by mtDNA variation. However extensive studies need to investigate this further.
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